US20180305373A1 - Alpha helix mimetics and methods relating thereto - Google Patents

Alpha helix mimetics and methods relating thereto Download PDF

Info

Publication number
US20180305373A1
US20180305373A1 US16/024,262 US201816024262A US2018305373A1 US 20180305373 A1 US20180305373 A1 US 20180305373A1 US 201816024262 A US201816024262 A US 201816024262A US 2018305373 A1 US2018305373 A1 US 2018305373A1
Authority
US
United States
Prior art keywords
optionally substituted
alkyl
bond
alkynyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/024,262
Inventor
Takenao Odagami
Yuji Kogami
Hiroyuki Kouji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prism BioLab Co Ltd
Original Assignee
Prism BioLab Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prism BioLab Co Ltd filed Critical Prism BioLab Co Ltd
Priority to US16/024,262 priority Critical patent/US20180305373A1/en
Assigned to Prism BioLab Co., Ltd. reassignment Prism BioLab Co., Ltd. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PRISM PHARMA CO., LTD.
Publication of US20180305373A1 publication Critical patent/US20180305373A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Definitions

  • the present invention relates generally to alpha-helix mimetic structures and to a chemical library relating thereto.
  • the invention also relates to applications in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics.
  • non-peptide compounds have been developed which more closely mimic the secondary structure of reverse-turns found in biologically active proteins or peptides.
  • U.S. Pat. No. 5,440,013 to Kahn and published PCT applications nos. WO94/03494, WO01/00210A1, and WO01/16135A2 to Kahn each disclose conformationally constrained, non-peptidic compounds, which mimic the three-dimensional structure of reverse-turns.
  • U.S. Pat. No. 5,929,237 and its continuation-in-part U.S. Pat. No. 6,013,458, both to Kahn disclose conformationally constrained compounds which mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins.
  • Kahn disclosed new conformationally constrained compounds which mimic the secondary structure of alpha-helix regions of biologically active peptide and proteins in WO2007/056513 and WO2007/056593.
  • the present invention also fulfills these needs, and provides further related advantages by providing conformationally constrained compounds which mimic the secondary structure of alpha-helix regions of biologically active peptides and proteins.
  • Wnt signaling pathway regulates a variety of processes including cell growth, oncogenesis, and development (Moon et al., 1997, Trends Genet. 13, 157-162; Miller et al., 1999, Oncogene 18, 7860-7872; Nusse and Varmus, 1992, Cell 69, 1073-1087; Cadigan and Nusse, 1997, Genes Dev. 11, 3286-3305; Peifer and Polakis, 2000 Science 287, 1606-1609; Polakis 2000, Genes Dev. 14, 1837-1851). Wnt signaling pathway has been intensely studied in a variety of organisms.
  • TCF4/ ⁇ -catenin mediated transcription by Wnt signal transduction has been found to play a key role in its biological functions (Molenaar et al., 1996, Cell 86:391-399; Gat et al., 1998 Cell 95:605-614; Orford et al., 1999 J. Cell. Biol. 146:855-868; Bienz and Clevers, 2000, Cell 103:311-20).
  • tumor suppressor gene adenomatous polyposis coli APC
  • APC tumor suppressor gene adenomatous polyposis coli
  • GSK serine kinase glycogen synthase kinase
  • ⁇ -catenin Su et al., 1993, Science 262, 1734-1737: Yost et al., 1996 Genes Dev. 10, 1443-1454: Hayashi et al., 1997, Proc. Natl. Acad. Sci. USA, 94, 242-247: Sakanaka et al., 1998, Proc. Natl. Acad. Sci. USA, 95, 3020-3023: Sakanaka and William, 1999, J. Biol. Chem 274, 14090-14093).
  • c-myc a known oncogene
  • TCF4/ ⁇ -catenin transcriptional pathway Crawford et al., 1999, Oncogene 18, 2883-2891: Shtutman et al., 1999, Proc. Natl. Acad. Sci.
  • Biol., 152, 1, 87-96) and APC mutation inhibits apoptosis by allowing constitutive survivin expression, a well-known anti-apoptotic protein (Tao Zhang et al., 2001, Cancer Research, 62, 8664-8667).
  • APCs principal role is that of a negative regulator of the Wnt signal transduction cascade.
  • a center feature of this pathway involves the modulation of the stability and localization of a cytosolic pool of ⁇ -catenin by interaction with a large Axin-based complex that includes APC. This interaction results in phosphorylation of ⁇ -catenin thereby targeting it for degradation.
  • CBP binding proteins were identified initially in protein interaction assays, first through its association with the transcription factor CREB (Chrivia et al., 1993, Nature, 365, 855-859) and later through its interaction with the adenoviral-transforming protein E1A (Stein et al., 1990, J. Viol., 64, 4421-4427: Eckner et al., 1994, Genes. Dev., 8, 869-884).
  • CBP had a potential to participate in variety of cellular functions including transcriptional coactivator function (Shikama et al., 1997, Trends. Cell. Biol., 7, 230-236: Janknecht and Hunter, 1996, Nature, 383, 22-23).
  • CBP/p300 potentiates ⁇ -catenin-mediated activation of the siamois promoter, a known Wnt target (Hecht et al., 2000, EMBO J. 19, 8, 1839-1850).
  • ⁇ -catenin interacts directly with the CREB-binding domain of CBP and ⁇ -catenin synergizes with CBP to stimulate the transcriptional activation of TCF4/ ⁇ -catenin (Ken-Ichi Takemaru and Randall T. Moon, 2000 J. Cell. Biol., 149, 2, 249-254).
  • the present invention relates generally to alpha-helix mimetic structures and to a chemical library relating thereto.
  • the invention also relates to applications in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics.
  • TCF4/ ⁇ -catenin and CBP complex of Wnt pathway can be taken as target molecules for the regulation of cell growth, oncogenesis and apoptosis of cells, etc. Accordingly, the present invention also addresses a need for compounds that block TCF4/ ⁇ -catenin transcriptional pathway by inhibiting CBP, and therefore can be used for treatment of cancer, especially colorectal cancer, and fibrotic diseases.
  • the present invention is directed to a new type of conformationally constrained compounds, which mimic the secondary structure of alpha-helix regions of biologically active peptides and proteins. This invention also discloses libraries containing such compounds, as well as the synthesis and screening thereof.
  • such compounds comprise a formula (Ia)
  • such compounds comprise a formula (Ib)
  • such compounds comprise a formula (Ic)
  • such compounds comprise a formula (Id)
  • such compounds comprise a formula (II):
  • such compounds comprise a formula (IIa′):
  • such compounds comprise a formula (IIb′):
  • the present invention is also directed to libraries containing one or more compounds of formula (I) above, as well as methods for synthesizing such libraries and methods for screening the same to identify biologically active compounds.
  • a pharmaceutical composition comprises the compound of formula (I) or pharmaceutically acceptable salt thereof, and, if necessary, together with a pharmaceutical acceptable carrier or diluent.
  • compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier or diluent are also disclosed.
  • a method of treating a cancerous condition or fibrosis by administering the compound of formula (I).
  • the present invention also provides methods for preventing or treating disorders associated with Wnt signaling pathway.
  • Disorders that may be treated or prevented using a compound or composition of the present invention include tumor or cancer (e.g., KSHV-associated tumor), fibrotic diseases, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, tuberous sclerosis complex, hair loss, and Alzheimer's disease.
  • Such methods comprise administering to a subject in need thereof a compound or composition of the present invention in an amount effective to achieve the desired outcome.
  • FIG. 1 (including FIGS. 1-1 to 1-6 ) and FIG. 2 (including FIGS. 2-1 and 2-2 ) provide a general synthetic scheme for preparing alpha-helix mimetics of the present invention.
  • the present invention relates generally to alpha-helix mimetic structures and to a chemical library relating thereto.
  • the present invention is also directed to conformationally constrained compounds that mimic the secondary structure of alpha-helix regions of biological peptide and proteins (also referred to herein as “alpha-helix mimetics”), and is also directed to chemical libraries relating thereto.
  • the alpha-helix mimetic structures of the present invention are useful as bioactive agents, including (but not limited to) use as diagnostic, prophylactic and/or therapeutic agents.
  • the alpha-helix mimetic structure libraries of this invention are useful in the identification of bioactive agents having such uses.
  • the libraries may contain from tens to hundreds to thousands (or greater) of individual alpha-helix structures (also referred to herein as “members”).
  • Optionally substituted means that a given radical may consist of only hydrogen substituents through available valencies or may further comprise one or more non-hydrogen substituents through available valencies.
  • a non-hydrogen substituent may be any substituent that may be bound to an atom of the given radical that is specified to be substituted.
  • substituents include, but are not limited to, —R 9 , —OR 9 , —COR 9 , —COOR 9 , —OCOR 9 , —CONR 9 R 4 , —NR 9 R 4 , —NR 4 COR 9 , —NR 4 COOR 9 , —SR 9 , —SO 2 R 9 , —SO 2 NR 9 R 4 , —SO 3 R 9 , —NHC(NHR 9 )NR 4 , —NHC(NH 2 )NH, —OPO(OH) 2 , —OPO(ONa) 2 , —CN, —NO 2 , halogen and methylenedioxy, wherein R 9 and R 4 are independently selected from hydrogen, optionally substituted, cyclic or noncyclic, alkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl.
  • Halogen means fluorine, chlorine, bromine or iodine.
  • Halo means fluoro, chloro, bromo or iodo.
  • Alkyl means a linear or branched, saturated, aliphatic radical having a chain of carbon atoms.
  • C X-Y alkyl is typically used where X and Y indicate the number of carbon atoms in the chain.
  • the number of carbon atoms in the chain is preferably 1 to 10, more preferably 1 to 6, further preferably 1 to 4.
  • Non-exclusive examples of alkyl include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, isohexyl, and the like.
  • “Noncyclic alkyl” equals to “alkyl” as used here.
  • Alkenyl means a linear or branched, carbon chain that contains at least one carbon-carbon double bond.
  • C X-Y alkenyl is typically used where X and Y indicate the number of carbon atoms in the chain.
  • the number of carbon atoms in the chain is preferably 2 to 10, more preferably 2 to 6.
  • Non-exclusive examples of alkenyl include ethenyl (vinyl), allyl, isopropenyl, 2-methylallyl, 1-pentenyl, hexenyl, heptenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, and the like.
  • Alkynyl means a linear or branched, carbon chain that contains at least one carbon-carbon triple bond.
  • C X-Y alkynyl is typically used where X and Y indicate the number of carbon atoms in the chain.
  • the number of carbon atoms in the chain is preferably 2 to 10, more preferably 2 to 6.
  • Non-exclusive examples of alkynyl include ethynyl, propargyl, 3-methyl-1-pentynyl, 2-heptynyl and the like.
  • Alkylene unless indicated otherwise, means a linear or branched, saturated, aliphatic, polyvalent carbon chain.
  • C X-Y alkylene is typically used where X and Y indicate the number of carbon atoms in the chain.
  • the number of carbon atoms in the chain is preferably 1 to 10, more preferably 1 to 6.
  • Non-exclusive examples of alkylene include methylene (—CH 2 —), ethylene (—CH 2 CH 2 —), methylmethylene (—CH(CH 3 )—), 1,2-propylene (—CH 2 CH(CH 3 )—), 1,3-propylene (—CH 2 CH 2 CH 2 —), 1,2-butylene (—CH 2 CH(CH 2 CH 3 )—), 1, 3-butylene (—CH 2 CH 2 CH(CH 3 )—), 1, 4-butylene (—CH 2 CH 2 CH 2 CH 2 —), 2-methyltetramethylene (—CH 2 CH(CH 3 ) CH 2 CH 2 —), pentamethylene (—CH 2 CH 2 CH 2 CH 2 CH 2 —), 1, 2, 3-propanetriyl, 1,3,3-propanetriyl and the like.
  • Oxy means the radical —O—. It is noted that the oxy radical may be further substituted with a variety of substituents to form different oxy groups including hydroxy, alkoxy, aryloxy, heteroaryloxy and the like.
  • Thio means the radical —S—. It is noted that the thio radical may be further substituted with a variety of substituents to form different thio groups including mercapto, alkylthio, arylthio, heteroarylthio and the like.
  • “Sulfinyl” means the radical —SO—. It is noted that the sulfinyl radical may be further substituted with a variety of substituents to form different sulfinyl groups including alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl and the like.
  • “Sulfonyl” means the radical —SO 2 —. It is noted that the sulfonyl radical may be further substituted with a variety of substituents to form different sulfonyl groups including alkylsulfonyl, arysulfonyl, heteroarylsulfonyl and the like.
  • Alkoxy means an oxygen moiety having a further alkyl substituent.
  • C X-Y alkoxy is typically used where X and Y indicate the number of carbon atoms in the chain. The number of carbon atoms in the chain is preferably 1 to 10, more preferably 1 to 6.
  • Non-exclusive examples of alkoxy include methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, isobutoxy, tert-butoxy, pentoxy, isopentoxy, neopentoxy, tert-pentoxy, hexyloxy, isohexyloxy, and the like.
  • Heteroatom refers to an atom that is not a carbon atom and hydrogen atom. Particular examples of heteroatoms include, but are not limited to nitrogen, oxygen, and sulfur.
  • Aryl means a monocyclic or polycyclic radical wherein each ring is aromatic or when fused with one or more rings forms an aromatic ring.
  • C X-Y aryl is typically used where X and Y indicate the number of carbon atoms in the ring assembly. The number of carbon atoms in the ring is preferably 6 to 14, more preferably 6 to 10.
  • Non-exclusive examples of aryl include phenyl, naphthyl, indenyl, azulenyl, biphenyl, fluorenyl, anthracenyl, phenalenyl and the like.
  • “Aryl” may partially be hydrogenated.
  • Non-exclusive examples of partially hydrogenated aryl include tetrahydronaphthyl, indanyl and the like.
  • Heteroaryl means a monocyclic or polycyclic aromatic radical wherein at least one ring atom is a heteroatom and the remaining ring atoms are carbon.
  • X-Y membered heteroaryl is typically used where X and Y indicate the number of carbon atoms and heteroatoms in the ring assembly. The number of carbon atoms and heteroatoms in the ring is preferably 5 to 14, more preferably 5 to 10.
  • Monocyclic heteroaryl groups include, but are not limited to, cyclic aromatic groups having five or six ring atoms, wherein at least one ring atom is a heteroatom and the remaining ring atoms are carbon.
  • the nitrogen atoms can be optionally quaternerized and the sulfur atoms can be optionally oxidized.
  • Non-exclusive examples of monocyclic heteroaryl group of this invention include, but are not limited to, those derived from furan, thiophene, pyrrole, imidazole, isothiazole, isoxazole, oxadiazole, oxazole, 1,2,3-oxadiazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, triazine, pyrroline, thiazole, 1,3,4-thiadiazole, triazole and tetrazole.
  • Heteroaryl also includes, but is not limited to, bicyclic or tricyclic rings, wherein the heteroaryl ring is fused to one or two rings independently selected from the group consisting of an aryl ring, a cycloalkyl ring, and another monocyclic heteroaryl or heterocycloalkyl ring.
  • Non-exclusive examples of bicyclic or tricyclic heteroaryl include, but are not limited to, those derived from benzofuran (ex. benzo[b]furan), benzothiophene (ex. benzo[b]thiophene), benzimidazole, benzotriazine (ex.
  • pyrazolo[1,5-a]pyridine imidazopyrimidine
  • imidazopyrimidine imidazo[1,2-a]pyrimidine
  • imidazo[1,2-c]pyrimidine imidazo[1,5-a]pyrimidine
  • imidazo[1,5-c]pyrimidine imidazo[1,5-c]pyrimidine
  • pyrrolopyridine ex. pyrrolo[2,3-b]pyridine, pyrrolo[2,3-c]pyridine, pyrrolo[3,2-c]pyridine, pyrrolo[3,2-b]pyridine
  • pyrrolopyrimidine ex.
  • pyrrolo[2,3-d]pyrimidine pyrrolo[3,2-d]pyrimidine, pyrrolo[1,2-c]pyrimidine, pyrrolo[1,2-a]pyrimidine
  • pyrrolopyrazine ex. pyrrolo[2, 3-b]pyrazine, pyrrolo[1,2-a]pyrazine
  • pyrrolopyridazine ex. pyrrolo[1,2-b]pyridazine
  • triazopyridine ex.
  • triazo[1,5-a]pyridine triazo[1,5-a]pyridine
  • pteridine purine, carbazole, acridine, permidine, 1,10-phenanthroline, phenoxathiin, phenoxazine, phenothiazine, phenazine, benzodioxole, benzodioxolane and the like.
  • the bicyclic or tricyclic heteroaryl rings can be attached to the parent molecule through either the heteroaryl group itself or the aryl, cycloalkyl, or heterocycloalkyl group to which it is fused.
  • Cycloalkyl means a non-aromatic, saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring radical.
  • C X-Y cycloalkyl is typically used where X and Y indicate the number of carbon atoms in the ring assembly. The number of carbon atoms in the ring is preferably 3 to 10, more preferably 3 to 8.
  • Non-exclusive examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,5-cyclohexadienyl, bicyclo[2.2.2]octyl, adamantan-1-yl, decahydronaphthyl, bicyclo[2.2.1]hept-1-yl, and the like. “Cyclic alkyl” equals to “cycloalkyl” as used here.
  • Heterocycloalkyl means cycloalkyl, as defined in this Application, provided that one or more of the atoms forming the ring is a heteroatom selected, independently from N, O, and S.
  • C X-Y heterocycloalkyl is typically used where X and Y indicate the number of carbon atoms and heteroatoms in the ring assembly.
  • the number of carbon atoms and heteroatoms in the ring is preferably 3 to 10, more preferably 3 to 8.
  • heterocycloalkyl examples include piperidyl, 4-morpholyl, 4-piperazinyl, pyrrolidinyl, perhydropyrrolizinyl, 1,4-diazaperhydroepinyl, 1,3-dioxanyl, 1,4-dioxanyl, tetrazolyl and the like.
  • arylalkyl means linear or branched alkyl group which is substituted by one or more aryl groups, such as benzyl, 1-phenylethyl, 2-phenylethyl, 3-phenylpropyl, 1-naphthylmethyl, 2-naphthylmethyl, benzhydryl, 2,2-diphenylethyl, trityl and the like.
  • “Monocyclic ring” as used herein refers to a monocyclic, saturated or unsaturated carbocyclic ring or a monocyclic, saturated or unsaturated heterocyclic ring.
  • “X- (to, or) Y-membered monocyclic ring” is typically used where X and Y indicate the number of carbon atoms and heteroatoms in the ring assembly. The number of carbon atoms and heteroatoms in the ring is preferably 4 to 7, more preferably 5 or 6.
  • “Monocyclic heterocyclic ring” means a monocyclic, aromatic or nonaromatic ring wherein at least one ring atom is a heteroatom (preferably S, N or O) and the remaining ring atoms are carbon. The nitrogen atoms can be optionally quaternerized and the sulfur atoms can be optionally oxidized.
  • Non-exclusive examples of monocyclic saturated carbocyclic ring include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane and the like.
  • Non-exclusive examples of monocyclic unsaturated carbocyclic ring include cyclopropene, cyclobutene, cyclopentene, cyclohexene, cycloheptene, cyclopentadiene, benzene, and the like.
  • Non-exclusive examples of monocyclic saturated heterocyclic ring include pyrrolidine, piperidine, morpholine, piperazine, 1,3-dioxane, 1,4-dioxane and the like.
  • Non-exclusive examples of monocyclic unsaturated heterocyclic ring include pyrazole, dihydro-pyrrole, pyrrole, dihydro-pyrazole, imidazole, thiophene, thiazole, isothiazole, thiadiazole, furan, oxazole, isoxazole, oxadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine and the like.
  • “Spiro ring” as used herein refers to saturated or unsaturated cycloalkane or saturated or unsaturated heterocycloalkane.
  • Cycloalkane means a non-aromatic, saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring.
  • C X-Y cycloalkane is typically used where X and Y indicate the number of carbon atoms in the ring assembly. The number of carbon atoms in the ring is preferably 3 to 10, more preferably 3 to 8.
  • Non-exclusive examples of cycloalkane include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane and the like.
  • Heterocycloalkane means cycloalkane, as defined in this Application, provided that one or more of the atoms forming the ring is a heteroatom selected, independently from N, O, and S.
  • C X-Y heterocycloalkane is typically used where X and Y indicate the number of carbon atoms and heteroatoms in the ring assembly.
  • the number of carbon atoms and heteroatoms in the ring is preferably 3 to 10, more preferably 3 to 8.
  • heterocycloalkane examples include piperidine, morpholine, piperazine, pyrrolidine, perhydropyrrolizine, tetrahydrofuran, tetrahydropyran, 1,3-dioxane, 1,4-dioxane and the like.
  • fused ring refers to a ring that is bonded to another ring to form a compound having a bicyclic structure when the ring atoms that are common to both rings are directly bound to each other.
  • fused rings include decalin, naphthalene, anthracene, phenanthrene, indole, furan, benzofuran, quinoline, and the like.
  • Compounds having fused ring systems may be saturated, partially saturated or aromatic.
  • “Bridging ring” as used herein refers to a ring that is bonded to another ring to form a compound having a bicyclic structure where two ring atoms that are common to both rings are not directly bound to each other.
  • Non-exclusive examples of common compounds having a bridging ring include adamantine, borneol, norbornane, 7-oxabicyclo[2.2.1]heptane, and the like.
  • Protected derivatives means derivatives of compound in which a reactive site or sites are blocked with protecting groups.
  • a comprehensive list of suitable protecting groups can be found in T. W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc. 1999.
  • “Isomers” mean any compound having an identical molecular formulae but differing in the nature or sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.” Stereoisomers that are not mirror images of one another are termed “diastereomers” and stereoisomers that are nonsuperimposable mirror images are termed “enantiomers” or sometimes “optical isomers.” A carbon atom bonded to four nonidentical substituents is termed a “chiral center.” A compound with one chiral center has two enantiomeric forms of opposite chirality.
  • a mixture of the two enantiomeric forms is termed a “racemic mixture.”
  • a compound that has more than one chiral center has 2 n-1 enantiomeric pairs, where n is the number of chiral centers.
  • Compounds with more than one chiral center may exist as either an individual diastereomer or as a mixture of diastereomers, termed a “diastereomeric mixture.”
  • a stereoisomer may be characterized by the absolute configuration of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center.
  • Enantiomers are characterized by the absolute configuration of their chiral centers and described by the R- and S-sequencing rules of Cahn, Ingold and Prelog. Conventions for stereochemical nomenclature, methods for the determination of stereochemistry and the separation of stereoisomers are well known in the art (e.g., see “Advanced Organic Chemistry”, 4th edition, March, Jerry, John Wiley & Sons, New York, 1992).
  • Animal includes humans, non-human mammals (e.g., mice, rats, dogs, cats, rabbits, cattle, horses, sheep, goats, swine, deer, and the like) and non-mammals (e.g., birds, and the like).
  • non-human mammals e.g., mice, rats, dogs, cats, rabbits, cattle, horses, sheep, goats, swine, deer, and the like
  • non-mammals e.g., birds, and the like.
  • Disease specifically includes any unhealthy condition of an animal or part thereof and includes an unhealthy condition that may be caused by, or incident to, medical or veterinary therapy applied to that animal, i.e., the “side effects” of such therapy.
  • “Pharmaceutically acceptable” means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary use as well as human pharmaceutical use.
  • “Pharmaceutically acceptable salt” means a salt of compounds of the present invention which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity.
  • Such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or with organic acids such as acetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, o-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid,
  • Pharmaceutically acceptable salt also include base addition salts which may be formed when acidic protons present are capable of reacting with inorganic or organic bases.
  • Acceptable inorganic bases include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide and calcium hydroxide.
  • Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine and the like.
  • Amount effective to treat means that amount which, when administered to an animal for treating a disease, is sufficient to effect such treatment for the disease.
  • Amount effective to prevent means that amount which, when administered to an animal for preventing a disease, is sufficient to effect such prophylaxis for the disease.
  • Effective amount equals to “amount effective to treat” and “amount effective to prevent”.
  • Treatment or “treat” means any administration of a compound of the present invention and includes:
  • an alpha-helix mimetic structure having the following formula (I):
  • A is —CHR 7 —, wherein R 7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl.
  • optionally substituted alkyl group examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carbamoylmethyl, carbamoylethyl, carbamoylpropyl, carbamoylbutyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methylthiomethyl, methylthioethyl, methylthiopropyl, methylthiobutyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, ethoxycarbonylmethyl, ethoxycarbonyl
  • alkenyl group examples include ethenyl, allyl, 1-propenyl, 2-methylallyl and the like.
  • alkynyl group examples include ethynyl, 1-propynyl and the like.
  • aryl group and heteroaryl group examples include biphenyl, phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolyl, thienyl, furyl, thiazolyl, oxazolyl, imidazolyl, tetrahydronaphthyl, naphthyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, benzotriazinyl, indenyl, pyridopyrimidinyl, pyridopyrazinyl, pyridopyridazinyl, pyridotriazinyl, benzofuryl, benzothienyl, indolyl, indazolyl, benzoxazolyl, benzimidazolyl
  • cycloalkyl and optionally substituted heterocycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl and the like.
  • A is —CHR 7 —, wherein R 7 is -Rc-R 70 wherein Rc is bond or optionally substituted lower alkylene, and R 70 is hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl.
  • lower alkylene group examples include methylene, ethylene, methylmethylene, 1,2-propylene, 1,3-propylene, 1,2-butylene, 1,3-butylene, 1,4-butylene, 1,2,3-propanetriyl, 1,3,3-propanetriyl and the like.
  • optionally substituted alkyl group examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carbamoylmethyl, carbamoylethyl, carbamoylpropyl, carbamoylbutyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methylthiomethyl, methylthioethyl, methylthiopropyl, methylthiobutyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, ethoxycarbonylmethyl, ethoxycarbonyl
  • aryl group and heteroaryl group examples include biphenyl, phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolyl, thienyl, furanyl, thiazolyl, oxazolyl, imidazolyl, tetrahydronaphthyl, naphthyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, benzotriazinyl, indenyl, pyridopyrimidinyl, pyridopyrazinyl, pyridopyridazinyl, pyridotriazinyl, benzofuranyl, benzothienyl, indolyl, indazolyl, benzoxazolyl, benzimidazoly
  • cycloalkyl group and heterocycloalkyl group include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl and the like.
  • R 70 is optionally substituted aryl or optionally substituted heteroaryl.
  • aryl group and heteroaryl group examples include biphenyl, phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolyl, thienyl, furanyl, thiazolyl, oxazolyl, imidazolyl, tetrahydronaphthyl, naphthyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, benzotriazinyl, indenyl, pyridopyrimidinyl, pyridopyrazinyl, pyridopyridazinyl, pyridotriazinyl, benzofuranyl, benzothiopenyl, indolyl, indazolyl, benzoxazolyl, benzimidazoly
  • aryl group and heteroaryl group include phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolyl, thienyl, furanyl, thiazolyl, oxazolyl, imidazolyl, naphthyl and the like.
  • aryl group include phenyl and the like.
  • R 7 examples include —R 9 , —OH, —OR 9 , —OC(O)R 9 , —OC(O)OR 9 , —COOH, —COR 9 , —COOR 9 , —CONH 2 , —CONHR 9 , —CONR 9 R 4 , —NH 2 , —NHR 9 , —NR 9 R 4 , —SH, —SR 9 , —SO 2 R 9 , —SO 2 NH 2 , —SO 2 NHR 9 , —SO 2 NR 9 R 4 —SO 3 H, —SOR 9 , —NHC(NH 2 )( ⁇ NH), —NHC(NHR 9 )( ⁇ NR 4 ), —OP( ⁇ O)(OH), —OP( ⁇ O)(ONa) 2 , —OP( ⁇ O)(OR 9 ) 2 , —OP( ⁇ O)(OR 9 )(OH), —OP( ⁇ O)(OH),
  • Preferred examples of the substituents include —OH, —COOH, —OC(O)R 9 , —OC(O)OR 9 , —NH 2 , —SH, —SO 3 H, —SOR 9 , —OP( ⁇ O)(OH) 2 , —OP( ⁇ O)(OR 9 ) 2 , —OP( ⁇ O)(OR 9 )(OH), —OP( ⁇ O)(ONa) 2 , —OP( ⁇ O)(OH)—O—P( ⁇ O)(OH) 2 , —OP( ⁇ O)(ONa)—O—OP( ⁇ O)(ONa) 2 , and halogen.
  • substituents include —OH, —OR 9 , —COOH, —OC(O)R 9 , —COOR 9 , —NH 2 , —NHR 9 , —NR 9 R 4 , —CONH 2 , —CONHR 9 , —CONR 9 R 4 , —OP( ⁇ O)(OH) 2 , —OP( ⁇ O)(ONa) 2 , and halogen.
  • R 7 is phenyl, benzyl, phenethyl, l-naphthyl, 2-naphthyl, 1-naphthylmethyl, 2-naphthylmethyl, 4-hydroxybenzyl, 4-benzyloxybenzyl, imidazolyl-5-methyl, methyl, n-butyl, isopropyl, isobutyl, hydroxymethyl, 4-aminobutyl, carboxymethyl, 2-carboxyethyl, carbamoylmethyl, 2-carbamoylethyl, ethoxycarbonylmethyl, 2-ethoxycarbonylethyl, benzyloxymethyl and the like.
  • E is bond, —CHR 5 —, —O— or —NR 8 —, wherein R 5 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl; and R 8 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl.
  • R 5 is lower alkyl, lower alkenyl, lower alkynyl or lower arylalkyl
  • R 8 is alkyl, alkynyl or arylalkyl.
  • lower alkyl group for R 5 examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl and the like.
  • lower alkenyl group for R 5 examples include ethenyl, allyl, 1-propenyl, 2-methylallyl and the like.
  • lower alkynyl group for R 5 examples include ethynyl, 1-propynyl and the like.
  • R 5 is arylalkyl or heteroarylalkyl represented by -Rd-R 50 wherein Rd is optionally substituted lower alkylene, and R 50 is optionally substituted aryl or optionally substituted heteroaryl.
  • lower alkylene group for Rd examples include methylene, ethylene, methylmethylene, 1,2-propylene, 1,3-propylene, 1,2-butylene, 1,3-butylene, 1,4-butylene, 1,2,3-propanetriyl, 1,3,3-propanetriyl and the like.
  • aryl group and heteroaryl group examples include biphenyl, phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolyl, thienyl, furanyl, thiazolyl, oxazolyl, imidazolyl, tetrahydronaphthyl, naphthyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, benzotriazinyl, indenyl, pyridopyrimidinyl, pyridopyrazinyl, pyridopyridazinyl, pyridotriazinyl, benzofuranyl, benzothienyl, indolyl, indazolyl, benzoxazolyl, benzimidazoly
  • alkyl group for R 8 examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl and the like.
  • alkenyl group for R 8 examples include ethenyl, allyl, 1-propenyl, 2-methylallyl and the like.
  • alkynyl group for R 8 examples include ethynyl, 1-propynyl and the like.
  • E is —CH 2 —, —O— or —N(CH 3 )—.
  • E when E is bond, then D is void, B is optionally substituted monocyclic ring, and G and Y are independently carbon atom or nitrogen atom.
  • B is void or optionally substituted monocyclic ring formed together with G and Y; when B is present, then D is void, and G and Y are independently carbon atom or nitrogen atom.
  • B is preferably optionally substituted 3-, 4-, 5-, 6- or 7 membered saturated or unsaturated monocyclic ring and more preferably optionally substituted 5- or 6-membered saturated or unsaturated monocyclic ring formed together with G and Y.
  • the preferable hetero atom is selected from S, N, and O and the number of hetero atoms is preferably an integer of 1-3.
  • Examples of monocyclic ring group include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, pyrrolidine, pyrazole, cyclopropene, cyclobutene, cyclopentene, cyclohexene, cycloheptene, cyclopentadiene, dihydro-pyrrole, pyrrole, pyrrolidine, dihydro-pyrazole, pyrazole, imidazole, thiophene, thiazole, isothiazole, thiadiazole, furan, oxazole, isooxazole, oxadiazole, benzene, pyridine, pyridazine, pyrimidine, pyrazine, triazine and the like.
  • Q 1 designates a structural sector of the compound
  • Q 1 is selected from one of the following group:
  • D is void or optionally substituted spiro ring formed together with Y; when D is present, then B is void, and Y is carbon atom and G is —NR 6 —, —O—, —CHR 6 — or —C(R 6 ) 2 —, wherein each R 6 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl. Specific embodiments for R 6 are explained in detail below.
  • spiro ring group examples include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, tetrahydropyran, tetrahydro-2H-thiopyran, azepane, cyclopentene and the like.
  • D is optionally substituted cycloalkane, preferably optionally substituted C 3-8 cycloalkane.
  • Q 2 designates a structural sector of the compound
  • spiro ring of Q 2 is selected from one of the following group:
  • the substituents of B or D are one or more of the chemical moieties selected from the group consisting of —R 9 , —OR 9 , —COR 9 , —COOR 9 , —OCOR 9 , —CONR 9 R 4 , —NR 9 R 4 , —NR 4 COR 9 , —NR 4 COOR 9 , —SR 9 , —SO 2 R 9 , —SO 2 NR 9 R 4 , —SO 3 R 9 , —NHC(NHR 9 ) NR 4 , halogen and methylenedioxy, wherein R 9 and R 4 are independently selected from hydrogen atom, optionally substituted, cyclic or noncyclic, alkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl.
  • G and Y are the same or different and each is —NR 6 —, —O—, —CHR 6 — or —C(R 6 ) 2 —, wherein each R 6 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl.
  • alkyl group for R 6 examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl and the like.
  • alkenyl group for R 6 examples include ethenyl, allyl, 1-propenyl, 2-methylallyl and the like.
  • alkynyl group for R 6 examples include ethynyl, 1-propynyl and the like.
  • R 6 is aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl or heteroarylalkyl represented by —Re—R 60 wherein Re is bond or optionally substituted lower alkylene, and R 60 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl.
  • lower alkylene group for Re examples include methylene, ethylene, methylmethylene, 1,2-propylene, 1,3-propylene, 1,2-butylene, 1,3-butylene, 1,4-butylene, 1,2,3-propanetriyl, 1,3,3-propanetriyl and the like.
  • aryl group and heteroaryl group for R 60 include biphenyl, phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolyl, thienyl, furanyl, thiazolyl, oxazolyl, imidazolyl, tetrahydronaphthyl, naphthyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, benzotriazinyl, indenyl, pyridopyrimidinyl, pyridopyrazinyl, pyridopyridazinyl, pyridotriazinyl, benzofuranyl, benzothienyl, indolyl, indazolyl, benzoxazolyl, benzimi
  • cycloalkyl group and heterocycloalkyl group include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl and the like.
  • At least one of G and Y is —NR 6′ —, —CHR 6′ — or —C(R 6′ ) 2 —, wherein each R 6′ is independently hydrogen, optionally substituted cyclic or noncyclic lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl.
  • R 6 or R 6′ is hydrogen, lower alkyl (ex. methyl) or lower alkenyl (ex. allyl).
  • R 1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl.
  • optionally substituted alkyl group examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carbamoylmethyl, carbamoylethyl, carbamoylpropyl, carbamoylbutyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methylthiomethyl, methylthioethyl, methylthiopropyl, methylthiobutyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, ethoxycarbonylmethyl, ethoxycarbonyl
  • alkenyl group examples include ethenyl, allyl, 1-propenyl, 2-methylallyl and the like.
  • alkynyl group examples include ethynyl, 1-propynyl and the like.
  • R 1 is —Ra—R 10 , wherein Ra is optionally substituted lower alkylene and R 10 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl or optionally substituted heteroaryl.
  • optionally substituted alkyl group examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carbamoylmethyl, carbamoylethyl, carbamoylpropyl, carbamoylbutyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methylthiomethyl, methylthioethyl, methylthiopropyl, methylthiobutyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, ethoxycarbonylmethyl, ethoxycarbonyl
  • lower alkylene group examples include methylene, ethylene, methylmethylene, 1,2-propylene, 1,3-propylene, 1,2-butylene, 1,3-butylene, 1,4-butylene, 1,2,3-propanetriyl, 1,3,3-propanetriyl and the like.
  • cycloalkyl group and heterocycloalkyl group include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl and the like.
  • aryl group and heteroaryl group examples include biphenyl, phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolyl, thienyl, furanyl, thiazolyl, oxazolyl, imidazolyl, naphthyl, tetrahydronaphthyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, benzotriazinyl, pyridopyrimidinyl, pyridopyrazinyl, pyridopyridazinyl, pyridotriazinyl, indenyl, benzofuranyl, benzothienyl, indolyl, indazolyl, benzoxazolyl, benzimidazoly
  • lower alkylene group examples include methylene, ethylene, 1,3-propylene and the like.
  • aryl group and heteroaryl group include bicyclic fused aryl group and bicyclic fused heteroaryl group such as naphthyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, benzotriazinyl, indenyl, pyridopyrimidinyl, pyridopyrazinyl, pyridopyridazinyl, pyridotriazinyl, benzofuryl, benzothienyl, indolyl, indazolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiadiazolyl, furopyridinyl, thienopyridinyl, pyrropyridinyl, oxazolopyridinyl, thiazolopyridinyl, imidazopyridin
  • R 1 examples include —R 4 , —OR 9 , —COR 9 , —COOR 9 , —OCOR 9 , —CONR 9 R 4 , —NR 9 R 4 , —NR 4 COR 9 , —NR 4 COOR 9 , —SR 9 , —SO 2 R 9 , SO 2 NR 9 R 4 , —SO 3 R 9 , —NHC(NHR 9 )NR 4 , —NHC(NH 2 )NH, —OPO(OH) 2, —OPO(ONa) 2 , —CN, —NO 2 , halogen and methylenedioxy, wherein R 9 and R 4 are independently selected from hydrogen atom, optionally substituted, cyclic or noncyclic, alkyl, aryl, heteroaryl, arylalkyl and heteroaryl.
  • substituents include —NH 2 , —OH, —OR 9 , —COOH, —COOR 9 , —NR 4 COR 9 , —CONH 2 , —CONHR 9 , —CONR 9 R 4 , —NHR 9 , —NR 9 R 4 and halogen.
  • substituents include —NH 2 , —OH, —COOH, —COOR 9 , —NR 4 COR 9 , —CONH 2 and halogen.
  • R 1 is isopentyl, benzyl, 2,4-difluorobenzyl, 4-hydroxybenzyl, 1-phenylethyl, 2-phenylethyl, 3-phenylpropyl, 3,3-diphenylpropyl, pyridyl-4-methyl, pyridyl-2-methyl, thienyl-2-methyl, thienyl-3-methyl, imidazolyl-5-methyl, 1-naphthylmethyl, 2-naphthylmethyl, 4-quinolinylmethyl, 8-quinolinylmethy, 1, 5-chloroquinolin-8-ylmethyl, 5-isoquinolynylmethyl, 8-isoquinolynylmethyl, 5-chloroisoquinolin-8-ylmethyl, indazolyl-7-ylmethyl, benzothiazol-4-ylmethyl, benzothiazol-7-ylmethyl
  • R 2 is —W 21 —W 22 —Rb—R 20 , wherein W 21 is —(CO)— or —(SO 2 )—; W 22 is bond, —O—, —NH— or optionally substituted lower alkylene; Rb is bond or optionally substituted alkylene; and R 20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl.
  • Examples of lower alkylene group for W 22 include methylene, ethylene, propylene, butylene and the like.
  • lower alkylene group for Rb examples include methylene, ethylene, methylmethylene, 1,2-propylene, 1,3-propylene, 1,2-butylene, 1,3-butylene, 1,4-butylene, 1,2,3-propanetriyl, 1,3,3-propanetriyl and the like.
  • optionally substituted alkyl group for R 20 examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carbamoylmethyl, carbamoylethyl, carbamoylpropyl, carbamoylbutyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methylthiomethyl, methylthioethyl, methylthiopropyl, methylthiobutyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, ethoxycarbonylmethyl, ethoxy
  • alkenyl group for R 20 examples include ethenyl, allyl, 1-propenyl, 2-methylallyl and the like.
  • alkynyl group for R 20 examples include ethynyl, 1-propynyl and the like.
  • aryl group and heteroaryl group for R 20 include biphenyl, phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolyl, thienyl, furanyl, thiazolyl, oxazolyl, imidazolyl, tetrahydronaphthyl, naphthyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, benzotriazinyl, indenyl, pyridopyrimidinyl, pyridopyrazinyl, pyridopyridazinyl, pyridotriazinyl, benzofuranyl, benzothienyl, indolyl, indazolyl, benzoxazolyl, benzimi
  • cycloalkyl group and heterocycloalkyl group include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl and the like.
  • R 2 is —W 21 —W 22 —Rb—R 20 , wherein W 21 is —(CO)— or —(SO 2 )—; W 22 is bond, —O—, —NH—, methylene, ethylene, propylene or butylene; Rb is bond, methylene, ethylene, methylmethylene, 1,2-propylene, 1,3-propylene, 1,2-butylene, 1,3-butylene, 1,4-butylene, 1,2,3-propanetriyl or 1,3,3-propanetriyl; and R 20 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, aminomethyl, aminoethyl, aminopropyl, aminobuty
  • R 2 is —W 21 —W 22 —Rb—R 20 , wherein W 21 is —(CO)—; W 22 is —NH—; Rb is bond, methylene or ethylene; and R 20 is optionally substituted biphenyl, optionally substituted phenyl, optionally substituted pyridyl, optionally substituted pyrimidyl, optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted thienyl, optionally substituted furanyl, optionally substituted thiazolyl, optionally substituted oxazolyl, optionally substituted imidazolyl, optionally substituted naphthyl or optionally substituted benzodioxolyl.
  • R 20 examples include, —R 9 , —OR 9 , —COR 9 , —COOR 9 , —OCOR 9 , —CONR 9 R 4 , —NR 9 R 4 , —NR 4 COR 9 , —NR 4 COOR 9 , —SR 9 , —SO 2 R 9 , SO 2 NR 9 R 4 , —SO 3 R 9 , —NHC(NHR 9 )NR 4 , —NHC(NH 2 )NH, —OPO(OH) 2 , —OPO(ONa) 2 , —CN, —NO 2 , halogen and methylenedioxy, wherein R 9 and R 4 are independently selected from hydrogen atom, optionally substituted, cyclic or noncyclic, alkyl, aryl, heteroaryl, arylalkyl and heteroaryl.
  • substituents include —R 9 , —NH 2 , —OH, —COOH, —COOR 9 , —CONH 2 , halogen and methylenedioxy.
  • R 3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or, optionally substituted alkynyl.
  • alkyl group examples include C 1-4 alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl and the like.
  • alkenyl group examples include ethenyl, allyl, 2-methylallyl and the like.
  • alkynyl group examples include 1-propynyl, ethynyl and the like.
  • R 3 is preferably hydrogen or C 1-4 alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, more preferably methyl or ethyl.
  • R 3 is hydrogen or methyl
  • R 7 is 4-hydroxy-benzyl; and R 2 represents —W 21 —W 22 —Rb—R 20 , wherein W 21 is —(CO)— or —(SO 2 )—; W 22 is bond, —O—, —NH— or optionally substituted lower alkylene; Rb is bond or optionally substituted alkylene; and R 20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl.
  • R 20 when D is void, E is bond, B is benzene, R 2 is —W 21 —W 22 —Rb—R 20 , wherein W 21 is —(CO)—, W 22 is —NH—, and Rb is bond, then R 20 should not be optionally substituted phenyl.
  • FIG. 1 and FIG. 2 The general syntheses of the compounds in this invention are illustrated in FIG. 1 and FIG. 2 , wherein Compound Ia′ indicates formulas (Ia) and (Id), Compound Ib′ indicates formulas (Ib) and (Ic).
  • R (including R 91 and R 92 in the formula (IIa′) and (IIb′)) illustrated in FIG. 1 and FIG. 2 is a protective group suitable for use in synthesis, where this protection group may be joined to a polymeric support to enable solid-phase synthesis.
  • Suitable R groups include alkyl groups and, in a preferred embodiment, R is a methyl or ethyl group.
  • LG illustrated in FIG. 1 is a leaving group, e.g., a halogen (Hal) group, methanesulfonyloxy, trifluoromethanesulfonyloxy, toluenesufonyloxy and the like.
  • a halogen (Hal) group methanesulfonyloxy, trifluoromethanesulfonyloxy, toluenesufonyloxy and the like.
  • P 1 and P 3 illustrated in FIG. 1 and FIG. 2 are a carboxylic acid protection group.
  • P 2 and P 5 illustrated in FIG. 1 are an amino protection group.
  • P 4 illustrated in FIG. 1 is a hydroxyl protection group.
  • Preferred protection groups include methyl, ethyl, benzyl, 9H-fluorenylmethyloxycarbonyl (FRoc), benzyloxycarbonyl (Cbz), t-butyl dimethylsilyl (TBDMS), t-butyloxycarbonyl (BOC), methyloxycarbonyl (MOC), and allyloxycarbonyl (Alloc).
  • FRoc benzyloxycarbonyl
  • TDMS t-butyl dimethylsilyl
  • BOC t-butyloxycarbonyl
  • MOC methyloxycarbonyl
  • Alloc allyloxycarbonyl
  • phthalimide formed together with an amino group to be protected.
  • Compound IV may be readily synthesized by reductive amination of H 2 N—R 1 with CH(OR) 2 —CR 3 O, by reductive amination of R 1′ —CHO (when R 1 ⁇ CH 2 R 1′ ) with CH(OR) 2 —CHR 3 NH 2 , by a displacement reaction between H 2 N—R 1 and CH(OR) 2 —CHR 3 -LG or by a displacement reaction between LG-R 1 and CH(OR) 2 —CHR 3 —NH 2 .
  • N-Protected amino acids are commercially available; for example, Fmoc amino acids are available from a variety of sources.
  • Fmoc amino acids are available from a variety of sources.
  • such compounds may be prepared from the corresponding amino acid by the reaction disclosed by Zaloom et al. (J. Org. Chem. 46:5173-76, 1981).
  • a Compound VI of this invention may have the indicated structure wherein G, E, B, and R 2 are as defined above.
  • Other suitable Compounds XI are commercially available from a variety of sources or can be prepared by methods well known in organic chemistry.
  • the alpha-helix mimetic compounds of formula (Ia′) may be synthesized by reacting a Compound IV with a Compound XXI to yield a combined Compound XV, followed by treating the combined Compound XV with piperidine to provide Compound VI, reacting the Compound VI with Compound V sequentially to provide a combined Compound IIa′, and then cyclizing this intermediate to yield an alpha-helix mimetic structure of formula (Ia′).
  • the alpha-helix mimetic compounds of formula (Ia′) may be synthesized by reacting a Compound V with a Compound XVIII to yield a combined Compound IX, followed by treating the Compound IX with lithium hydroxide, sodium hydroxide or potassium hydroxide to provide Compound III. As illustrated in FIG. 1 , the Compound III reacts with Compound IV sequentially to provide a combined Compound IIa′, followed by cyclizing this intermediate to yield an alpha-helix mimetic structure of formula (Ia′).
  • alpha-helix mimetic compounds of formula (Ib′) may be synthesized by the methods similar to those in FIG. 1 .
  • a compound having the following general formula (II) is a novel intermediate compound for preparing the compound of the formula (I).
  • optionally substituted alkyl for R 91 and R 92 include those as defined for R 7 and the like.
  • linker and solid support for R 91 and R 92 include those for preparing the libraries as explained below.
  • the order of addition of the reagents is not particularly limited, and, for example, an acid may be added to Compound II or vice versa.
  • the acid to be used in the cyclization reaction is not particularly limited, and examples thereof include inorganic acids such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid and the like; organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, methanesulfonic acid, p-toluenesulfonic acid, trifluoromethanesulfonic acid; hydrogen chloride solution; hydrogen bromide solution; hydrogen fluoride and the like
  • the amount of the acid to be used in the cyclization reaction is generally 0.001 mol to 1000 mol, preferably 1 mol to 100 mol, more preferably 5 mol to 50 mol, relative to 1 mol of Compound II.
  • the cyclization reaction may be performed with or without solvent.
  • the solvent to be used in the cyclization reaction may be any as long as it does not inhibit the reaction. Examples thereof include ethers such as tetrahydrofuran (THF), methyl tert-butyl ether, 1,4-dioxane, diethylene glycol dimethyl ether (diglyme), ethylene glycol dimethyl ether, 1,3-dioxolane, 2-methyltetrahydrofuran and the like; aprotic polar solvents such as N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAc), dimethyl sulfoxide (DMSO), sulfolane, N-methyl-2-pyrrolidinone (NMP), 1,3-dimethyl-2-imidazolidinone (DMI), hexamethyl phosphoramide (HMPA), acetonitrile, propionitrile and the like; halogenated solvents such as methylene chlor
  • reaction temperature in the cyclization reaction depends on the reagent to be used and the like, it is generally from ⁇ 40° C. to 120° C., preferably from ⁇ 20° C. to 60° C., more preferably from ⁇ 10° C. to 40° C.
  • the reaction time is generally 0.5 hr to 96 hr, preferably 1 hr to 48 hr.
  • the compound (I) to be obtained in the cyclization reaction can be isolated and purified by a conventional method such as extraction, water-washing, acid washing, alkali washing, crystallization, recrystallization, silica gel column chromatography.
  • the compounds of the present invention, salts thereof and derivatives thereof useful as prodrugs are excellent in pharmacological action selectivity, safety (various toxicities and safety pharmacology), pharmacokinetic performance, physicochemical property and the like, and therefore the usefulness as active ingredients of medicaments can be confirmed.
  • tests concerning safety include, but not be limited to, the following list including cytotoxic tests (e.g., tests using HL60 cells, hepatocytes, etc., and the like), genotoxicity tests (e.g., Ames test, mouse lymphoma TK test, chromosomal aberration test, micronucleus test and the like), skin sensitization tests (e.g., Buehler method, GPMT method, APT method, LLNA test and the like), skin photosensitization tests (e.g., Adjuvant and Strip method and the like), eye irritation tests (e.g., single instillation, short-term continuation instillation, repetitive instillation and the like), safety pharmacology tests for the cardiovascular system (e.g., telemetry method, APD method, hERG inhibition assay and the like), safety pharmacology tests for the central nervous system (e.g., FOB method, modified version of Irwin method and the like), safety pharmacology tests for the respiratory system
  • tests concerning pharmacokinetic performance include, but not be limited to, the following list including cytochrome P450 enzyme inhibition or induction tests, cell permeability tests (e.g., tests using CaCO-2 cells, MDCK cells etc., and the like), drug transporter ATPase assay, oral absorption tests, blood concentration transition measurement tests, metabolism tests (e.g., stability test, metabolite molecular species test, reactivity test and the like), solubility tests (e.g., solubility test based on turbidity method and the like), and the like.
  • cytochrome P450 enzyme inhibition or induction tests include cell permeability tests (e.g., tests using CaCO-2 cells, MDCK cells etc., and the like), drug transporter ATPase assay, oral absorption tests, blood concentration transition measurement tests, metabolism tests (e.g., stability test, metabolite molecular species test, reactivity test and the like), solubility tests (e.g., solubility test based on tur
  • tests concerning physicochemical property include, but not be limited to, the following list including chemical stability test (e.g., stability test using HPLC etc., and the like), partition coefficient (e.g., partition test using octanol phase/water phase and the like), ionization constant test, crystallization test, and the like.
  • chemical stability test e.g., stability test using HPLC etc., and the like
  • partition coefficient e.g., partition test using octanol phase/water phase and the like
  • ionization constant test e.g., crystallization test, crystallization test, and the like.
  • the compound of the present invention are useful as bioactive agents, such as diagnostic, prophylactic, and therapeutic agents.
  • the alpha-helix mimetic structures of the present invention may be used for modulating a cell signaling transcription factor related peptides in a warm-blooded animal, by a method comprising administering to the animal an effective amount of the compound of formula (I), (Ia), (Ib), (Ic) or (Id).
  • the compounds of the formula (I), (Ia), (Ib), (Ic) or (Id) can be used for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, such as colorectal cancer, and so forth.
  • a pharmaceutical composition comprises the compound of formula (I), (Ia), (Ib), (Ic) or (Id) or a pharmaceutically acceptable salt thereof, and, if desired or necessary, together with a pharmaceutical acceptable carrier.
  • a pharmaceutical composition comprising an effective amount of the compound having general formula (I), (Ia), (Ib), (Ic) or (Id) and pharmaceutically acceptable carrier, which can be used for treatment of disorders modulated by Wnt signaling pathway, especially by TCF4- ⁇ -catenin-CBP complex.
  • the present invention is to provide a method for inhibiting the growth of tumor cells by using the above-described composition of the present invention; a method for inducing apoptosis of tumor cells by using the above-described composition of the present invention; a method for treating a disorder modulated by TCF4- ⁇ -catenin-CBP complex by using the above-described composition of the present invention; and a method of treating cancer such as colorectal cancer by administering the composition of the present invention together with other anti-cancer agent such as 5-fluorouracil (5-FU), taxol, cisplatin, mitomycin C, tegafur, raltitrexed, capecitabine, and irinotecan, etc.
  • 5-fluorouracil 5-FU
  • libraries containing alpha-helix mimetic structures of the present invention are disclosed. Once assembled, the libraries of the present invention may be screened to identify individual members having bioactivity. Such screening of the libraries for bioactive members may involve; for example, evaluating the binding activity of the members of the library or evaluating the effect the library members have on a functional assay. Screening is normally accomplished by contacting the library members (or a subset of library members) with a target of interest, such as, for example, an antibody, enzyme, receptor or cell line. Library members which are capable of interacting with the target of interest, are referred to herein as “bioactive library members” or “bioactive mimetics”.
  • a bioactive mimetic may be a library member which is capable of binding to an antibody or receptor, or which is capable of inhibiting an enzyme, or which is capable of eliciting or antagonizing a functional response associated, for example, with a cell line.
  • the screening of the libraries of the present invention determines which library members are capable of interacting with one or more biological targets of interest.
  • the bioactive mimetic or mimetics may then be identified from the library members.
  • the identification of a single (or limited number) of bioactive mimetic(s) from the library yields alpha-helix mimetic structures which are themselves biologically active, and thus are useful as diagnostic, prophylactic or therapeutic agents, and may further be used to significantly advance identification of lead compounds in these fields.
  • Synthesis of the peptide mimetics of the library of the present invention may be accomplished using known peptide synthesis techniques, in combination with the first, second and third component pieces of this invention. More specifically, any amino acid sequence may be added to the N-terminal and/or C-terminal of the conformationally constrained alpha-helix mimetic.
  • the mimetics may be synthesized on a solid support (such as PAM resin) by known techniques (see, e.g., John M. Stewart and Janis D. Young, Solid Phase Peptide Synthesis, 1984, Pierce Chemical Comp., Rockford, Ill.) or on a silyl-linked resin by alcohol attachment (see Randolph et al., J. Am Chem. Soc. 117:5712-14, 1995).
  • a combination of both solution and solid phase synthesis techniques may be utilized to synthesize the peptide mimetics of this invention.
  • a solid support may be utilized to synthesize the linear peptide sequence up to the point that the conformationally constrained alpha-helix is added to the sequence.
  • a suitable conformationally constrained alpha-helix mimetic structure which has been previously synthesized by solution synthesis techniques may then be added as the next “amino acid” to the solid phase synthesis (i.e., the conformationally constrained alpha-helix mimetic, which has both an N-terminus and a C-terminus, may be utilized as the next amino acid to be added to the linear peptide).
  • the conformationally constrained alpha-helix mimetic structures Upon incorporation of the conformationally constrained alpha-helix mimetic structures into the sequence, additional amino acids may then be added to complete the peptide bound to the solid support.
  • the linear N-terminus and C-terminus protected peptide sequences may be synthesized on a solid support, removed from the support, and then coupled to the conformationally constrained alpha-helix mimetic structures in solution using known solution coupling techniques.
  • combinatorial chemistry techniques permit a vast number of compounds to be rapidly prepared by the sequential combination of reagents to a basic molecular scaffold.
  • Combinatorial techniques can be used to construct peptide libraries derived from the naturally occurring amino acids. For example, by taking 20 mixtures of 20 suitably protected and different amino acids and coupling each with one of the 20 amino acids, a library of 400 (i.e., 20 2 ) dipeptides is created. Repeating the procedure seven times results in the preparation of a peptide library comprised of about 26 billion (i.e., 20 8 ) octapeptides.
  • synthesis of the peptide mimetics of the library of the present invention may be accomplished using known peptide synthesis techniques, such as those disclosed, for example, in WO 2005/116032, which is incorporated herein by reference.
  • the present invention provides methods for screening the libraries for bioactivity and isolating bioactive library members.
  • data of biological activity is determined in the following manner.
  • Compounds are assayed by using a method of the following reporter gene assay.
  • Screening for inhibitory action of the Wnt signaling pathway can be carried out according to the following procedure using the stably transfected cell line Hek-293, STF1.1.
  • the libraries of the present invention also can be screened for bioactivity by other various techniques and methods.
  • the screening assay may be performed by (1) contacting the mimetics of a library with a biological target of interest, such as a receptor, to allow binding between the mimetics of the library and the target to occur, and (2) detecting the binding event by an appropriate assay, such as the calorimetric assay disclosed by Lam et al. (Nature 354:82-84, 1991) or Griminski et al. (Biotechnology 12:1008-1011, 1994) (both of which are incorporated herein by reference).
  • the library members are in solution and the target is immobilized on a solid phase.
  • the library may be immobilized on a solid phase and may be probed by contacting it with the target in solution.
  • a method for carrying out a binding assay also can be applied as follows.
  • the method can include providing a composition that includes a first co-activator, an interacting protein, and a test compound.
  • the amino acid structure of the first co-activator includes a binding motif of LXXLL, LXXLI or FxxFF wherein X is any amino acid.
  • the method further includes detecting an alteration in binding between the first co-activator and the interacting protein due to the presence of the compound, and then characterizing the test compound in terms of its effect on the binding.
  • the assay may be carried out by any means that can measure the effect of a test compound on the binding between two proteins.
  • Two-Hybrid and Split-Hybrid systems are known in the art and can be utilized in the method of the present invention, including the so-called Two-Hybrid and Split-Hybrid systems.
  • the Two-Hybrid system and various means to carry out an assay using this system, are described in, e.g., U.S. Pat. No. 6,410,245.
  • the Split-Hybrid system has been described by, e.g., Hsiu-Ming Shiu et al. Proc. Natl. Acad. Sci. USA, 93:13896-13901, November 1996; and John D. Crispino, et al. Molecular Cell, 3:1-20, February 1999.
  • a fusion protein is utilized where protein X is fused to the lexA DNA binding domains (pLexA) and protein Y is fused to the transcription activator VP16 (pSHM.1-LacZ).
  • pSHM.1-LacZ transcription activator VP16
  • Interaction between lexA-X and VP16-Y leads to the expression of the Tetracycline repressor protein (TetR).
  • TetR prevents transcription of the HIS3 reporter gene, making the cells unable to grow on media lacking histidine. Disruption of protein-protein interaction will restore the ability of the cells to grow on such media by shutting down expression of the tetracycline repressor.
  • compounds of the present invention may be added to the growing cells, and if the addition of the compound restores the ability of the cells to grow on the media, the compound may be seen as an effective disruptor of the protein-protein interaction.
  • the yeast strains required to make the Split-Hybrid system work can be employed with two hybrid LexA/VP16 constructs such as those described by Stanley M. Hollenberg, et al. Molecular and Cellular Biology 15(7):3813-3822, July 1995.
  • a useful modification of the Split-Hybrid system was utilized by Takemaru, K. I. and Moon, R. T. J. of Cell Biol. 149:249-254, 2000.
  • reporter gene assays for AP-1, ELISA for example, blocking the production of IL-2 by a T-cell line after stimulation with CD3 and CD28 to look for inhibitors of IL-2 transcription.
  • Direct binding assays can be performed by surface plasmon resonance spectroscopy (Biacore, Sweden, manufactures suitable instruments) or ELISA.
  • Exemplary transcriptional regulators include, without limitation, VP16, VP64, p300, CBP, PCAF.SRC1 PvALF, AtHD2A and ERF-2. See, for example, Robyr et al. (2000) Mol. Endocrinol. 14:329-347; Collingwood et al. (1999) J. Mol. Endocrinol. 23:255-275; Leo et al. (2000) Gene 245:1-11; Manteuffel-Cymborowska (1999) Acta Biochim. Pol. 46:77-89; McKenna et al. (1999) J. Steroid Biochem. Mol. Biol. 69:3-12; Malik et al. (2000) Trends Biochem.
  • exemplary transcription factors include, without limitation, OsGAI, HALF-1, C1, AP1, ARF-5, -6, -7, and -8, CPRF1, CPRF4, MYC-RP/GP, and TRAB1. See, for example, Ogawa et al. (2000) Gene 245:21-29; 5 Okanami et al. (1996) Genes Cells 1:87-99; Goff et al. (1991) Genes Dev. 5:298-309; Cho et al. (1999) Plant Mol. Biol.
  • the transcriptional coactivator can be a human transcriptional coactivator.
  • the transcriptional coactivator is a member of the p300/CBP family of co-activators which have histone acetyltransferase activity.
  • p300 is described for example by Eckner et al., 1994 and CBP by Bannister and Kouzarides, 1996.
  • reference to p300/CBP refers to human allelic and synthetic variants of p300, and to other mammalian variants and allelic and synthetic variants thereof, as well as fragments of said human and mammalian forms of p300.
  • the interacting protein is a transcription factor or a second co-activator.
  • the interacting protein is any one of RIP140; SRC-1 (NCoA-1); TIF2 (GRIP-1; SRC-2); p (CIP; RAC3; ACTR; AIB-1; TRAM-1; SRC-3); CBP (p300); TRAPs (DRIPs); PGC-1; CARM-1; PRIP (ASC-2; AIB3; RAP250; NRC); GT-198; and SHARP (CoAA; p68; p72).
  • the interacting protein is any one of TAL 1; p73; MDm2; TBP; HIF-1; Ets-1; RXR; p65; AP-1; Pit-1; HNF-4; Stat2; HPV E2; BRCA1; p45 (NF-E2); c-Jun; c-myb; Tax; Sap 1; YY1; SREBP; ATF-1; ATF-4; Cubitus; Interruptus ; Gli3; MRF; AFT-2; JMY; dMad; PyLT: HPV E6; CITTA; Tat; SF-1; E2F; junB; RNA helicase A; C/EBP R; GATA-1; Neuro D; Microphthalimia; E1A; TFIIB; p53; P/CAF; Twist; Myo D; pp90 RSK; c-Fos; and SV40 Large T.
  • the interacting protein is any one of ERAP140; RIP140; RIP160; Trip1; SWI1 (SNF); ARA70; RAP46; TIF1; TIF2; GRIP1; and TRAP.
  • the interacting protein is any one of VP16; VP64; p300; CBP; PCAF; SRC1 PvALF; AtHD2A; ERF-2; OsGAI; HALF-1; C1; AP-1; ARF-5; ARF-6; ARF-7; ARF-8; CPRF1; CPRF4; MYC-RP/GP; and TRAB1.
  • the first co-activator is CBP or p300.
  • the test compound is selected from compounds as described herein. For example, compounds having the formula (I), (Ia), (Ib), (Ic) or (Id).
  • a test compound can be evaluated at several different concentrations, where these concentrations will be selected, in part, based on the conditions of the assay, e.g., the concentrations of the first co-activator and the interacting protein. Concentrations in the range of about 0.1 to 10 ⁇ M may be used.
  • the assay evaluates the relative efficacy of two compounds to affect the binding interaction between two proteins, where at least one of those two compounds is a compound of the present invention. The more effective compound can than serve as a reference compound in a study of the relationship between compound structure and compound activity.
  • Compounds of general formula (I), (Ia), (Ib), (Ic) or (Id) may inhibit CBP-mediated transcriptional activation in cancer cells due to their specific binding to CBP.
  • the compounds of the present invention may also inhibit the survivin expression in SW480 cells, and therefore, inhibit the oncogenic activity in cancer cells.
  • the compounds of the present invention can be used for inhibiting cancer cells, and thus, would be useful for the regulation of cell growth.
  • the compounds of the present invention can be also advantageously used for inducing apoptosis in cells.
  • the present invention is also related to prodrugs using the libraries containing one or more compounds of formula (I), (Ia), (Ib), (Ic) or (Id).
  • a prodrug is typically designed to release the active drug in the body during or after absorption by enzymatic and/or chemical hydrolysis.
  • the prodrug approach is an effective means of improving the oral bioavailability or i.v. administration of poorly water-soluble drugs by chemical derivatization to more water-soluble compounds.
  • esters containing an ionizable group e.g., phosphate group, carboxylate group, alkylamino group
  • the present invention provides pharmaceutical compositions containing a compound having the general formula (I), (Ia), (Ib), (Ic) or (Id). These compositions may be used in various methods (e.g., treating cancer, fibrosis or Alzheimer's disease) of the present invention as described in detail below.
  • the pharmaceutical composition of the present invention is formulated to be compatible with its intended route of administration.
  • routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration.
  • Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. In addition, pH may be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
  • the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
  • the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the active compound, e.g., a compound having general formula (I), (Ia), (Ib), (Ic) or (Id) in the required amount, in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules.
  • Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed.
  • Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
  • the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
  • a lubricant such as magnesium stearate or Sterotes
  • a glidant such as colloidal silicon dioxide
  • the compounds are delivered in the form of an aerosol spray from pressured container or dispenser that contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
  • a suitable propellant e.g., a gas such as carbon dioxide, or a nebulizer.
  • Systemic administration can also be by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
  • Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
  • the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
  • the compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
  • suppositories e.g., with conventional suppository bases such as cocoa butter and other glycerides
  • retention enemas for rectal delivery.
  • the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
  • the materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc.
  • Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a 5 predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
  • a pharmaceutical composition of the present invention is one suitable for oral administration in unit dosage form such as a tablet or capsule that contains from about 1 mg to about 1 g of the compound of this invention.
  • a pharmaceutical composition of the present invention is one suitable for intravenous, subcutaneous or intramuscular injection.
  • a patient may receive, for example, an intravenous, subcutaneous or intramuscular dose of about 1 ⁇ g/kg to about 1 g/kg of the compound of the present invention.
  • the intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection or by continuous infusion over a period of time.
  • a patient will receive a daily oral dose approximately equivalent to the daily parenteral dose, the composition being administered 1 to 4 times per day.
  • the compound of the formula (I), (Ia), (Ib), (Ic) or (Id) of the present invention can be administered intravenously (particularly preferably, by continuous drip infusion or rapid intravenous administration) to mammals inclusive of human.
  • the dose is selected appropriately depending on various factors such as the body weight and/or age of patients, and/or the degree of the symptom and an administration route.
  • the dose of the compound of the formula (I), (Ia), (Ib), (Ic) or (Id) for intravenous administration is generally in the range of 1 to 10000 mg/day/m 2 human body surface area, preferably in the range of 1 to 5000 mg/day/m 2 human body surface area, and more preferably 10 to 5000 mg/day/m 2 human body surface area by continuous drip infusion administration.
  • composition containing the compound of general formula (I), (Ia), (Ib), (Ic) or (Id) can be used for treatment of disorders modulated by Wnt signaling pathway, especially cancer, more especially colorectal cancer.
  • the present invention provides methods for inhibiting tumor growth.
  • Such methods comprise the step of administering to a subject (e.g., a mammalian subject) having a tumor a compound with general formula (I), (Ia), (Ib), (Ic) or (Id) in an amount effective to inhibit tumor growth.
  • a subject e.g., a mammalian subject
  • a compound or composition inhibits tumor growth if the tumor sizes are statistically significantly smaller in subjects with the treatment of the compound or composition than those without the treatment.
  • the inhibitory effect of a particular compound or composition of the present invention on tumor growth may be characterized by any appropriate methods known in the art. For instance, the effect of the compound or composition on survivin expression may be measured. Compounds or compositions down-regulate survivin expression are likely to have inhibitory effects on tumor growth.
  • assays using tumor cell lines e.g., soft agar assays using SW480 cells
  • animal models for tumor growth e.g., nude mice grafted with tumor cells and Min mouse model
  • Other exemplary animal models or xenografts for tumor growth include those for breast cancer (Guo et al., Cancer Res.
  • the compound or composition that inhibits tumor growth may be administrated into a subject with a tumor via an appropriate route depending on, for example, the tissue in which the tumor resides.
  • the appropriate dosage may be determined using knowledge and techniques known in the art as described above.
  • the effect of the treatment of the compound or composition on tumor growth may also be monitored using methods known in the art. For instance, various methods may be used for monitoring the progression and/or growth of colorectal cancer, including colonoscopy, sigmoidoscopy, biopsy, computed tomograph, ultrasound, magnetic resonance imaging, and positron emission tomography. Methods for monitoring the progression and/or growth of ovarian cancer include, for example, ultrasound, computed tomography, magnetic resonance imaging, chest X-ray, laparoscopy, and tissue sampling.
  • the present invention provides a method for treating or preventing cancer or fibrosis.
  • Such methods comprise the step of administering to a subject in need thereof a compound or composition having general formula (I), (Ia), (Ib), (Ic) or (Id) in an amount effective to treat or prevent cancer or fibrosis in the subject.
  • Treating cancer (or fibrosis) is understood to encompass reducing or eliminating cancer progression, e.g., cancer growth and metastasis (or fibrosis, as applicable).
  • Preventing cancer (or fibrosis) is understood to encompass preventing or delaying the onset of cancer (or fibrosis, as applicable).
  • Various types of cancer may be treated or prevented by the present invention.
  • a subject in need of treatment may be a human or non-human primate or other animal with various types of cancer.
  • a subject in need of prevention may be a human or non-human primate or other animal that is at risk for developing cancer or fibrosis.
  • Methods for diagnosing cancer (or fibrosis) and screening for individuals with high risk of cancer (or fibrosis) are known in the art and may be used in the present invention.
  • colorectal cancer may be diagnosized by fecal occult blood test, sigmoidoscopy, colonoscopy, barium enema with air contrast, and virtual colonoscopy.
  • An individal with high risk of colorectal cancer may have one or more colorectal cancer risk factors such as a strong family history of colorectal cancer or polyps, a known family history of hereditary colorectal cancer syndromes, a personal history of adenomatous polyps, and a personal history of chronic inflammatory bowel disease.
  • colorectal cancer risk factors such as a strong family history of colorectal cancer or polyps, a known family history of hereditary colorectal cancer syndromes, a personal history of adenomatous polyps, and a personal history of chronic inflammatory bowel disease.
  • a compound with general formula (I), (Ia), (Ib), (Ic) or (Id) useful in cancer (or fibrosis) treatment or prevention may be identified by appropriate methods known in the art. Methods that may be used to select compounds for inhibitory effect on tumor growth as described above may also be used. The route of administration, the dosage of a given compound, the effectiveness of the treatment may be determined using knowledge and techniques known in the art. Factors that may be considered in making such a determination include, for example, type and stage of the cancer (or fibrosis) to be treated.
  • the compound with general formula (I), (Ia), (Ib), (Ic) or (Id) useful in cancer treatment and prevention may be administered in combination with an other anti-neoplastic agent.
  • the anti-neoplastic agent refers to a compound that inhibits tumor growth.
  • the other anti-neoplastic agent include alkylating agents such as thiotepa and CYTOXAN® cyclophosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethiylenethiophosphoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolast
  • dynemicin including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chromophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, ADRLAMYCIN® doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, e
  • examples of the other anti-neoplastic agent also include anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including NOLVADEX® tamoxifen), raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and FARESTON toremifene; aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazoles, aminoglutethimide, MEGASE® megestrol acetate, AROMASIN® exemestane, formestane, fadrozole, RIVISOR® vorozole, FEMARA® letrozole, and ARIMIDEX®.
  • SERMs selective estrogen receptor modulators
  • anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; as well as troxacitabine (a 1,3-dioxolane nucleoside cytosine analog); antisense oligonucleotides, particularly those which inhibit expression of genes in signaling pathways implicated in abherant cell proliferation, such as, for example, PKC-alpha, Ralf and H-Ras; ribozymes such as a VEGF expression inhibitor (e.g., ANGIOZYME® ribozyme) and a HER2 expression inhibitor; vaccines such as gene therapy vaccines, for example, ALLOVECTIN® vaccine, LEUVECTIN® vaccine, and VAXID® vaccine; PROLEUKIN® rIL-2; LURTOTECAN® topoisomerase 1 inhibitor; ABARELIX® rmRH; and pharmaceutically acceptable salts, acids or derivatives of any of the above
  • examples of the other anti-neoplastic agent also include a “growth inhibitory agent” referring to a compound or composition which inhibits growth of a cell in vitro and/or in vivo.
  • the growth inhibitory agent may be one which significantly reduces the percentage of cells in S phase.
  • growth inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce G1 arrest and M-phase arrest.
  • Classical M-phase blockers include the vincas (vincristine and vinblastine), TAXOL®, and topo II inhibitors such as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin.
  • DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C.
  • examples of the other anti-neoplastic agent also include a “molecular target drug” that blocks the proliferation and metastasis of cancer by interfering with specific molecules involved in carcinogenesis (the process by which normal cells become cancer cells), tumor growth, or tumor spread.
  • kinase inhibitors that inhibit kinase activity on tumors, including, for example, imatinib, erlotinib, gefitinib, sunitinib, sorafenib, dasatinib, nilotinib; antibodies that bind to the cell surface molecule on tumor cells or to the growth factor and the like such as, for example, ibritumomab, cetuximab, trastuzumab, panitumumab, bevacizumab, rituximab; and proteasome inhibitors that inhibit the proteasome which regulates protein expression and function by degradation of ubiquitinylated proteins, such as bortezomib; and pharmaceutically acceptable salts, acids or derivatives of any of above.
  • a compound with general formula (I), (Ia), (Ib), (Ic) or (Id) administered in combination with an anti-neoplastic agent does not necessarily require that the compound and the anti-neoplastic agent be administered concurrently.
  • the compound and the agent may be administered separately as long as at a time point, they both have effects on same cancer cells.
  • the administration mode may be exemplified by (1) administration of a single preparation obtained by simultaneously formulating the compound of formula (I), (Ia), (Ib), (Ic) or (Id) and the other anti-neoplastic agent, (2) simultaneous administration through the same administration route of two preparations obtained by separately formulating the compound of formula (I), (Ia), (Ib), (Ic) or (Id) and the other anti-neoplastic agent, (3) administration with a time interval through the same administration route of two preparations obtained by separately formulating the compound of formula (I), (Ia), (Ib), (Ic) or (Id) and the other anti-neoplastic agent, (4) simultaneous administration through different administration routes of two preparations obtained by separately formulating the compound of formula (I) and the other anti-neoplastic agent, (5) administration with a time interval through different administration routes of two preparations obtained by separately formulating the compound of formula (I), (Ia), (Ib), (Ic) or (Id) and the other anti-neo
  • the amount of the other anti-neoplastic agent to be administered can be appropriately selected with reference to the clinically used dosage.
  • the mixing ratio of the compound of formula (I), (Ia), (Ib), (Ic) or (Id) and the other anti-neoplastic agent can be appropriately selected in accordance with the subject of administration, administration route, disease to be treated, symptoms, combination, and the like.
  • the compound of the present invention can be also used in combination with, for example, gene therapy involving VEGF, TNFa or the like, or therapeutic methods involving various antibody medicines or the like.
  • the present invention provides methods for promoting apoptosis in cancer cells.
  • Such methods comprise the step of contacting cancer cells with a compound having general formula (I), (Ia), (Ib), (Ic) or (Id) in an amount effective to promote apoptosis in these cells.
  • a compound promotes apoptosis if the number of cancer cells undergoing apoptosis is statistically significantly larger in the presence of the compound than that in the absence of the compound.
  • Such compounds may be identified by methods known in the art (e.g., measuring caspase activities and/or cell death) using cultured cancer cell lines, xenografts, or animal cancer models.
  • the compound is more active in promoting apoptosis in cancer cells than in normal cells.
  • Cancer cells treatable by the present method may be from various tissue origins.
  • a method for treating a disorder modulated by Wnt signaling pathway in which the method comprises administering to a patient a safe and effective amount of the compounds having general formula (I), (Ia), (Ib), (Ic) or (Id) is disclosed.
  • Pharmaceutical composition containing the compound of the present invention can be also used for this purpose.
  • the compounds having general formula (I), (Ia), (Ib), (Ic) or (Id) or the pharmaceutical composition containing thereof can be useful for the treatment of disorder modulated by TCF4/ ⁇ -catenin/CBP complex, which is believed to be responsible for initiating the overexpression of cancer cells related to Wnt signaling pathway.
  • the present invention also provides compounds and methods for inhibiting survivin expression.
  • Survivin is a target gene of the TCF/ ⁇ -catenin pathway, and more specifically is a target gene of the TCF/ ⁇ -catenin/CBP pathway. It is a member of the IAP (Inhibitor of Apoptosis Protein) family of proteins.
  • Biological activity associated with survivin includes: highly expressed at G2/M, regulating cell cycle entry and exit; associated with microtubule, centrosomes, centromeres and midbody depending upon the phases of the cell cycle; and anti-apoptosis via interacting directly or indirectly with caspases (e.g., caspase 3, 7 and 9).
  • survivin In connection with cancer, survivin is widely and highly expressed in tumor cells, but expressed to little or no extent in normal tissue cells. Also, it has been observed that cancer patients whose tumors expressed survivin had a decreased overall survival. Furthermore, the degree of survivin expression has been correlated with other cancer markers, e.g., Ki67, PNCA, p53, APC, etc.
  • the effect of a particular compound of the present invention on survivin expression may be characterized by methods known in the art. Such methods include methods for characterizing survivin expression at the transcriptional or translational level. Exemplary methods for characterizing survivin expression at the transcriptional level are: cDNA microarray, reverse transcription-polymerase chain reaction (RT-PCR), chromatin immunoprecipitation (ChIP), and assays for reporter activities driven by survivin promoter. Exemplary methods for characterizing survivin expression at the translational level are: Western blot analysis, immunochemistry and caspase activities. Detailed descriptions of the above exemplary methods may be found in the examples below.
  • the present invention provides methods for inhibiting survivin expression. Such methods comprise the step of contacting a survivin-expressing cell with a compound of the present invention in an amount effective to inhibit survivin expression.
  • a compound inhibits survivin expression if survivin expression in a cell is decreased in the presence of the compound compared to survivin expression in the absence of the compound.
  • Survivin-expressing cells include tumor cells that express, such as cells in or from lung cancer, breast cancer, stomach cancer, pancreatic cancer, liver cancer, uterus cancer, ovarian cancer, gliomas, melanoma, colorectal cancer, lymphoma and leukemia.
  • the step of contacting the survivin-expressing cells with the compound may be performed in vitro, ex vivo, or in vivo.
  • a compound useful in inhibiting survivin expression may be identified, and the effects of a particular compound of the present invention may be characterized, by appropriate methods known in the art, as described in detail above.
  • compositions of the present invention also may inhibit the expression of survivin. Blanc-Brude et al., Nat. Medicine 8:987 (2002), have shown that survivin is a critical regulator of smooth muscle cell apoptosis which is important in pathological vessel-wall remodeling. Accordingly, another aspect of the present invention provides a method of treating or preventing restenosis associated with angioplasty comprising administering to a subject in need thereof a safe and effective amount of an alpha-helix mimetic of the present invention. In one embodiment the invention treats the restenosis, i.e., administration of an alpha-helix mimetic of the present invention to a subject having restenosis achieves a reduction in the severity, extent, or degree, etc. of the restenosis.
  • the invention prevents the restenosis, i.e., administration of an alpha-helix mimetic of the present invention to a subject that is anticipated to develop new or additional restenosis achieves a reduction in the anticipated severity, extent, or degree, etc. of the restenosis.
  • the subject is a mammalian subject.
  • Compounds of the present invention also may inhibit TCF/ ⁇ -catenin transcription.
  • another aspect of the present invention provides a method of treating or preventing polycystic kidney disease comprising administering to a subject in need thereof a safe and effective amount of an alpha-helix mimetic of the present invention.
  • the invention treats the polycystic kidney disease, i.e., administration of an alpha-helix mimetic of the present invention to a subject having polycystic kidney disease achieves a reduction in the severity, extent, or degree, etc.
  • the invention prevents polycystic kidney disease, i.e., administration of an alpha-helix mimetic of the present invention to a subject that is anticipated to develop new or additional polycystic kidney disease achieves a reduction in the anticipated severity, extent, or degree, etc. of the polycystic kidney disease.
  • the subject is a mammalian subject.
  • Compounds of the present invention also may inhibit the expression of Wnt signaling.
  • another aspect of the present invention provides a method of treating or preventing aberrant angiogenesis disease comprising administering to a subject in need thereof a safe and effective amount of an alpha-helix mimetic of the present invention.
  • the invention treats the aberrant angiogenesis disease, i.e., administration of an alpha-helix mimetic of the present invention to a subject having aberrant angiogenesis disease achieves a reduction in the severity, extent, or degree, etc.
  • the invention prevents aberrant angiogenesis disease, i.e., administration of an alpha-helix mimetic of the present invention to a subject that is anticipated to develop new or additional aberrant angiogenesis disease achieves a reduction in the anticipated severity, extent, or degree, etc. of the aberrant angiogenesis disease.
  • the subject is a mammalian subject.
  • Compounds of the present invention also may inhibit Wnt TCF/ ⁇ -catenin signalling. Accordingly, another aspect of the invention provides a method of treating or preventing tuberous sclerosis complex (TSC) comprising administering to a subject in need thereof a safe and effective amount of an alpha-helix mimetic the present invention.
  • TSC tuberous sclerosis complex
  • Subjects having TSC typically develop multiple focal lesions in the brain, heart, kidney and other tissues (see, e.g., Gomez, M. R. Brain Dev. 17(suppl): 55-57 (1995)).
  • TSC1 which expresses hamartin
  • TSC2 which expresses tuberin
  • G1/S arrest see, e.g., Miloloza, A. et al., Hum. Mol. Genet. 9: 1721-1727 (2000).
  • Other studies have shown that hamartin and tuberin function at the level of the ⁇ -catenin degradation complex, and more specifically that these proteins negatively regulate ⁇ -catenin stability and activity by participating in the ⁇ -catenin degradation complex (see, e.g., Mak, B. C., et al. J. Biol. Chem. 278(8): 5947-5951, (2003)).
  • ⁇ -catenin is a 95-kDa protein that participates in cell adhesion through its association with members of the membrane-bound cadherin family, and in cell proliferation and differentiation as a key component of the Wnt/Wingless pathway (see, e.g., Daniels, D. L., et al., Trends Biochem. Sci 26: 672-678 (2001)). Misregulation of this pathway has been shown to be oncogenic in humans and rodents.
  • the present invention provides compounds that modulate ⁇ -catenin activity, and particularly its interactions with other proteins, and accordingly may be used in the treatment of TSC.
  • the invention treats TSC, i.e., administration of an alpha-helix mimetic of the present invention to a subject having TSC achieves a reduction in the severity, extent, or degree, etc. of the TSC.
  • the invention prevents TSC, i.e., administration of an alpha-helix mimetic of the present invention to a subject that is anticipated to develop new or additional TSC achieves a reduction in the anticipated severity, extent, or degree, etc. of the TSC.
  • the subject is a mammalian subject.
  • KSHV Kaposi's sarcoma-associated herpesvirus
  • LANA latency-associated nuclear antigen
  • the present invention provides compounds and methods for inhibiting ⁇ -catenin protein interactions, e.g., ⁇ -catenin/TCF complex formation.
  • the compounds of the present invention thwart the LANA-induced accumulation of R-catenin/TCF complex and, at least in part, the consequences of KSHV infection.
  • another aspect of the present invention provides a method of treating or preventing conditions due to infection by Karposi's sarcoma-associated herpesvirus (KSHV).
  • KSHV Karposi's sarcoma-associated herpesvirus
  • Such conditions include KSHV-associated tumors, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).
  • the method comprises administering to a subject in need thereof a safe and effective amount of an alpha-helix mimetic the present invention.
  • the invention treats the KSHV-associated tumor, i.e., administration of an alpha-helix mimetic of the present invention to a subject having a KSHV-associated tumor achieves a reduction in the severity, extent, or degree, etc. of the tumor.
  • the invention prevents a KSHV-associated tumor, i.e., administration of an alpha-helix mimetic of the present invention to a subject that is anticipated to develop new or additional KSHV-associated tumors achieves a reduction in the anticipated severity, extent, or degree, etc. of the tumor.
  • the subject is a mammalian subject.
  • LEF/TCF DNA-binding proteins act in concert with activated ⁇ -catenin (the product of Wnt signaling) to transactivate downstream target genes.
  • DasGupta, R. and Fuchs, E. Development 126(20):4557-68 (1999) demonstrated the importance of activated LEF/TCF complexes at distinct times in hair development and cycling when changes in cell fate and differentiation commitments take place.
  • ⁇ -catenin has been shown to be essential for hair follicle formation, its overexpression causing the “furry” phenotype in mice (Gat, U., et al. Cell 95:605-614 (1998) and Fuchs, E. Harvey Lect. 94:47-48 (1999).
  • the present invention provides a method for modulating hair growth comprising administering to a subject in need thereof a safe and effective amount of an alpha-helix mimetic the present invention, where the amount is effective to modulate hair growth in the subject.
  • the subject is a mammalian subject.
  • the present invention also provides compounds that may be useful in treating or preventing Alzheimer's disease.
  • Alzheimer's disease is a neurodegenerative disease with progressive dementia. This disease is accompanied by three main structural changes in the brain, namely, i) intracellular protein deposits (also known as neurofibrillary tangles, or NET), ii) extracellular protein deposits termed amyloid plaques that are surrounded by dystrophic neuritis, and iii) diffuse loss of neurons.
  • intracellular protein deposits also known as neurofibrillary tangles, or NET
  • amyloid plaques that are surrounded by dystrophic neuritis
  • diffuse loss of neurons iibrillary tangles
  • the compounds or compositions of the present invention may rescue defects in neuronal differentiation caused by a presenilin-1 mutation and may decrease the number, or rate at which neuronal precursor populations differentiate to neurons in Alzheimer's brains.
  • Presenilins are transmembrane proteins whose functions are related to trafficking, turnover and cleavage of Notch and Amyloid Precursor Protein. Missense mutations in presenilin-1 (PS-1) are associated with early-onset familial Alzheimer's disease (Fraser et al., Biochem. Soc. Symp. 67, 89 (2001)).
  • PS-1 presenilin-1
  • the compounds of the present invention may be applicable not only to individuals with PS-1 familial Alzheimer's mutations, but also to general Alzheimer's patients.
  • the present invention can provide a method for treating or preventing Alzheimer's disease comprising administering to a subject in need thereof a safe and effective amount of an alpha-helix mimetic of the present invention, where the amount is effective to treat or prevent Alzheimer's disease in the subject.
  • Treating Alzheimer's disease is understood to encompass reducing or eliminating the manifestation of symptoms characteristic of Alzheimer's disease, or delaying the progression of this disease.
  • Preventing Alzheimer's disease is understood to encompass preventing or delaying the onset of this disease.
  • a subject in need of treatment may be a human or non-human primate or other animal that is at various stages of Alzheimer's disease.
  • Methods for diagnosing Alzheimer's disease are known in the art (see, e.g., Dinsmore, J. Am. Osteopath. Assoc. 99.9, Suppl. p: S1-6, 1999; Kurz et al., J. Neural Transm. Suppl. 62: 127-33, 2002; Storey et al., Front Viosci. 7: e155-84, 2002; Marin et al., Geriatrics 57: 36-40, 2002; Kril and Halliday, Int. Rev. Neurobiol.
  • a subject in need of prevention may be a human or non-human primate or other animal that is at risk for developing Alzheimer's disease, such as an individual having a mutation of certain genes responsible for this disease (e.g., genes encoding amyloid precursor protein, presenilin-1, and presenilin-2), and/or a gene involved in the pathogenesis of this disease (e.g., apolipoprotein E gene) (Rocchi et al., Brain Res. Bull. 61: 1-24, 2003).
  • genes responsible for this disease e.g., genes encoding amyloid precursor protein, presenilin-1, and presenilin-2
  • a gene involved in the pathogenesis of this disease e.g., apolipoprotein E gene
  • Compounds with structures as set forth in formula (I), (Ia), (Ib), (Ic) or (Id) may be screened for their activities in treating or preventing Alzheimer's disease by any appropriate methods known in the art. Such screening may be initially performed using in vitro cultured cells (e.g, PC-12 cells). Compounds capable of rescuing defects in neuronal differentiation caused by a presenilin-1 mutation may be further screened using various animal models for Alzheimer's disease. Alternatively, compounds with structures as set forth in formula (I), (Ia), (Ib), (Ic) or (Id) may be directedly tested in animal models for Alzheimer's disease.
  • Alzheimer's disease may be characterized or monitored by methods known in the art for evaluating the progress of Alzheimer's disease, including those described above for diagnosing this disease.
  • the present invention also provides methods for promoting neurite outgrowth.
  • Such methods comprise the step of contacting a neuron with a compound according to formula (I), (Ia), (Ib), (Ic) or (Id) in an amount effective to promote neurite outgrowth.
  • neurodegenerative diseases e.g., glaucoma, macular degeneration, Parkinson's Disease, and Alzheimer's disease
  • a compound promotes neurite outgrowth if the neurite lengths of neurons are statistically significantly longer in the presence of the compound than those in the absence of the compound.
  • Such a compound may be identified using in vitro cultured cells (e.g, PC-12 cells, neuroblastoma B104 cell) (Bitar et al., Cell Tissue Res.
  • the resulting treated neuron if generated in vitro, may be transplanted into a tissue in need thereof (Lacza et al., Brain Res. Protoc. 11: 145-54, 2003; Chu et al., Neurosci. Lett 343: 129-33, 2003; Fukunaga et al., Cell Transplant 8: 435-41, 1999).
  • the present invention also provides methods for promoting differentiation of a neural stem cell comprising contacting a neural stem cell with a compound according to formula (I), (Ia), (Ib), (Ic) or (Id) in an amount effective to promote differentiation of a neural stem cell.
  • Such methods are also useful in treating neurodegenerative diseases (e.g., glaucoma, macular degeneration, Parkinson's Disease, and Alzheimer's disease) and injuries to nervous system.
  • Neurodegenerative diseases e.g., glaucoma, macular degeneration, Parkinson's Disease, and Alzheimer's disease
  • Neurodegenerative diseases e.g., glaucoma, macular degeneration, Parkinson's Disease, and Alzheimer's disease
  • Neurodegenerative diseases e.g., glaucoma, macular degeneration, Parkinson's Disease, and Alzheimer's disease
  • Neurodegenerative diseases e.g., glaucoma, macular degeneration, Parkinson's Disease, and Alzheimer's disease
  • Neurodegenerative diseases e.
  • a compound promotes differentiation of neural stem cells if neural stem cells exhibit a statistically significantly higher degree of differentiation in the presence of the compound than in the absence of the compound.
  • Such a compound may be identified using assays involving in vitro cultured stem cells or animal models (Albranches et al., Biotechnol. Lett. 25: 725-30, 2003; Deng et al., Exp. Neurol. 182: 373-82, 2003; Munoz-Elias et al., Stem Cells 21: 437-48, 2003; Kudo et al., Biochem. Pharmacol. 66: 289-95, 2003; Wan et al., Chin. Med. J.
  • the neural stem cell may be a cultured stem cell, a stem cell freshly isolated from its source tissue, or a stem cell within its source organism.
  • contacting the neural stem cell with a compound according to the present invention may be carried out either in vitro (for a cultured or freshly isolated stem cell) or in vivo (for a stem cell within its source organism).
  • the resulting differentiated neural cell if generated in vitro, may be transplanted into a tissue in need thereof (Lacza et al., supra; Chu et al., supra; Fukunaga et al., supra).
  • a tissue includes a brain tissue or other nervous tissue that suffers from a trauma or a neurodegenerative disease.
  • the compound(s) of the present invention or pharmaceutical formulations containing one or more compounds of the present invention are useful in the treatment and/or prevention of fibrosis in general.
  • fibrosis in general.
  • TGF- ⁇ Transforming growth factor ⁇
  • ECM extracellular matrix
  • Fibroproliferative diseases are generally caused by the activation of resident stellate cells which are found in most organs. This activation of stellate cells leads to their conversion to myofibroblasts which display characteristics of muscle and non-muscle cells. Activated stellate cells initiate inflammatory signals, principally mediated through TGF- ⁇ . Inflammatory cytokines and mediators in addition to TGF- ⁇ , lead to proliferation of myofibroblasts. Stellate-derived myofibroblasts proliferate and replace healthy, functional organ cells with extra-cellular matrix that exhibit muscle and connective tissue traits. Ultimately, organ failure results when the nonfunctional fibrotic honeycomb matrix replaces a critical number of healthy cells.
  • fibrosis The initial cause of fibrosis is believed to be the result of injury or insult to organ tissues. This cellular injury to organ tissues can often be traced to toxic or infectious agents. Pulmonary fibrosis, or interstitial lung disease, is often the result of smoking, chronic asthma, chronic obstructive pulmonary disease (COPD) or pneumonia. Fibrosis affects nearly all tissues and organ systems. Non-limiting examples of disorders in which fibrosis is a major cause of morbidity and mortality are listed below.
  • Interstitial lung disease includes a wide range of distinct disorders in which pulmonary inflammation and fibrosis are the final common pathway of pathology. There are more than 150 causes of ILD, including sarcoidosis, silicosis, adverse drug reactions, infections and collagen vascular diseases and systemic sclerosis (scleroderma).
  • Idiopathic pulmonary fibrosis is the most common type of ILD. Liver cirrhosis has similar causes to ILD, with viral hepatitis, schistosomiasis and chronic alcoholism being the major causes worldwide.
  • Kidney disease including diabetes can damage and scar the kidneys, which leads to progressive loss of function. Untreated hypertension can also contribute to the fibroproliferation of the kidneys.
  • Heart disease associated with scar tissue can impair the heart's pumping ability.
  • Eye disease includes macular degeneration and retinal and vitreal retinopathy can impair vision.
  • Chronic pancreatitis is an irreversible disease of the pancreas characterized by chronic inflarmmnation and fibrosis which leads to the loss of endocrine and exocrine function.
  • Fibroproliferative disorders include systemic and local scleroderma.
  • Scleroderma is a chronic connective tissue disease that may be localized or systemic, and may have an affect in many organs and tissues of the body.
  • Keloids and hypertrophic scars which can occur after surgery, traumatic wounds, burns, or even scratches. They manifest as an overgrowth of scar tissue at the site of injury.
  • Atherosclerosis and restenosis refers to the re-narrowing of a coronary artery after angioplasty to treat atherosclerosis.
  • Scarring associated with trauma can be associated with overgrowth of scar tissue at the site of the trauma-related injury. Surgical complications can lead to fibrosis in any organ in which scar tissue and fibroproliferation result from the surgical procedures.
  • Chemotherapy induced fibrosis can occur in, for example, the lungs following chemotherapy, manifests as pulmonary fibrosis, and can be severe enough to require lung transplant, even in cases where the underlying malignancy did not affect the lungs.
  • RIF Radiation-induced fibrosis
  • Pulmonary fibrosis destroys the lung's ability to transport oxygen and other gases into or out of the blood.
  • This disease modifies the delicate and elastic tissues of the lung, changing these tissues into thicker, stiff fibrous tissue. This change or replacement of the original tissue is similar to the permanent scarring that can occur to other damaged tissues.
  • Scarring of the lung reduces the lung's ability to allow gases to pass (i.e. oxygen, carbon dioxide) into or out of the blood. Gradually, the air sacs of the lungs become replaced by fibrotic tissue. When the scar forms, the tissue becomes thicker causing an irreversible loss of the tissue's ability to transfer oxygen into the bloodstream.
  • Symptoms include shortness of breath, particularly with exertion; chronic dry, hacking cough; fatigue and weakness; discomfort in the chest; loss of appetite; and rapid weight loss.
  • pulmonary fibrosis Several causes of pulmonary fibrosis are known and they include occupational and environmental exposures. Many jobs, particularly those that involve mining or that expose workers to asbestos or metal dusts, can cause pulmonary fibrosis. Workers doing these kinds of jobs may inhale small particles (like silica dusts or asbestos fibers) that can damage the lungs, especially the small airways and air sacs, and cause the scarring associated with fibrosis. Agricultural workers also can be affected. Some organic substances, such as moldy hay, cause an allergic reaction in the lung. This reaction is called Farmer's Lung and can cause pulmonary fibrosis. Other fumes found on farms are directly toxic to the lungs.
  • small particles like silica dusts or asbestos fibers
  • Agricultural workers also can be affected. Some organic substances, such as moldy hay, cause an allergic reaction in the lung. This reaction is called Farmer's Lung and can cause pulmonary fibrosis. Other fumes found on farms are directly toxic to the lungs.
  • Sarcoidosis a disease characterized by the formation of granulomas (areas of inflammatory cells), which can attack any area of the body but most frequently affects the lungs.
  • Certain medicines may have the undesirable side effect of causing pulmonary fibrosis, as can radiation, such as treatment for breast cancer.
  • radiation such as treatment for breast cancer.
  • Connective tissue or collagen diseases such as systemic sclerosis are also associated with pulmonary fibrosis. Although genetic and familial factors may be involved, this cause is not as common as the other causes listed above.
  • COPD Chronic Obstructive Pulmonary Disease
  • IPF Idiopathic Pulmonary Fibrosis
  • IPF interstitial lung disease
  • IPF IPF
  • Pulmonary rehabilitation, and oxygen therapy can reduce the lifestyle-altering effects of IPF, but do not provide a cure.
  • CK2 kinase activity has been shown to promote cell survival by increasing survivin expression via 0-catenin TCF/LEF-mediated transcription. Tapia, 1C. et al., Proc. Nat. Acad. Sci. U.S.A. 103: 15079-84 (2006). This pathway therefore provides another opportunity to utilize the present compounds to alter the ⁇ -catenin-mediated gene transcription processes.
  • Survivin expression is upregulated in hyperproliferative neovasculature (Simosa, H. F. et al., J. Vase. Surg. 41:682-690, 2005). Survivin was specifically expressed in human other sclerotic plaque and stenotic vein grafts. In a rabbit model of hyperplasia after balloon injury of iliofemoral arteries, treatment with a phosphorylation-defective survivin mutant vector reduced the neointimal area. The correlation between survinin expression and regulation of a smooth muscle cell phenotype after vascular injury points to survivin as a target for therapy in treating vascular disease.
  • the compounds disclosed herein can be administered in the form of coated stents, for example in connection with angioplasty.
  • the methods for preparing coated stents are described in the art and would be modified as needed for use with the compounds of the invention.
  • U.S. Pat. No. 7,097,850 discloses and teaches methods of coating a stent with a variety of bioactive compounds.
  • U.S. Pat. No. 7,087,078 discloses methods of preparing a stent with at least one active ingredient.
  • Bone marrow cells contribute to transplant-associated atherosclerosis (Sata, M., Trends Cardiovasc. Med. 13:249-253, 2003). Bone marrow cells also contribute to the pathogenesis of lesion formation after mechanical vascular injury (Sata, M. et al., Nat. Med. 8:403-409, 2002). Thus, by treating atherosclerosis and vascular damage with one of more compounds of the invention, reduction in vascular lesion formation can be accomplished.
  • Lymphangioleiomyomatosis is a disease that occurs in some patients with tuberous sclerosis complex (Moss, J. et al., Am. J. Respir. Crit Care Med. 163:669-671, 2001).
  • Cystic lung disease in LAM is characterized by abnormal smooth muscle cell proliferation.
  • Compounds disclosed herein are expected to find use in regulating and alleviating the cell proliferation, thus moderating the clinical symptoms.
  • TGF- ⁇ is the immediate cause of the fibrosis.
  • This over-expression of TGF- ⁇ has been shown to cause pulmonary fibrosis in mice.
  • An abnormally high TGF- ⁇ signal causes healthy epithelial cells in the lung to die via apoptosis.
  • Cell death leads to the replacement of healthy lung tissue by thick, poor functioning scar tissue.
  • Apoptosis of healthy epithelial cells is required prior to the development of pulmonary fibrosis (Elias et al).
  • TGF- ⁇ is an ideal therapeutic target.
  • TGF- ⁇ is a member of the transforming growth factor -superfamily which consists of secreted polypeptide signaling molecules involved in cell proliferation and differentiation, apoptosis, deposition of extracellular matrix (ECM) and cell adhesion.
  • ECM extracellular matrix
  • TGF- ⁇ is a potent inhibitor of cell growth, and has immunosuppressive properties. However, TGF- ⁇ also causes the deposition of ECM components leading to fibrosis.
  • a role for TGF- ⁇ as a key mediator in the development of fibrosis relates to its ability to act as a chemoattractant for fibroblasts, stimulate fibroblast procollagen gene expression/collagen protein synthesis, and inhibit collagen breakdown.
  • TGF- ⁇ further stabilizes the ECM by inhibiting the expression of ECM proteases and stimulating the expression of ECM protease inhibitors.
  • the fibrinolysis system is essential in ECM accumulation and fibrosis. Inhibition of fibrinolysis results in the accumulation of fibrin and ECM.
  • Plasminogen activator inhibitor-1 (PAI-1) is the key inhibitor of fibrinolysis.
  • the PAI-promoter contains several transcription factor binding sites including an AP-1 and Smad binding elements that promote PAI-1 induction by TGF- ⁇ .
  • PAI-1 is the primary inhbitor of both tissue-type (TPA) and urokinase-type plasminogen (uPA) activator.
  • TGF- ⁇ and PAI-1 work in tandem to produce the characteristic tissue of fibrosis.
  • mice in which the PAI-1 gene is deleted are protected from developing PF. Additionally, adenovirus-mediated transfer of the uPA gene to the lung significantly reduces the production of lung hydroxyproline and attenuated the bleomycin-induced increase in lung collagen, both hallmarks of fibrosis.
  • the TGF- ⁇ signaling pathway is complex. TGF- ⁇ family members bind to specific pairs of receptor serine/threonine kinases. Upon binding, the ligand acts to assemble two type I and two type II receptors into a complex. The type II receptor phosphorylates the type I receptor that subsequently phosphorylates the intracellular substrates Smad 2 and Smad 3.
  • TGF- ⁇ may originally act as a “healing molecule” in the lung or liver after initial inflammation and injury to the tissue. However, with continued inflammation/injury the balance may be shifted to excessive fibroproliferation and ECM deposition, leading to an “endless healing” process and development of fibrosis. Thus, complete inhibition of TGF- ⁇ could initially undermine the healing process.
  • TGF- ⁇ is highly expressed in airway epithelium and macrophages of small airways in patients with COPD.
  • anti-inflammatory therapies such as corticosteroids and interferon- ⁇
  • TGF- ⁇ signaling an important goal is to identify small molecules that interact with previously identified molecular pathways (i.e. TGF- ⁇ signaling) involved in the development of fibrosis to prevent the progression or reverse the fibrosis seen in patients.
  • Vertebrate Wnt proteins are homologues of the Drosophila wingless gene and have been shown to play important roles in regulating cell differentiation, proliferation, and polarity.
  • Wnt proteins are cysteine-rich secreted glycoproteins that signal through at least three known pathways.
  • This hypophosphorylated ⁇ -catenin is then translocated to the nucleus, where it binds to members of the LEF/TCF family of transcription factors. Binding of ⁇ -catenin converts LEF/TCF factors from repressors to activators, thereby switching on cell-specific gene transcription.
  • Wnt proteins can signal through either activate calmodulin kinase II and protein kinase C (known as the Wnt/Ca++ pathway) or jun N-terminal kinase (also known as the planar cell polarity pathway).
  • Wnt1 was first identified from a retroviral integration in mice that caused mammary tumors. Tsukamoto, A. S. et al., Cell 55:619-625 (1988); and Jue, S. F. et al., Mol. Cell. Biol. 12:321-328 (1992).
  • Overexpression of protein kinase CK2 in the mammary gland which potentiates R-catenin-dependent Wnt signaling, also increases the incidence of mammary tumors in transgenic mice.
  • Austin-Bollag E.
  • J. Pathol. 162:1497-1502, 2003 investigated -catenin mutations in IPF patients but did not identify any. This is consistent with a mechanism in which the aberrant activation of the Wnt pathway is a response and not a cause of IPF.
  • the lung arises from the primitive foregut endoderm starting at approximately E9.5 during mouse development.
  • This primitive epithelium is surrounded by mesodermally derived multipotent mesenchymal cells, which in time will differentiate into several cell lineages including bronchial and vascular smooth muscle, pulmonary fibroblasts, and endothelial cells of the vasculature.
  • the airway epithelium evolves and grows through a process termed branching morphogenesis. This process results in the three-dimensional arborized network of airways required to generate sufficient surface area for postnatal respiration.
  • Mouse embryonic lung development can be divided into at least four stages: embryonic (E9.5 to E12.5), pseudoglandular (E12.5 to E16.0), canalicular (E16.0 to E17.5), and saccular/alveolar (E17.5 to postnatal).
  • epithelial-mesenchymal signaling plays an important role in the regulation of both epithelial and mesenchymal cell differentiation and development.
  • Several important signaling molecules are expressed in the airway epithelium and signal to the adjacent mesenchyme including members of the bone morphogenetic family (BMP-4), transforming growth factor family (TGF- ⁇ 1, -2), and sonic hedgehog (SHH).
  • BMP-4 bone morphogenetic family
  • TGF- ⁇ 1, -2 transforming growth factor family
  • SHH sonic hedgehog
  • the mesenchyme expresses several signaling molecules such as FGF-7, -9, and -10, important for lung epithelial development and proliferation. Gain of function and loss of function experiments in mice have demonstrated an important role for each of these factors in regulating lung epithelial and mesenchymal proliferation and differentiation.
  • Wnt signaling also plays a role during lung development.
  • Kispert A., et al., Development 1996, 122:3627-3637; Lin, Y., et al., Dev. Dyn. 2001, 222:26-39; Monkley, S. l., et al., Development 1996, 122:3343-3353; Yamaguchi, T. P., et al., Development 1999, 126:1211-1223; Weidenfeld, J., et al., J. Biol. Chem.
  • Wnt5a and Wnt7b are expressed at high levels exclusively in the developing airway epithelium during lung development.
  • Wnt2, Wnt5a, and Wnt7b have been inactivated through homologous recombination in mice.
  • Wnt2-null mice do not display an overt lung phenotype and Wnt5a null mice have late-stage lung maturation defects, corresponding to expression of Wnt5a later in lung development. (Monkley, (1996); Li, C. et al., Dev. Biol. 248:68-81 (2000).
  • Wnt7b Inactivation of Wnt7b results in either early embryo demise because of defects in extra-embryonic tissues or perinatal demise because of defects in lung development. Parr, B. A., et al., Dev. Biol. 237:324-332 (2001); Shu, W. et al., Development 129:4831-4842 (2002)). These lung defects include decreased mesenchymal proliferation, lung hypoplasia caused by reduced branching, and pulmonary vascular smooth muscle defects leading to blood vessel hemorrhage in the lung (Shu, W. (2002)). Thus, Wnt signaling regulates important aspects of both epithelial and mesenchymal development during gestation, likely through both autocrine and paracrine signaling mechanisms.
  • Type 2 pneumocytes appear to express high levels of ⁇ -catenin both in the embryo and in the adult. (Tebar, 2001).
  • Type 2 cells are precursors of type 1 cells, which form the thin diffusible stratum important for gas exchange in the lung. Type 2 cells have been shown to re-enter the cell cycle, grow, and differentiate into type 1 cells in some models of lung re-epithelialization. (Borok, Z. et al., Am. J. Respir. Cell Mol. Biol. 12:50-55 (1995); Danto, S. I. et al., Am. J. Respir. Cell Mol. Biol. 12:497-502 (1995)).
  • type 2 cells proliferate excessively during idiopathic fibrosis (IPF) and other proliferative lung diseases, and increased nuclear ⁇ -catenin in these cells suggests that Wnt signaling regulates this proliferation.
  • IPF idiopathic fibrosis
  • Increased proliferation of type 2 cells in IPF may also inhibit their differentiation into type 1 cells because excessive proliferation is often antagonistic to cellular differentiation.
  • expression of certain important transcriptional and signaling regulators in the lung decreases with gestational age.
  • Nuclear ⁇ -catenin is found in the mesenchyme adjacent to the airway epithelium (Chilosi, 2003), and this is significant especially because these cells appear to be myofibroblastic in nature and may contribute to bronchial and vascular smooth muscle in the lung.
  • Wnt signals in these mesenchymal cells could be autocrine in nature, it is just as likely that the mesenchymal cells are responding to a paracrine signal from the airway epithelium where Wnts such as Wnt5a and Wnt7b are expressed. In this way, the epithelium may be responsible for causing the aberrant activation of Wnt signaling in adjacent mesenchyme, leading to increased fibrosis and damage to the lung.
  • Wnt signaling has been shown to affect cell motility and invasiveness of melanoma cells.
  • Wnt signaling has been shown to affect cell motility and invasiveness of melanoma cells.
  • melanoma cells overexpressing Wnt5a displayed increased adhesiveness, which correlated to a reorganized actin cytoskeleton (Weer, 2002).
  • matrilysin In IPF lung tissue (Chilosi, 2003), the important extracellular matrix metalloproteinase matrilysin was overexpressed in some of the cells containing high levels of nuclear ⁇ -catenin. This is supported by previous studies showing that matrilysin is a molecular target of Wnt signaling. (Crawford, H. C., Oncogene 18:2883-2891, 1999). Matrilysin has been linked to a role in carcinogenesis both in intestinal and endometrial tumors. Increased matrilysin expression strongly correlates with increased nuclear ⁇ -catenin expression and inhibition of this nuclear translocation results in decreased matrilysin expression. (Crawford, 1999).
  • the mechanism may involve increased degradation of the extracellular matrix from increased matrilysin expression, leading to decreased cell adhesion and increased cell motility. In IPF, this might reduce the ability of both epithelial and mesenchymal cells to properly restructure the alveolar architecture after injury.
  • extracellular matrix integrity may be required for type 1 cell differentiation, because of their flattened morphology and the very large surface area that they cover in the alveolus. This process may contribute to an increase in type 2 cell proliferation, which in turn could decrease type 1 cell differentiation.
  • Wnt signaling is aberrantly activated in IPF.
  • unregulated activation of the Wnt signaling pathway could be a physiological response to either lung injury or the repair process, possibly because of the requirement of the Wnt pathway for proliferation in cells such as type 2 alveolar epithelium and adjoining myofibroblasts.
  • Wnt signaling should deactivate once the repair process is complete, leading to a return to normal proliferation.
  • aberrant Wnt signaling is the initiating event leading to increased cell proliferation in type 2 cells, which may inhibit their ability to differentiate into type 1 cells and restructure the alveolar architecture properly.
  • myofibroblasts Increased nuclear ⁇ -catenin was detected in the mesenchyme adjacent to the airway epithelium, described as myofibroblasts (Chilosi, 2003). These myofibroblasts can induce apoptosis in neighboring epithelial cells in vitro and in vivo, probably through degradation of the extracellular matrix (Ubal, B. D. et al., Am. J. Physiol. 275:L1192-L1199, 1998; Dhal, B. D. et al., Am. J. Physiol. 269:L819-L822, 1995; Selman, M. et al., Am. J. Physiol. 279:L562-L574, 2000).
  • Connective tissue growth factor is a 36 to 38 kD cysteine-rich peptide containing 349 amino acids. It belongs to the CCN (CTGF, cyr 61/cef 10, nov) family of growth factors.
  • CTGF Connective tissue growth factor
  • the gene for CTGF was originally cloned from a human umbilical endothelial cell cDNA library. CTGF has been detected in endothelial cells, fibroblasts, cartilaginous cells, smooth muscle cells, and some cancer cell lines. Earlier studies revealed that TGF- ⁇ 1 increases CTGF mRNA markedly in human foreskin fibroblasts. PDGF, EGF, and FGF were also shown to induce CTGF expression, but their effects were only transient and weak.
  • CTGF Connective tissue growth factor has diverse bioactivities. Depending on cell types, CTGF was shown to trigger mitogenesis, chemotaxis, ECM production, apoptosis, and angiogenesis. In earlier studies, CTGF was noted to have mitogenic and chemotactic effects on fibroblasts. CTGF was also reported to enhance the mRNA expression of ⁇ 1(I) collagen, fibronectin, and as integrin in fibroblasts. The finding that TGF- ⁇ increases CTGF synthesis and that TGF- ⁇ and CTGF share many functions is consistent with the hypothesis that CTGF is a downstream mediator of TGF- ⁇ .
  • CTGF The mechanism by which CTGF exerts its effects on cells, especially its signal transduction, is still unclear.
  • CTGF was reported to bind to the surface of fibroblasts with high affinity, and this binding was competed with recombinant PDGF BB. This suggests that CTGF binds to a certain class of PDGF receptors, or that there is some cross reactivity of PDGF BB with CTGF receptors.
  • Connective tissue growth factor mRNA has been detected in fibroblasts of sclerotic lesions of patients with systemic sclerosis.
  • CTGF mRNA was detected in fibroblasts in tissues from sclerotic stage more than the inflammatory stage, which suggests a close correlation between CTGF and fibrosis. Similar results were also obtained in keloid and other fibrotic diseases. Subsequently, expression of CTGF has been reported in a variety of fibrosis, such as liver fibrosis, pulmonary fibrosis, and heart fibrosis.
  • CTGF is also implicated in dermal fibrosis of scleroderma. However, the detailed role of CTGF in fibrosis is still unclear. Further studies are needed to clarify this point.
  • the CCN family comprises cysteine-rich 61 (CYR61/CCN1), connective tissue growth factor (CTGF/CCN2), nephroblastoma overexpressed (NOV/CCN3), and Wnt-induced secreted proteins-1 (WISP-1/CCN4), -2 (WISP-2/CCN5) and -3 (WISP-3/CCN6). These proteins stimulate mitosis, adhesion, apoptosis, extracellular matrix production, growth arrest and migration of multiple cell types. Many of these activities probably occur through the ability of CCN proteins to bind and activate cell surface integrins.
  • CTGF Connective tissue growth factor
  • Each of the above conditions can benefit from treatment with one or more compounds of the present invention.
  • Each of the types of fibrosis described above can be treated with one or more compounds of the present invention.
  • the indication of “Buch” means use of Buch sepacore preparative chromatography system (produced by Buch), and one or several columns selected from cartridge columns Si6M-12 ⁇ 75 mm, 12 ⁇ 150 mm, 40 ⁇ 75 mm and 40 ⁇ 150 mm produced by the same manufacturer depending on the amount of sample.
  • the indication of “Purif” means use of Moritex Purif preparative chromatography system (produced by Moritex), and one or several columns selected from cartridge columns 20, 35, 60, 200 and 400 produced by the same manufacturer were used depending on the amount of sample.
  • Silica gel 60N spherical shape, neutral, 40 to 100 ⁇ m, produced by Kanto Chemicals
  • PTLC Preparative thin layer chromatography
  • LCMS liquid chromatography-mass spectrometry
  • Platform-LC type mass spectrometry apparatus ZQ2000 produced by Micromass was used as the mass spectrometer, and the measurement was performed by the electrospray ionization (ESI) method.
  • ESI electrospray ionization
  • a liquid chromatography apparatus an apparatus produced by waters was used.
  • a separation column Develosil C30-UG-5 (50 ⁇ 4.6 mm, Nomura Kagaku Co., Ltd.) for method “A” or Agilent ZOBAX SB-C (2.1 ⁇ 50 mm, Agilent) in the tables mentioned below was used.
  • Examples I-2, I-253, I-254, I-255, I-257, I-259 and I-260 showed inhibitory activity of not less than 1% not more than 50% less than 50% at the concentration of 10 ⁇ M.
  • the compounds of Examples 1-4, I-250, I-251, I-252, I-261, I-262, I-268, I-270 and I-271 showed excellent inhibitory activity of not less than 50% at the concentration of 10 ⁇ M.
  • reaction mixture was concentrated in vacuo and the residue was diluted with ethyl acetate 600 ml and washed with water 300 ml and brine 300 ml.
  • the organic phase was dried over magnesium sulfate and filtered and the mother solution was concentrated in vacuo to obtain the title compound 42 g (93%).
  • the mother solution was concentrated in vacuo and the residue was diluted with ethyl acetate 200 ml and washed with water 100 ml and brine 100 ml.
  • the organic phase was dried over magnesium sulfate and filtered and the mother solution was concentrated in vacuo.
  • the residue was diluted in ethanol 50 ml and the mixture was added to 4N hydrochloric acid in dioxane 0.25 ml.
  • the reaction mixture was refluxed for 18 hours and concentrated in vacuo.
  • the residue was diluted with ethyl acetate 200 ml and washed with saturated sodium bicarbonate 200 ml and brine 200 ml.
  • the organic phase was dried over magnesium sulfate and filtered and the mother solution was concentrated in vacuo.
  • the reaction mixture was diluted with ethyl acetate 20 ml and washed with saturated aqueous sodium bicarbonate 20 ml, water 20 ml and brine 20 ml.
  • the organic phase was dried over magnesium sulfate and filtered.
  • the reaction mixture was diluted with ethyl acetate 50 ml and washed with saturated aqueous sodium bicarbonate 50 ml, water 50 ml and brine 50 ml.
  • the organic phase was dried over magnesium sulfate and filtered.
  • the reaction mixture was basified with 2N-sodium hydroxide 60 ml and washed with ether 100 ml.
  • the aqueous phase was acidified with 2N-hydrochloric acid 85 ml.
  • the aqueous phase was filtered and washed with H 2 O.
  • the solid was dried in vacuo to obtain the title compound 6.46 g (yield 39%)
  • the reaction mixture was concentrated in vacuo and diluted with ethyl acetate 500 ml and washed with saturated sodium bicarbonate solution 500 ml, water 500 ml and brine 500 ml.
  • the organic phase was dried over magnesium sulfate and filtered.
  • the reaction mixture was diluted with chloroform 50 ml and washed with water 50 ml twice and brine 50 ml twice and dried over magnesium sulfate and filtered.
  • Typical examples of the compound having general formula II of the present invention that can be obtained by reacting and treating corresponding intermediates using any of the methods described in the present specification including the examples described above are shown in Tables XIII-1 to XIII-25.
  • the compounds were prepared according to the preparation methods of the compound numbers (e.g., “II-1”) shown in the columns of “Syn” in the Tables, “Int_1” and “Int_2” indicate intermediate compound numbers. “n.d.” in the columns of “yield” means not determined in this step and was used to further reaction.
  • the column of “R”, “R 1 ”, “R 2 ” and “R 3 ” were indicated as chemical groups in the general formula II.
  • Typical examples of the compound I of the present invention that can be given by reacting and treating corresponding starting compounds using any of the methods described in the present specification are shown in Tables XIV-1 to XIV-25.
  • the compounds were prepared according to the preparation methods of the compound numbers (e.g., “I-1”) shown in the columns of “Syn” in the Tables. “Int” means an intermediate compound number.
  • data indicated by “RT” mean data of liquid chromatography retention time.
  • Mass data of mass spectrometry were shown.
  • elution conditions of the liquid chromatography are described.
  • the indication “A” for elution condition means that measurement was performed by elution with a linear gradient of 5 to 100% (v/v) Solution B from 0 minute to 5 minutes and then with 100% Solution B until 6 minutes.
  • the compound of the formula (I) in the present invention blocks TCF4/ ⁇ -catenin transcriptional pathway by inhibiting CBP, and therefore can be used for treatment of cancer, especially colorectal cancer, and fibrotic diseases.

Abstract

Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a chemical library relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation application of U.S. patent application Ser. No. 14/720,690, filed May 22, 2015, which is a divisional application of U.S. patent application Ser. No. 13/319,071, filed Dec. 28, 2011, now U.S. Pat. No. 9,040,531, which is a 371 nationalization application of PCT/JP2010/058141, filed May 7, 2010, which claims the benefit of U.S. Provisional Patent Application No. 61/176,348, filed May 7, 2009, and U.S. Provisional Patent Application No. 61/176,363, filed May 7, 2009, the disclosures of which are hereby incorporated herein by reference in their entirety.
    • TECHNICAL FIELD
  • The present invention relates generally to alpha-helix mimetic structures and to a chemical library relating thereto.
  • The invention also relates to applications in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics.
    • BACKGROUND ART
  • Recently, non-peptide compounds have been developed which more closely mimic the secondary structure of reverse-turns found in biologically active proteins or peptides. For example, U.S. Pat. No. 5,440,013 to Kahn and published PCT applications nos. WO94/03494, WO01/00210A1, and WO01/16135A2 to Kahn each disclose conformationally constrained, non-peptidic compounds, which mimic the three-dimensional structure of reverse-turns. In addition, U.S. Pat. No. 5,929,237 and its continuation-in-part U.S. Pat. No. 6,013,458, both to Kahn, disclose conformationally constrained compounds which mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins.
  • In relation to reverse-turn mimetics, Kahn disclosed new conformationally constrained compounds which mimic the secondary structure of alpha-helix regions of biologically active peptide and proteins in WO2007/056513 and WO2007/056593.
  • While significant advances have been made in the synthesis and identification of conformationally constrained, reverse-turn and alpha-helix mimetics, there remains a need in the art for small molecules which mimic the secondary structure of peptides. There is also a need in the art for libraries containing such members, as well as techniques for synthesizing and screening the library members against targets of interest, particularly biological targets, to identify bioactive library members.
  • The present invention also fulfills these needs, and provides further related advantages by providing conformationally constrained compounds which mimic the secondary structure of alpha-helix regions of biologically active peptides and proteins.
  • Wnt signaling pathway regulates a variety of processes including cell growth, oncogenesis, and development (Moon et al., 1997, Trends Genet. 13, 157-162; Miller et al., 1999, Oncogene 18, 7860-7872; Nusse and Varmus, 1992, Cell 69, 1073-1087; Cadigan and Nusse, 1997, Genes Dev. 11, 3286-3305; Peifer and Polakis, 2000 Science 287, 1606-1609; Polakis 2000, Genes Dev. 14, 1837-1851). Wnt signaling pathway has been intensely studied in a variety of organisms. The activation of TCF4/β-catenin mediated transcription by Wnt signal transduction has been found to play a key role in its biological functions (Molenaar et al., 1996, Cell 86:391-399; Gat et al., 1998 Cell 95:605-614; Orford et al., 1999 J. Cell. Biol. 146:855-868; Bienz and Clevers, 2000, Cell 103:311-20).
  • In the absence of Wnt signals, tumor suppressor gene adenomatous polyposis coli (APC) simultaneously interacts with the serine kinase glycogen synthase kinase (GSK)-3β and β-catenin (Su et al., 1993, Science 262, 1734-1737: Yost et al., 1996 Genes Dev. 10, 1443-1454: Hayashi et al., 1997, Proc. Natl. Acad. Sci. USA, 94, 242-247: Sakanaka et al., 1998, Proc. Natl. Acad. Sci. USA, 95, 3020-3023: Sakanaka and William, 1999, J. Biol. Chem 274, 14090-14093). Phosphorylation of APC by GSK-3β regulates the interaction of APC with β-catenin, which in turn may regulate the signaling function of β-catenin (B. Rubinfeld et al., Science 272, 1023, 1996). Wnt signaling stabilizes β-catenin allowing its translocation to the nucleus where it interacts with members of the lymphoid enhancer factor (LEF1)/T-cell factor (TCF4) family of transcription factors (Behrens et al., 1996 Nature 382, 638-642: Hsu et al., 1998, Mol. Cell. Biol. 18, 4807-4818: Roose et al., 1999 Science 285, 1923-1926).
  • Recently c-myc, a known oncogene, was shown to be a target gene for β-catenin/TCF4-mediated transcription (He et al., 1998 Science 281 1509-1512: Kolligs et al., 1999 Mol. Cell. Biol. 19, 5696-5706). Many other important genes, including cyclin D1, and metalloproteinase, which are also involved in oncogenesis, have been identified to be regulated by TCF4/β-catenin transcriptional pathway (Crawford et al., 1999, Oncogene 18, 2883-2891: Shtutman et al., 1999, Proc. Natl. Acad. Sci. USA., 11, 5522-5527: Tetsu and McCormick, 1999 Nature, 398, 422-426). Moreover, overexpression of several downstream mediators of Wnt signaling has been found to regulate apoptosis (Moris et al., 1996, Proc. Natl. Acad. Sci. USA, 93, 7950-7954: He et al., 1999, Cell 99, 335-345: Orford et al., 1999 J. Cell. Biol., 146, 855-868: Strovel and Sussman, 1999, Exp. Cell. Res., 253, 637-648). Overexpression of APC in human colorectal cancer cells induced apoptosis (Moris et al., 1996, Proc. Natl. Acad. Sci. USA., 93, 7950-7954), ectopic expression of β-catenin inhibited apoptosis associated with loss of attachment to extracellular matrix (Orford et al., 1999, J. Cell Biol. 146, 855-868). Inhibition of TCF4/β-catenin transcription by expression of dominant-negative mutant of TCF4 blocked Wnt-1-mediated cell survival and rendered cells sensitive to apoptotic stimuli such as anti-cancer agent (Shaoqiong Chen et al., 2001, J. Cell. Biol., 152, 1, 87-96) and APC mutation inhibits apoptosis by allowing constitutive survivin expression, a well-known anti-apoptotic protein (Tao Zhang et al., 2001, Cancer Research, 62, 8664-8667).
  • Although mutations in the Wnt gene have not been found in human cancer, a mutation in APC or Q-catenin, as is the case in the majority of colorectal tumors, results in inappropriate activation of TCF4, overexpression of c-myc and production of neoplastic growth (Bubinfeld et al., 1997, Science, 275, 1790-1792: Morin et al., 1997, Science, 275, 1787-1790: Casa et al., 1999, Cell. Growth. Differ. 10, 369-376). The tumor suppressor gene (APC) is lost or inactivated in 85% of colorectal cancers and in a variety of other cancers as well (Kinzler and Vogelstein, 1996, Cell 87, 159-170). APCs principal role is that of a negative regulator of the Wnt signal transduction cascade. A center feature of this pathway involves the modulation of the stability and localization of a cytosolic pool of β-catenin by interaction with a large Axin-based complex that includes APC. This interaction results in phosphorylation of β-catenin thereby targeting it for degradation.
  • CREB binding proteins (CBP)/p300 were identified initially in protein interaction assays, first through its association with the transcription factor CREB (Chrivia et al., 1993, Nature, 365, 855-859) and later through its interaction with the adenoviral-transforming protein E1A (Stein et al., 1990, J. Viol., 64, 4421-4427: Eckner et al., 1994, Genes. Dev., 8, 869-884). CBP had a potential to participate in variety of cellular functions including transcriptional coactivator function (Shikama et al., 1997, Trends. Cell. Biol., 7, 230-236: Janknecht and Hunter, 1996, Nature, 383, 22-23). CBP/p300 potentiates β-catenin-mediated activation of the siamois promoter, a known Wnt target (Hecht et al., 2000, EMBO J. 19, 8, 1839-1850). β-catenin interacts directly with the CREB-binding domain of CBP and β-catenin synergizes with CBP to stimulate the transcriptional activation of TCF4/β-catenin (Ken-Ichi Takemaru and Randall T. Moon, 2000 J. Cell. Biol., 149, 2, 249-254).
    • SUMMARY OF THE INVENTION
  • The present invention relates generally to alpha-helix mimetic structures and to a chemical library relating thereto. The invention also relates to applications in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics.
  • From the above background discussions, it is seen that TCF4/β-catenin and CBP complex of Wnt pathway can be taken as target molecules for the regulation of cell growth, oncogenesis and apoptosis of cells, etc. Accordingly, the present invention also addresses a need for compounds that block TCF4/β-catenin transcriptional pathway by inhibiting CBP, and therefore can be used for treatment of cancer, especially colorectal cancer, and fibrotic diseases. In aspects thereof, the present invention is directed to a new type of conformationally constrained compounds, which mimic the secondary structure of alpha-helix regions of biologically active peptides and proteins. This invention also discloses libraries containing such compounds, as well as the synthesis and screening thereof.
  • (1) A compound having the following general formula (I):
  • Figure US20180305373A1-20181025-C00001
  • wherein
    • Figure US20180305373A1-20181025-P00001
      is single bond or double bond;
    • A is —CHR7—,
      • wherein
        • R7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
    • E is bond, —CHR5—, —O— or —NR8—,
      • wherein
        • R5 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl; and
        • R8 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
    • B is void or optionally substituted monocyclic ring formed together with G and Y;
    • D is void or optionally substituted spiro ring formed together with Y;
      with the proviso that
    • B and D are not both present;
      when B is present, then G and Y are independently carbon atom or nitrogen atom,
      when D is present, then Y is carbon atom and G is —NR6—, —O—, —CHR6— or —C(R6)2—,
      when both B and D are void, then G and Y are the same or different and each is —NR6—, —O—, —CHR6— or —C(R6)2—,
      • wherein
        • each R6 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl, and
          when E is bond, then D is void, B is optionally substituted monocyclic ring, and G and Y are independently carbon atom or nitrogen atom;
    • R1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
    • R2 is —W21—W2—Rb—R20,
      • wherein
      • W2 is —(CO)— or —(SO2)—,
      • W22 is bond, —O—, —NH— or optionally substituted lower alkylene,
      • Rb is bond or optionally substituted alkylene, and
      • R20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl;
    • R3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
      with the proviso that
      when D is void, E is bond, B is benzene, and R2 is —W21—W22—Rb—R20,
      wherein W21 is —(CO)—, W22 is —NH—, and Rb is bond, then R20 should not be optionally substituted phenyl;
      or a pharmaceutically acceptable salt thereof.
      (2) The compound according to (1) mentioned above, wherein, in the formula (I),
    • D is void, and
    • B is optionally substituted 3-, 4-, 5-, 6- or 7-membered saturated or unsaturated mono cyclic ring formed together with G and Y.
      (3) The compound according to (1) mentioned above, wherein, in the formula (I),
    • D is void, and
    • B is optionally substituted 4-, 5-, 6- or 7 membered saturated or unsaturated heterocyclic ring formed together with G and Y and the hetero atom is selected from S, N and O and the number of hetero atoms is an integer of 1-3.
      (4) The compound according to (1) mentioned above, wherein, in the formula (I),
    • D is void;
    • B is optionally substituted 5- or 6-membered saturated or unsaturated heterocyclic ring formed together with G and Y and the hetero atom is selected from S, N and O and the number of hetero atoms is an integer of 1-3.
      (5) The compound according to (1) mentioned above, wherein, in the formula (I),
    • B is void;
    • D is optionally substituted spiro ring; and
    • G is —NR6′—, —CHR6—, —C(R6)2— or —O—,
      • wherein
        • each R6 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl, and
        • R6′ is optionally substituted cyclic or noncyclic lower alkyl, optionally substituted_aryl, optionally substituted heteroaryl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl.
          (6) The compound according to (1) mentioned above, wherein, in the formula (I),
    • B is void;
    • D is optionally substituted C3-8 cycloalkane; and
    • G is —NR6′—, —CHR6—, —C(R)2— or —O—,
      • wherein
        • each R6 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl, and
        • R6′ is optionally substituted cyclic or noncyclic lower alkyl, optionally substituted_aryl, optionally substituted heteroaryl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl.
          (7) The compound according to (1) mentioned above, wherein, in the formula (I),
    • both B and D are void, and
    • at least one of G and Y is —NR6′—, —CHR6—, —C(R6)2— or —O—,
      • wherein
        • each R6 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl, and
        • R6′ is optionally substituted cyclic or noncyclic lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl.
          (8) The compound according to (1) mentioned above, wherein, in the formula (I),
    • both B and D are void; and
    • G is —NR6′—, —CHR6′—, —C(R6′)2—, or —O—,
      • wherein
        • each R6′ is independently optionally substituted cyclic or noncyclic lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl.
          (9) The compound according to (1) mentioned above, wherein, in the formula (I),
    • both B and D are void;
    • G is —NR6′— or —O—,
      • wherein
        • R6′ is optionally substituted lower alkyl, optionally substituted alkenyl or optionally substituted aryl; and
    • Y is —CHR6— or —C(R6)2—,
      • wherein
        • each R6 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl.
          (10) The compound according to (1) mentioned above, wherein, in the formula (I),
    • both B and D are void;
    • G is —NR6′—, or —O—,
      • wherein
        • R6′ is optionally substituted lower alkyl, or optionally substituted alkenyl; and
    • Y is —CHR6— or —C(R6)2—,
      • wherein
        • R6 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl.
          (11) The compound according to (1) mentioned above, wherein, in the formula (I),
    • E is —CHR5—, —O—, or —NR8—,
      • wherein
        • R5 is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl or optionally substituted lower alkynyl, and
        • R8 is hydrogen, lower alkyl, lower alkenyl or lower alkynyl.
          (12) The compound according to (1) mentioned above, wherein, in the formula (I),
    • E is —CHR5—, —O—, or —NR8—,
      • wherein
        • R5 is hydrogen or optionally substituted lower alkyl, and
        • R8 is hydrogen, lower alkyl, lower alkenyl or lower alkynyl.
          (13) The compound according to (1) mentioned above, wherein, in the formula (I),
    • E is —CHR5—, —O—, or —NR8—,
      • wherein
        • R5 is hydrogen, or lower alkyl, and
        • R8 is hydrogen, lower alkyl, lower alkenyl or lower alkynyl.
          (14) The compound according to (1) mentioned above, wherein, in the formula (I),
    • E is —CHR5—, —O—, or —NR8—,
      • wherein
        • R5 is hydrogen, lower alkyl, lower alkenyl or lower alkynyl, and
        • R8 is hydrogen or alkyl.
          (15) The compound according to (1) mentioned above, wherein, in the formula (I),
    • E is —CHR5—, —O—, or —NR8—,
      • wherein
      • R5 is hydrogen or lower alkyl, and
      • R8 is hydrogen or lower alkyl.
        (16) The compound according to (1) mentioned above, wherein, in the formula (I),
    • E is —O—, or —NR8—,
      • wherein
      • R8 is hydrogen or lower alkyl.
        (17) The compound according to (1) mentioned above, wherein, in the formula (I),
        D is void, B is optionally substituted monocyclic ring and E is bond.
        (18) The compound according to (1) mentioned above, wherein, in the formula (I),
    • R3 is hydrogen or C1-4 alkyl group.
      (19) The compound according to (1) mentioned above, wherein, in the formula (I),
    • R3 is hydrogen.
      (20) The compound according to (1) mentioned above, wherein, in the formula (I),
    • D is void; and
    • B is selected from optionally substituted cyclopropane, optionally substituted cyclobutane, optionally substituted cyclopentane, optionally substituted cyclohexane, optionally substituted cycloheptane, optionally substituted pyrrolidine, optionally substituted pyrazole, optionally substituted cyclopropene, optionally substituted cyclobutene, optionally substituted cyclopentene, optionally substituted cyclohexene, optionally substituted cycloheptene, optionally substituted cyclopentadiene, optionally substituted dihydro-pyrrole, optionally substituted pyrrole, optionally substituted dihydro-pyrazole, optionally substituted imidazole, optionally substituted thiophene, optionally substituted thiazole, optionally substituted isothiazole, optionally substituted thiadiazole, optionally substituted furan, optionally substituted oxazole, optionally substituted isoxazole, optionally substituted oxadiazole, optionally substituted benzene, optionally substituted pyridine, optionally substituted pyridazine, optionally substituted pyrimidine, optionally substituted pyrazine and optionally substituted triazine formed together with G and Y.
      (21) The compound according to any one of (1)-(4) and (11)-(20) mentioned above, wherein, in the formula (I),
    • B is present and is optionally substituted by one or more of the chemical moieties selected from the group consisting of —R9, —OR9, —COR9, —COOR9, —CONR9R4, —NR9R4, —SR9, —SO2R9, —SO2NR9R4, —SO3R9, —NHC(NHR9)NR4, and halogen,
      • wherein
      • R9 and R4 are independently selected from hydrogen atom, optionally substituted, cyclic or noncyclic alkyl, aryl, heteroaryl, arylalkyl and hetroarylalkyl.
        (22) The compound according to (1) mentioned above, wherein, in the formula (I),
    • B is void; and
    • D is optionally substituted cycloalkane.
      (23) The compound according to (22) mentioned above, wherein, in the formula (I),
    • B is void; and
    • D is optionally substituted C3-8 cycloalkane.
      (24) The compound according to (22) mentioned above, wherein, in the formula (I),
    • B is void;
    • D is optionally substituted C3-6 cycloalkane.
      (25) The compound according to (1) mentioned above, wherein, in the formula (I),
    • R1 is —Ra—R10,
      • wherein
      • Ra is optionally substituted lower alkylene and
        • R10 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl.
          (26) The compound according to (23) mentioned above, wherein, in the formula (I),
    • R1 is —Ra—R10,
      • wherein
      • Ra is optionally substituted lower alkylene and
        • R10 is hydrogen, optionally substituted aryl or optionally substituted heteroaryl.
          (27) The compound according to (25) mentioned above, wherein, in the formula (I),
    • R10 is hydrogen, optionally substituted methyl, optionally substituted ethyl, optionally substituted propyl, optionally substituted isopropyl, optionally substituted isobutyl, optionally substituted cyclohexyl, optionally substituted benzhydryl, optionally substituted biphenyl, optionally substituted phenyl, optionally substituted pyridyl, optionally substituted pyrimidyl, optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted thienyl, optionally substituted furanyl, optionally substituted thiazolyl, optionally substituted oxazolyl, optionally substituted imidazolyl, optionally substituted naphthyl, optionally substituted tetrahydronaphthyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl, optionally substituted quinoxalinyl, optionally substituted cinnolinyl, optionally substituted naphthyridinyl, optionally substituted benzotriazinyl, optionally substituted pyridopyrimidinyl, optionally substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl, optionally substituted pyridotriazinyl, optionally substituted indenyl, optionally substituted benzofuranyl, optionally substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrrolopyridinyl, optionally substituted oxazolopyridinyl, optionally substituted thiazolopyridinyl or optionally substituted imidazopyridinyl.
      (28) The compound according to (26) mentioned above, wherein, in the formula (I),
    • R10 is hydrogen, optionally substituted biphenyl, optionally substituted phenyl, optionally substituted pyridyl, optionally substituted pyrimidyl, optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted thienyl, optionally substituted furanyl, optionally substituted thiazolyl, optionally substituted oxazolyl, optionally substituted imidazolyl, optionally substituted naphthyl, optionally substituted tetrahydronaphthyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl, optionally substituted quinoxalinyl, optionally substituted cinnolinyl, optionally substituted naphthyridinyl, optionally substituted benzotriazinyl, optionally substituted pyridopyrimidinyl, optionally substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl, optionally substituted pyridotriazinyl, optionally substituted indenyl, optionally substituted benzofuranyl, optionally substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrrolopyridinyl, optionally substituted oxazolopyridinyl, optionally substituted thiazolopyridinyl or optionally substituted imidazopyridinyl.
      (29) The compound according to (1) mentioned above, wherein, in the formula (I),
    • R2 is —W21—W22—Rb—R20;
      • wherein
      • W21 is —(CO)— or —(SO2)—,
        • W22 is bond, —O—, —NH— or optionally substituted lower alkylene,
        • Rb is bond or optionally substituted lower alkylene, and
        • R20 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl.
          (30) The compound according to (29) mentioned above, wherein, in the formula (I),
    • R2 is —W21—W22—Rb—R20;
      • wherein
      • W21 is —(CO)— or —(SO2)—,
      • W2 is —O— or —NH—,
      • Rb is bond or optionally substituted lower alkylene, and
      • R20 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl.
        (31) The compound according to (29) and (30) mentioned above, wherein, in the formula (I),
    • R20 is optionally substituted methyl, optionally substituted ethyl, optionally substituted propyl, optionally substituted butyl, optionally substituted isopropyl, optionally substituted isobutyl, optionally substituted cyclohexyl, optionally substituted benzhydryl, optionally substituted biphenyl, optionally substituted phenyl, optionally substituted pyridyl, optionally substituted pyrimidyl, optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted thienyl, optionally substituted furanyl, optionally substituted thiazolyl, optionally substituted oxazolyl, optionally substituted imidazolyl, optionally substituted naphthyl, optionally substituted tetrahydronaphthyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl, optionally substituted quinoxalinyl, optionally substituted cinnolinyl, optionally substituted naphthyridinyl, optionally substituted benzotriazinyl, optionally substituted pyridopyrimidinyl, optionally substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl, optionally substituted pyridotriazinyl, optionally substituted indenyl, optionally substituted benzofuranyl, optionally substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrrolopyridinyl, optionally substituted oxazolopyridinyl, optionally substituted thiazolopyridinyl, optionally substituted benzodioxolyl or optionally substituted imidazopyridinyl.
      (32) The compound according to (1) mentioned above, wherein, in the formula (I),
    • R of A is -Rc-R0,
      • wherein
      • Rc is bond or optionally substituted lower alkylene, and
      • R70 is hydrogen, optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl.
        (33) The compound according to (32) mentioned above, wherein, in the formula (I),
    • R7 of A is -Rc-R70
      • wherein
        • Rc is bond or optionally substituted lower alkylene, and
        • R70 is hydrogen, optionally substituted aryl or optionally substituted heteroaryl.
          (34) The compound according to (32) mentioned above, wherein, in the formula (I),
    • R70 is hydrogen, optionally substituted methyl, optionally substituted ethyl, optionally substituted propyl, optionally substituted butyl, optionally substituted isopropyl, optionally substituted isobutyl, optionally substituted biphenyl, optionally substituted phenyl, optionally substituted pyridyl, optionally substituted pyrimidyl, optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted thienyl, optionally substituted furanyl, optionally substituted thiazolyl, optionally substituted oxazolyl, optionally substituted imidazolyl, optionally substituted naphthyl, optionally substituted tetrahydronaphthyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl, optionally substituted quinoxalinyl, optionally substituted cinnolinyl, optionally substituted naphthyridinyl, optionally substituted benzotriazinyl, optionally substituted pyridopyrimidinyl, optionally substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl, optionally substituted pyridotriazinyl, optionally substituted indenyl, optionally substituted benzofuranyl, optionally substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrrolopyridinyl, optionally substituted oxazolopyridinyl, optionally substituted thiazolopyridinyl or optionally substituted imidazopyridinyl.
      (35) The compound according to (33) mentioned above, wherein, in the formula (I),
    • R70 is hydrogen, optionally substituted biphenyl, optionally substituted phenyl, optionally substituted pyridyl, optionally substituted pyrimidyl, optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted thienyl, optionally substituted furanyl, optionally substituted thiazolyl, optionally substituted oxazolyl, optionally substituted imidazolyl, optionally substituted naphthyl, optionally substituted tetrahydronaphthyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl, optionally substituted quinoxalinyl, optionally substituted cinnolinyl, optionally substituted naphthyridinyl, optionally substituted benzotriazinyl, optionally substituted pyridopyrimidinyl, optionally substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl, optionally substituted pyridotriazinyl, optionally substituted indenyl, optionally substituted benzofuranyl, optionally substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrrolopyridinyl, optionally substituted oxazolopyridinyl, optionally substituted thiazolopyridinyl or optionally substituted imidazopyridinyl.
      (36) The compound according to (1) mentioned above, wherein, in the formula (I),
    • D is void;
    • B is optionally substituted 4-, 5-, 6- or 7 membered saturated or unsaturated heterocyclic ring formed together with G and Y and the hetero atom is selected from S, N and O and the number of hetero atoms is an integer of 1-3;
    • R1 is —Ra—R10,
      • wherein
      • Ra is optionally substituted lower alkylene and
        • R10 is Hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl;
    • R2 is —W21—W22—Rb—R20,
      • wherein
      • W21 is —(CO)— or —(SO2)—,
      • W22 is bond, —O—, —NH— or optionally substituted lower alkylene,
      • Rb is bond or optionally substituted lower alkylene, and
      • R20 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl; and
    • R7 of A is -Rc-R70,
      • wherein
        • Rc is bond or optionally substituted lower alkylene, and
        • R70 is hydrogen, optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl.
          (37) The compound according to (1) mentioned above, wherein, in the formula (I),
    • B is void;
    • D is optionally substituted C3-8 cycloalkane;
    • G is —NR6′—, —CHR6′—, —C(R6′)2—, or —O—,
      • wherein
        • each R6′ is independently hydrogen, optionally substituted cyclic or noncyclic lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl;
    • R1 is —Ra—R10,
      • wherein
      • Ra is optionally substituted lower alkylene and
        • R10 is Hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl;
    • R2 is —W21—W22—Rb—R20,
      wherein
    • W21 is —(CO)— or —(SO2)—,
    • W22 is bond, —O—, —NH— or optionally substituted lower alkylene,
    • Rb is bond or optionally substituted lower alkylene, and
    • R20 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl; and
    • R7 of A is -Rc-R70,
      wherein
    • Rc is bond or optionally substituted lower alkylene, and
    • R70 is hydrogen, optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl.
      (38) The compound according to (1) mentioned above, wherein, in the formula (I),
    • both B and D are void;
    • G is —NR6′—, —CHR6′—, —C(R6′)2—, or —O—,
      • wherein
      • each R6′ is independently hydrogen, optionally substituted cyclic or noncyclic lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl;
    • R1 is —Ra—R10,
      • wherein
      • Ra is optionally substituted lower alkylene and
        • R10 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl;
    • R2 is —W21—W22—Rb—R20,
      • wherein
      • W21 is —(CO)— or —(SO2)—,
      • W22 is bond, —O—, —NH— or optionally substituted lower alkylene,
      • Rb is bond or optionally substituted lower alkylene, and
      • R20 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl; and
    • R7 of A is -Rc-R70,
      • wherein
      • Rc is bond or optionally substituted lower alkylene, and
      • R70 is hydrogen, optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl.
        (39) The compound according to (1) mentioned above, wherein, in the formula (I),
    • E is —CHR5—, —O—, or —NR8—,
      • wherein
      • R5 is hydrogen or optionally substituted lower alkyl, and
      • R8 is hydrogen, lower alkyl, lower alkenyl or lower alkynyl;
    • R1 is —Ra—R10,
      • wherein
      • Ra is optionally substituted lower alkylene and R10 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl;
    • R2 is —W21—W22—Rb—R20,
      • wherein
      • W21 is —(CO)— or —(SO2)—,
      • W22 is bond, —O—, —NH— or optionally substituted lower alkylene,
      • Rb is bond or optionally substituted lower alkylene, and
      • R20 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl; and
    • R7 of A is -Rc-R70,
      • wherein
      • Rc is bond or optionally substituted lower alkylene, and
      • R70 is hydrogen, optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl.
        (40) The compound according to (1) mentioned above, wherein, in the formula (I),
    • D is void and E is bond;
    • R1 is —Ra—R10,
      • wherein
      • Ra is optionally substituted lower alkylene and R10 is Hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl;
    • R2 is —W21—W22—Rb—R20,
      • wherein
      • W21 is —(CO)— or —(SO2)—,
      • W22 is bond, —O—, —NH— or optionally substituted lower alkylene,
      • Rb is bond or optionally substituted lower alkylene, and
      • R20 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl; and
    • R7 of A is -Rc-R70,
      • wherein
      • Rc is bond or optionally substituted lower alkylene, and
      • R70 is Hydrogen, optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl.
        (41) The compound according to (1) mentioned above, wherein, in the formula (I),
    • both B and D are void;
    • G is —NR6′—, —CHR6′—, —C(R6′)2—, or —O—,
      • wherein
      • each R6′ is independently hydrogen, optionally substituted cyclic or noncyclic lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl; and
    • E is —CHR5—, —O—, or —NR8—,
      • wherein
      • R5 is hydrogen or optionally substituted lower alkyl, and
      • R8 is hydrogen, lower alkyl, lower alkenyl or lower alkynyl.
        (42) The compound according to (1) mentioned above, wherein, in the formula (I),
    • B is void;
    • D is optionally substituted C3-8 cycloalkane;
    • G is —NR6′—, —CHR6′—, —C(R6′)2—, or —O—,
      • wherein
      • each R6′ is independently hydrogen, optionally substituted cyclic or noncyclic lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl;
    • E is —CHR5—, —O—, or —NR8—
      • wherein
      • R5 is hydrogen or optionally substituted lower alkyl, and
      • R8 is hydrogen, lower alkyl, lower alkenyl or lower alkynyl;
    • R1 is —Ra—R10,
      • wherein
      • Ra is optionally substituted lower alkylene and R10 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl;
    • R2 is —W21—W22—Rb—R20;
      • wherein
      • W21 is —(CO)— or —(SO2)—,
      • W22 is bond, —O—, —NH— or optionally substituted lower alkylene,
      • Rb is bond or optionally substituted lower alkylene, and
      • R20 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl; and
    • R7 of A is -Rc-R70,
      • wherein
      • Rc is bond or optionally substituted lower alkylene, and
      • R70 is Hydrogen, optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl.
        (43) The compound according to (1) mentioned above, wherein, in the formula (I),
    • both B and D are void;
    • G is —NR6′—, —CHR6′—, —C(R6′)2—, or —O—,
      • wherein
      • each R6′ is independently hydrogen, optionally substituted cyclic or noncyclic lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl;
    • E is —CHR5—, —O—, or —NR8—,
      • wherein
      • R5 is hydrogen or optionally substituted lower alkyl, and
      • R8 is hydrogen, lower alkyl, lower alkenyl or lower alkynyl;
    • R1 is —Ra—R10,
      • wherein
      • Ra is optionally substituted lower alkylene and R10 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl.
    • R2 is —W21—W22—Rb—R20,
      • wherein
      • W21 is —(CO)— or —(SO2)—,
      • W22 is bond, —O—, —NH— or optionally substituted lower alkylene,
      • Rb is bond or optionally substituted lower alkylene, and
      • R20 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl.
    • R7 of A is -Rc-R70,
      • wherein
      • Rc is bond or optionally substituted lower alkylene, and
      • R70 is hydrogen, optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl.
  • In further embodiment of formula (I), such compounds comprise a formula (Ia)
  • Figure US20180305373A1-20181025-C00002
  • wherein
    • Figure US20180305373A1-20181025-P00001
      is single bond or double bond;
    • A is —CHR7—,
      • wherein
        • R7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
    • E is —CHR5—, —O— or —NR8—,
      • wherein
      • R5 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl; and
      • R8 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
    • B is optionally substituted monocyclic ring formed together with G and Y;
    • G and Y are independently carbon atom or nitrogen atom;
    • R1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
    • R2 is —W21—W22—Rb—R20,
      • wherein
      • W21 is —(CO)— or —(SO2)—,
      • W22 is bond, —O—, —NH— or optionally substituted lower alkylene,
      • Rb is bond or optionally substituted alkylene, and
      • R20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl; and
    • R3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl.
  • In further another embodiment of formula (I), such compounds comprise a formula (Ib)
  • Figure US20180305373A1-20181025-C00003
  • wherein
    • A is —CHR7—,
      • wherein
        • R7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
    • E is —CHR5—, —O— or —NR8—,
      • wherein
      • R5 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl; and
    • R8 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
    • D is optionally substituted spiro ring,
    • G is —NR6—, —O—, —CHR6— or —C(R6)2—,
      • wherein
      • each R6 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl;
    • R1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
    • R2 is —W21—W22—Rb—R20,
      • wherein
      • W21 is —(CO)— or —(SO2)—,
      • W22 is bond, —O—, —NH— or optionally substituted lower alkylene,
      • Rb is bond or optionally substituted alkylene, and
      • R20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl;
    • R3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl.
  • In further another embodiment of formula (I), such compounds comprise a formula (Ic)
  • Figure US20180305373A1-20181025-C00004
  • wherein
    • A is —CHR7—,
      • wherein
        • R7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
    • E is —CHR5—, —O— or —NR8—,
      • wherein
        • R5 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl, and
    • R8 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
    • G is —NR6—, —O—, —CHR6— or —C(R6)2—,
      • wherein
        • each R6 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl;
    • R1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
    • R2 is —W21—W22—Rb—R20,
      • wherein
      • W21 is —(CO)— or —(SO2)—,
      • W22 is bond, —O—, —NH— or optionally substituted lower alkylene,
      • Rb is bond or optionally substituted alkylene,
      • R20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl; and
    • R3 is hydrogen or optionally substituted alkyl.
  • In further another embodiment of formula (I), such compounds comprise a formula (Id)
  • Figure US20180305373A1-20181025-C00005
  • wherein
    • Figure US20180305373A1-20181025-P00001
      single bond or double bond;
    • A is —CHR7—,
      • wherein
        • R7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
    • B is optionally substituted monocyclic ring;
    • G is carbon atom or nitrogen atom;
    • R1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
    • R2 is —W21—W22—Rb—R20,
      • wherein
      • W21 is —(CO)— or —(SO2)—,
      • W22 is bond, —O—, —NH— or optionally substituted lower alkylene,
      • Rb is bond or optionally substituted alkylene, and
      • R20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl; and
    • R3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
      with the proviso that
      when B is benzene, and R2 is —W2—W22—Rb—R20; wherein W21 is —(CO)—; W2 is —NH—; Rb is bond, then R20 should not be optionally substituted phenyl.
  • In further another embodiment of formula (I), such compounds comprise a formula (II):
  • Figure US20180305373A1-20181025-C00006
  • wherein
    • Figure US20180305373A1-20181025-P00001
      is single bond or double bond;
    • A is —CHR7—,
      • wherein
        • R7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
    • E is bond, —CHR5—, —O— or —NR8—,
      • wherein
      • R5 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl; and
      • R8 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
    • B is void or optionally substituted monocyclic ring formed together with G and Y;
    • D is void or optionally substituted spiro ring formed together with Y;
      with the proviso that
    • B and D are not both present,
      when B is present, then G and Y are independently carbon atom or nitrogen atom,
      when D is present, then Y is carbon atom and G is —NR6—, —O—, —CHR6— or —C(R6)2—,
      when both B and D are void, then G and Y are the same or different and each is —NR6—, —O—, —CHR6— or —C(R6)2—,
      • wherein
        • each R6 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl, and
          when E is bond, then D is void, B is optionally substituted monocyclic ring, and G and Y are independently carbon atom or nitrogen atom;
    • R1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
    • R2 is —W21—W22—Rb—R20,
      • wherein
      • W21 is —(CO)— or —(SO2)—;
      • W22 is bond, —O—, —NH— or optionally substituted lower alkylene;
      • Rb is bond or optionally substituted alkylene; and
      • R20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl;
    • R3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
    • R91 is selected from optionally substituted alkyl, linker and solid support; and
    • R92 is selected from optionally substituted alkyl, linker and solid support;
      with the proviso that
      when D is void, E is bond, B is benzene, and R2 is —W21—W22—Rb—R20, wherein W21 is —(CO)—, W22 is —NH—, and Rb is bond, then R20 should not be optionally substituted phenyl;
  • In further another embodiment of formula (I), such compounds comprise a formula (IIa′):
  • Figure US20180305373A1-20181025-C00007
  • wherein
    • Figure US20180305373A1-20181025-P00001
      is single bond or double bond;
    • A is —CHR7—,
      • wherein
        • R7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
    • E is bond, —CHR5—, —O— or —NR8—,
      • wherein
      • R5 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl; and
      • R8 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
    • B is void or optionally substituted monocyclic ring formed together with G and Y;
    • G and Y are independently carbon atom or nitrogen atom;
      with the proviso that
      when E is bond, then B is optionally substituted monocyclic ring, and G and Y are independently carbon atom or nitrogen atom;
    • R1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
    • R is —W21—W22—Rb—R20,
      • wherein
      • W21 is —(CO)— or —(SO2)—;
      • W22 is bond, —O—, —NH— or optionally substituted lower alkylene;
      • Rb is bond or optionally substituted alkylene; and
      • R20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl;
    • R3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
    • R91 is selected from optionally substituted alkyl, linker and solid support; and
    • R92 is selected from optionally substituted alkyl, linker and solid support;
      with the proviso that
      when E is bond, B is benzene, and R2 is —W21—W22—Rb—R20, wherein W21 is —(CO)—, W22 is —NH—, and Rb is bond, then R20 should not be optionally substituted phenyl;
  • In further another embodiment of formula (I), such compounds comprise a formula (IIb′):
  • Figure US20180305373A1-20181025-C00008
  • wherein
    • Figure US20180305373A1-20181025-P00001
      is single bond or double bond;
    • A is —CHR7—,
      • wherein
        • R7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
    • E is —CHR5—, —O— or —NR8—,
      • wherein
      • R5 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl; and
      • R8 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
    • D is void or optionally substituted spiro ring formed together with Y;
      with the proviso that
      when D is present, Y is carbon atom and G is —NR6—, —O—, —CHR6— or —C(R6)2—, and
      when D is void, then G and Y are the same or different and each is —NR6—, —O—, —CHR6— or —C(R6)2—,
      • wherein
        • each R6 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl;
    • R1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
    • R2 is —W21—W22—Rb—R20,
      • wherein
      • W21 is —(CO)— or —(SO2)—;
      • W22 is bond, —O—, —NH— or optionally substituted lower alkylene;
      • Rb is bond or optionally substituted alkylene; and
      • R20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl;
    • R3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
    • R91 is selected from optionally substituted alkyl, linker and solid support; and
    • R92 is selected from optionally substituted alkyl, linker and solid support;
      or a salt thereof.
  • The present invention is also directed to libraries containing one or more compounds of formula (I) above, as well as methods for synthesizing such libraries and methods for screening the same to identify biologically active compounds.
  • In another embodiment, a pharmaceutical composition comprises the compound of formula (I) or pharmaceutically acceptable salt thereof, and, if necessary, together with a pharmaceutical acceptable carrier or diluent. Compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier or diluent are also disclosed.
  • In another embodiment, there is a method of treating a cancerous condition or fibrosis by administering the compound of formula (I). The present invention also provides methods for preventing or treating disorders associated with Wnt signaling pathway. Disorders that may be treated or prevented using a compound or composition of the present invention include tumor or cancer (e.g., KSHV-associated tumor), fibrotic diseases, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, tuberous sclerosis complex, hair loss, and Alzheimer's disease. Such methods comprise administering to a subject in need thereof a compound or composition of the present invention in an amount effective to achieve the desired outcome.
  • These and other aspects of this invention will be apparent upon reference to the attached figure and following detailed description. To this end, various references are set forth herein, which describe in more detail certain procedures, compounds and/or compositions, and are incorporated by reference in their entirety.
    • BRIEF DESCRIPTION OF DRAWINGS
  • FIG. 1 (including FIGS. 1-1 to 1-6) and FIG. 2 (including FIGS. 2-1 and 2-2) provide a general synthetic scheme for preparing alpha-helix mimetics of the present invention.
    •  DETAILED DESCRIPTION OF THE INVENTION
  • The present invention relates generally to alpha-helix mimetic structures and to a chemical library relating thereto. The present invention is also directed to conformationally constrained compounds that mimic the secondary structure of alpha-helix regions of biological peptide and proteins (also referred to herein as “alpha-helix mimetics”), and is also directed to chemical libraries relating thereto. The alpha-helix mimetic structures of the present invention are useful as bioactive agents, including (but not limited to) use as diagnostic, prophylactic and/or therapeutic agents. The alpha-helix mimetic structure libraries of this invention are useful in the identification of bioactive agents having such uses. In the practice of the present invention, the libraries may contain from tens to hundreds to thousands (or greater) of individual alpha-helix structures (also referred to herein as “members”).
    • Definitions
  • Unless otherwise stated, the following terms used in the specification and claims shall have the following meanings for the purposes of this application.
  • “Lower”, unless indicated otherwise, means that the number of the carbon atoms constituting the given radicals is between one and six.
  • “Optionally substituted”, unless otherwise stated, means that a given radical may consist of only hydrogen substituents through available valencies or may further comprise one or more non-hydrogen substituents through available valencies. In general, a non-hydrogen substituent may be any substituent that may be bound to an atom of the given radical that is specified to be substituted. Examples of substituents include, but are not limited to, —R9, —OR9, —COR9, —COOR9, —OCOR9, —CONR9R4, —NR9R4, —NR4COR9, —NR4COOR9, —SR9, —SO2R9, —SO2NR9R4, —SO3R9, —NHC(NHR9)NR4, —NHC(NH2)NH, —OPO(OH)2, —OPO(ONa)2, —CN, —NO2, halogen and methylenedioxy, wherein R9 and R4 are independently selected from hydrogen, optionally substituted, cyclic or noncyclic, alkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl.
  • “Halogen” means fluorine, chlorine, bromine or iodine.
  • “Halo” means fluoro, chloro, bromo or iodo.
  • “Alkyl” means a linear or branched, saturated, aliphatic radical having a chain of carbon atoms. CX-Y alkyl is typically used where X and Y indicate the number of carbon atoms in the chain. The number of carbon atoms in the chain is preferably 1 to 10, more preferably 1 to 6, further preferably 1 to 4. Non-exclusive examples of alkyl include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, isohexyl, and the like. “Noncyclic alkyl” equals to “alkyl” as used here.
  • “Alkenyl” means a linear or branched, carbon chain that contains at least one carbon-carbon double bond. CX-Y alkenyl is typically used where X and Y indicate the number of carbon atoms in the chain. The number of carbon atoms in the chain is preferably 2 to 10, more preferably 2 to 6. Non-exclusive examples of alkenyl include ethenyl (vinyl), allyl, isopropenyl, 2-methylallyl, 1-pentenyl, hexenyl, heptenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, and the like.
  • “Alkynyl” means a linear or branched, carbon chain that contains at least one carbon-carbon triple bond. CX-Y alkynyl is typically used where X and Y indicate the number of carbon atoms in the chain. The number of carbon atoms in the chain is preferably 2 to 10, more preferably 2 to 6. Non-exclusive examples of alkynyl include ethynyl, propargyl, 3-methyl-1-pentynyl, 2-heptynyl and the like.
  • “Alkylene”, unless indicated otherwise, means a linear or branched, saturated, aliphatic, polyvalent carbon chain. CX-Y alkylene is typically used where X and Y indicate the number of carbon atoms in the chain. The number of carbon atoms in the chain is preferably 1 to 10, more preferably 1 to 6. Non-exclusive examples of alkylene include methylene (—CH2—), ethylene (—CH2CH2—), methylmethylene (—CH(CH3)—), 1,2-propylene (—CH2CH(CH3)—), 1,3-propylene (—CH2CH2CH2—), 1,2-butylene (—CH2CH(CH2CH3)—), 1, 3-butylene (—CH2CH2CH(CH3)—), 1, 4-butylene (—CH2CH2CH2CH2—), 2-methyltetramethylene (—CH2CH(CH3) CH2CH2—), pentamethylene (—CH2CH2CH2CH2CH2—), 1, 2, 3-propanetriyl, 1,3,3-propanetriyl and the like.
  • “Oxy” means the radical —O—. It is noted that the oxy radical may be further substituted with a variety of substituents to form different oxy groups including hydroxy, alkoxy, aryloxy, heteroaryloxy and the like.
  • “Thio” means the radical —S—. It is noted that the thio radical may be further substituted with a variety of substituents to form different thio groups including mercapto, alkylthio, arylthio, heteroarylthio and the like.
  • “Sulfinyl” means the radical —SO—. It is noted that the sulfinyl radical may be further substituted with a variety of substituents to form different sulfinyl groups including alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl and the like.
  • “Sulfonyl” means the radical —SO2—. It is noted that the sulfonyl radical may be further substituted with a variety of substituents to form different sulfonyl groups including alkylsulfonyl, arysulfonyl, heteroarylsulfonyl and the like.
  • “Alkoxy” means an oxygen moiety having a further alkyl substituent. CX-Y alkoxy is typically used where X and Y indicate the number of carbon atoms in the chain. The number of carbon atoms in the chain is preferably 1 to 10, more preferably 1 to 6. Non-exclusive examples of alkoxy include methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, isobutoxy, tert-butoxy, pentoxy, isopentoxy, neopentoxy, tert-pentoxy, hexyloxy, isohexyloxy, and the like.
  • “Heteroatom” refers to an atom that is not a carbon atom and hydrogen atom. Particular examples of heteroatoms include, but are not limited to nitrogen, oxygen, and sulfur.
  • “Aryl” means a monocyclic or polycyclic radical wherein each ring is aromatic or when fused with one or more rings forms an aromatic ring. CX-Y aryl is typically used where X and Y indicate the number of carbon atoms in the ring assembly. The number of carbon atoms in the ring is preferably 6 to 14, more preferably 6 to 10. Non-exclusive examples of aryl include phenyl, naphthyl, indenyl, azulenyl, biphenyl, fluorenyl, anthracenyl, phenalenyl and the like. “Aryl” may partially be hydrogenated. Non-exclusive examples of partially hydrogenated aryl include tetrahydronaphthyl, indanyl and the like.
  • “Heteroaryl” means a monocyclic or polycyclic aromatic radical wherein at least one ring atom is a heteroatom and the remaining ring atoms are carbon. “X-Y membered heteroaryl” is typically used where X and Y indicate the number of carbon atoms and heteroatoms in the ring assembly. The number of carbon atoms and heteroatoms in the ring is preferably 5 to 14, more preferably 5 to 10. Monocyclic heteroaryl groups include, but are not limited to, cyclic aromatic groups having five or six ring atoms, wherein at least one ring atom is a heteroatom and the remaining ring atoms are carbon. The nitrogen atoms can be optionally quaternerized and the sulfur atoms can be optionally oxidized. Non-exclusive examples of monocyclic heteroaryl group of this invention include, but are not limited to, those derived from furan, thiophene, pyrrole, imidazole, isothiazole, isoxazole, oxadiazole, oxazole, 1,2,3-oxadiazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, triazine, pyrroline, thiazole, 1,3,4-thiadiazole, triazole and tetrazole. “Heteroaryl” also includes, but is not limited to, bicyclic or tricyclic rings, wherein the heteroaryl ring is fused to one or two rings independently selected from the group consisting of an aryl ring, a cycloalkyl ring, and another monocyclic heteroaryl or heterocycloalkyl ring. Non-exclusive examples of bicyclic or tricyclic heteroaryl include, but are not limited to, those derived from benzofuran (ex. benzo[b]furan), benzothiophene (ex. benzo[b]thiophene), benzimidazole, benzotriazine (ex. benzo[e][1,2,4]triazine, benzo[d][1,2,3]triazine), pyridopyrimidine (ex. pyrido[4,3-d]pyrimidine, pyrido[3,4-d]pyrimidine, pyrido[3,2-d]pyrimidine, pyrido[2,3-d]pyrimidine), pyridopyrazine (ex. pyrido[3,4-b]pyrazine, pyrido[2,3-b]pyrazine), pyridopyridazine (ex. pyrido[2,3-c]pyridazine, pyrido[3,4-c]pyridazine, pyrido[4,3-c]pyridazine, pyrido[3,2-c]pyridazine), pyridotriazine (ex. pyrido[2,3-d][1,2,3]triazine, pyrido[3,4-d][1,2,3]triazine, pyrido[4,3-d][1,2,3]triazine, pyrido[3,2-d][1,2,3]triazine, pyrido[3,4-e][1,2,4]triazine, pyrido[3,2-e][1,2,4]triazine), benzothiadiazole (ex. benzo[c][1,2,5]thiadiazole), fulopyridine (ex. furo[3,2-b]pyridine, furo[3,2-c]pyridine, furo[2,3-c]pyridine, furo[2,3-b]pyridine), oxazolopyridine (ex. oxazolo[4,5-b]pyridine, oxazolo[4,5-c]pyridine, oxazolo[5,4-c]pyridine, oxazolo[5,4-b]pyridine), thiazolopyridine (ex. thiazolo[4,5-b]pyridine, thiazolo[4,5-c]pyridine, thiazolo[5,4-c]pyridine, thiazolo[5,4-b]pyridine), imidazopyridine (ex. imidazo[1,2-a]pyridine, imidazo[4,5-c]pyridine, imidazo[1,5-a]pyridine), quinazoline, thienopyridine (ex. thieno[2,3-c]pyridine, thieno[3,2-b]pyridine, thieno[2,3-b]pyridine), indolizine, quinoline, isoquinoline, phthalazine, quinoxaline, cinnoline, naphthyridine, quinolizine, indole, isoindole, indazole, indoline, benzoxazole, benzopyrazole, benzothiazole, pyrazolopyridine (ex. pyrazolo[1,5-a]pyridine), imidazopyrimidine (ex. imidazo[1,2-a]pyrimidine, imidazo[1,2-c]pyrimidine, imidazo[1,5-a]pyrimidine, imidazo[1,5-c]pyrimidine), pyrrolopyridine (ex. pyrrolo[2,3-b]pyridine, pyrrolo[2,3-c]pyridine, pyrrolo[3,2-c]pyridine, pyrrolo[3,2-b]pyridine), pyrrolopyrimidine (ex. pyrrolo[2,3-d]pyrimidine, pyrrolo[3,2-d]pyrimidine, pyrrolo[1,2-c]pyrimidine, pyrrolo[1,2-a]pyrimidine), pyrrolopyrazine (ex. pyrrolo[2, 3-b]pyrazine, pyrrolo[1,2-a]pyrazine), pyrrolopyridazine (ex. pyrrolo[1,2-b]pyridazine), triazopyridine (ex. triazo[1,5-a]pyridine), pteridine, purine, carbazole, acridine, permidine, 1,10-phenanthroline, phenoxathiin, phenoxazine, phenothiazine, phenazine, benzodioxole, benzodioxolane and the like. The bicyclic or tricyclic heteroaryl rings can be attached to the parent molecule through either the heteroaryl group itself or the aryl, cycloalkyl, or heterocycloalkyl group to which it is fused.
  • “Cycloalkyl” means a non-aromatic, saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring radical. CX-Y cycloalkyl is typically used where X and Y indicate the number of carbon atoms in the ring assembly. The number of carbon atoms in the ring is preferably 3 to 10, more preferably 3 to 8. Non-exclusive examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,5-cyclohexadienyl, bicyclo[2.2.2]octyl, adamantan-1-yl, decahydronaphthyl, bicyclo[2.2.1]hept-1-yl, and the like. “Cyclic alkyl” equals to “cycloalkyl” as used here.
  • “Heterocycloalkyl” means cycloalkyl, as defined in this Application, provided that one or more of the atoms forming the ring is a heteroatom selected, independently from N, O, and S. CX-Y heterocycloalkyl is typically used where X and Y indicate the number of carbon atoms and heteroatoms in the ring assembly. The number of carbon atoms and heteroatoms in the ring is preferably 3 to 10, more preferably 3 to 8. Non-exclusive examples of heterocycloalkyl include piperidyl, 4-morpholyl, 4-piperazinyl, pyrrolidinyl, perhydropyrrolizinyl, 1,4-diazaperhydroepinyl, 1,3-dioxanyl, 1,4-dioxanyl, tetrazolyl and the like.
  • Moreover, the above-mentioned definitions can apply to groups wherein the above-mentioned substituents are connected. For example, “arylalkyl” means linear or branched alkyl group which is substituted by one or more aryl groups, such as benzyl, 1-phenylethyl, 2-phenylethyl, 3-phenylpropyl, 1-naphthylmethyl, 2-naphthylmethyl, benzhydryl, 2,2-diphenylethyl, trityl and the like.
  • “Monocyclic ring” as used herein refers to a monocyclic, saturated or unsaturated carbocyclic ring or a monocyclic, saturated or unsaturated heterocyclic ring. “X- (to, or) Y-membered monocyclic ring” is typically used where X and Y indicate the number of carbon atoms and heteroatoms in the ring assembly. The number of carbon atoms and heteroatoms in the ring is preferably 4 to 7, more preferably 5 or 6. “Monocyclic heterocyclic ring” means a monocyclic, aromatic or nonaromatic ring wherein at least one ring atom is a heteroatom (preferably S, N or O) and the remaining ring atoms are carbon. The nitrogen atoms can be optionally quaternerized and the sulfur atoms can be optionally oxidized.
  • Non-exclusive examples of monocyclic saturated carbocyclic ring include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane and the like.
  • Non-exclusive examples of monocyclic unsaturated carbocyclic ring include cyclopropene, cyclobutene, cyclopentene, cyclohexene, cycloheptene, cyclopentadiene, benzene, and the like.
  • Non-exclusive examples of monocyclic saturated heterocyclic ring include pyrrolidine, piperidine, morpholine, piperazine, 1,3-dioxane, 1,4-dioxane and the like.
  • Non-exclusive examples of monocyclic unsaturated heterocyclic ring include pyrazole, dihydro-pyrrole, pyrrole, dihydro-pyrazole, imidazole, thiophene, thiazole, isothiazole, thiadiazole, furan, oxazole, isoxazole, oxadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine and the like.
  • “Spiro ring” as used herein refers to saturated or unsaturated cycloalkane or saturated or unsaturated heterocycloalkane.
  • “Cycloalkane” means a non-aromatic, saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring. CX-Y cycloalkane is typically used where X and Y indicate the number of carbon atoms in the ring assembly. The number of carbon atoms in the ring is preferably 3 to 10, more preferably 3 to 8. Non-exclusive examples of cycloalkane include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane and the like.
  • “Heterocycloalkane” means cycloalkane, as defined in this Application, provided that one or more of the atoms forming the ring is a heteroatom selected, independently from N, O, and S. CX-Y heterocycloalkane is typically used where X and Y indicate the number of carbon atoms and heteroatoms in the ring assembly. The number of carbon atoms and heteroatoms in the ring is preferably 3 to 10, more preferably 3 to 8. Non-exclusive examples of heterocycloalkane include piperidine, morpholine, piperazine, pyrrolidine, perhydropyrrolizine, tetrahydrofuran, tetrahydropyran, 1,3-dioxane, 1,4-dioxane and the like.
  • “Fused ring” as used herein refers to a ring that is bonded to another ring to form a compound having a bicyclic structure when the ring atoms that are common to both rings are directly bound to each other. Non-exclusive examples of fused rings include decalin, naphthalene, anthracene, phenanthrene, indole, furan, benzofuran, quinoline, and the like. Compounds having fused ring systems may be saturated, partially saturated or aromatic.
  • “Bridging ring” as used herein refers to a ring that is bonded to another ring to form a compound having a bicyclic structure where two ring atoms that are common to both rings are not directly bound to each other. Non-exclusive examples of common compounds having a bridging ring include adamantine, borneol, norbornane, 7-oxabicyclo[2.2.1]heptane, and the like.
  • “Protected derivatives” means derivatives of compound in which a reactive site or sites are blocked with protecting groups. A comprehensive list of suitable protecting groups can be found in T. W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc. 1999.
  • “Isomers” mean any compound having an identical molecular formulae but differing in the nature or sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.” Stereoisomers that are not mirror images of one another are termed “diastereomers” and stereoisomers that are nonsuperimposable mirror images are termed “enantiomers” or sometimes “optical isomers.” A carbon atom bonded to four nonidentical substituents is termed a “chiral center.” A compound with one chiral center has two enantiomeric forms of opposite chirality. A mixture of the two enantiomeric forms is termed a “racemic mixture.” A compound that has more than one chiral center has 2n-1 enantiomeric pairs, where n is the number of chiral centers. Compounds with more than one chiral center may exist as either an individual diastereomer or as a mixture of diastereomers, termed a “diastereomeric mixture.” When one chiral center is present, a stereoisomer may be characterized by the absolute configuration of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center. Enantiomers are characterized by the absolute configuration of their chiral centers and described by the R- and S-sequencing rules of Cahn, Ingold and Prelog. Conventions for stereochemical nomenclature, methods for the determination of stereochemistry and the separation of stereoisomers are well known in the art (e.g., see “Advanced Organic Chemistry”, 4th edition, March, Jerry, John Wiley & Sons, New York, 1992).
  • “Animal” includes humans, non-human mammals (e.g., mice, rats, dogs, cats, rabbits, cattle, horses, sheep, goats, swine, deer, and the like) and non-mammals (e.g., birds, and the like).
  • “Disease” specifically includes any unhealthy condition of an animal or part thereof and includes an unhealthy condition that may be caused by, or incident to, medical or veterinary therapy applied to that animal, i.e., the “side effects” of such therapy.
  • “Pharmaceutically acceptable” means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary use as well as human pharmaceutical use.
  • “Pharmaceutically acceptable salt” means a salt of compounds of the present invention which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity. Such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or with organic acids such as acetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, o-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4′-methylenebis(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid and the like.
  • Pharmaceutically acceptable salt also include base addition salts which may be formed when acidic protons present are capable of reacting with inorganic or organic bases. Acceptable inorganic bases include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide and calcium hydroxide. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine and the like.
  • “Amount effective to treat” means that amount which, when administered to an animal for treating a disease, is sufficient to effect such treatment for the disease.
  • “Amount effective to prevent” means that amount which, when administered to an animal for preventing a disease, is sufficient to effect such prophylaxis for the disease.
  • “Effective amount” equals to “amount effective to treat” and “amount effective to prevent”.
  • “Treatment” or “treat” means any administration of a compound of the present invention and includes:
  • (1) preventing the disease from occurring in an animal which may be predisposed to the disease but does not yet experience or display the pathology or symptomatology of the disease,
  • (2) inhibiting the disease in an animal that is experiencing or displaying the pathology or symptomatology of the disease (i.e., arresting further development of the pathology and/or symptomatology), or
  • (3) ameliorating the disease in an animal that is experiencing or displaying the pathology or symptomatology of the disease (i.e., reversing the pathology and/or symptomatology).
  • It is noted in regard to all of the definitions provided herein that the definitions should be interpreted as being open ended in the sense that further substituents beyond those specified may be included.
    • Alpha-Helix Mimetic
  • In one aspect of the present invention, an alpha-helix mimetic structure is disclosed having the following formula (I):
  • Figure US20180305373A1-20181025-C00009
  • wherein
    • Figure US20180305373A1-20181025-P00001
      is single bond or double bond;
    • A is —CHR7—,
      • wherein
        • R7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
    • E is bond, —CHR5—, —O— or —NR8—,
      • wherein
      • R5 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl; and
      • R8 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
        B is void or optionally substituted monocyclic ring formed together with G and Y,
        D is void or optionally substituted spiro ring formed together with Y,
        with the proviso that
        B and D are not both present,
        when B is present, then G and Y are independently carbon atom or nitrogen atom,
        when D is present, then Y is carbon atom and G is —NR6—, —O—, —CHR6— or —C(R6)2—,
        when both B and D are void, then G and Y are the same or different and each is —NR6—, —O—, —CHR6— or —C(R6)2—
      • wherein
      • each R6 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl; and
        when E is bond, then D is void, B is optionally substituted monocyclic ring, and G and Y are independently carbon atom or nitrogen atom;
    • R1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
    • R2 is —W21—W22—Rb—R20,
      • wherein
      • W21 is —(CO)— or —(SO2)—;
      • W22 is bond, —O—, —NH— or optionally substituted lower alkylene;
      • Rb is bond or optionally substituted lower alkylene, and
      • R20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl; and
    • R3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
      with the proviso that
      when D is void, E is bond, B is benzene, and R2 is —W21—W22—Rb—R20, wherein W21 is —(CO)—, W22 is —NH—, and Rb is bond, then R20 should not be optionally substituted phenyl;
      or a pharmaceutically acceptable salt thereof.
  • In one embodiment of formula (I), A is —CHR7—, wherein R7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl.
  • Examples of optionally substituted alkyl group include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carbamoylmethyl, carbamoylethyl, carbamoylpropyl, carbamoylbutyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methylthiomethyl, methylthioethyl, methylthiopropyl, methylthiobutyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, ethoxycarbonylmethyl, ethoxycarbonylethyl, benzyloxymethyl, benzyloxyethyl, benzyloxypropyl, benzyloxybutyl and the like.
  • Examples of alkenyl group include ethenyl, allyl, 1-propenyl, 2-methylallyl and the like.
  • Examples of alkynyl group include ethynyl, 1-propynyl and the like.
  • Examples of aryl group and heteroaryl group include biphenyl, phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolyl, thienyl, furyl, thiazolyl, oxazolyl, imidazolyl, tetrahydronaphthyl, naphthyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, benzotriazinyl, indenyl, pyridopyrimidinyl, pyridopyrazinyl, pyridopyridazinyl, pyridotriazinyl, benzofuryl, benzothienyl, indolyl, indazolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiadiazolyl, furopyridinyl, thienopyridinyl, pyrropyridinyl, oxazolopyridinyl, thiazolopyridinyl, imidazopyridinyl and the like.
  • Examples of cycloalkyl and optionally substituted heterocycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl and the like.
  • In another embodiment of formula (I), A is —CHR7—, wherein R7 is -Rc-R70 wherein Rc is bond or optionally substituted lower alkylene, and R70 is hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl.
  • Examples of lower alkylene group include methylene, ethylene, methylmethylene, 1,2-propylene, 1,3-propylene, 1,2-butylene, 1,3-butylene, 1,4-butylene, 1,2,3-propanetriyl, 1,3,3-propanetriyl and the like.
  • Examples of optionally substituted alkyl group include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carbamoylmethyl, carbamoylethyl, carbamoylpropyl, carbamoylbutyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methylthiomethyl, methylthioethyl, methylthiopropyl, methylthiobutyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, ethoxycarbonylmethyl, ethoxycarbonylethyl, benzyloxymethyl, benzyloxyethyl, benzyloxypropyl, benzyloxybutyl and the like.
  • Examples of aryl group and heteroaryl group include biphenyl, phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolyl, thienyl, furanyl, thiazolyl, oxazolyl, imidazolyl, tetrahydronaphthyl, naphthyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, benzotriazinyl, indenyl, pyridopyrimidinyl, pyridopyrazinyl, pyridopyridazinyl, pyridotriazinyl, benzofuranyl, benzothienyl, indolyl, indazolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiadiazolyl, furopyridinyl, thienopyridinyl, pyrropyridinyl, oxazolopyridinyl, thiazolopyridinyl, imidazopyridinyl and the like.
  • Examples of cycloalkyl group and heterocycloalkyl group include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl and the like.
  • In a particular embodiment of formula (I), in the above-mentioned embodiments R70 is optionally substituted aryl or optionally substituted heteroaryl.
  • Examples of aryl group and heteroaryl group include biphenyl, phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolyl, thienyl, furanyl, thiazolyl, oxazolyl, imidazolyl, tetrahydronaphthyl, naphthyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, benzotriazinyl, indenyl, pyridopyrimidinyl, pyridopyrazinyl, pyridopyridazinyl, pyridotriazinyl, benzofuranyl, benzothiopenyl, indolyl, indazolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiadiazolyl, furopyridinyl, thienopyridinyl, pyrrolopyridinyl, oxazolopyridinyl, thiazolopyridinyl, imidazopyridinyl and the like.
  • Preferred examples of aryl group and heteroaryl group include phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolyl, thienyl, furanyl, thiazolyl, oxazolyl, imidazolyl, naphthyl and the like.
  • Most preferred example of aryl group include phenyl and the like.
  • Examples of substituents for R7 include —R9, —OH, —OR9, —OC(O)R9, —OC(O)OR9, —COOH, —COR9, —COOR9, —CONH2, —CONHR9, —CONR9R4, —NH2, —NHR9, —NR9R4, —SH, —SR9, —SO2R9, —SO2NH2, —SO2NHR9, —SO2NR9R4—SO3H, —SOR9, —NHC(NH2)(═NH), —NHC(NHR9)(═NR4), —OP(═O)(OH), —OP(═O)(ONa)2, —OP(═O)(OR9)2, —OP(═O)(OR9)(OH), —OP(═O)(OH)—O—P(═O)(OH)2, —OP(═O)(ONa)—O—OP(═O)(ONa)2, —CN, —NO2 and halogen, wherein R9 and R4 is independently selected from linear or branched chain, cyclic or noncyclic, substituted or unsubstituted, alkyl chain, aryl and arylalkyl moieties.
  • Preferred examples of the substituents include —OH, —COOH, —OC(O)R9, —OC(O)OR9, —NH2, —SH, —SO3H, —SOR9, —OP(═O)(OH)2, —OP(═O)(OR9)2, —OP(═O)(OR9)(OH), —OP(═O)(ONa)2, —OP(═O)(OH)—O—P(═O)(OH)2, —OP(═O)(ONa)—O—OP(═O)(ONa)2, and halogen.
  • Most preferred examples of the substituents include —OH, —OR9, —COOH, —OC(O)R9, —COOR9, —NH2, —NHR9, —NR9R4, —CONH2, —CONHR9, —CONR9R4, —OP(═O)(OH)2, —OP(═O)(ONa)2, and halogen.
  • In a particular embodiment of formula (I), in the above-mentioned embodiments R7 is phenyl, benzyl, phenethyl, l-naphthyl, 2-naphthyl, 1-naphthylmethyl, 2-naphthylmethyl, 4-hydroxybenzyl, 4-benzyloxybenzyl, imidazolyl-5-methyl, methyl, n-butyl, isopropyl, isobutyl, hydroxymethyl, 4-aminobutyl, carboxymethyl, 2-carboxyethyl, carbamoylmethyl, 2-carbamoylethyl, ethoxycarbonylmethyl, 2-ethoxycarbonylethyl, benzyloxymethyl and the like.
  • In one embodiment of formula (I), E is bond, —CHR5—, —O— or —NR8—, wherein R5 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl; and R8 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl.
  • In another embodiment of formula (I), in the above-mentioned embodiments R5 is lower alkyl, lower alkenyl, lower alkynyl or lower arylalkyl, and R8 is alkyl, alkynyl or arylalkyl.
  • Examples of lower alkyl group for R5 include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl and the like.
  • Examples of lower alkenyl group for R5 include ethenyl, allyl, 1-propenyl, 2-methylallyl and the like.
  • Examples of lower alkynyl group for R5 include ethynyl, 1-propynyl and the like.
  • In another embodiment of formula (I), R5 is arylalkyl or heteroarylalkyl represented by -Rd-R50 wherein Rd is optionally substituted lower alkylene, and R50 is optionally substituted aryl or optionally substituted heteroaryl.
  • Examples of lower alkylene group for Rd include methylene, ethylene, methylmethylene, 1,2-propylene, 1,3-propylene, 1,2-butylene, 1,3-butylene, 1,4-butylene, 1,2,3-propanetriyl, 1,3,3-propanetriyl and the like.
  • Examples of aryl group and heteroaryl group include biphenyl, phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolyl, thienyl, furanyl, thiazolyl, oxazolyl, imidazolyl, tetrahydronaphthyl, naphthyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, benzotriazinyl, indenyl, pyridopyrimidinyl, pyridopyrazinyl, pyridopyridazinyl, pyridotriazinyl, benzofuranyl, benzothienyl, indolyl, indazolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiadiazolyl, furopyridinyl, thienopyridinyl, pyrropyridinyl, oxazolopyridinyl, thiazolopyridinyl, imidazopyridinyl and the like.
  • Examples of alkyl group for R8 include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl and the like.
  • Examples of alkenyl group for R8 include ethenyl, allyl, 1-propenyl, 2-methylallyl and the like.
  • Examples of alkynyl group for R8 include ethynyl, 1-propynyl and the like.
  • In a particular embodiment of formula (I), in the above-mentioned embodiments E is —CH2—, —O— or —N(CH3)—.
  • In another embodiment of formula (I), in the above-mentioned embodiments E is bond with the proviso that
  • when E is bond, then D is void, B is optionally substituted monocyclic ring, and G and Y are independently carbon atom or nitrogen atom.
  • In one embodiment of formula (I), B is void or optionally substituted monocyclic ring formed together with G and Y; when B is present, then D is void, and G and Y are independently carbon atom or nitrogen atom.
  • B is preferably optionally substituted 3-, 4-, 5-, 6- or 7 membered saturated or unsaturated monocyclic ring and more preferably optionally substituted 5- or 6-membered saturated or unsaturated monocyclic ring formed together with G and Y.
  • When B is heterocyclic ring formed together with G and Y, the preferable hetero atom is selected from S, N, and O and the number of hetero atoms is preferably an integer of 1-3.
  • Examples of monocyclic ring group include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, pyrrolidine, pyrazole, cyclopropene, cyclobutene, cyclopentene, cyclohexene, cycloheptene, cyclopentadiene, dihydro-pyrrole, pyrrole, pyrrolidine, dihydro-pyrazole, pyrazole, imidazole, thiophene, thiazole, isothiazole, thiadiazole, furan, oxazole, isooxazole, oxadiazole, benzene, pyridine, pyridazine, pyrimidine, pyrazine, triazine and the like.
  • In a particular embodiment of formula (I), in the above-mentioned embodiments Q1 designates a structural sector of the compound;
  • Figure US20180305373A1-20181025-C00010
  • wherein Q1 is selected from one of the following group:
  • Figure US20180305373A1-20181025-C00011
    Figure US20180305373A1-20181025-C00012
    Figure US20180305373A1-20181025-C00013
    Figure US20180305373A1-20181025-C00014
    Figure US20180305373A1-20181025-C00015
    Figure US20180305373A1-20181025-C00016
    Figure US20180305373A1-20181025-C00017
  • and the like.
  • In one embodiment of formula (I), D is void or optionally substituted spiro ring formed together with Y; when D is present, then B is void, and Y is carbon atom and G is —NR6—, —O—, —CHR6— or —C(R6)2—, wherein each R6 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl. Specific embodiments for R6 are explained in detail below.
  • B and D are not both present.
  • Examples of spiro ring group include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, tetrahydropyran, tetrahydro-2H-thiopyran, azepane, cyclopentene and the like.
  • In another embodiment of formula (I), D is optionally substituted cycloalkane, preferably optionally substituted C3-8 cycloalkane.
  • In a particular embodiment of formula (I), in the above-mentioned embodiments Q2 designates a structural sector of the compound;
  • Figure US20180305373A1-20181025-C00018
  • wherein spiro ring of Q2 is selected from one of the following group:
  • Figure US20180305373A1-20181025-C00019
    Figure US20180305373A1-20181025-C00020
  • and the like.
  • The substituents of B or D are one or more of the chemical moieties selected from the group consisting of —R9, —OR9, —COR9, —COOR9, —OCOR9, —CONR9R4, —NR9R4, —NR4COR9, —NR4COOR9, —SR9, —SO2R9, —SO2NR9R4, —SO3R9, —NHC(NHR9) NR4, halogen and methylenedioxy, wherein R9 and R4 are independently selected from hydrogen atom, optionally substituted, cyclic or noncyclic, alkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl.
  • In one embodiment of formula (I), when both B and D are void, G and Y are the same or different and each is —NR6—, —O—, —CHR6— or —C(R6)2—, wherein each R6 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl.
  • Examples of alkyl group for R6 include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl and the like.
  • Examples of alkenyl group for R6 include ethenyl, allyl, 1-propenyl, 2-methylallyl and the like.
  • Examples of alkynyl group for R6 include ethynyl, 1-propynyl and the like.
  • In another embodiment of formula (I), R6 is aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl or heteroarylalkyl represented by —Re—R60 wherein Re is bond or optionally substituted lower alkylene, and R60 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl.
  • Examples of lower alkylene group for Re include methylene, ethylene, methylmethylene, 1,2-propylene, 1,3-propylene, 1,2-butylene, 1,3-butylene, 1,4-butylene, 1,2,3-propanetriyl, 1,3,3-propanetriyl and the like.
  • Examples of aryl group and heteroaryl group for R60 include biphenyl, phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolyl, thienyl, furanyl, thiazolyl, oxazolyl, imidazolyl, tetrahydronaphthyl, naphthyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, benzotriazinyl, indenyl, pyridopyrimidinyl, pyridopyrazinyl, pyridopyridazinyl, pyridotriazinyl, benzofuranyl, benzothienyl, indolyl, indazolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiadiazolyl, furopyridinyl, thienopyridinyl, pyrropyridinyl, oxazolopyridinyl, thiazolopyridinyl, imidazopyridinyl and the like.
  • Examples of cycloalkyl group and heterocycloalkyl group include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl and the like.
  • In another embodiment of formula (I), at least one of G and Y is —NR6′—, —CHR6′— or —C(R6′)2—, wherein each R6′ is independently hydrogen, optionally substituted cyclic or noncyclic lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl.
  • In a particular embodiment of formula (I), in the above-mentioned embodiments R6 or R6′ is hydrogen, lower alkyl (ex. methyl) or lower alkenyl (ex. allyl).
  • In one embodiment of formula (I), R1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl.
  • Examples of optionally substituted alkyl group include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carbamoylmethyl, carbamoylethyl, carbamoylpropyl, carbamoylbutyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methylthiomethyl, methylthioethyl, methylthiopropyl, methylthiobutyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, ethoxycarbonylmethyl, ethoxycarbonylethyl, benzyloxymethyl, benzyloxyethyl, benzyloxypropyl, benzyloxybutyl, 3,3-diphenylpropyl and the like.
  • Examples of alkenyl group include ethenyl, allyl, 1-propenyl, 2-methylallyl and the like.
  • Examples of alkynyl group include ethynyl, 1-propynyl and the like.
  • In another embodiment of formula (I), R1 is —Ra—R10, wherein Ra is optionally substituted lower alkylene and R10 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl or optionally substituted heteroaryl.
  • Examples of optionally substituted alkyl group include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carbamoylmethyl, carbamoylethyl, carbamoylpropyl, carbamoylbutyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methylthiomethyl, methylthioethyl, methylthiopropyl, methylthiobutyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, ethoxycarbonylmethyl, ethoxycarbonylethyl, benzyloxymethyl, benzyloxyethyl, benzyloxypropyl, benzyloxybutyl, 3,3-diphenylpropyl and the like.
  • Examples of lower alkylene group include methylene, ethylene, methylmethylene, 1,2-propylene, 1,3-propylene, 1,2-butylene, 1,3-butylene, 1,4-butylene, 1,2,3-propanetriyl, 1,3,3-propanetriyl and the like.
  • Examples of cycloalkyl group and heterocycloalkyl group include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl and the like.
  • Examples of aryl group and heteroaryl group include biphenyl, phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolyl, thienyl, furanyl, thiazolyl, oxazolyl, imidazolyl, naphthyl, tetrahydronaphthyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, benzotriazinyl, pyridopyrimidinyl, pyridopyrazinyl, pyridopyridazinyl, pyridotriazinyl, indenyl, benzofuranyl, benzothienyl, indolyl, indazolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiadiazolyl, furopyridinyl, thienopyridinyl, pyrrolopyridinyl, oxazolopyridinyl, thiazolopyridinyl, imidazopyridinyl and the like.
  • Preferred examples of lower alkylene group include methylene, ethylene, 1,3-propylene and the like.
  • Preferred examples of aryl group and heteroaryl group include bicyclic fused aryl group and bicyclic fused heteroaryl group such as naphthyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, benzotriazinyl, indenyl, pyridopyrimidinyl, pyridopyrazinyl, pyridopyridazinyl, pyridotriazinyl, benzofuryl, benzothienyl, indolyl, indazolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiadiazolyl, furopyridinyl, thienopyridinyl, pyrropyridinyl, oxazolopyridinyl, thiazolopyridinyl, imidazopyridinyl and the like.
  • Examples of substituents for R1 include —R4, —OR9, —COR9, —COOR9, —OCOR9, —CONR9R4, —NR9R4, —NR4COR9, —NR4COOR9, —SR9, —SO2R9, SO2NR9R4, —SO3R9, —NHC(NHR9)NR4, —NHC(NH2)NH, —OPO(OH) 2, —OPO(ONa)2, —CN, —NO2, halogen and methylenedioxy, wherein R9 and R4 are independently selected from hydrogen atom, optionally substituted, cyclic or noncyclic, alkyl, aryl, heteroaryl, arylalkyl and heteroaryl.
  • Preferred examples of the substituents include —NH2, —OH, —OR9, —COOH, —COOR9, —NR4COR9, —CONH2, —CONHR9, —CONR9R4, —NHR9, —NR9R4 and halogen.
  • More preferred examples of the substituents include —NH2, —OH, —COOH, —COOR9, —NR4COR9, —CONH2 and halogen.
  • In a particular embodiment of formula (I), in the above-mentioned embodiments R1 is isopentyl, benzyl, 2,4-difluorobenzyl, 4-hydroxybenzyl, 1-phenylethyl, 2-phenylethyl, 3-phenylpropyl, 3,3-diphenylpropyl, pyridyl-4-methyl, pyridyl-2-methyl, thienyl-2-methyl, thienyl-3-methyl, imidazolyl-5-methyl, 1-naphthylmethyl, 2-naphthylmethyl, 4-quinolinylmethyl, 8-quinolinylmethy, 1, 5-chloroquinolin-8-ylmethyl, 5-isoquinolynylmethyl, 8-isoquinolynylmethyl, 5-chloroisoquinolin-8-ylmethyl, indazolyl-7-ylmethyl, benzothiazol-4-ylmethyl, benzothiazol-7-ylmethyl, 7-fluorobenzothiazol-4-ylmethyl, 4-fluorobenzothiazol-7-ylmethyl, 2-aminobenzothiazol-4-ylmethyl, 2-aminobenzothiazol-7-ylmethyl, 2-amino-7-fluorobenzothiazol-4-ylmethyl, 2-amino-4-fluorobenzothiazol-7-ylmethyl, 2-tert-butoxycarbonylaminobenzothiazol-4-ylmethyl, benzoxazol-4-ylmethyl, benzoxazol-7-ylmethyl, 7-fluorobenzoxazol-4-ylmethyl, 4-fluorobenzoxazol-7-ylmethyl, 2-aminobenzoxazol-4-ylmethyl, 2-aminobenzoxazol-7-ylmethyl, 2-amino-7-fluorobenzoxazol-4-ylmethyl, 2-amino-4-fluorobenzoxazol-7-ylmethyl, benzothiophen-3-ylmethyl, 7-fluorobenzothiophen-3-ylmethyl, benzothiophen-4-ylmethyl, benzothiophen-7-ylmethyl, 7-fluorobenzothiophen-4-ylmethyl, 4-fluorobenzothiophen-7-ylmethyl, benzothiadiazol-4-ylmethyl, benzofuran-3-ylmethyl, 7-fluorobenzofuran-3-ylmethyl, benzofuran-4-ylmethyl, benzofuran-7-ylmethyl, 7-fuorobenzofuran-4-ylmethyl or 4-fluorobenzofuran-7-ylmethyl.
  • In one embodiment of formula (I), R2 is —W21—W22—Rb—R20, wherein W21 is —(CO)— or —(SO2)—; W22 is bond, —O—, —NH— or optionally substituted lower alkylene; Rb is bond or optionally substituted alkylene; and R20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl.
  • Examples of lower alkylene group for W22 include methylene, ethylene, propylene, butylene and the like.
  • Examples of lower alkylene group for Rb include methylene, ethylene, methylmethylene, 1,2-propylene, 1,3-propylene, 1,2-butylene, 1,3-butylene, 1,4-butylene, 1,2,3-propanetriyl, 1,3,3-propanetriyl and the like.
  • Examples of optionally substituted alkyl group for R20 include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carbamoylmethyl, carbamoylethyl, carbamoylpropyl, carbamoylbutyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methylthiomethyl, methylthioethyl, methylthiopropyl, methylthiobutyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, ethoxycarbonylmethyl, ethoxycarbonylethyl, benzyloxymethyl, benzyloxyethyl, benzyloxypropyl, benzyloxybutyl, 3,3-diphenylpropyl and the like.
  • Examples of alkenyl group for R20 include ethenyl, allyl, 1-propenyl, 2-methylallyl and the like.
  • Examples of alkynyl group for R20 include ethynyl, 1-propynyl and the like.
  • Examples of aryl group and heteroaryl group for R20 include biphenyl, phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolyl, thienyl, furanyl, thiazolyl, oxazolyl, imidazolyl, tetrahydronaphthyl, naphthyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, benzotriazinyl, indenyl, pyridopyrimidinyl, pyridopyrazinyl, pyridopyridazinyl, pyridotriazinyl, benzofuranyl, benzothienyl, indolyl, indazolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiadiazolyl, furopyridinyl, thienopyridinyl, pyrrolopyridinyl, oxazolopyridinyl, thiazolopyridinyl, imidazopyridinyl, benzodioxolyl and the like.
  • Examples of cycloalkyl group and heterocycloalkyl group include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl and the like.
  • In a further embodiment of formula (I), in the above-mentioned embodiments R2 is —W21—W22—Rb—R20, wherein W21 is —(CO)— or —(SO2)—; W22 is bond, —O—, —NH—, methylene, ethylene, propylene or butylene; Rb is bond, methylene, ethylene, methylmethylene, 1,2-propylene, 1,3-propylene, 1,2-butylene, 1,3-butylene, 1,4-butylene, 1,2,3-propanetriyl or 1,3,3-propanetriyl; and R20 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carbamoylmethyl, carbamoylethyl, carbamoylpropyl, carbamoylbutyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methylthiomethyl, methylthioethyl, methylthiopropyl, methylthiobutyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, ethoxycarbonylmethyl, ethoxycarbonylethyl, benzyloxymethyl, benzyloxyethyl, benzyloxypropyl, benzyloxybutyl, 3,3-diphenylpropyl, ethenyl, ethynyl, allyl, 1-propynyl, 2-methylallyl, 1-propynyl, optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl, optionally substituted cyclohexyl, optionally substituted cycloheptyl, optionally substituted adamantyl, optionally substituted biphenyl, optionally substituted phenyl, optionally substituted pyridyl, optionally substituted pyrimidyl, optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted thienyl, optionally substituted furanyl, optionally substituted thiazolyl, optionally substituted oxazolyl, optionally substituted imidazolyl, optionally substituted naphthyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl, optionally substituted quinoxalinyl, optionally substituted cinnolinyl, optionally substituted naphthyridinyl, optionally substituted benzotriazinyl, optionally substituted pyridopyrimidinyl, optionally substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl, optionally substituted pyridotriazinyl, optionally substituted benzofuranyl, optionally substituted benzothiopenyl, optionally substituted indolyl, optionally substituted indenyl, optionally substituted benzooxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl, optionally substituted oxazolopyridinyl, optionally substituted thiazolopyridinyl, optionally substituted imidazopyridinyl, optionally substituted benzodioxolyl and the like.
  • In particular embodiment of formula (I), in the above-mentioned embodiments R2 is —W21—W22—Rb—R20, wherein W21 is —(CO)—; W22 is —NH—; Rb is bond, methylene or ethylene; and R20 is optionally substituted biphenyl, optionally substituted phenyl, optionally substituted pyridyl, optionally substituted pyrimidyl, optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted thienyl, optionally substituted furanyl, optionally substituted thiazolyl, optionally substituted oxazolyl, optionally substituted imidazolyl, optionally substituted naphthyl or optionally substituted benzodioxolyl.
  • Examples of substituents for R20 include, —R9, —OR9, —COR9, —COOR9, —OCOR9, —CONR9R4, —NR9R4, —NR4COR9, —NR4COOR9, —SR9, —SO2R9, SO2NR9R4, —SO3R9, —NHC(NHR9)NR4, —NHC(NH2)NH, —OPO(OH)2, —OPO(ONa)2, —CN, —NO2, halogen and methylenedioxy, wherein R9 and R4 are independently selected from hydrogen atom, optionally substituted, cyclic or noncyclic, alkyl, aryl, heteroaryl, arylalkyl and heteroaryl.
  • Preferred examples of the substituents include —R9, —NH2, —OH, —OR9, —COOH, —COOR9′—CONH2, —CONHR9, —CONR9R4, —NHR9, —NR9R4, halogen and methylenedioxy.
  • More preferred examples of the substituents include —R9, —NH2, —OH, —COOH, —COOR9, —CONH2, halogen and methylenedioxy.
  • In one embodiment of formula (I), R3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or, optionally substituted alkynyl.
  • Preferable examples of alkyl group include C1-4 alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl and the like.
  • Examples of alkenyl group include ethenyl, allyl, 2-methylallyl and the like.
  • Examples of alkynyl group include 1-propynyl, ethynyl and the like.
  • R3 is preferably hydrogen or C1-4 alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, more preferably methyl or ethyl.
  • In particular embodiment of formula (I), in the above-mentioned embodiments R3 is hydrogen or methyl.
  • In a further embodiment of formula (I), in the above-mentioned embodiments R7 is 4-hydroxy-benzyl; and R2 represents —W21—W22—Rb—R20, wherein W21 is —(CO)— or —(SO2)—; W22 is bond, —O—, —NH— or optionally substituted lower alkylene; Rb is bond or optionally substituted alkylene; and R20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl.
  • In order to avoid an accidental anticipation, the following proviso is added to the formula (I);
  • when D is void, E is bond, B is benzene, R2 is —W21—W22—Rb—R20, wherein W21 is —(CO)—, W22 is —NH—, and Rb is bond, then R20 should not be optionally substituted phenyl.
  • The general syntheses of the compounds in this invention are illustrated in FIG. 1 and FIG. 2, wherein Compound Ia′ indicates formulas (Ia) and (Id), Compound Ib′ indicates formulas (Ib) and (Ic).
  • The general synthesis of the compounds in this invention, represented by the formula (Ia) wherein B is present and D is void and formula (Id) wherein B is present and E is void, may be synthesized by the technique illustrated in FIG. 1.
  • The compounds in this invention, represented by the formula (Ib) and (Ic) wherein D is present or void and B is void can also be synthesized by the similar method illustrated in FIG. 2.
  • The general synthesis of the compounds in this invention, represented by the formula (IIa′) wherein B is present and D is void and may be synthesized by the technique illustrated in FIG. 1.
  • The compounds in this invention, represented by the formula (IIb′) wherein D is present or void and B is void can also be synthesized by the similar method illustrated in FIG. 2.
  • R (including R91 and R92 in the formula (IIa′) and (IIb′)) illustrated in FIG. 1 and FIG. 2 is a protective group suitable for use in synthesis, where this protection group may be joined to a polymeric support to enable solid-phase synthesis. Suitable R groups include alkyl groups and, in a preferred embodiment, R is a methyl or ethyl group.
  • LG illustrated in FIG. 1 is a leaving group, e.g., a halogen (Hal) group, methanesulfonyloxy, trifluoromethanesulfonyloxy, toluenesufonyloxy and the like.
  • P1 and P3 illustrated in FIG. 1 and FIG. 2 are a carboxylic acid protection group. P2 and P5 illustrated in FIG. 1 are an amino protection group. P4 illustrated in FIG. 1 is a hydroxyl protection group. Preferred protection groups include methyl, ethyl, benzyl, 9H-fluorenylmethyloxycarbonyl (FRoc), benzyloxycarbonyl (Cbz), t-butyl dimethylsilyl (TBDMS), t-butyloxycarbonyl (BOC), methyloxycarbonyl (MOC), and allyloxycarbonyl (Alloc). For an amino protective group, also preferred is phthalimide formed together with an amino group to be protected.
  • Compound IV may be readily synthesized by reductive amination of H2N—R1 with CH(OR)2—CR3O, by reductive amination of R1′—CHO (when R1═CH2R1′) with CH(OR)2—CHR3NH2, by a displacement reaction between H2N—R1 and CH(OR)2—CHR3-LG or by a displacement reaction between LG-R1 and CH(OR)2—CHR3—NH2.
  • N-Protected amino acids are commercially available; for example, Fmoc amino acids are available from a variety of sources. In the case of the azido derivative of an amino acid serving as the Compound XV, such compounds may be prepared from the corresponding amino acid by the reaction disclosed by Zaloom et al. (J. Org. Chem. 46:5173-76, 1981).
  • A Compound VI of this invention may have the indicated structure wherein G, E, B, and R2 are as defined above. Other suitable Compounds XI are commercially available from a variety of sources or can be prepared by methods well known in organic chemistry.
  • Compound X, XI, XII, XIII, XIV, XVIII, XIX, XX, XXIV, XXIX, XXX, XXXIII, XXXIV, XXXV, XXXIV, XXXVII, XL, XLI, XLII, XLIV, XLV, XLVI and XLVII are commercially available from a variety of sources or can be prepared by methods well known in organic chemistry.
  • As illustrated in FIG. 1, the alpha-helix mimetic compounds of formula (Ia′) may be synthesized by reacting a Compound IV with a Compound XXI to yield a combined Compound XV, followed by treating the combined Compound XV with piperidine to provide Compound VI, reacting the Compound VI with Compound V sequentially to provide a combined Compound IIa′, and then cyclizing this intermediate to yield an alpha-helix mimetic structure of formula (Ia′). Or, the alpha-helix mimetic compounds of formula (Ia′) may be synthesized by reacting a Compound V with a Compound XVIII to yield a combined Compound IX, followed by treating the Compound IX with lithium hydroxide, sodium hydroxide or potassium hydroxide to provide Compound III. As illustrated in FIG. 1, the Compound III reacts with Compound IV sequentially to provide a combined Compound IIa′, followed by cyclizing this intermediate to yield an alpha-helix mimetic structure of formula (Ia′).
  • As illustrated in FIG. 2, the alpha-helix mimetic compounds of formula (Ib′) may be synthesized by the methods similar to those in FIG. 1.
  • A compound having the following general formula (II) is a novel intermediate compound for preparing the compound of the formula (I).
  • Figure US20180305373A1-20181025-C00021
  • wherein
    • Figure US20180305373A1-20181025-P00001
      is single bond or double bond;
    • A is —CHR7—,
      • wherein
        • R7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
    • E is bond, —CHR5—, —O— or —NR8—,
      • wherein
      • R5 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl, and
      • R8 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
    • B is void or optionally substituted monocyclic ring formed together with G and Y;
    • D is void or optionally substituted spiro ring formed together with Y;
      with the proviso that
    • B and D are not both present,
      when B is present, then G and Y are independently carbon atom or nitrogen atom,
      when D is present, then Y is carbon atom and G is —NR6—, —O—, —CHR6— or —C(R6)2—,
      when both B and D are void, then G and Y are the same or different and each is —NR6—, —O—, —CHR6— or —C(R6)2—,
      • wherein
        • each R6 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl, and
          when E is bond, then D is void, B is optionally substituted monocyclic ring, and G and Y are independently carbon atom or nitrogen atom;
    • R1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
    • R2 is —W21—W22—Rb—R20,
      • wherein
      • W21 is —(CO)— or —(SO2)—,
      • W22 is bond, —O—, —NH— or optionally substituted lower alkylene,
      • Rb is bond or optionally substituted alkylene, and
      • R20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl;
    • R3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
    • R91 is selected from optionally substituted alkyl, linker and solid support; and
    • R92 is selected from optionally substituted alkyl, linker and solid support;
      with the proviso that
      when D is void, E is bond, B is benzene, and R2 is —W21—W22—Rb—R20,
      wherein W21 is —(CO)—, W22 is —NH—, and Rb is bond, then R20 should not be optionally substituted phenyl.
  • Examples and preferable embodiments of A, E, D, B, G, Y, R1, R2, and R3 in the formula (II) are the same as those for the formula (I).
  • Examples of optionally substituted alkyl for R91 and R92 include those as defined for R7 and the like.
  • Examples of linker and solid support for R91 and R92 include those for preparing the libraries as explained below.
  • The cyclization reaction of Compound II for preparing Compound (I) is explained in detail in the following.
  • This cyclization reaction can be carried out by reacting the Compound II with an acid.
  • The order of addition of the reagents is not particularly limited, and, for example, an acid may be added to Compound II or vice versa.
  • The acid to be used in the cyclization reaction is not particularly limited, and examples thereof include inorganic acids such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid and the like; organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, methanesulfonic acid, p-toluenesulfonic acid, trifluoromethanesulfonic acid; hydrogen chloride solution; hydrogen bromide solution; hydrogen fluoride and the like
  • In addition, water, anisole, m-cresol, ethanedithiol, thioanisole or triisopropylsilane can be used with along the acid.
  • The amount of the acid to be used in the cyclization reaction is generally 0.001 mol to 1000 mol, preferably 1 mol to 100 mol, more preferably 5 mol to 50 mol, relative to 1 mol of Compound II.
  • The cyclization reaction may be performed with or without solvent. The solvent to be used in the cyclization reaction may be any as long as it does not inhibit the reaction. Examples thereof include ethers such as tetrahydrofuran (THF), methyl tert-butyl ether, 1,4-dioxane, diethylene glycol dimethyl ether (diglyme), ethylene glycol dimethyl ether, 1,3-dioxolane, 2-methyltetrahydrofuran and the like; aprotic polar solvents such as N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAc), dimethyl sulfoxide (DMSO), sulfolane, N-methyl-2-pyrrolidinone (NMP), 1,3-dimethyl-2-imidazolidinone (DMI), hexamethyl phosphoramide (HMPA), acetonitrile, propionitrile and the like; halogenated solvents such as methylene chloride, 1,2-dichloroethane, carbon tetrachloride, monochlorobenzene and the like; aromatic hydrocarbon such as benzene, toluene, xylene and the like; water and the like, and a mixed solvent thereof. When a mixed solvent is used, the solvents may be mixed at optional ratios.
  • While the reaction temperature in the cyclization reaction depends on the reagent to be used and the like, it is generally from −40° C. to 120° C., preferably from −20° C. to 60° C., more preferably from −10° C. to 40° C. The reaction time is generally 0.5 hr to 96 hr, preferably 1 hr to 48 hr.
  • The compound (I) to be obtained in the cyclization reaction can be isolated and purified by a conventional method such as extraction, water-washing, acid washing, alkali washing, crystallization, recrystallization, silica gel column chromatography.
  • Furthermore continuing the explanation, the compounds of the present invention, salts thereof and derivatives thereof useful as prodrugs are excellent in pharmacological action selectivity, safety (various toxicities and safety pharmacology), pharmacokinetic performance, physicochemical property and the like, and therefore the usefulness as active ingredients of medicaments can be confirmed.
  • Examples of tests concerning pharmacological action selectivity include, but not be limited to, the following list including inhibition or activation assays on various pharmacological target receptors, inhibition assays on various pharmacological target enzymes, ion channels or transporters, cell tests to be used for the evaluation for various pharmacological action, and the like.
  • Examples of tests concerning safety include, but not be limited to, the following list including cytotoxic tests (e.g., tests using HL60 cells, hepatocytes, etc., and the like), genotoxicity tests (e.g., Ames test, mouse lymphoma TK test, chromosomal aberration test, micronucleus test and the like), skin sensitization tests (e.g., Buehler method, GPMT method, APT method, LLNA test and the like), skin photosensitization tests (e.g., Adjuvant and Strip method and the like), eye irritation tests (e.g., single instillation, short-term continuation instillation, repetitive instillation and the like), safety pharmacology tests for the cardiovascular system (e.g., telemetry method, APD method, hERG inhibition assay and the like), safety pharmacology tests for the central nervous system (e.g., FOB method, modified version of Irwin method and the like), safety pharmacology tests for the respiratory system (e.g., measurement method using a respiratory function measuring apparatus, measurement method using a blood gas analyzer and the like), general toxicity tests, and the like.
  • Examples of tests concerning pharmacokinetic performance include, but not be limited to, the following list including cytochrome P450 enzyme inhibition or induction tests, cell permeability tests (e.g., tests using CaCO-2 cells, MDCK cells etc., and the like), drug transporter ATPase assay, oral absorption tests, blood concentration transition measurement tests, metabolism tests (e.g., stability test, metabolite molecular species test, reactivity test and the like), solubility tests (e.g., solubility test based on turbidity method and the like), and the like.
  • Examples of tests concerning physicochemical property include, but not be limited to, the following list including chemical stability test (e.g., stability test using HPLC etc., and the like), partition coefficient (e.g., partition test using octanol phase/water phase and the like), ionization constant test, crystallization test, and the like.
  • The compound of the present invention are useful as bioactive agents, such as diagnostic, prophylactic, and therapeutic agents. For example, the alpha-helix mimetic structures of the present invention may be used for modulating a cell signaling transcription factor related peptides in a warm-blooded animal, by a method comprising administering to the animal an effective amount of the compound of formula (I), (Ia), (Ib), (Ic) or (Id).
  • In another embodiment, there is a method of treating a cancerous condition or fibrosis by administering the compound of formula (I), (Ia), (Ib), (Ic) or (Id). The compounds of the formula (I), (Ia), (Ib), (Ic) or (Id) can be used for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, such as colorectal cancer, and so forth.
  • In another embodiment, a pharmaceutical composition comprises the compound of formula (I), (Ia), (Ib), (Ic) or (Id) or a pharmaceutically acceptable salt thereof, and, if desired or necessary, together with a pharmaceutical acceptable carrier. In another aspect, it is an object of the present invention to provide a pharmaceutical composition comprising an effective amount of the compound having general formula (I), (Ia), (Ib), (Ic) or (Id) and pharmaceutically acceptable carrier, which can be used for treatment of disorders modulated by Wnt signaling pathway, especially by TCF4-β-catenin-CBP complex.
  • Further, the present invention is to provide a method for inhibiting the growth of tumor cells by using the above-described composition of the present invention; a method for inducing apoptosis of tumor cells by using the above-described composition of the present invention; a method for treating a disorder modulated by TCF4-β-catenin-CBP complex by using the above-described composition of the present invention; and a method of treating cancer such as colorectal cancer by administering the composition of the present invention together with other anti-cancer agent such as 5-fluorouracil (5-FU), taxol, cisplatin, mitomycin C, tegafur, raltitrexed, capecitabine, and irinotecan, etc.
  • In another aspect of this invention, libraries containing alpha-helix mimetic structures of the present invention are disclosed. Once assembled, the libraries of the present invention may be screened to identify individual members having bioactivity. Such screening of the libraries for bioactive members may involve; for example, evaluating the binding activity of the members of the library or evaluating the effect the library members have on a functional assay. Screening is normally accomplished by contacting the library members (or a subset of library members) with a target of interest, such as, for example, an antibody, enzyme, receptor or cell line. Library members which are capable of interacting with the target of interest, are referred to herein as “bioactive library members” or “bioactive mimetics”. For example, a bioactive mimetic may be a library member which is capable of binding to an antibody or receptor, or which is capable of inhibiting an enzyme, or which is capable of eliciting or antagonizing a functional response associated, for example, with a cell line. In other words, the screening of the libraries of the present invention determines which library members are capable of interacting with one or more biological targets of interest. Furthermore, when interaction does occur, the bioactive mimetic (or mimetics) may then be identified from the library members. The identification of a single (or limited number) of bioactive mimetic(s) from the library yields alpha-helix mimetic structures which are themselves biologically active, and thus are useful as diagnostic, prophylactic or therapeutic agents, and may further be used to significantly advance identification of lead compounds in these fields.
  • Synthesis of the peptide mimetics of the library of the present invention may be accomplished using known peptide synthesis techniques, in combination with the first, second and third component pieces of this invention. More specifically, any amino acid sequence may be added to the N-terminal and/or C-terminal of the conformationally constrained alpha-helix mimetic. To this end, the mimetics may be synthesized on a solid support (such as PAM resin) by known techniques (see, e.g., John M. Stewart and Janis D. Young, Solid Phase Peptide Synthesis, 1984, Pierce Chemical Comp., Rockford, Ill.) or on a silyl-linked resin by alcohol attachment (see Randolph et al., J. Am Chem. Soc. 117:5712-14, 1995).
  • In addition, a combination of both solution and solid phase synthesis techniques may be utilized to synthesize the peptide mimetics of this invention. For example, a solid support may be utilized to synthesize the linear peptide sequence up to the point that the conformationally constrained alpha-helix is added to the sequence. A suitable conformationally constrained alpha-helix mimetic structure which has been previously synthesized by solution synthesis techniques may then be added as the next “amino acid” to the solid phase synthesis (i.e., the conformationally constrained alpha-helix mimetic, which has both an N-terminus and a C-terminus, may be utilized as the next amino acid to be added to the linear peptide). Upon incorporation of the conformationally constrained alpha-helix mimetic structures into the sequence, additional amino acids may then be added to complete the peptide bound to the solid support. Alternatively, the linear N-terminus and C-terminus protected peptide sequences may be synthesized on a solid support, removed from the support, and then coupled to the conformationally constrained alpha-helix mimetic structures in solution using known solution coupling techniques.
  • As to methods for constructing the libraries, traditional combinatorial chemistry techniques (see, e.g., Gallop et al., J. Med. Chem. 37:1233-1251, 1994) permit a vast number of compounds to be rapidly prepared by the sequential combination of reagents to a basic molecular scaffold. Combinatorial techniques can be used to construct peptide libraries derived from the naturally occurring amino acids. For example, by taking 20 mixtures of 20 suitably protected and different amino acids and coupling each with one of the 20 amino acids, a library of 400 (i.e., 202) dipeptides is created. Repeating the procedure seven times results in the preparation of a peptide library comprised of about 26 billion (i.e., 208) octapeptides.
  • Specifically, synthesis of the peptide mimetics of the library of the present invention may be accomplished using known peptide synthesis techniques, such as those disclosed, for example, in WO 2005/116032, which is incorporated herein by reference.
  • In a further aspect of this invention, the present invention provides methods for screening the libraries for bioactivity and isolating bioactive library members.
  • In one embodiment, data of biological activity is determined in the following manner. Compounds are assayed by using a method of the following reporter gene assay.
    • Reporter Gene Assay
  • Screening for inhibitory action of the Wnt signaling pathway can be carried out according to the following procedure using the stably transfected cell line Hek-293, STF1.1.
    • Growth Medium: DMEM, 10% FBS, Pen-Strep, supplemented with 400 μg/mL G418 to maintain selection of SuperTOPFLASH driven Luciferase gene
    • 1. On the day prior to assay, split cells into a white opaque 96-well plate at 20,000 cells per well in 200 μl of complete growth medium
    • 2. Incubate the plate overnight at 37° C., 5% CO2 and allow the cells to attach
    • 3. Next day, prepare the inhibitors to be tested in complete growth medium, without G418, at 2× the desired final concentration (all conditions are done in duplicates)
    • 4. Carefully remove the old medium from each well using a multiple pipettor
    • 5. Add 50 μl of fresh growth medium (without G148) containing the inhibitor to each well
    • 6. Be sure to include 2 wells containing medium only, 2 wells for stimulation control, 2 wells for DMSO control, and wells for the positive control ICG-001 (2, 5, and 10 micromolar)
    • 7. Once all inhibitors and controls are added, incubate the plate for 1 hour at 37° C., 5% CO2
    • 8. While plate is incubating, prepare fresh 20 mM LiCl in complete growth medium (without G418)
    • 9. After 1 hour, remove plate from incubator and add 50 μl of the medium containing 20 mM LiCl to each well, except for the two wells of the unstimulated control (add 50 μl of just complete medium)
    • 10. Incubate the plate for 24 hours at 37° C., 5% CO2
    • 11. After 24 hours, add 100 μl of BrightGlo (Promega, Cat. #: G7573) to each well
    • 12. Shake plate for 5 minutes to ensure complete lysis
    • 13. Read plate on the Packard TopCount
  • The libraries of the present invention also can be screened for bioactivity by other various techniques and methods. For example, the screening assay may be performed by (1) contacting the mimetics of a library with a biological target of interest, such as a receptor, to allow binding between the mimetics of the library and the target to occur, and (2) detecting the binding event by an appropriate assay, such as the calorimetric assay disclosed by Lam et al. (Nature 354:82-84, 1991) or Griminski et al. (Biotechnology 12:1008-1011, 1994) (both of which are incorporated herein by reference). In a preferred embodiment, the library members are in solution and the target is immobilized on a solid phase. Alternatively, the library may be immobilized on a solid phase and may be probed by contacting it with the target in solution.
  • A method for carrying out a binding assay also can be applied as follows. The method can include providing a composition that includes a first co-activator, an interacting protein, and a test compound. The amino acid structure of the first co-activator includes a binding motif of LXXLL, LXXLI or FxxFF wherein X is any amino acid. The method further includes detecting an alteration in binding between the first co-activator and the interacting protein due to the presence of the compound, and then characterizing the test compound in terms of its effect on the binding. The assay may be carried out by any means that can measure the effect of a test compound on the binding between two proteins. Many such assays are known in the art and can be utilized in the method of the present invention, including the so-called Two-Hybrid and Split-Hybrid systems. The Two-Hybrid system, and various means to carry out an assay using this system, are described in, e.g., U.S. Pat. No. 6,410,245. The Split-Hybrid system has been described by, e.g., Hsiu-Ming Shiu et al. Proc. Natl. Acad. Sci. USA, 93:13896-13901, November 1996; and John D. Crispino, et al. Molecular Cell, 3:1-20, February 1999. In the Split-Hybrid system, a fusion protein is utilized where protein X is fused to the lexA DNA binding domains (pLexA) and protein Y is fused to the transcription activator VP16 (pSHM.1-LacZ). Interaction between lexA-X and VP16-Y leads to the expression of the Tetracycline repressor protein (TetR). TetR prevents transcription of the HIS3 reporter gene, making the cells unable to grow on media lacking histidine. Disruption of protein-protein interaction will restore the ability of the cells to grow on such media by shutting down expression of the tetracycline repressor. Accordingly, compounds of the present invention may be added to the growing cells, and if the addition of the compound restores the ability of the cells to grow on the media, the compound may be seen as an effective disruptor of the protein-protein interaction. The yeast strains required to make the Split-Hybrid system work can be employed with two hybrid LexA/VP16 constructs such as those described by Stanley M. Hollenberg, et al. Molecular and Cellular Biology 15(7):3813-3822, July 1995. A useful modification of the Split-Hybrid system was utilized by Takemaru, K. I. and Moon, R. T. J. of Cell Biol. 149:249-254, 2000.
  • Other assay formats can also be suitable. For example, reporter gene assays for AP-1, ELISA, for example, blocking the production of IL-2 by a T-cell line after stimulation with CD3 and CD28 to look for inhibitors of IL-2 transcription. Direct binding assays (between coactivators and their partners) can be performed by surface plasmon resonance spectroscopy (Biacore, Sweden, manufactures suitable instruments) or ELISA.
  • Exemplary transcriptional regulators include, without limitation, VP16, VP64, p300, CBP, PCAF.SRC1 PvALF, AtHD2A and ERF-2. See, for example, Robyr et al. (2000) Mol. Endocrinol. 14:329-347; Collingwood et al. (1999) J. Mol. Endocrinol. 23:255-275; Leo et al. (2000) Gene 245:1-11; Manteuffel-Cymborowska (1999) Acta Biochim. Pol. 46:77-89; McKenna et al. (1999) J. Steroid Biochem. Mol. Biol. 69:3-12; Malik et al. (2000) Trends Biochem. Sci. 25:277-283; and Lemon et al. (1999) Curr. Opin. Genet. Dev. 9:499-504. Other exemplary transcription factors include, without limitation, OsGAI, HALF-1, C1, AP1, ARF-5, -6, -7, and -8, CPRF1, CPRF4, MYC-RP/GP, and TRAB1. See, for example, Ogawa et al. (2000) Gene 245:21-29; 5 Okanami et al. (1996) Genes Cells 1:87-99; Goff et al. (1991) Genes Dev. 5:298-309; Cho et al. (1999) Plant Mol. Biol. 40:419-429; Ulmason et al. (1999) Proc. Natl. Acad. Sci. USA 96:5844-5849; Sprenger-Haussels et al. (2000) Plant J. 22:1-8; Gong et al. (1999) Plant Mol. Biol. 41:33-44; and Hobo et al. (1999) Proc. Natl. Acad. Sci. USA 96:15,348-15,353.
  • The transcriptional coactivator can be a human transcriptional coactivator. In another embodiment, the transcriptional coactivator is a member of the p300/CBP family of co-activators which have histone acetyltransferase activity. p300 is described for example by Eckner et al., 1994 and CBP by Bannister and Kouzarides, 1996. For the 5 purposes of the present invention, reference to p300/CBP refers to human allelic and synthetic variants of p300, and to other mammalian variants and allelic and synthetic variants thereof, as well as fragments of said human and mammalian forms of p300. In one aspect of the assay, the interacting protein is a transcription factor or a second co-activator. In one aspect of the assay, the interacting protein is any one of RIP140; SRC-1 (NCoA-1); TIF2 (GRIP-1; SRC-2); p (CIP; RAC3; ACTR; AIB-1; TRAM-1; SRC-3); CBP (p300); TRAPs (DRIPs); PGC-1; CARM-1; PRIP (ASC-2; AIB3; RAP250; NRC); GT-198; and SHARP (CoAA; p68; p72). In another aspect of the assay, the interacting protein is any one of TAL 1; p73; MDm2; TBP; HIF-1; Ets-1; RXR; p65; AP-1; Pit-1; HNF-4; Stat2; HPV E2; BRCA1; p45 (NF-E2); c-Jun; c-myb; Tax; Sap 1; YY1; SREBP; ATF-1; ATF-4; Cubitus; Interruptus; Gli3; MRF; AFT-2; JMY; dMad; PyLT: HPV E6; CITTA; Tat; SF-1; E2F; junB; RNA helicase A; C/EBP R; GATA-1; Neuro D; Microphthalimia; E1A; TFIIB; p53; P/CAF; Twist; Myo D; pp90 RSK; c-Fos; and SV40 Large T. In another aspect of the assay, the interacting protein is any one of ERAP140; RIP140; RIP160; Trip1; SWI1 (SNF); ARA70; RAP46; TIF1; TIF2; GRIP1; and TRAP. In another aspect of the invention, the interacting protein is any one of VP16; VP64; p300; CBP; PCAF; SRC1 PvALF; AtHD2A; ERF-2; OsGAI; HALF-1; C1; AP-1; ARF-5; ARF-6; ARF-7; ARF-8; CPRF1; CPRF4; MYC-RP/GP; and TRAB1. In another aspect of the invention, the first co-activator is CBP or p300.
  • The test compound is selected from compounds as described herein. For example, compounds having the formula (I), (Ia), (Ib), (Ic) or (Id). Typically, a test compound can be evaluated at several different concentrations, where these concentrations will be selected, in part, based on the conditions of the assay, e.g., the concentrations of the first co-activator and the interacting protein. Concentrations in the range of about 0.1 to 10 μM may be used. In one aspect, the assay evaluates the relative efficacy of two compounds to affect the binding interaction between two proteins, where at least one of those two compounds is a compound of the present invention. The more effective compound can than serve as a reference compound in a study of the relationship between compound structure and compound activity.
  • Compounds of general formula (I), (Ia), (Ib), (Ic) or (Id) may inhibit CBP-mediated transcriptional activation in cancer cells due to their specific binding to CBP. The compounds of the present invention may also inhibit the survivin expression in SW480 cells, and therefore, inhibit the oncogenic activity in cancer cells.
  • The compounds of the present invention can be used for inhibiting cancer cells, and thus, would be useful for the regulation of cell growth. The compounds of the present invention can be also advantageously used for inducing apoptosis in cells.
  • The present invention is also related to prodrugs using the libraries containing one or more compounds of formula (I), (Ia), (Ib), (Ic) or (Id). A prodrug is typically designed to release the active drug in the body during or after absorption by enzymatic and/or chemical hydrolysis. The prodrug approach is an effective means of improving the oral bioavailability or i.v. administration of poorly water-soluble drugs by chemical derivatization to more water-soluble compounds. The most commonly used prodrug approach for increasing aqueous solubility of drugs containing a hydroxyl group is to produce esters containing an ionizable group; e.g., phosphate group, carboxylate group, alkylamino group (Fleisher et al., Advanced Drug Delivery Reviews, 115-130, 1996; Davis et al., Cancer Res., 7247-7253).
  • In other aspects, the present invention provides pharmaceutical compositions containing a compound having the general formula (I), (Ia), (Ib), (Ic) or (Id). These compositions may be used in various methods (e.g., treating cancer, fibrosis or Alzheimer's disease) of the present invention as described in detail below.
  • The pharmaceutical composition of the present invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. In addition, pH may be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the active compound, e.g., a compound having general formula (I), (Ia), (Ib), (Ic) or (Id) in the required amount, in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules.
  • Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser that contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
  • Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
  • The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
  • In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
  • It can be advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a 5 predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
  • For instance, in certain embodiments, a pharmaceutical composition of the present invention is one suitable for oral administration in unit dosage form such as a tablet or capsule that contains from about 1 mg to about 1 g of the compound of this invention. In some other embodiments, a pharmaceutical composition of the present invention is one suitable for intravenous, subcutaneous or intramuscular injection. A patient may receive, for example, an intravenous, subcutaneous or intramuscular dose of about 1 μg/kg to about 1 g/kg of the compound of the present invention. The intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection or by continuous infusion over a period of time. Alternatively a patient will receive a daily oral dose approximately equivalent to the daily parenteral dose, the composition being administered 1 to 4 times per day.
  • Preferably, the compound of the formula (I), (Ia), (Ib), (Ic) or (Id) of the present invention can be administered intravenously (particularly preferably, by continuous drip infusion or rapid intravenous administration) to mammals inclusive of human.
  • In the case, the dose is selected appropriately depending on various factors such as the body weight and/or age of patients, and/or the degree of the symptom and an administration route. For example, the dose of the compound of the formula (I), (Ia), (Ib), (Ic) or (Id) for intravenous administration is generally in the range of 1 to 10000 mg/day/m2 human body surface area, preferably in the range of 1 to 5000 mg/day/m2 human body surface area, and more preferably 10 to 5000 mg/day/m2 human body surface area by continuous drip infusion administration.
  • The pharmaceutical composition containing the compound of general formula (I), (Ia), (Ib), (Ic) or (Id) can be used for treatment of disorders modulated by Wnt signaling pathway, especially cancer, more especially colorectal cancer.
  • In one aspect, the present invention provides methods for inhibiting tumor growth. Such methods comprise the step of administering to a subject (e.g., a mammalian subject) having a tumor a compound with general formula (I), (Ia), (Ib), (Ic) or (Id) in an amount effective to inhibit tumor growth. A compound or composition inhibits tumor growth if the tumor sizes are statistically significantly smaller in subjects with the treatment of the compound or composition than those without the treatment.
  • The inhibitory effect of a particular compound or composition of the present invention on tumor growth may be characterized by any appropriate methods known in the art. For instance, the effect of the compound or composition on survivin expression may be measured. Compounds or compositions down-regulate survivin expression are likely to have inhibitory effects on tumor growth. In addition, assays using tumor cell lines (e.g., soft agar assays using SW480 cells) and animal models for tumor growth (e.g., nude mice grafted with tumor cells and Min mouse model) may also be used to evaluate the inhibitory effect on tumor growth of a given compound or composition as described in detail in the examples. Other exemplary animal models or xenografts for tumor growth include those for breast cancer (Guo et al., Cancer Res. 62: 4678-84, 2002; Lu et al., Breast Cancer Res. Treat. 57: 183-92, 1999), pancreatic cancer (Bouvet et al., Cancer Res. 62: 1534-40, 2002), ovarian tumor (Nilsson et al., Cancer Chemother. Pharmacol. 49: 93-100, 2002; Bao et al., Gynecol. Oncol. 78: 373-9, 2000), melanoma (Demidem et al., Cancer Res. 61: 2294-300, 2001), colorectal cancer (Brown et al., Dig. Dis. Sci. 45: 1578-84, 2000; Tsunoda et al., Anticancer Res. 19: 1149-52, 1999; Cao et al., Clin. Cancer Res. 5: 267-74, 1999; Shawler et al., J. Immunother. Emphasis Tumor Immunol. 17: 201-8, 1995; McGregor et al., Dis. Colon. Rectum. 36: 834-9, 1993; Verstijnen et al., Anticancer Res. 8: 1193-200, 1988), hepatocellular cancer (Labonte et al., Hepatol. Res. 18: 72-85, 2000), and gastric cancer (Takahashi et al., Int. J. Cancer 85: 243-7, 2000).
  • The compound or composition that inhibits tumor growth may be administrated into a subject with a tumor via an appropriate route depending on, for example, the tissue in which the tumor resides. The appropriate dosage may be determined using knowledge and techniques known in the art as described above. The effect of the treatment of the compound or composition on tumor growth may also be monitored using methods known in the art. For instance, various methods may be used for monitoring the progression and/or growth of colorectal cancer, including colonoscopy, sigmoidoscopy, biopsy, computed tomograph, ultrasound, magnetic resonance imaging, and positron emission tomography. Methods for monitoring the progression and/or growth of ovarian cancer include, for example, ultrasound, computed tomography, magnetic resonance imaging, chest X-ray, laparoscopy, and tissue sampling.
  • In a related aspect, the present invention provides a method for treating or preventing cancer or fibrosis. Such methods comprise the step of administering to a subject in need thereof a compound or composition having general formula (I), (Ia), (Ib), (Ic) or (Id) in an amount effective to treat or prevent cancer or fibrosis in the subject. Treating cancer (or fibrosis) is understood to encompass reducing or eliminating cancer progression, e.g., cancer growth and metastasis (or fibrosis, as applicable). Preventing cancer (or fibrosis) is understood to encompass preventing or delaying the onset of cancer (or fibrosis, as applicable). Various types of cancer may be treated or prevented by the present invention. They include, but are not limited to, lung cancer, breast cancer, colorectal cancer, stomach cancer, pancreatic cancer, liver cancer, uterus cancer, ovarian cancer, gliomas, melanoma, lymphoma, and leukemia. A subject in need of treatment may be a human or non-human primate or other animal with various types of cancer.
  • A subject in need of prevention may be a human or non-human primate or other animal that is at risk for developing cancer or fibrosis. Methods for diagnosing cancer (or fibrosis) and screening for individuals with high risk of cancer (or fibrosis) are known in the art and may be used in the present invention. For instance, colorectal cancer may be diagnosized by fecal occult blood test, sigmoidoscopy, colonoscopy, barium enema with air contrast, and virtual colonoscopy. An individal with high risk of colorectal cancer may have one or more colorectal cancer risk factors such as a strong family history of colorectal cancer or polyps, a known family history of hereditary colorectal cancer syndromes, a personal history of adenomatous polyps, and a personal history of chronic inflammatory bowel disease.
  • A compound with general formula (I), (Ia), (Ib), (Ic) or (Id) useful in cancer (or fibrosis) treatment or prevention may be identified by appropriate methods known in the art. Methods that may be used to select compounds for inhibitory effect on tumor growth as described above may also be used. The route of administration, the dosage of a given compound, the effectiveness of the treatment may be determined using knowledge and techniques known in the art. Factors that may be considered in making such a determination include, for example, type and stage of the cancer (or fibrosis) to be treated.
  • The compound with general formula (I), (Ia), (Ib), (Ic) or (Id) useful in cancer treatment and prevention may be administered in combination with an other anti-neoplastic agent. The anti-neoplastic agent refers to a compound that inhibits tumor growth.
  • Specific examples of the other anti-neoplastic agent include alkylating agents such as thiotepa and CYTOXAN® cyclophosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethiylenethiophosphoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics such as the enediyne antibiotics (e.g., calicheamicin, especially calicheamicin gamma 11 and calicheamicin omega 11 (see, e.g., Agnew, Chem Intl. Ed. Engl. 33:183-186 (1994)); dynemicin, including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chromophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, ADRLAMYCIN® doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalarnycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU), tegafur, raltitrexed; folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK® polysaccharide complex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2′,2″-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside (“Ara-C”); cyclophosphamide; thiotepa; taxoids, e.g., TAXOL® paclitaxel (Bristol-Myers Squibb Oncology, Princeton, N.J.), ABRAXANE™ Cremophor-free, albumin-engineered nanoparticle formulation of paclitaxel (American Pharmaceutical Partners, Schaumberg, Ill.), and TAXOTERE® doxetaxel (Rhne-Poulenc Rorer, Antony, France); chloranbucil; GEMZAR® gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum coordination complexes such as cisplatin, oxaliplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; NAVELBINE® vinorelbine; novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; irinotecan (e.g., CPT-11); topoisomerase inhibitor RFS 2000; difluorometlhylornithine (DMFO); retinoids such as retinoic acid; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above.
  • In addition, examples of the other anti-neoplastic agent also include anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including NOLVADEX® tamoxifen), raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and FARESTON toremifene; aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazoles, aminoglutethimide, MEGASE® megestrol acetate, AROMASIN® exemestane, formestane, fadrozole, RIVISOR® vorozole, FEMARA® letrozole, and ARIMIDEX®. anastrozole; and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; as well as troxacitabine (a 1,3-dioxolane nucleoside cytosine analog); antisense oligonucleotides, particularly those which inhibit expression of genes in signaling pathways implicated in abherant cell proliferation, such as, for example, PKC-alpha, Ralf and H-Ras; ribozymes such as a VEGF expression inhibitor (e.g., ANGIOZYME® ribozyme) and a HER2 expression inhibitor; vaccines such as gene therapy vaccines, for example, ALLOVECTIN® vaccine, LEUVECTIN® vaccine, and VAXID® vaccine; PROLEUKIN® rIL-2; LURTOTECAN® topoisomerase 1 inhibitor; ABARELIX® rmRH; and pharmaceutically acceptable salts, acids or derivatives of any of the above.
  • Moreover, examples of the other anti-neoplastic agent also include a “growth inhibitory agent” referring to a compound or composition which inhibits growth of a cell in vitro and/or in vivo. Thus, the growth inhibitory agent may be one which significantly reduces the percentage of cells in S phase. Examples of growth inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce G1 arrest and M-phase arrest. Classical M-phase blockers include the vincas (vincristine and vinblastine), TAXOL®, and topo II inhibitors such as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin. Those agents that arrest G1 also spill over into S-phase arrest, for example, DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C.
  • Furthermore, examples of the other anti-neoplastic agent also include a “molecular target drug” that blocks the proliferation and metastasis of cancer by interfering with specific molecules involved in carcinogenesis (the process by which normal cells become cancer cells), tumor growth, or tumor spread. Specific examples of the “molecular target drug” include kinase inhibitors that inhibit kinase activity on tumors, including, for example, imatinib, erlotinib, gefitinib, sunitinib, sorafenib, dasatinib, nilotinib; antibodies that bind to the cell surface molecule on tumor cells or to the growth factor and the like such as, for example, ibritumomab, cetuximab, trastuzumab, panitumumab, bevacizumab, rituximab; and proteasome inhibitors that inhibit the proteasome which regulates protein expression and function by degradation of ubiquitinylated proteins, such as bortezomib; and pharmaceutically acceptable salts, acids or derivatives of any of above.
  • Further information can be found in The Molecular Basis of Cancer, Mendelsohn and Israel, eds., Chapter 1, entitled “Cell cycle regulation, oncogenes, and antineoplastic drugs” by Murakami et al. (W B Saunders: Philadelphia, 1995), especially p. 13.
  • A compound with general formula (I), (Ia), (Ib), (Ic) or (Id) administered in combination with an anti-neoplastic agent does not necessarily require that the compound and the anti-neoplastic agent be administered concurrently. The compound and the agent may be administered separately as long as at a time point, they both have effects on same cancer cells.
  • For example, the administration mode may be exemplified by (1) administration of a single preparation obtained by simultaneously formulating the compound of formula (I), (Ia), (Ib), (Ic) or (Id) and the other anti-neoplastic agent, (2) simultaneous administration through the same administration route of two preparations obtained by separately formulating the compound of formula (I), (Ia), (Ib), (Ic) or (Id) and the other anti-neoplastic agent, (3) administration with a time interval through the same administration route of two preparations obtained by separately formulating the compound of formula (I), (Ia), (Ib), (Ic) or (Id) and the other anti-neoplastic agent, (4) simultaneous administration through different administration routes of two preparations obtained by separately formulating the compound of formula (I) and the other anti-neoplastic agent, (5) administration with a time interval through different administration routes of two preparations obtained by separately formulating the compound of formula (I), (Ia), (Ib), (Ic) or (Id) and the other anti-neoplastic agent (e.g., administration in order of the compound of formula (I), (Ia), (Ib), (Ic) or (Id) and then the other anti-neoplastic agent, or administration in the reverse order), or the like. The amount of the other anti-neoplastic agent to be administered can be appropriately selected with reference to the clinically used dosage. The mixing ratio of the compound of formula (I), (Ia), (Ib), (Ic) or (Id) and the other anti-neoplastic agent can be appropriately selected in accordance with the subject of administration, administration route, disease to be treated, symptoms, combination, and the like.
  • In addition, the compound of the present invention can be also used in combination with, for example, gene therapy involving VEGF, TNFa or the like, or therapeutic methods involving various antibody medicines or the like.
  • In a further related aspect, the present invention provides methods for promoting apoptosis in cancer cells. Such methods comprise the step of contacting cancer cells with a compound having general formula (I), (Ia), (Ib), (Ic) or (Id) in an amount effective to promote apoptosis in these cells. A compound promotes apoptosis if the number of cancer cells undergoing apoptosis is statistically significantly larger in the presence of the compound than that in the absence of the compound. Such compounds may be identified by methods known in the art (e.g., measuring caspase activities and/or cell death) using cultured cancer cell lines, xenografts, or animal cancer models. Preferably, the compound is more active in promoting apoptosis in cancer cells than in normal cells. Cancer cells treatable by the present method may be from various tissue origins.
  • In another aspect of the present invention, a method for treating a disorder modulated by Wnt signaling pathway in which the method comprises administering to a patient a safe and effective amount of the compounds having general formula (I), (Ia), (Ib), (Ic) or (Id) is disclosed. Pharmaceutical composition containing the compound of the present invention can be also used for this purpose. In this connection, it is found in the present invention that the compounds having general formula (I), (Ia), (Ib), (Ic) or (Id) or the pharmaceutical composition containing thereof can be useful for the treatment of disorder modulated by TCF4/β-catenin/CBP complex, which is believed to be responsible for initiating the overexpression of cancer cells related to Wnt signaling pathway. Thus, it is another aspect of the present invention to provide a method for the treatment of disorder modulated by TCF4/β-catenin/CBP complex, using the compounds having the general formula (I), (Ia), (Ib), (Ic) or (Id).
  • The present invention also provides compounds and methods for inhibiting survivin expression. Survivin is a target gene of the TCF/β-catenin pathway, and more specifically is a target gene of the TCF/β-catenin/CBP pathway. It is a member of the IAP (Inhibitor of Apoptosis Protein) family of proteins. Biological activity associated with survivin includes: highly expressed at G2/M, regulating cell cycle entry and exit; associated with microtubule, centrosomes, centromeres and midbody depending upon the phases of the cell cycle; and anti-apoptosis via interacting directly or indirectly with caspases (e.g., caspase 3, 7 and 9). In connection with cancer, survivin is widely and highly expressed in tumor cells, but expressed to little or no extent in normal tissue cells. Also, it has been observed that cancer patients whose tumors expressed survivin had a decreased overall survival. Furthermore, the degree of survivin expression has been correlated with other cancer markers, e.g., Ki67, PNCA, p53, APC, etc.
  • The effect of a particular compound of the present invention on survivin expression may be characterized by methods known in the art. Such methods include methods for characterizing survivin expression at the transcriptional or translational level. Exemplary methods for characterizing survivin expression at the transcriptional level are: cDNA microarray, reverse transcription-polymerase chain reaction (RT-PCR), chromatin immunoprecipitation (ChIP), and assays for reporter activities driven by survivin promoter. Exemplary methods for characterizing survivin expression at the translational level are: Western blot analysis, immunochemistry and caspase activities. Detailed descriptions of the above exemplary methods may be found in the examples below.
  • As described above, the present invention provides methods for inhibiting survivin expression. Such methods comprise the step of contacting a survivin-expressing cell with a compound of the present invention in an amount effective to inhibit survivin expression. A compound inhibits survivin expression if survivin expression in a cell is decreased in the presence of the compound compared to survivin expression in the absence of the compound. Survivin-expressing cells include tumor cells that express, such as cells in or from lung cancer, breast cancer, stomach cancer, pancreatic cancer, liver cancer, uterus cancer, ovarian cancer, gliomas, melanoma, colorectal cancer, lymphoma and leukemia. The step of contacting the survivin-expressing cells with the compound may be performed in vitro, ex vivo, or in vivo. A compound useful in inhibiting survivin expression may be identified, and the effects of a particular compound of the present invention may be characterized, by appropriate methods known in the art, as described in detail above.
  • Compounds of the present invention also may inhibit the expression of survivin. Blanc-Brude et al., Nat. Medicine 8:987 (2002), have shown that survivin is a critical regulator of smooth muscle cell apoptosis which is important in pathological vessel-wall remodeling. Accordingly, another aspect of the present invention provides a method of treating or preventing restenosis associated with angioplasty comprising administering to a subject in need thereof a safe and effective amount of an alpha-helix mimetic of the present invention. In one embodiment the invention treats the restenosis, i.e., administration of an alpha-helix mimetic of the present invention to a subject having restenosis achieves a reduction in the severity, extent, or degree, etc. of the restenosis. In another embodiment the invention prevents the restenosis, i.e., administration of an alpha-helix mimetic of the present invention to a subject that is anticipated to develop new or additional restenosis achieves a reduction in the anticipated severity, extent, or degree, etc. of the restenosis. Optionally, the subject is a mammalian subject.
  • Compounds of the present invention also may inhibit TCF/β-catenin transcription. Rodova et al., J. Biol. Chem. 277:29577 (2002), have shown that PKD-1 promoter is a target of the TCF/f-catenin pathway. Accordingly, another aspect of the present invention provides a method of treating or preventing polycystic kidney disease comprising administering to a subject in need thereof a safe and effective amount of an alpha-helix mimetic of the present invention. In one embodiment the invention treats the polycystic kidney disease, i.e., administration of an alpha-helix mimetic of the present invention to a subject having polycystic kidney disease achieves a reduction in the severity, extent, or degree, etc. of the polycystic kidney disease. In another embodiment the invention prevents polycystic kidney disease, i.e., administration of an alpha-helix mimetic of the present invention to a subject that is anticipated to develop new or additional polycystic kidney disease achieves a reduction in the anticipated severity, extent, or degree, etc. of the polycystic kidney disease. Optionally, the subject is a mammalian subject.
  • Compounds of the present invention also may inhibit the expression of Wnt signaling. Hanai et al., J. Cell Bio. 158:529 (2002), have shown that endostatin, a known anti-angiogenic factor, inhibits Wnt signaling. Accordingly, another aspect of the present invention provides a method of treating or preventing aberrant angiogenesis disease comprising administering to a subject in need thereof a safe and effective amount of an alpha-helix mimetic of the present invention. In one embodiment the invention treats the aberrant angiogenesis disease, i.e., administration of an alpha-helix mimetic of the present invention to a subject having aberrant angiogenesis disease achieves a reduction in the severity, extent, or degree, etc. of the aberrant angiogenesis disease. In another embodiment the invention prevents aberrant angiogenesis disease, i.e., administration of an alpha-helix mimetic of the present invention to a subject that is anticipated to develop new or additional aberrant angiogenesis disease achieves a reduction in the anticipated severity, extent, or degree, etc. of the aberrant angiogenesis disease. Optionally, the subject is a mammalian subject.
  • Compounds of the present invention also may inhibit Wnt TCF/β-catenin signalling. Accordingly, another aspect of the invention provides a method of treating or preventing tuberous sclerosis complex (TSC) comprising administering to a subject in need thereof a safe and effective amount of an alpha-helix mimetic the present invention. Subjects having TSC typically develop multiple focal lesions in the brain, heart, kidney and other tissues (see, e.g., Gomez, M. R. Brain Dev. 17(suppl): 55-57 (1995)). Studies in mammalian cells have shown that overexpression of TSC1 (which expresses hamartin) and TSC2 (which expresses tuberin) negatively regulates cell proliferation and induces G1/S arrest (see, e.g., Miloloza, A. et al., Hum. Mol. Genet. 9: 1721-1727 (2000)). Other studies have shown that hamartin and tuberin function at the level of the β-catenin degradation complex, and more specifically that these proteins negatively regulate β-catenin stability and activity by participating in the β-catenin degradation complex (see, e.g., Mak, B. C., et al. J. Biol. Chem. 278(8): 5947-5951, (2003)). β-catenin is a 95-kDa protein that participates in cell adhesion through its association with members of the membrane-bound cadherin family, and in cell proliferation and differentiation as a key component of the Wnt/Wingless pathway (see, e.g., Daniels, D. L., et al., Trends Biochem. Sci 26: 672-678 (2001)). Misregulation of this pathway has been shown to be oncogenic in humans and rodents. The present invention provides compounds that modulate β-catenin activity, and particularly its interactions with other proteins, and accordingly may be used in the treatment of TSC. Thus, in one embodiment the invention treats TSC, i.e., administration of an alpha-helix mimetic of the present invention to a subject having TSC achieves a reduction in the severity, extent, or degree, etc. of the TSC. In another embodiment the invention prevents TSC, i.e., administration of an alpha-helix mimetic of the present invention to a subject that is anticipated to develop new or additional TSC achieves a reduction in the anticipated severity, extent, or degree, etc. of the TSC. Optionally, the subject is a mammalian subject.
  • Compounds of the present invention also may inhibit the expression of Wnt signalling. The Kaposi's sarcoma-associated herpesvirus (KSHV) latency-associated nuclear antigen (LANA) is expressed in all KSHV-associated tumors, including Kaposi's sarcoma (KS) and β-cell malignancies such as primary effusion lymphoma (PEL) and multicentric Castleman's disease. Fujimuro, M. et al., Nature Medicine 9(3):300-306 (2003), have shown that LANA acts to stabilize β-catenin, apparently by redistribtution of the negative regular GSK-3β. The present invention provides compounds and methods for inhibiting β-catenin protein interactions, e.g., β-catenin/TCF complex formation. Thus, the compounds of the present invention thwart the LANA-induced accumulation of R-catenin/TCF complex and, at least in part, the consequences of KSHV infection. Accordingly, another aspect of the present invention provides a method of treating or preventing conditions due to infection by Karposi's sarcoma-associated herpesvirus (KSHV). Such conditions include KSHV-associated tumors, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL). The method comprises administering to a subject in need thereof a safe and effective amount of an alpha-helix mimetic the present invention. In one embodiment the invention treats the KSHV-associated tumor, i.e., administration of an alpha-helix mimetic of the present invention to a subject having a KSHV-associated tumor achieves a reduction in the severity, extent, or degree, etc. of the tumor. In another embodiment the invention prevents a KSHV-associated tumor, i.e., administration of an alpha-helix mimetic of the present invention to a subject that is anticipated to develop new or additional KSHV-associated tumors achieves a reduction in the anticipated severity, extent, or degree, etc. of the tumor. Optionally, the subject is a mammalian subject.
  • LEF/TCF DNA-binding proteins act in concert with activated β-catenin (the product of Wnt signaling) to transactivate downstream target genes. DasGupta, R. and Fuchs, E. Development 126(20):4557-68 (1999) demonstrated the importance of activated LEF/TCF complexes at distinct times in hair development and cycling when changes in cell fate and differentiation commitments take place. Furthermore, in skin morphogenesis, β-catenin has been shown to be essential for hair follicle formation, its overexpression causing the “furry” phenotype in mice (Gat, U., et al. Cell 95:605-614 (1998) and Fuchs, E. Harvey Lect. 94:47-48 (1999). See also Xia, X. et al. Proc. Natl. Acad. Sci. USA 98:10863-10868 (2001). Compounds of the present invention have been shown to inhibit the expression of Wnt signaling, and interfere with formation of β-catenin complexes. Accordingly, the present invention provides a method for modulating hair growth comprising administering to a subject in need thereof a safe and effective amount of an alpha-helix mimetic the present invention, where the amount is effective to modulate hair growth in the subject. Optionally, the subject is a mammalian subject.
  • The present invention also provides compounds that may be useful in treating or preventing Alzheimer's disease. Alzheimer's disease (AD) is a neurodegenerative disease with progressive dementia. This disease is accompanied by three main structural changes in the brain, namely, i) intracellular protein deposits (also known as neurofibrillary tangles, or NET), ii) extracellular protein deposits termed amyloid plaques that are surrounded by dystrophic neuritis, and iii) diffuse loss of neurons.
  • The compounds or compositions of the present invention may rescue defects in neuronal differentiation caused by a presenilin-1 mutation and may decrease the number, or rate at which neuronal precursor populations differentiate to neurons in Alzheimer's brains. Presenilins are transmembrane proteins whose functions are related to trafficking, turnover and cleavage of Notch and Amyloid Precursor Protein. Missense mutations in presenilin-1 (PS-1) are associated with early-onset familial Alzheimer's disease (Fraser et al., Biochem. Soc. Symp. 67, 89 (2001)). The compounds of the present invention may be applicable not only to individuals with PS-1 familial Alzheimer's mutations, but also to general Alzheimer's patients.
  • In addition, the present invention can provide a method for treating or preventing Alzheimer's disease comprising administering to a subject in need thereof a safe and effective amount of an alpha-helix mimetic of the present invention, where the amount is effective to treat or prevent Alzheimer's disease in the subject. Treating Alzheimer's disease is understood to encompass reducing or eliminating the manifestation of symptoms characteristic of Alzheimer's disease, or delaying the progression of this disease. Preventing Alzheimer's disease is understood to encompass preventing or delaying the onset of this disease.
  • A subject in need of treatment may be a human or non-human primate or other animal that is at various stages of Alzheimer's disease. Methods for diagnosing Alzheimer's disease are known in the art (see, e.g., Dinsmore, J. Am. Osteopath. Assoc. 99.9, Suppl. p: S1-6, 1999; Kurz et al., J. Neural Transm. Suppl. 62: 127-33, 2002; Storey et al., Front Viosci. 7: e155-84, 2002; Marin et al., Geriatrics 57: 36-40, 2002; Kril and Halliday, Int. Rev. Neurobiol. 48: 167-217, 2001; Gurwitz, Trends Neurosci. 23: 386, 2000; Muller-Spahn and Hock, Eur. Arch. Psychiatry Clin. Neurosci. 249 Suppl. 3: 37-42; Fox and Rossor, Rev. Neuro. (Paris) 155 Suppl. 4: S33-7, 1999), including the use of neuropsychological measures, functional imaging measures, biological markers, and autopsy of brain tissue. A subject in need of prevention may be a human or non-human primate or other animal that is at risk for developing Alzheimer's disease, such as an individual having a mutation of certain genes responsible for this disease (e.g., genes encoding amyloid precursor protein, presenilin-1, and presenilin-2), and/or a gene involved in the pathogenesis of this disease (e.g., apolipoprotein E gene) (Rocchi et al., Brain Res. Bull. 61: 1-24, 2003).
  • Compounds with structures as set forth in formula (I), (Ia), (Ib), (Ic) or (Id) may be screened for their activities in treating or preventing Alzheimer's disease by any appropriate methods known in the art. Such screening may be initially performed using in vitro cultured cells (e.g, PC-12 cells). Compounds capable of rescuing defects in neuronal differentiation caused by a presenilin-1 mutation may be further screened using various animal models for Alzheimer's disease. Alternatively, compounds with structures as set forth in formula (I), (Ia), (Ib), (Ic) or (Id) may be directedly tested in animal models for Alzheimer's disease. Many model systems are known in the art and may be used in the present invention (see, e.g., Rowan et al., Philos. Trans. R. Soc. Lond. B. Biol. Sci. 358: 821-8, 2003; Lemere et al., Neurochem. Res. 28: 1017-27, 2003; Sant'Angelo et al., Neurochem. Res. 28: 1009-15, 2003; Weiner Harv. Rev. Psychiatry 4: 306-16, 1997). The effects of the selected compounds on treating or preventing Alzheimer's disease may be characterized or monitored by methods known in the art for evaluating the progress of Alzheimer's disease, including those described above for diagnosing this disease.
  • The present invention also provides methods for promoting neurite outgrowth. Such methods comprise the step of contacting a neuron with a compound according to formula (I), (Ia), (Ib), (Ic) or (Id) in an amount effective to promote neurite outgrowth. These methods are useful in treating neurodegenerative diseases (e.g., glaucoma, macular degeneration, Parkinson's Disease, and Alzheimer's disease) and injuries to nervous system. A compound promotes neurite outgrowth if the neurite lengths of neurons are statistically significantly longer in the presence of the compound than those in the absence of the compound. Such a compound may be identified using in vitro cultured cells (e.g, PC-12 cells, neuroblastoma B104 cell) (Bitar et al., Cell Tissue Res. 298: 233-42, 1999; Pellitteri et al., Eur. J. Histochem. 45: 367-76, 2001; Satoh et al., Biochem. Biophys. Res. Commun. 258: 50-3, 1999; Hirata and Fujisawa, J. Neurobiol. 32:415-25, 1997; Chauvet et al., Glia 18: 211-23, 1996; Vetter and Bishop, Curr. Biol. 5: 168-78, 1994; Koo et al., Proc. Natl. Acad. Sci. USA 90: 4748-52, 1993; Skubitz et al., J. Cell Biol. 115: 1137-48, 1991; O'Shea et al., Neuron 7: 231-7, 1991; Rydel and Greene, Proc. Natl. Acad. Sci. USA 85: 1257-61, 1988) or using explants (Kato et al., Brain Res. 31: 143-7, 1983; Vanhems et al., Eur. J. Neurosci. 2: 776-82, 1990; Carri et al., Int. J. Dev. Neurosci. 12: 567-78, 1994). Contacting a neuron with a compound according to the present invention may be carried out in vitro or in vivo. The resulting treated neuron, if generated in vitro, may be transplanted into a tissue in need thereof (Lacza et al., Brain Res. Protoc. 11: 145-54, 2003; Chu et al., Neurosci. Lett 343: 129-33, 2003; Fukunaga et al., Cell Transplant 8: 435-41, 1999).
  • The present invention also provides methods for promoting differentiation of a neural stem cell comprising contacting a neural stem cell with a compound according to formula (I), (Ia), (Ib), (Ic) or (Id) in an amount effective to promote differentiation of a neural stem cell. Such methods are also useful in treating neurodegenerative diseases (e.g., glaucoma, macular degeneration, Parkinson's Disease, and Alzheimer's disease) and injuries to nervous system. “Neural stem cell” refers to a clonogenic, undifferentiated, multipotent cell capable of differentiating into a neuron, an astrocyte or an oligodendrocyte under appropriate conditions. A compound promotes differentiation of neural stem cells if neural stem cells exhibit a statistically significantly higher degree of differentiation in the presence of the compound than in the absence of the compound. Such a compound may be identified using assays involving in vitro cultured stem cells or animal models (Albranches et al., Biotechnol. Lett. 25: 725-30, 2003; Deng et al., Exp. Neurol. 182: 373-82, 2003; Munoz-Elias et al., Stem Cells 21: 437-48, 2003; Kudo et al., Biochem. Pharmacol. 66: 289-95, 2003; Wan et al., Chin. Med. J. 116: 428-31, 2003; Kawamorita et al., Hum. Cell 15: 178-82, 2002; Stavridis and Smith, Biochem. Soc. Trans. 31: 45-9, 2003; Pachenik et al., Reprod. Nutr. Dev. 42: 317-26, 2002; Fukunaga et al., supra). The neural stem cell may be a cultured stem cell, a stem cell freshly isolated from its source tissue, or a stem cell within its source organism. Thus, contacting the neural stem cell with a compound according to the present invention may be carried out either in vitro (for a cultured or freshly isolated stem cell) or in vivo (for a stem cell within its source organism). The resulting differentiated neural cell, if generated in vitro, may be transplanted into a tissue in need thereof (Lacza et al., supra; Chu et al., supra; Fukunaga et al., supra). Such a tissue includes a brain tissue or other nervous tissue that suffers from a trauma or a neurodegenerative disease.
  • In an embodiment of the present invention, the compound(s) of the present invention or pharmaceutical formulations containing one or more compounds of the present invention are useful in the treatment and/or prevention of fibrosis in general. Below is a further description of examples of various types/forms of fibrosis that are treatable with the compounds of the present invention.
  • Transforming growth factor β (TGF-β), a key mediator in the development of fibrosis, is important in cell proliferation and differentiation, apoptosis, and deposition of extracellular matrix (ECM). TGF-β signaling activates both the Smad and AP-1 transcription pathways. TGF-β in the airways of patients with pulmonary fibrosis (PF) may function initially as a “healing molecule” involved in the diminution of initial airway inflammation and in tissue repair. However, with continued inflammatory response such as may occur in PF, the balance may be shifted, to excessive ECM deposition and development of airway fibrosis.
  • Fibroproliferative diseases are generally caused by the activation of resident stellate cells which are found in most organs. This activation of stellate cells leads to their conversion to myofibroblasts which display characteristics of muscle and non-muscle cells. Activated stellate cells initiate inflammatory signals, principally mediated through TGF-β. Inflammatory cytokines and mediators in addition to TGF-β, lead to proliferation of myofibroblasts. Stellate-derived myofibroblasts proliferate and replace healthy, functional organ cells with extra-cellular matrix that exhibit muscle and connective tissue traits. Ultimately, organ failure results when the nonfunctional fibrotic honeycomb matrix replaces a critical number of healthy cells.
  • The initial cause of fibrosis is believed to be the result of injury or insult to organ tissues. This cellular injury to organ tissues can often be traced to toxic or infectious agents. Pulmonary fibrosis, or interstitial lung disease, is often the result of smoking, chronic asthma, chronic obstructive pulmonary disease (COPD) or pneumonia. Fibrosis affects nearly all tissues and organ systems. Non-limiting examples of disorders in which fibrosis is a major cause of morbidity and mortality are listed below.
    • Major-Organ Fibrosis
  • Interstitial lung disease (ILD) includes a wide range of distinct disorders in which pulmonary inflammation and fibrosis are the final common pathway of pathology. There are more than 150 causes of ILD, including sarcoidosis, silicosis, adverse drug reactions, infections and collagen vascular diseases and systemic sclerosis (scleroderma).
  • Idiopathic pulmonary fibrosis (IPF) is the most common type of ILD. Liver cirrhosis has similar causes to ILD, with viral hepatitis, schistosomiasis and chronic alcoholism being the major causes worldwide.
  • Kidney disease including diabetes can damage and scar the kidneys, which leads to progressive loss of function. Untreated hypertension can also contribute to the fibroproliferation of the kidneys.
  • Heart disease associated with scar tissue can impair the heart's pumping ability.
  • Eye disease includes macular degeneration and retinal and vitreal retinopathy can impair vision.
  • Chronic pancreatitis is an irreversible disease of the pancreas characterized by chronic inflarmmnation and fibrosis which leads to the loss of endocrine and exocrine function.
  • Fibroproliferative disorders include systemic and local scleroderma. Scleroderma is a chronic connective tissue disease that may be localized or systemic, and may have an affect in many organs and tissues of the body.
  • Keloids and hypertrophic scars, which can occur after surgery, traumatic wounds, burns, or even scratches. They manifest as an overgrowth of scar tissue at the site of injury.
  • Atherosclerosis and restenosis. Restenosis refers to the re-narrowing of a coronary artery after angioplasty to treat atherosclerosis. Scarring associated with trauma can be associated with overgrowth of scar tissue at the site of the trauma-related injury. Surgical complications can lead to fibrosis in any organ in which scar tissue and fibroproliferation result from the surgical procedures.
  • Chemotherapy induced fibrosis can occur in, for example, the lungs following chemotherapy, manifests as pulmonary fibrosis, and can be severe enough to require lung transplant, even in cases where the underlying malignancy did not affect the lungs.
  • Radiation-induced fibrosis (RIF) is a serious and common complication of radiation therapy that may cause chronic pain, neuropathy, limited movement of joints, and swelling of the lymph nodes. It occurs most often in breast, head, neck, and connective tissues. RIF may develop from 4-6 months to 1-2 years following exposure to radiation therapy, and it becomes more severe over time. Risk factors for developing RIF include high radiation dose, large volumes of tissue exposed to radiation, and radiation combined with surgery, chemotherapy, or both.
  • Burns can lead to fibrosis when there is an overproduction of ECM proteins. Excessive ECM deposition causes the tissue to become fibrotic.
    • Pulmonary Fibrosis
  • Pulmonary fibrosis destroys the lung's ability to transport oxygen and other gases into or out of the blood. This disease modifies the delicate and elastic tissues of the lung, changing these tissues into thicker, stiff fibrous tissue. This change or replacement of the original tissue is similar to the permanent scarring that can occur to other damaged tissues. Scarring of the lung reduces the lung's ability to allow gases to pass (i.e. oxygen, carbon dioxide) into or out of the blood. Gradually, the air sacs of the lungs become replaced by fibrotic tissue. When the scar forms, the tissue becomes thicker causing an irreversible loss of the tissue's ability to transfer oxygen into the bloodstream. Symptoms include shortness of breath, particularly with exertion; chronic dry, hacking cough; fatigue and weakness; discomfort in the chest; loss of appetite; and rapid weight loss.
  • Several causes of pulmonary fibrosis are known and they include occupational and environmental exposures. Many jobs, particularly those that involve mining or that expose workers to asbestos or metal dusts, can cause pulmonary fibrosis. Workers doing these kinds of jobs may inhale small particles (like silica dusts or asbestos fibers) that can damage the lungs, especially the small airways and air sacs, and cause the scarring associated with fibrosis. Agricultural workers also can be affected. Some organic substances, such as moldy hay, cause an allergic reaction in the lung. This reaction is called Farmer's Lung and can cause pulmonary fibrosis. Other fumes found on farms are directly toxic to the lungs.
  • Another cause is Sarcoidosis, a disease characterized by the formation of granulomas (areas of inflammatory cells), which can attack any area of the body but most frequently affects the lungs.
  • Certain medicines may have the undesirable side effect of causing pulmonary fibrosis, as can radiation, such as treatment for breast cancer. Connective tissue or collagen diseases such as systemic sclerosis are also associated with pulmonary fibrosis. Although genetic and familial factors may be involved, this cause is not as common as the other causes listed above.
  • In Chronic Obstructive Pulmonary Disease (COPD), connective tissue proliferation and fibrosis can characterize severe COPD. COPD can develop as a result of smoking or chronic asthma.
    • Idiopathic Pulmonary Fibrosis (IPF)
  • When all known causes of interstitial lung disease have been ruled out, the condition is called “idiopathic” (of unknown origin) pulmonary fibrosis (IPF). Over 83,000 Americans are living with IPF, and more than 31,000 new cases develop each year. This debilitating condition involves scarring of the lungs. The lungs' air sacs develop scar, or fibrotic tissue, which gradually interferes with the body's ability to transfer the oxygen into the bloodstream, preventing vital organs and tissue from obtaining enough oxygen to function normally.
  • There are several theories as to what may cause IPF, including viral illness and allergic or environmental exposure (including tobacco smoke). These theories are still being researched. Bacteria and other microorganisms are not thought to be the cause of IPF. There is also a familial form of the disease, known as familial idiopathic pulmonary fibrosis. Additional research is being done to determine whether there is a genetic tendency to develop the disease, as well as to determine other causes of IPF.
  • Patients with IPF suffer similar symptoms to those with pulmonary fibrosis when their lungs lose the ability to transfer oxygen into the bloodstream. The symptoms include shortness of breath, particularly during or after physical activity; spasmodic, dry cough; gradual, unintended weight loss; fatigue and weakness; chest discomfort; clubbing, or enlargement of the ends of the fingers (or sometimes the toes) due to a buildup of tissue. These symptoms can greatly reduce IPF patients' quality of life. Pulmonary rehabilitation, and oxygen therapy can reduce the lifestyle-altering effects of IPF, but do not provide a cure.
  • In order to develop a treatment for fibrotic disease, it is important to focus on the common pathway to the ultimate pathology that is shared by the disease states, regardless of cause or of tissue in which it is manifested. Several components of the causative pathway are discussed below, particularly in relation to the role of β-catenin.
    • Other Pathological Conditions
  • Survivin, an inhibitor of apoptosis, is implicated in pulmonary hypertension. CK2 kinase activity has been shown to promote cell survival by increasing survivin expression via 0-catenin TCF/LEF-mediated transcription. Tapia, 1C. et al., Proc. Nat. Acad. Sci. U.S.A. 103: 15079-84 (2006). This pathway therefore provides another opportunity to utilize the present compounds to alter the β-catenin-mediated gene transcription processes.
  • McMurtry, M. S. et al., J. Clin. Invest. 115:1461-1463 (2005) reported that survivin was expressed in the pulmonary arteries of patients with pulmonary arterial hypertension, but not in the pulmonary arteries of patients without pulmonary arterial hypertension. Comparable results were found in rats treated with monocrotaline to induce pulmonary arterial hypertension. In the rats, survival was prolonged and the pulmonary arterial hypertension was reversed by gene therapy with inhalation of an adenovirus carrying a survivin mutant with dominant-negative properties.
  • Survivin expression is upregulated in hyperproliferative neovasculature (Simosa, H. F. et al., J. Vase. Surg. 41:682-690, 2005). Survivin was specifically expressed in human other sclerotic plaque and stenotic vein grafts. In a rabbit model of hyperplasia after balloon injury of iliofemoral arteries, treatment with a phosphorylation-defective survivin mutant vector reduced the neointimal area. The correlation between survinin expression and regulation of a smooth muscle cell phenotype after vascular injury points to survivin as a target for therapy in treating vascular disease.
  • Survivin is amenable to targeting by administration of a compound disclosed herein via one or more of the routes as described herein. Without being bound by a particular mode of action, the compounds disclosed herein can be administered in the form of coated stents, for example in connection with angioplasty. The methods for preparing coated stents are described in the art and would be modified as needed for use with the compounds of the invention. For example, U.S. Pat. No. 7,097,850 discloses and teaches methods of coating a stent with a variety of bioactive compounds. U.S. Pat. No. 7,087,078 discloses methods of preparing a stent with at least one active ingredient. Both coronary and peripheral stents are amenable to incorporating one or more compounds disclosed herein. Further teachings regarding drug-coated stents is available in Grube, E. et al., Herz 29:162-6 (2004) and W. L. Hunter, Adv Drug Deliv Rev. 58:347-9 (2006).
  • Bone marrow cells contribute to transplant-associated atherosclerosis (Sata, M., Trends Cardiovasc. Med. 13:249-253, 2003). Bone marrow cells also contribute to the pathogenesis of lesion formation after mechanical vascular injury (Sata, M. et al., Nat. Med. 8:403-409, 2002). Thus, by treating atherosclerosis and vascular damage with one of more compounds of the invention, reduction in vascular lesion formation can be accomplished.
  • Survivin also plays a role in vein graft hyperplasia (Wang, G. J. et al., Arterioscler. Thromb. Vase. Biol. 25:2091-2087, 2005). Bypass grafts often develop intimal hyperplasia, a fibroproliferative lesion characterized by intimal thickening. Rabbit vein grafts were treated with adenoviral survivin constructs. Transgene expression was demonstrated in all the adenovirus-treated grafts. Treatment with a dominant negative mutant adenovirus decreased cellular proliferation in the early phase of graft remodeling. The data provide evidence for an important role of survivin in the regulation of vein graft remodeling in this system as well, and further support a role for the compounds of the invention in conjunction with bypass grafts.
  • Lymphangioleiomyomatosis (LAM) is a disease that occurs in some patients with tuberous sclerosis complex (Moss, J. et al., Am. J. Respir. Crit Care Med. 163:669-671, 2001).
  • Cystic lung disease in LAM is characterized by abnormal smooth muscle cell proliferation. Compounds disclosed herein are expected to find use in regulating and alleviating the cell proliferation, thus moderating the clinical symptoms.
    • The Role of TGF-β
  • In pulmonary fibrosis, the normally thin lung tissue is replaced with thick, coarse scar tissue that impairs the flow of oxygen into the blood and leads to a loss of lung function. A growing body of research suggests that excess TGF-β is the immediate cause of the fibrosis. This over-expression of TGF-β has been shown to cause pulmonary fibrosis in mice. An abnormally high TGF-β signal causes healthy epithelial cells in the lung to die via apoptosis. Cell death leads to the replacement of healthy lung tissue by thick, poor functioning scar tissue. Apoptosis of healthy epithelial cells is required prior to the development of pulmonary fibrosis (Elias et al). One form of treatment of fibrotic lung disorders involves administering drugs that specifically inhibit TGF-β, which in turn blocks apoptosis, preventing the formation of fibrotic tissue in the lung. However, for reasons discussed below, TGF-β itself may not be an ideal therapeutic target.
  • TGF-β is a member of the transforming growth factor -superfamily which consists of secreted polypeptide signaling molecules involved in cell proliferation and differentiation, apoptosis, deposition of extracellular matrix (ECM) and cell adhesion. TGF-β is a potent inhibitor of cell growth, and has immunosuppressive properties. However, TGF-β also causes the deposition of ECM components leading to fibrosis. A role for TGF-β as a key mediator in the development of fibrosis relates to its ability to act as a chemoattractant for fibroblasts, stimulate fibroblast procollagen gene expression/collagen protein synthesis, and inhibit collagen breakdown. TGF-β further stabilizes the ECM by inhibiting the expression of ECM proteases and stimulating the expression of ECM protease inhibitors. The fibrinolysis system is essential in ECM accumulation and fibrosis. Inhibition of fibrinolysis results in the accumulation of fibrin and ECM. Plasminogen activator inhibitor-1 (PAI-1) is the key inhibitor of fibrinolysis. The PAI-promoter contains several transcription factor binding sites including an AP-1 and Smad binding elements that promote PAI-1 induction by TGF-β. PAI-1 is the primary inhbitor of both tissue-type (TPA) and urokinase-type plasminogen (uPA) activator. Thus, TGF-β and PAI-1 work in tandem to produce the characteristic tissue of fibrosis.
  • In the bleomycin-induced model of pulmonary fibrosis (PF), mice in which the PAI-1 gene is deleted are protected from developing PF. Additionally, adenovirus-mediated transfer of the uPA gene to the lung significantly reduces the production of lung hydroxyproline and attenuated the bleomycin-induced increase in lung collagen, both hallmarks of fibrosis. The TGF-β signaling pathway is complex. TGF-β family members bind to specific pairs of receptor serine/threonine kinases. Upon binding, the ligand acts to assemble two type I and two type II receptors into a complex. The type II receptor phosphorylates the type I receptor that subsequently phosphorylates the intracellular substrates Smad 2 and Smad 3. This complex then binds Smad 4 and translocates to the nucleus for signal propagation. TGF-(can also activate AP-1 transcription via the MAPK pathway. TGF-β may originally act as a “healing molecule” in the lung or liver after initial inflammation and injury to the tissue. However, with continued inflammation/injury the balance may be shifted to excessive fibroproliferation and ECM deposition, leading to an “endless healing” process and development of fibrosis. Thus, complete inhibition of TGF-β could initially undermine the healing process.
  • TGF-β is highly expressed in airway epithelium and macrophages of small airways in patients with COPD. Using anti-inflammatory therapies, such as corticosteroids and interferon-γ, to treat PF has been disappointing due to variable efficacy and significant adverse effects. Therefore, an important goal is to identify small molecules that interact with previously identified molecular pathways (i.e. TGF-β signaling) involved in the development of fibrosis to prevent the progression or reverse the fibrosis seen in patients.
    • Wnt Signaling and Human Disease
  • Vertebrate Wnt proteins are homologues of the Drosophila wingless gene and have been shown to play important roles in regulating cell differentiation, proliferation, and polarity. Cadijan, K. M. et al., Genes Dev. 11:3286-3305 (1997); Parr, B. A. et al., Curr. Opin. Genet. Dev. 4:523-528 (1994); Smalley, M. J. et al., Cancer Met. Rev. 18:215-230 (1999); and Willert, K. et al., Curr. Opin. Genet. Dev. 8:95-102 (1998). Wnt proteins are cysteine-rich secreted glycoproteins that signal through at least three known pathways. The best understood of these, commonly called the canonical pathway, involves binding of Wnt proteins to frizzled cell surface receptors and low-density lipoprotein cell surface co-receptors, thereby inhibiting glycogensynthase kinase 313 (GSK-313) phosphorylation of the cytoskeletal protein Q-catenin. This hypophosphorylated β-catenin is then translocated to the nucleus, where it binds to members of the LEF/TCF family of transcription factors. Binding of β-catenin converts LEF/TCF factors from repressors to activators, thereby switching on cell-specific gene transcription. The other two pathways that Wnt proteins can signal through either activate calmodulin kinase II and protein kinase C (known as the Wnt/Ca++ pathway) or jun N-terminal kinase (also known as the planar cell polarity pathway).
  • Several components of the Wnt pathway have been implicated in tumorigenesis in humans and mice, and studies of those have in turn identified a role for β-catenin. Wnt1 was first identified from a retroviral integration in mice that caused mammary tumors. Tsukamoto, A. S. et al., Cell 55:619-625 (1988); and Jue, S. F. et al., Mol. Cell. Biol. 12:321-328 (1992). Overexpression of protein kinase CK2 in the mammary gland, which potentiates R-catenin-dependent Wnt signaling, also increases the incidence of mammary tumors in transgenic mice. Landesman-Bollag, E. et al., Oncogene 20:3247-3257 (2001); and Song, D. H. et al., J. Biol. Chem. 275:23790-23797 (2000). Gut epithelia has revealed the most extensive correlation between Wnt signaling and tumorigenesis. Several reports have described mutations in β-catenin itself in some colon tumors and these mutations occur in or near the GSK-313 phosphorylation sites. Polakis, P. et al., Adv. Exp. Med. Biol. 470:23-32 (1999); and Morin, P. J. et al., Science 275:1787-1790 (1997). Chilosi and colleagues (Chilosi, M. et al., Am. J. Pathol. 162:1497-1502, 2003) investigated -catenin mutations in IPF patients but did not identify any. This is consistent with a mechanism in which the aberrant activation of the Wnt pathway is a response and not a cause of IPF.
    • Lung Development and Wnt Signaling
  • In the mouse, the lung arises from the primitive foregut endoderm starting at approximately E9.5 during mouse development. (Warburton, D. et al., Mech. Dev. 92:55-81, 2000). This primitive epithelium is surrounded by mesodermally derived multipotent mesenchymal cells, which in time will differentiate into several cell lineages including bronchial and vascular smooth muscle, pulmonary fibroblasts, and endothelial cells of the vasculature. During gestation, the airway epithelium evolves and grows through a process termed branching morphogenesis. This process results in the three-dimensional arborized network of airways required to generate sufficient surface area for postnatal respiration. Mouse embryonic lung development can be divided into at least four stages: embryonic (E9.5 to E12.5), pseudoglandular (E12.5 to E16.0), canalicular (E16.0 to E17.5), and saccular/alveolar (E17.5 to postnatal).
  • During development, epithelial-mesenchymal signaling plays an important role in the regulation of both epithelial and mesenchymal cell differentiation and development. Several important signaling molecules are expressed in the airway epithelium and signal to the adjacent mesenchyme including members of the bone morphogenetic family (BMP-4), transforming growth factor family (TGF-β1, -2), and sonic hedgehog (SHH). In turn, the mesenchyme expresses several signaling molecules such as FGF-7, -9, and -10, important for lung epithelial development and proliferation. Gain of function and loss of function experiments in mice have demonstrated an important role for each of these factors in regulating lung epithelial and mesenchymal proliferation and differentiation. Bellusci, S., et al., Development 1997, 124:4867-4878; Simonet, W. S., et al., Proc. Natl. Acad. Sci. USA 1995, 92:12461-12465; Clark, J C., et al., Am. J. Physiol. 2001, 280:L705-L715; Min, R., et al., Genes Dev. 1998, 12:3156-3161; Motoyama, I., et al., Nat. Genet. 1998, 20:54-57; Litingtung, Y, et al., Nat. Genet. 1998, 20:58-61; Pepicelli, C. V., et al., Curr. Biol. 1998, 8:1083-1086; Weaver, M., et al., Development 1999, 126:4005-4015.
  • Wnt signaling also plays a role during lung development. Several Wnt genes are expressed in the developing and adult lung including Wnt2, Wnt2b/13, Wnt7b, Wnt5a, and Wntll. Kispert, A., et al., Development 1996, 122:3627-3637; Lin, Y., et al., Dev. Dyn. 2001, 222:26-39; Monkley, S. l., et al., Development 1996, 122:3343-3353; Yamaguchi, T. P., et al., Development 1999, 126:1211-1223; Weidenfeld, J., et al., J. Biol. Chem. 2002, 277:21061-21070. Of these, Wnt5a and Wnt7b are expressed at high levels exclusively in the developing airway epithelium during lung development. Wnt2, Wnt5a, and Wnt7b have been inactivated through homologous recombination in mice. Wnt2-null mice do not display an overt lung phenotype and Wnt5a null mice have late-stage lung maturation defects, corresponding to expression of Wnt5a later in lung development. (Monkley, (1996); Li, C. et al., Dev. Biol. 248:68-81 (2000). Inactivation of Wnt7b results in either early embryo demise because of defects in extra-embryonic tissues or perinatal demise because of defects in lung development. Parr, B. A., et al., Dev. Biol. 237:324-332 (2001); Shu, W. et al., Development 129:4831-4842 (2002)). These lung defects include decreased mesenchymal proliferation, lung hypoplasia caused by reduced branching, and pulmonary vascular smooth muscle defects leading to blood vessel hemorrhage in the lung (Shu, W. (2002)). Thus, Wnt signaling regulates important aspects of both epithelial and mesenchymal development during gestation, likely through both autocrine and paracrine signaling mechanisms.
  • Accumulation of nuclear β-catenin has been observed in both epithelial and mesenchymal (myofibroblasts) cell lineages in adult human lung. Other reports support these observations during mouse lung development. (Tebar, R., et al., Mech. Dev. 109:437-440 (2001)). Type 2 pneumocytes appear to express high levels of β-catenin both in the embryo and in the adult. (Tebar, 2001). Type 2 cells are precursors of type 1 cells, which form the thin diffusible stratum important for gas exchange in the lung. Type 2 cells have been shown to re-enter the cell cycle, grow, and differentiate into type 1 cells in some models of lung re-epithelialization. (Borok, Z. et al., Am. J. Respir. Cell Mol. Biol. 12:50-55 (1995); Danto, S. I. et al., Am. J. Respir. Cell Mol. Biol. 12:497-502 (1995)).
  • Importantly, type 2 cells proliferate excessively during idiopathic fibrosis (IPF) and other proliferative lung diseases, and increased nuclear β-catenin in these cells suggests that Wnt signaling regulates this proliferation. (Kawanami, O., et al., Lab. Invest. 46:39-53 (1982); Kasper, M. et al., Histol. Histopathol. 11:463-483 (1996)). Increased proliferation of type 2 cells in IPF may also inhibit their differentiation into type 1 cells because excessive proliferation is often antagonistic to cellular differentiation. In this context, it is important to note that expression of certain important transcriptional and signaling regulators in the lung decreases with gestational age. Forced overexpression of some of these such as BMP-4, GATA6, and Foxa2 results in aberrant lung development that exhibits many aspects of arrested lung epithelial maturity. (Weaver, 1999; Koutsourakis, M. et al., Mech. Dev. 105: 105-114, 2001; Zhou, L. et al., Dev. Dyn. 210:305-314, 1997). Thus, a careful balance of the correct spatial and temporal expression of certain regulatory genes is required for normal lung development, and improper activation of these pathways can result in severe defects in epithelial differentiation.
  • Nuclear β-catenin is found in the mesenchyme adjacent to the airway epithelium (Chilosi, 2003), and this is significant especially because these cells appear to be myofibroblastic in nature and may contribute to bronchial and vascular smooth muscle in the lung. Although Wnt signals in these mesenchymal cells could be autocrine in nature, it is just as likely that the mesenchymal cells are responding to a paracrine signal from the airway epithelium where Wnts such as Wnt5a and Wnt7b are expressed. In this way, the epithelium may be responsible for causing the aberrant activation of Wnt signaling in adjacent mesenchyme, leading to increased fibrosis and damage to the lung. This is particularly relevant because of the increase in the number of type 2 cells in the airways of IPF patients. This may also be reflective of a switch to an embryonic phenotype in the alveolus, where type 1 cells are rare. In turn, this would result in an increase in expression of several genes, including Wnts such as Wnt7b, whose expression is dramatically down-regulated in postnatal development. (Weidenfeld, 2002; Shu, 2002.) The increased level of Wnts may inhibit the proper differentiation of more mature alveolar cells such as type 1 cells, impairing the repair process.
  • Because nuclear translocation of β-catenin is a result of Wnt signaling activity, its presence in cells such as distal airway epithelium and in mesenchyme adjacent to airway. epithelium suggests that epithelial-mesenchymal Wnt signaling is active and likely plays an important role during both lung development and disease states such as IPF.
    • Regulation of Cell-Matrix Interactions by Wnt Signaling
  • A link has been shown between Wnt signaling and regulation of cell-matrix interactions including cell adhesion and migration. In particular, Wnt signaling has been shown to affect cell motility and invasiveness of melanoma cells. (Weeraratna, A. T. et al., Cancer Cell 1:279-288 (2002)). In this system, melanoma cells overexpressing Wnt5a displayed increased adhesiveness, which correlated to a reorganized actin cytoskeleton (Weer, 2002). These data suggest that Wnt5a expression correlates directly with the metastatic ability of melanoma tumors. In IPF lung tissue (Chilosi, 2003), the important extracellular matrix metalloproteinase matrilysin was overexpressed in some of the cells containing high levels of nuclear β-catenin. This is supported by previous studies showing that matrilysin is a molecular target of Wnt signaling. (Crawford, H. C., Oncogene 18:2883-2891, 1999). Matrilysin has been linked to a role in carcinogenesis both in intestinal and endometrial tumors. Increased matrilysin expression strongly correlates with increased nuclear β-catenin expression and inhibition of this nuclear translocation results in decreased matrilysin expression. (Crawford, 1999). Without being bound by a specific hypothesis, the mechanism may involve increased degradation of the extracellular matrix from increased matrilysin expression, leading to decreased cell adhesion and increased cell motility. In IPF, this might reduce the ability of both epithelial and mesenchymal cells to properly restructure the alveolar architecture after injury. In addition, extracellular matrix integrity may be required for type 1 cell differentiation, because of their flattened morphology and the very large surface area that they cover in the alveolus. This process may contribute to an increase in type 2 cell proliferation, which in turn could decrease type 1 cell differentiation.
    • Wnt Signaling and IPF
  • Without being bound by a specific hypothesis, several models could explain the finding that Wnt signaling is aberrantly activated in IPF. First, unregulated activation of the Wnt signaling pathway could be a physiological response to either lung injury or the repair process, possibly because of the requirement of the Wnt pathway for proliferation in cells such as type 2 alveolar epithelium and adjoining myofibroblasts. In this model, Wnt signaling should deactivate once the repair process is complete, leading to a return to normal proliferation. In the second model, aberrant Wnt signaling is the initiating event leading to increased cell proliferation in type 2 cells, which may inhibit their ability to differentiate into type 1 cells and restructure the alveolar architecture properly. Either injury-induced or spontaneous mutations in certain components of the canonical Wnt pathway or in regulatory molecules that regulate this pathway may result in this dysregulation of cell proliferation. The fact that nuclear β-catenin is up-regulated in other lung proliferative diseases suggests that the previous data (Chilosi, 2003) may be a response and not a primary causative event in IPF. Moreover, the unregulated proliferation in type 2 cells and mesenchymal fibroblasts along with the increased presence of nuclear β-catenin suggests that the Wnt pathway is continuously stimulated in lung diseases such as IPF and that inhibitors of Wnt signaling may provide a means to control this proliferation. Increased nuclear β-catenin was detected in the mesenchyme adjacent to the airway epithelium, described as myofibroblasts (Chilosi, 2003). These myofibroblasts can induce apoptosis in neighboring epithelial cells in vitro and in vivo, probably through degradation of the extracellular matrix (Ubal, B. D. et al., Am. J. Physiol. 275:L1192-L1199, 1998; Dhal, B. D. et al., Am. J. Physiol. 269:L819-L822, 1995; Selman, M. et al., Am. J. Physiol. 279:L562-L574, 2000). In addition, in IPF there appears to be either a lack of re-epithelialization or an increase in type 2 cells with little if any maturation of type 1 cells, leading to injured areas with exposed mesodermal components or re-epithelialized with immature type 2 cells. Since it has been demonstrated that type 2 cells express high levels of TGF-β1, which is a profibrotic cytokine, in IPF either scenario would inhibit the proper re-epithelialization of these injured areas, causing more fibrosis (Kapanci, Y., et al., Am. J. Respir. Crit. Care Med. 152:2163-2169, 1995; Khalil, N., et al., Am. 1. Respir. Cell Mol. Biol. 5: 155-162, 1991). This process could go unchecked and eventually lead to massive changes in tissue architecture, eventual tissue destruction, and loss of lung function.
  • Connective tissue growth factor (CTGF) is a 36 to 38 kD cysteine-rich peptide containing 349 amino acids. It belongs to the CCN (CTGF, cyr 61/cef 10, nov) family of growth factors. The gene for CTGF was originally cloned from a human umbilical endothelial cell cDNA library. CTGF has been detected in endothelial cells, fibroblasts, cartilaginous cells, smooth muscle cells, and some cancer cell lines. Earlier studies revealed that TGF-β1 increases CTGF mRNA markedly in human foreskin fibroblasts. PDGF, EGF, and FGF were also shown to induce CTGF expression, but their effects were only transient and weak.
  • Connective tissue growth factor has diverse bioactivities. Depending on cell types, CTGF was shown to trigger mitogenesis, chemotaxis, ECM production, apoptosis, and angiogenesis. In earlier studies, CTGF was noted to have mitogenic and chemotactic effects on fibroblasts. CTGF was also reported to enhance the mRNA expression of α1(I) collagen, fibronectin, and as integrin in fibroblasts. The finding that TGF-β increases CTGF synthesis and that TGF-β and CTGF share many functions is consistent with the hypothesis that CTGF is a downstream mediator of TGF-β.
  • The mechanism by which CTGF exerts its effects on cells, especially its signal transduction, is still unclear. CTGF was reported to bind to the surface of fibroblasts with high affinity, and this binding was competed with recombinant PDGF BB. This suggests that CTGF binds to a certain class of PDGF receptors, or that there is some cross reactivity of PDGF BB with CTGF receptors.
  • Connective tissue growth factor mRNA has been detected in fibroblasts of sclerotic lesions of patients with systemic sclerosis. In patients with localized scleroderma, CTGF mRNA was detected in fibroblasts in tissues from sclerotic stage more than the inflammatory stage, which suggests a close correlation between CTGF and fibrosis. Similar results were also obtained in keloid and other fibrotic diseases. Subsequently, expression of CTGF has been reported in a variety of fibrosis, such as liver fibrosis, pulmonary fibrosis, and heart fibrosis.
  • CTGF is also implicated in dermal fibrosis of scleroderma. However, the detailed role of CTGF in fibrosis is still unclear. Further studies are needed to clarify this point.
  • The CCN family comprises cysteine-rich 61 (CYR61/CCN1), connective tissue growth factor (CTGF/CCN2), nephroblastoma overexpressed (NOV/CCN3), and Wnt-induced secreted proteins-1 (WISP-1/CCN4), -2 (WISP-2/CCN5) and -3 (WISP-3/CCN6). These proteins stimulate mitosis, adhesion, apoptosis, extracellular matrix production, growth arrest and migration of multiple cell types. Many of these activities probably occur through the ability of CCN proteins to bind and activate cell surface integrins.
  • Connective tissue growth factor (CTGF) has been identified as a potential target of Wnt and BMP signaling. It has been confirmed by microarray results, and demonstrated that CTGF was up-regulated at the early stage of B:MP9 and Wnt3A stimulations and that Wnt3A-regulated CTGF expression was β-catenin-dependent.
  • Each of the above conditions can benefit from treatment with one or more compounds of the present invention. Each of the types of fibrosis described above can be treated with one or more compounds of the present invention.
  • The following non-limiting examples illustrate the compounds, compositions, and methods of use of this invention.
    • EXAMPLES
  • The present invention will be further specifically explained with reference to examples. However, the scope of the present invention is not limited to the following examples. In the examples, for thin layer chromatography (TLC), Precoated Silica Gel 60 F254 (produced by Merck, product number: 5715-1M) was used. After development with chloroform:methanol (1:0 to 1:1) or ethyl acetate:hexane (1:0 to 0:1), spots were observed by UV irradiation (254 nm) or color development with ninhydrine or phosphomoribdic acid solution in ethanol. For drying organic solvent, anhydrous magnesium sulfate or anhydrous sodium sulfate was used. As for column chromatography, the indication of “Buch” means use of Buch sepacore preparative chromatography system (produced by Buch), and one or several columns selected from cartridge columns Si6M-12×75 mm, 12×150 mm, 40×75 mm and 40×150 mm produced by the same manufacturer depending on the amount of sample. As for column chromatography, the indication of “Purif” means use of Moritex Purif preparative chromatography system (produced by Moritex), and one or several columns selected from cartridge columns 20, 35, 60, 200 and 400 produced by the same manufacturer were used depending on the amount of sample. For flash column chromatography, Silica gel 60N (spherical shape, neutral, 40 to 100 μm, produced by Kanto Chemicals) was used. Preparative thin layer chromatography (hereinafter abbreviated as “PTLC”) was performed by using one or several plates of PLC Plate Silica Gel 60 F254 (20×20 cm, thickness: 2 mm, concentration zone: 4 cm, produced by Merck, product number: 13793-1M) were used depending on the amount of sample.
  • The indication of “LCMS” means that mass spectrum was measured by liquid chromatography-mass spectrometry (LC/MS). Platform-LC type mass spectrometry apparatus ZQ2000 (produced by Micromass) was used as the mass spectrometer, and the measurement was performed by the electrospray ionization (ESI) method. As a liquid chromatography apparatus, an apparatus produced by waters was used. As a separation column, Develosil C30-UG-5 (50×4.6 mm, Nomura Kagaku Co., Ltd.) for method “A” or Agilent ZOBAX SB-C (2.1×50 mm, Agilent) in the tables mentioned below was used. Elution was performed at a flow rate of 1 ml/minute, and Solution A=water [containing 0.1% (v/v) formic acid] and Solution B=acetonitrile [containing 0.1% (v/v) formic acid] for method “A” were used as solvents.
  • In the tables mentioned below, data indicated by “RT” mean data of liquid chromatography retention time. In the columns of “Mass”, data of mass spectrometry were shown (the indication “N.D” means that no molecular ion peak was detected). In the columns of “method”, elution conditions of the liquid chromatography are described. For the indication of retention time in the liquid chromatography, the indication “A” for elution condition means that measurement was performed by elution with a linear gradient of 5 to 100% (v/v) Solution B from 0 minute to 5 minutes and then with 100% Solution B until 6 minutes.
  • In the tables, the compounds having inhibitory activity more than 50% at the concentration of 10 microM(μM) determined by reporter gene assay are shown below.
    • Reporter Gene Assay
  • Screening for inhibitory action of the Wnt signaling pathway was carried out according to the following procedure using the stably transfected cell line Hek-293, STF1.1
    • Growth Medium: DMEM, 10% FBS, Pen-Strep, supplemented with 400 μg/mL G418 to maintain selection of SuperTOPFLASH driven Luciferase gene
    • 1. On the day prior to assay, split cells into a white opaque 96-well plate at 20,000 cells per well in 200 μl of complete growth medium
    • 2. Incubate the plate overnight at 37° C., 5% CO2 and allow the cells to attach
    • 3. Next day, prepare the inhibitors to be tested in complete growth medium, without G418, at 2× the desired final concentration (all conditions are done in duplicates)
    • 4. Carefully remove the old medium from each well using a multiple pipettor
    • 5. Add 50 μl of fresh growth medium (without G148) containing the inhibitor to each well
    • 6. Be sure to include 2 wells containing medium only, 2 wells for stimulation control, 2 wells for DMSO control, and wells for the positive control ICG-001 (2, 5, and 10 micromolar)
    • 7. Once all inhibitors and controls are added, incubate the plate for 1 hour at 37° C., 5% CO2
    • 8. While plate is incubating, prepare fresh 20 mM LiCl in complete growth medium (without G418)
    • 9. After 1 hour, remove plate from incubator and add 50 μl of the medium containing 20 mM LiCl to each well, except for the two wells of the unstimulated control (add 50 μl of just complete medium)
    • 10. Incubate the plate for 24 hours at 37° C., 5% CO2
    • 11. After 24 hours, add 100 μl of BrightGlo (Promega, Cat. #: G7573) to each well
    • 12. Shake plate for 5 minutes to ensure complete lysis
    • 13. Read plate on the Packard TopCount
  • Many compounds of the Examples showed inhibitory activity. For example, the compounds of Examples I-2, I-253, I-254, I-255, I-257, I-259 and I-260 showed inhibitory activity of not less than 1% not more than 50% less than 50% at the concentration of 10 μM. In addition, the compounds of Examples 1-4, I-250, I-251, I-252, I-261, I-262, I-268, I-270 and I-271 showed excellent inhibitory activity of not less than 50% at the concentration of 10 μM.
    • Example XXXVIII-1 Synthesis of (S)-benzyl 1-(methoxy(methyl)amino)-1-oxopropan-2-ylcarbamate (Compound XXXVIII-1)
  • To a solution of N-methoxy-N-methylamine hydrochloride 21.95 g (225 mmol) in 1N sodium hydroxide 225 ml, a solution of (S)-2-(benzyloxycarbonylamino)propanoic acid 33.48 g (150 mmol) and 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride 62.26 g (225 mmol) in acetonitrile 225 ml was added and the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated in vacuo and the residue was diluted with ethyl acetate 600 ml and washed with water 300 ml and brine 300 ml. The organic phase was dried over magnesium sulfate and filtered and the mother solution was concentrated in vacuo to obtain the title compound 42 g (93%).
    • Example XX-1 Synthesis of (S)-benzyl 1,1-diethoxypropan-2-ylcarbamate (Compound XX-1)
  • To a solution of (S)-benzyl 1-(methoxy(methyl)amino)-1-oxopropan-2-ylcarbamate (Compound XXXVIII-1) 5.33 g (20.0 mmol) in tetrahydrofuran 40 ml, a 2M solution of lithium aluminum hydride in tetrahydrofuran 10 ml was added at 0° C. for 0.5 hr. The resulting solution was stirred at room temperature for 2 hours. The reaction mixture was cooled to 0° C. and saturated ammonium chloride aq. 10 ml was added drop wisely. The precipitate was filtered on celite and washed with methanol 50 ml. The mother solution was concentrated in vacuo and the residue was diluted with ethyl acetate 200 ml and washed with water 100 ml and brine 100 ml. The organic phase was dried over magnesium sulfate and filtered and the mother solution was concentrated in vacuo. The residue was diluted in ethanol 50 ml and the mixture was added to 4N hydrochloric acid in dioxane 0.25 ml. The reaction mixture was refluxed for 18 hours and concentrated in vacuo. The residue was diluted with ethyl acetate 200 ml and washed with saturated sodium bicarbonate 200 ml and brine 200 ml. The organic phase was dried over magnesium sulfate and filtered and the mother solution was concentrated in vacuo. The residue was purified on silica gel column chromatography (n-hexane:ethyl acetate=100:0 to 80:20) to obtain the title compound 3.55 g (63%, 2 steps).
    • Example XIV-1 Synthesis of (S)-1,1-diethoxypropan-2-amine (Compound XIV-1)
  • To a solution of (S)-benzyl 1,1-diethoxypropan-2-ylcarbamate (Compound XX-1) 844 mg (3.00 mmol) in methanol 50 ml, 5% palladium on carbon 30 mg was added and the mixture was stirred at room temperature for 2 hours under hydrogen atmosphere. The reaction mixture was filtered on celite and washed with methanol 200 ml and the mother solution was concentrated in vacuo to obtain the title compound 442 mg (100%).
    • Example IV-1 Synthesis of N-benzyl-2,2-diethoxyethanamine (Compound IV-1)
  • A solution of benzaldehyde 5.1 ml (50.0 mmol) in 2,2-diethoxyethanamine 10.9 ml (75.0 mmol) was stirred at room temperature for 0.5 hour. The reaction mixture was diluted with tetrahydrofuran 450 ml and triacetoxyborohydride 32.0 g (150 mmol) was added and the mixture was stirred overnight. The reaction mixture was diluted with ethyl acetate 500 ml and washed with saturated sodium bicarbonate 500 ml, water 500 ml and brine 500 ml. The organic phase was dried over magnesium sulfate and filtered. The filtrate was concentrated in vacuo and the residue was purified on silica gel column chromatography (n-hexane:ethyl acetate=70:30 to 50:50) to obtain the title compound 7.8 g (yield 70%).
  • The following compounds shown in Table I were obtained by a similar method to described above.
  • TABLE I
    yield
    Example No. structure chemical name (%)
    IV-2
    Figure US20180305373A1-20181025-C00022
         		2,2-diethoxy-N-(naphthalen-1-ylmethyl)ethanamine 68
    IV-3
    Figure US20180305373A1-20181025-C00023
         		2,2-diethoxy-N-(quinolin-8-ylmethyl)ethanamine 100
    IV-4
    Figure US20180305373A1-20181025-C00024
         		N-(benzo[b]thiophen-3-ylmethyl)-2,2- diethoxyethanamine 86
    IV-5
    Figure US20180305373A1-20181025-C00025
         		2,2-diethoxy-N-(pyridin-4-ylmethyl)ethanamine 44
    IV-6
    Figure US20180305373A1-20181025-C00026
         		N-(2,4-difluorobenzyl)-2,2-diethoxyethanamine 36
    • Example IV-7 Synthesis of N-(2,2-diethoxyethyl)-3-methylbutan-1-amine (Compound IV-7)
  • To a solution of 2,2-diethoxyethanamine 2.91 ml (20 mmol) in acetonitrile 50 ml, potassium carbonate 2.0 g (15 mmol) and a solution of isoamylbromide 1.26 ml (10 mmol) in acetonitrile 20 ml were added and the mixture was stirred at 65° C. overnight. The reaction mixture was concentrated in vacuo and the residue was diluted with ethyl acetate 100 ml and washed with water 100 ml and brine 100 ml. The organic phase was dried over magnesium sulfate and filtered. The filtrate was concentrated in vacuo and the residue was purified on BUch silica gel column chromatography (n-hexane:ethyl acetate=90:10 to 80:20) to obtain the title compound 1.57 g (77%).
  • The following compounds shown in Table II were obtained by a similar method to described above.
  • TABLE II
    yield
    Example No. structure chemical name (%)
    IV-8
    Figure US20180305373A1-20181025-C00027
         		2,2-diethoxy-N-phenethylethanamine 94
    IV-9
    Figure US20180305373A1-20181025-C00028
         		N-(2,2-diethoxyethyl)-3-phenylpropan-1-amine 27
    IV-10
    Figure US20180305373A1-20181025-C00029
         		N-(2,2-diethoxyethyl)-3,3-diphenylpropan-1-amine 61
    IV-11
    Figure US20180305373A1-20181025-C00030
         		2,2-diethoxy-N-(naphthalen-2-ylmethyl)ethanamine 78
    IV-12
    Figure US20180305373A1-20181025-C00031
         		tert-butyl 4-((2,2- diethoxyethylamino)methyl)benzo[d]thiazol-2- ylcarbamate 85
    • Example IV-13 Synthesis of (R)-2,2-diethoxy-N-(1-phenylethyl) ethanamine (Compound IV-13)
  • To a solution of (R)-(+)-1-phenylethylamine 66.6 g (550 mmol) in acetonitrile 300 ml, 2-bromo-1,1-diethoxyethane 41.3 ml (270 mmol) and potassium carbonate 70.7 g (405 mmol) were added and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo and the residue was diluted with ethyl acetate 300 ml and washed with water 500 ml and brine 500 ml. The organic phase was dried with magnesium sulfate and filtered. The filtrate was concentrated in vacuo and the residue was purified on silica gel column chromatography (n-hexane:ethyl acetate=5:1 and 1:1) to obtain the title compound 46.0 g (70%).
  • The following compound shown in Table III was obtained by a similar method to that described above.
  • TABLE III
    yield
    Example No. structure chemical name (%)
    IV-14
    Figure US20180305373A1-20181025-C00032
         		2,2-diethoxy-N-(pyridin-2-ylmethyl)ethanamine 65
    • Example IV-15 Synthesis of (S)—N-benzyl-1,1-diethoxypropan-2-amine (Compound IV-15)
  • To a solution of (S)-1,1-diethoxypropan-2-amine (Compound XIV-1) 682 mg (3.55 mmol) in tetrahydrofuran 2 ml, benzaldehyde 337 mg (3.55 mmol) was added and the mixture was stirred at room temperature for 0.5 hour. The reaction mixture was diluted with tetrahydrofuran 3 ml and sodium triacetoxyborohydride 829 mg (3.91 mmol) was added and the mixture was stirred at room temperature for 18 hours. The reaction mixture was diluted with ethyl acetate 50 ml and washed with saturated sodium bicarbonate aq. 50 ml twice, water 50 ml twice and brine 50 ml twice. The organic phase was dried over magnesium sulfate and filtered and the mother solution was concentrated in vacuo to obtain the title compound 826 mg (98%).
  • The following compounds shown in Table IV were obtained by a similar method to that described above.
  • TABLE IV
    yield
    Example No. structure chemical name (%)
    IV-16
    Figure US20180305373A1-20181025-C00033
         		(S)-1,1-diethoxy-N-(naphthalen-1-ylmethyl)propan-2- amine 67
    IV-17
    Figure US20180305373A1-20181025-C00034
         		(S)-1,1-diethoxy-N-(quinolin-8-ylmethyl)propan-2- amine 91
    IV-18
    Figure US20180305373A1-20181025-C00035
         		(S)-N-(benzo[b]thiophen-3-ylmethyl)-1, 1- diethoxypropan-2-amine 97
    • Example XV-1 Synthesis of (S)-(9H-fluoren-9-yl)methyl 1-(benzyl(2,2-diethoxyethyl)amino)-1-oxopropan-2-ylcarbamate (Compound XV-1)
  • To a solution of (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)propanoic acid 1.98 g (6.0 mmol), a solution of l-hydroxybenzotriazol 1.01 g (7.5 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 1.44 g (7.5 mmol) in dichloromethane 20 ml, and a solution of N-benzyl-2,2-diethoxyethanamine (Compound IV-1) 1.12 g (5.0 mmol) and 4-dimethylaminopyridine 61 mg (0.5 mmol) in dichloromethane 5 ml were added and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate 20 ml and washed with saturated aqueous sodium bicarbonate 20 ml, water 20 ml and brine 20 ml. The organic phase was dried over magnesium sulfate and filtered. The filtrate was concentrated in vacuo and the residue was purified on silica gel column chromatography (n-hexane:ethyl acetate=90:10 to 70:30) to obtain the title compound 1.1 g (yield 42%).
  • The following compounds shown in Tables V-1 to V-4 were obtained by a similar method to that described above. In the Tables, “Int_1” means an intermediate compound number and “Int_X” is corresponding to carboxylic acid.
  • TABLE V-1
    Example yield
    No. chemical name (%) Int_1 Int_X
    XV-2 (S)-(9H-fluoren-9-yl)methyl 1-(benzyl(2,2-diethoxyethyl)amino)- 85 IV-1 Fmoc-Tyr(tBu)-OH
    3-(4-tert-butoxyphenyl)-1-oxopropan-2-ylcarbamate
    XV-3 N-Benzyl-N-(2,2-dimethoxyethyl)-6-(tert-butoxycarbonylamino)- 84 IV-1 Fmoc-Lys(Boc)-OH
    2-(S)-(9H-fluoren-9-yl)methoxycarbonylaminohexamide
    XV-4 (S)-(9H-fluoren-9-yl)methyl 3-(4-tert-butoxyphenyl)-1-((2,2- 55 IV-2 Fmoc-Tyr(tBu)-OH
    diethoxyethyl)(naphthalen-1-ylmethyl)amino)-1-oxopropan-2-
    ylcarbamate
    XV-5 (S)-tert-butyl 3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4- 44 IV-2 Fmoc-Asp(OtBu)-OH
    ((2,2-diethoxyethyl)(naphthalen-1-ylmethyl)amino)-4-
    oxobutanoate
    XV-6 (S)-(9H-fluoren-9-yl)methyl 3-(4-tert-butoxyphenyl)-1-((2,2- 80 IV-3 Fmoc-Tyr(tBu)-OH
    diethoxyethyl)(quinolin-8-ylmethyl)amino)-1-oxopropan-2-
    ylcarbamate
    XV-7 (S)-(9H-fluoren-9-yl)methyl 1-((2,2-diethoxyethyl)(quinolin-8- 31 IV-3 Fmoc-Asn(Trt)-OH
    ylmethyl)amino)-1,4-dioxo-4-(tritylamino)butan-2-ylcarbamate
    XV-8 (S)-(9H-fluoren-9-yl)methyl 1-((benzo[b]thiophen-3- 68 IV-4 Fmoc-Ala-OH
    ylmethyl)(2,2-diethoxyethyl)amino)-1-oxopropan-2-ylcarbamate
    XV-9 (S)-(9H-fluoren-9-yl)methyl 1-((benzo[b]thiophen-3- 71 IV-4 Fmoc-Tyr(tBu)-OH
    ylmethyl)(2,2-diethoxyethyl)amino)-3-(4-tert-butoxyphenyl)-1-
    oxopropan-2-ylcarbamate
    XV-10 (S)-(9H-fluoren-9-yl)methyl 1-((2,2- 71 IV-7 Fmoc-Ala-OH
    diethoxyethyl)(isopentyl)amino)-1-oxopropan-2-ylcarbamate
    XV-11 (S)-(9H-fluoren-9-yl)methyl 3-(4-tert-butoxyphenyl)-1-((2,2- 64 IV-7 Fmoc-Tyr(tBu)-OH
    diethoxyethyl)(isopentyl)amino)-1-oxopropan-2-ylcarbamate
    XV-12 (S)-(9H-fluoren-9-yl)methyl 6-(tert-butoxycarbonylamino)-1- 65 IV-7 Fmoc-Lys(Boc)-OH
    ((2,2-diethoxyethyl)(isopentyl)amino)-1-oxohexan-2-
    ylcarbamate
    XV-13 (S)-tert-butyl 3-(((9H-fluoren-9-yl)methyl9H-fluoren-9- 65 IV-7 Fmoc-Asp(OtBu)-OH
    yl)methoxy)carbonylamino)-4-((2,2-
    diethoxyethyl)(isopentyl)amino)-4-oxobutanoate
    XV-14 (S)-(9H-fluoren-9-yl)methyl 1-((2,2- 65 IV-7 Fmoc-Asn(Trt)-OH
    diethoxyethyl)(isopentyl)amino)-1,4-dioxo-4-(tritylamino)butan-
    2-ylcarbamate
    XV-15 (S)-(9H-fluoren-9-yl)methyl 3-tert-butoxy-1-((2,2- 75 IV-7 Fmoc-Ser(tBu)-OH
    diethoxyethyl)(isopentyl)amino)-1-oxopropan-2-ylcarbamate
    XV-16 (S)-(9H-fluoren-9-yl)methyl 1-((2,2- 69 IV-7 Fmoc-Leu-OH
    diethoxyethyl)(isopentyl)amino)-4-methyl-1-oxopentan-2-
    ylcarbamate
  • TABLE V-2
    Example yield
    No. chemical name (%) Int_1 Int_X
    XV-17 (S)-(9H-fluoren-9-yl)methyl 2-((2,2- 62 IV-7 Fmoc-Phg-OH
    diethoxyethyl)(isopentyl)amino)-2-oxo-1-phenylethylcarbamate
    XV-18 (S)-(9H-fluoren-9-yl)methyl 1-((2,2- 76 IV-7 Fmoc-Phe-OH
    diethoxyethyl)(isopentyl)amino)-1-oxo-3-phenylpropan-2-
    ylcarbamate
    XV-19 (S)-(9H-fluoren-9-yl)methyl 1-((2,2- 75 IV-7 Fmoc-Hph-OH
    diethoxyethyl)(isopentyl)amino)-1-oxo-4-phenylbutan-2-
    ylcarbamate
    XV-20 (S)-(9H-fluoren-9-yl)methyl 3-(benzyloxy)-1-((2,2- 57 IV-7 Fmoc-Ser(Bzl)-OH
    diethoxyethyl)(isopentyl)amino)-1-oxopropan-2-ylcarbamate
    XV-21 (S)-(9H-fluoren-9-yl)methyl 1-((2,2- 61 IV-7 Fmoc-Ala(1-Naph)-OH
    diethoxyethyl)(isopentyl)amino)-3-(naphthalen-1-yl)-1-
    oxopropan-2-ylcarbamate
    XV-22 (S)-(9H-fluoren-9-yl)methyl 1-((2,2- 53 IV-7 Fmoc-Ala(2-Naph)-OH
    diethoxyethyl)(isopentyl)amino)-3-(naphthalen-2-yl)-1-
    oxopropan-2-ylcarbamate
    XV-23 (S)-(9H-fluoren-9-yl)methyl 1-((2,2- 45 IV-8 Fmoc-Ala-OH
    diethoxyethyl)(phenethyl)amino)-1-oxopropan-2-ylcarbamate
    XV-24 (S)-(9H-fluoren-9-yl)methyl 3-(4-tert-butoxyphenyl)-1-((2,2- 68 IV-8 Fmoc-Tyr(tBu)-OH
    diethoxyethyl)(phenethyl)amino)-1-oxopropan-2-ylcarbamate
    XV-25 (S)-(9H-fluoren-9-yl)methyl 6-(tert-butoxycarbonylamino)-1- 72 IV-8 Fmoc-Lys(Boc)-OH
    ((2,2-diethoxyethyl)(phenethyl)amino)-1-oxohexan-2-
    ylcarbamate
    XV-26 (S)-tert-butyl 3-((((9H-fluoren-9-yl)methyl9H-fluoren-9- 57 IV-8 Fmoc-Asp(OtBu)-OH
    yl)methoxy)carbonylamino)-4-((2,2-
    diethoxyethyl)(phenethyl)amino)-4-oxobutanoate
    XV-27 (S)-(9H-fluoren-9-yl)methyl 1-((2,2- 50 IV-8 Fmoc-Asn(Trt)-OH
    diethoxyethyl)(phenethyl)amino)-1,4-dioxo-4-(tritylamino)butan-
    2-ylcarbamate
    XV-28 (S)-(9H-fluoren-9-yl)methyl 3-tert-butoxy-1-((2,2- 79 IV-8 Fmoc-Ser(tBu)-OH
    diethoxyethyl)(phenethyl)amino)-1-oxopropan-2-yl carbamate
    XV-29 (S)-(9H-fluoren-9-yl)methyl 1-((2,2- 79 IV-8 Fmoc-Leu-OH
    diethoxyethyl)(phenethyl)amino)-4-methyl-1-oxopentan-2-
    ylcarbamate
    XV-30 (S)-(9H-fluoren-9-yl)methyl 1-((2,2- 65 IV-8 Fmoc-Hph-OH
    diethoxyethyl)(phenethyl)amino)-1-oxo-4-phenylbutan-2-
    ylcarbamate
    XV-31 (S)-(9H-fluoren-9-yl)methyl 3-(benzyloxy)-1-((2,2- 61 IV-9 Fmoc-Ser(Bzl)-OH
    diethoxyethyl)(3-phenylpropyl)amino)-1-oxopropan-2-
    ylcarbamate
  • TABLE V-3
    Example yield
    No. chemical name (%) Int_1 Int_X
    XV-32 (S)-(9H-fluoren-9-yl)methyl 1-((2,2-diethoxyethyl)(3- 65 IV-9 Cbz-Ala(1-Naph)-OH
    phenylpropyl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-
    ylcarbamate
    XV-33 (S)-(9H-fluoren-9-yl)methyl 1-((2,2-diethoxyethyl)(3- 84 IV-9 Cbz-Ala(2-Naph)-OH
    phenylpropyl)amino)-3-(naphthalen-2-yl)-1-oxopropan-2-
    ylcarbamate
    XV-34 (S)-(9H-fluoren-9-yl)methyl 1-((2,2-diethoxyethyl)(3,3- 82 IV-10 Fmoc-Ala-OH
    diphenylpropyl)amino)-1-oxopropan-2-ylcarbamate
    XV-35 (S)-(9H-fluoren-9-yl)methyl 3-(4-tert-butoxyphenyl)-1-((2,2- 77 IV-10 Fmoc-Tyr(tBu)-OH
    diethoxyethyl)(3,3-diphenylpropyl)amino)-1-oxopropan-2-
    ylcarbamate
    XV-36 (S)-(9H-fluoren-9-yl)methyl 6-(tert-butoxycarbonylamino)-1- 63 IV-10 Fmoc-Lys(Boc)-OH
    ((2,2-diethoxyethyl)(3,3-diphenylpropyl)amino)-1-oxohexan-2-
    ylcarbamate
    XV-37 (S)-tert-butyl 3-((((9H-fluoren-9-yl)methyl9H-fluoren-9- 71 IV-10 Fmoc-Asp(OtBu)-OH
    yl)methoxy)carbonylamino)-4-((2,2-diethoxyethyl)(3,3-
    diphenylpropyl)amino)-4-oxobutanoate
    XV-38 (S)-(9H-fluoren-9-yl)methyl 1-((2,2-diethoxyethyl)(3,3- 68 IV-10 Fmoc-Asn(Trt)-OH
    diphenylpropyl)amino)-1,4-dioxo-4-(tritylamino)butan-2-
    ylcarbamate
    XV-39 (S)-(9H-fluoren-9-yl)methyl 1-((2,2-diethoxyethyl)(3,3- 84 IV-10 Fmoc-Leu-OH
    diphenylpropyl)amino)-4-methyl-1-oxopentan-2-ylcarbamate
    XV-40 (S)-(9H-fluoren-9-yl)methyl 2-((2,2-diethoxyethyl)(3,3- 90 IV-10 Fmoc-Phg-OH
    diphenylpropyl)amino)-2-oxo-1-phenylethylcarbamate
    XV-41 (S)-(9H-fluoren-9-yl)methyl 1-((2,2-diethoxyethyl)(3,3- 88 IV-10 Fmoc-Phe-OH
    diphenylpropyl)amino)-1-oxo-3-phenylpropan-2-ylcarbamate
    XV-42 (S)-(9H-fluoren-9-yl)methyl 3-(benzyloxy)-1-((2,2- 89 IV-10 Fmoc-Ser(Bzl)-OH
    diethoxyethyl)(3,3-diphenylpropyl)amino)-1-oxopropan-2-
    ylcarbamate
    XV-43 (S)-(9H-fluoren-9-yl)methyl 1-((2,2-diethoxyethyl)(3,3- 89 IV-10 Fmoc-Ala(1-Naph)-OH
    diphenylpropyl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-
    ylcarbamate
    XV-44 (S)-(9H-fluoren-9-yl)methyl 1-((2,2-diethoxyethyl)(3,3- 91 IV-10 Fmoc-Ala(2-Naph)-OH
    diphenylpropyl)amino)-3-(naphthalen-2-yl)-1-oxopropan-2-
    ylcarbamate
    XV-45 (S)-(9H-fluoren-9-yl)methyl 1-((2,2-diethoxyethyl)(naphthalen-2- 92 IV-11 Fmoc-Ala-OH
    ylmethyl)amino)-1-oxopropan-2-ylcarbamate
    XV-46 (S)-(9H-fluoren-9-yl)methyl 3-(4-tert-butoxyphenyl)-1-((2,2- 85 IV-11 Fmoc-Tyr(tBu)-OH
    diethoxyethyl)(naphthalen-2-ylmethyl)amino)-1-oxopropan-2-
    ylcarbamate
  • TABLE V-4
    Example yield
    No. chemical name (%) Int_1 Int_X
    XV-47 (S)-(9H-fluoren-9-yl)methyl 6-(tert-butoxycarbonylamino)-1- 76 IV-11 Fmoc-Lys(Boc)-OH
    ((2,2-diethoxyethyl)(naphthalen-2-ylmethyl)amino)-1-oxohexan-
    2-ylcarbamate
    XV-48 (S)-tert-butyl 3-((((9H-fluoren-9-yl)methyl9H-fluoren-9- 74 IV-11 Fmoc-Asp(OtBu)-OH
    yl)methoxy)carbonylamino)-4-((2,2-diethoxyethyl)(naphthalen-
    2-ylmethyl)amino)-4-oxobulanoate
    XV-49 (S)-(9H-fluoren-9-yl)methyl 1-((2,2-diethoxyethyl)(naphthalen-2- 67 IV-11 Fmoc-Asn(Trt)-OH
    ylmethyl)amino)-1,4-dioxo-4-(tritylamino)butan-2-ylcarbamate
    XV-50 (S)-(9H-fluoren-9-yl)methyl 3-tert-butoxy-1-((2,2- 75 IV-11 Fmoc-Ser(tBu)-OH
    diethoxyethyl)(naphthalen-2-ylmethyl)amino)-1-oxopropan-2-
    ylcarbamate
    XV-51 (S)-(9H-fluoren-9-yl)methyl 1-((2,2-diethoxyethyl)(naphthalen-2- 77 IV-11 Fmoc-Leu-OH
    ylmethyl)amino)-4-methyl-1-oxopentan-2-ylcarbamate
    XV-52 (S)-(9H-fluoren-9-yl)methyl 2-((2,2-diethoxyethyl)(naphthalen-2- 82 IV-11 Fmoc-Phg-OH
    ylmethyl)amino)-2-oxo-1-phenylethylcarbamate
    XV-53 (S)-(9H-fluoren-9-yl)methyl 1-((2,2-diethoxyethyl)(naphthalen-2- 86 IV-11 Fmoc-Phe-OH
    ylmethyl)amino)-1-oxo-3-phenylpropan-2-ylcarbamate
    XV-54 (S)-(9H-fluoren-9-yl)methyl 1-((2,2-diethoxyethyl)(naphthalen-2- 79 IV-11 Fmoc-Hph-OH
    ylmethyl)amino)-1-oxo-4-phenylbutan-2-ylcarbamate
    XV-55 (S)-tert-butyl 4-((2-(9H-fluoren-9- 100 IV-12 Fmoc-Tyr(tBu)-OH
    yl)methoxycarbonylamino-3-(4-tert-butoxyphenyl)-N-(2,2-
    diethoxyethyl)propanamido)methyl)benzo[d]thiazol-2-
    ylcarbamate
    XV-56 (9H-fluoren-9-yl)methyl (S)-3-(4-tert-butoxyphenyl)-1- 87 IV-13 Fmoc-Tyr(tBu)-OH
    ((2,2-diethoxyethyl)((R)-1-phenylethyl)amino)-1-
    oxopropan-2-ylcarbamate
    XV-57 (S)-(9H-fluoren-9-yl)methyl 3-(4-tert-butoxyphenyl)-1- 78 IV-5 Fmoc-Tyr(tBu)-OH
    ((2,2-diethoxyethyl)(pyridin-4-ylmethyl)amino)-1-
    oxopropan-2-ylcarbamate
    XV-58 (S)-(9H-fluoren-9-yl)methyl 3-(4-tert-butoxyphenyl)-1- 90 IV-14 Fmoc-Tyr(tBu)-OH
    ((2,2-diethoxyethyl)(pyridin-2-ylmethyl)amino)-1-
    oxopropan-2-ylcarbamate
    XV-59 (S)-(9H-fluoren-9-yl)methyl 3-(4-tert-butoxyphenyl)-1- 36 IV-6 Fmoc-Tyr(tBu)-OH
    ((2,2-diethoxyethyl)(2,4-difluorobenzyl)amino)-1-
    oxopropan-2-ylcarbamate
    • Example XV-60 Synthesis of (9H-fluoren-9-yl)methyl (S)-1-((S)-(1,1-diethoxypropan-2-yl)(benzyl)amino)-1-oxopropan-2-ylcarbamate (Compound XV-60)
  • To a solution of (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)propanoic acid 68 mg (0.22 mmol) and 0-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 84 mg (0.22 mmol) in dichloromethane 1 ml, a solution of (S)—N-benzyl-1,1-diethoxypropan-2-amine (Compound IV-15) 47 mg (0.2 mmol) and N,N′-diisopropylethylamine 38 ml (0.22 mmol) in dichloromethane 1 ml was added and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate 50 ml and washed with saturated aqueous sodium bicarbonate 50 ml, water 50 ml and brine 50 ml. The organic phase was dried over magnesium sulfate and filtered. The filtrate was concentrated in vacuo and the residue was purified on silica gel column chromatography (n-hexane:ethyl acetate=9:1 to 7:3) to obtain the title compound 48 mg (45%).
  • The following compounds shown in Table VI were obtained by a similar method to that described above. In the Table, “Int_1” means an intermediate compound number and “Int_X” is corresponding to carboxylic acid.
  • TABLE VI
    Example yield
    No. chemical name (%) Int_1 Int_X
    XV-61 (9H-fluoren-9-yl)methyl (S)-1-(benzyl((S)-1,1-diethoxypropan-2- 77 IV-15 Fmoc-Tyr(tBu)-OH
    yl)amino)-3-(4-tert-butoxyphenyl)-1-oxopropan-2-ylcarbamate
    XV-62 (S)-tert-butyl 3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4- 52 IV-15 Fmoc-Asp(OtBu)-OH
    (benzyl((S)-1,1-diethoxypropan-2-yl)amino)-4-oxobutanoate
    XV-63 (9H-fluoren-9-yl)methyl (S)-1-(((S)-1,1-diethoxypropan-2- 32 IV-16 Fmoc-Ala-OH
    yl)(naphthalen-1-ylmethyl)amino)-1-oxopropan-2-ylcarbamate
    XV-64 (9H-fluoren-9-yl)methyl(S)-3-(4-tert-butoxyphenyl)-1-(((S)-1,1- 79 IV-16 Fmoc-Tyr(tBu)-OH
    diethoxypropan-2-yl)(naphthalen-1-ylmethyl)amino)-1-
    oxopropan-2-ylcarbamate
    XV-65 (9H-fluoren-9-yl)methyl (S)-6-(tert-butoxycarbonylamino)-1- 22 IV-16 Fmoc-Lys(Boc)-OH
    (((S)-1,1-diethoxypropan-2-yl)(naphthalen-1-ylmethyl)amino)-1-
    oxohexan-2-ylcarbamate
    XV-66 (S)-tert-butyl 3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4- 35 IV-16 Fmoc-Asp(OtBu)-OH
    (((S)-1,1-diethoxypropan-2-yl)(naphthalen-1-ylmethyl)amino)-4-
    oxobutanoate
    XV-67 (9H-fluoren-9-yl)methyl (S)-1-(((S)-1,1-diethoxypropan-2- 42 IV-17 Fmoc-Ala-OH
    yl)(quinolin-8-ylmethyl)amino)-1-oxopropan-2-ylcarbamate
    XV-68 (9H-fluoren-9-yl)methyl (S)-3-(4-tert-butoxyphenyl)-1-(((S)-1,1- 68 IV-17 Fmoc-Tyr(tBu)-OH
    diethoxypropan-2-yl)(quinolin-8-ylmethyl)amino)-1-oxopropan-
    2-ylcarbamate
    XV-69 (9H-fluoren-9-yl)methyl (S)-6-(tert-butoxycarbonylamino)-1- 65 IV-17 Fmoc-Lys(Boc)-OH
    (((S)-1,1-diethoxypropan-2-yl)(quinolin-8-ylmethyl)amino)-1-
    oxohexan-2-ylcarbamate
    XV-70 (9H-fluoren-9-yl)methyl (S)-1-(((S)-1,1-diethoxypropan-2- 44 IV-17 Fmoc-Asn(Trt)-OH
    yl)(quinolin-8-ylmethyl)amino)-1,4-dioxo-4-(tritylamino)butan-2-
    ylcarbamate
    XV-71 (9H-fluoren-9-yl)methyl (S)-1-((benzo[b]thiophen-3- 61 IV-18 Fmoc-Tyr(tBu)-OH
    ylmethyl)((S)-1,1-diethoxypropan-2-yl)amino)-3-(4-tert-
    butoxyphenyl)-1-oxopropan-2-ylcarbamate
    XV-72 (9H-fluoren-9-yl)methyl (S)-6-(tert-butoxycarbonylamino)-1- 59 IV-18 Fmoc-Lys(Boc)-OH
    ((benzo[b]thiophen-3-ylmethyl)((S)-1,1-diethoxypropan-2-
    yl)amino)-1-oxohexan-2-ylcarbamate
    XV-73 (S)-tert-butyl 3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4- 40 IV-18 Fmoc-Asp(OtBu)-OH
    ((benzo[b]thiophen-3-ylmethyl)((S)-1,1-diethoxypropan-2-
    yl)amino)-4-oxobutanoate
    XV-74 (9H-fluoren-9-yl)methyl (S)-1-((benzo[b]thiophen-3- 35 IV-18 Fmoc-Asn(Trt)-OH
    ylmethyl)((S)-1,1-diethoxypropan-2-yl)amino)-1,4-dioxo-4-
    (tritylamino)butan-2-ylcarbamate
    • Example VI-1 Synthesis of (S)-2-amino-N-benzyl-N-(2,2-diethoxyethyl)propanamide (Compound VI-1)
  • To (S)-(9H-fluoren-9-yl)methyl 1-(benzyl(2,2-diethoxyethyl)amino)-1-oxopropan-2-ylcarbamate (Compound XV-1) 1.12 g (2.1 mmol), 25%-piperidine/dichloromethane 16 ml was added and the mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated in vacuo and the residue was purified on silica gel column chromatography (n-hexane:ethyl acetate=100:0 to 70:30, chloroform:methanol=100:0 to 80:20) to obtain the title compound 640 mg (yield 100%).
  • The following compounds shown in Tables VII-1 to VII-4 were obtained by a similar method to that described above. In the Tables, “Int_1” means an intermediate compound number.
  • TABLE VII-1
    Example yield
    No. chemical name (%) Int_1
    VI-2 (S)-2-amino-N-benzyl-3-(4-tert-butoxyphenyl)-N-(2,2- 91 XV-2
    diethoxyethyl)propanamide
    VI-3 (S)-tert-butyl 5-amino-6-(benzyl(2,2-diethoxyethyl)amino)-6- 100 XV-3
    oxohexylcarbamate
    VI-4 (S)-2-amino-3-(4-tert-butoxyphenyl)-N-(2,2-diethoxyethyl)-N- 100 XV-4
    (naphthalen-1-ylmethyl)propanamide
    VI-5 (S)-tert-butyl 3-amino-4-((2,2-diethoxyethyl)(naphthalen-1- 87 XV-5
    ylmethyl)amino)-4-oxobutanoate
    VI-6 (S)-2-amino-3-(4-tert-butoxyphenyl)-N-(2,2-diethoxyethyl)-N- 20 XV-6
    (quinolin-8-ylmethyl)propanamide
    VI-7 (S)-2-amino-N1-(2,2-diethoxyethyl)-N1-(quinolin-8-ylmethyl)-N4- 77 XV-7
    tritylsuccinamide
    VI-8 (S)-2-amino-N-(benzo[b]thiophen-3-ylmethyl)-N-(2,2- 81 XV-8
    diethoxyethyl)propanamide
    VI-9 (S)-2-amino-N-(benzo[b]thiophen-3-ylmethyl)-3-(4-tert- 60 XV-9
    butoxyphenyl)-N-(2,2-diethoxyethyl)propanamide
    VI-10 (S)-2-amino-N-(2,2-diethoxyethyl)-N-isopentylpropanamide 86 XV-10
    VI-11 (S)-2-amino-3-(4-tert-butoxyphenyl)-N-(2,2-diethoxyethyl)-N- 98 XV-11
    isopentylpropanamide
    VI-12 (S)-tert-butyl 5-amino-6-((2,2-diethoxyethyl)(isopentyl)amino)-6- 98 XV-12
    oxohexylcarbamate
    VI-13 (S)-tert-butyl 3-amino-4-((2,2-diethoxyethyl)(isopentyl)amino)-4- 83 XV-13
    oxobutanoate
    VI-14 (S)-2-amino-N1-(2,2-diethoxyethyl)-N1-isopentyl-N4- 85 XV-14
    tritylsuccinamide
    VI-15 (S)-2-amino-3-tert-butoxy-N-(2,2-diethoxyethyl)-N- 72 XV-15
    isopentylpropanamide
    VI-16 (S)-2-amino-N-(2,2-diethoxyethyl)-N-isopentyl-4- 74 XV-16
    methylpentanamide
    VI-17 (S)-2-amino-N-(2,2-diethoxyethyl)-N-isopentyl-2-phenylacetamide 88 XV-17
    VI-18 (S)-2-amino-N-(2,2-diethoxyethyl)-N-isopentyl-3- 85 XV-18
    phenylpropanamide
    VI-19 (S)-2-amino-N-(2,2-diethoxyethyl)-N-isopentyl-4- 83 XV-19
    phenylbutanamide
    VI-20 (S)-2-amino-3-(benzyloxy)-N-(2,2-diethoxyethyl)-N- 76 XV-20
    isopentylpropanamide
  • TABLE VII-2
    Example yield
    No. chemical name (%) Int_1
    VI-21 (S)-2-amino-N-(2,2-diethoxyethyl)-N-isopentyl-3-(naphthalen-1- 90 XV-21
    yl)propanamide
    VI-22 (S)-2-amino-N-(2,2-diethoxyethyl)-N-isopentyl-3-(naphthalen-2- 90 XV-22
    yl)propanamide
    VI-23 (S)-2-amino-N-(2,2-diethoxyethyl)-N-phenethylpropanamide 83 XV-23
    VI-24 (S)-2-amino-3-(4-tert-butoxyphenyl)-N-(2,2-diethoxyethyl)-N- 86 XV-24
    phenethylpropanamide
    VI-25 (S)-tert-butyl 5-amino-6-((2,2-diethoxyethyl)(phenethyl)amino)-6- 91 XV-25
    oxohexylcarbamate
    VI-26 (S)-tert-butyl 3-amino-4-((2,2-diethoxyethyl)(phenethyl)amino)-4- 73 XV-26
    oxobutanoate
    VI-27 (S)-2-amino-N1-(2,2-diethoxyethyl)-N1-phenethyl-N4- 60 XV-27
    tritylsuccinamide
    VI-28 (S)-2-amino-3-tert-butoxy-N-(2,2-diethoxyethyl)-N- 79 XV-28
    phenethylpropanamide
    VI-29 (S)-2-amino-N-(2,2-diethoxyethyl)-4-methyl-N- 88 XV-29
    phenethylpentanamide
    VI-30 (S)-2-amino-N-(2,2-diethoxyethyl)-N-phenethyl-4- 83 XV-30
    phenylbutanamide
    VI-31 (S)-2-amino-3-(benzyloxy)-N-(2,2-diethoxyethyl)-N-(3- 75 XV-31
    phenylpropyl)propanamide
    VI-34 (S)-2-amino-N-(2,2-diethoxyethyl)-N-(3,3- 89 XV-34
    diphenylpropyl)propanamide
    VI-35 (S)-2-amino-3-(4-tert-butoxyphenyl)-N-(2,2-diethoxyethyl)-N-(3,3- 85 XV-35
    diphenylpropyl)propanamide
    VI-36 (S)-tert-butyl 5-amino-6-((2,2-diethoxyethyl)(3,3- 78 XV-36
    diphenylpropyl)amino)-6-oxohexylcarbamate
    VI-37 (S)-tert-butyl 3-amino-4-((2,2-diethoxyethyl)(3,3- 68 XV-37
    diphenylpropyl)amino)-4-oxobutanoate
    VI-38 (S)-2-amino-N1-(2,2-diethoxyethyl)-N1-(3,3-diphenylpropyl)-N4- 65 XV-38
    tritylsuccinamide
    VI-39 (S)-2-amino-N-(2,2-diethoxyethyl)-N-(3,3-diphenylpropyl)-4- 87 XV-39
    methylpentanamide
    VI-40 (S)-2-amino-N-(2,2-diethoxyethyl)-N-(3,3-diphenylpropyl)-2- 85 XV-40
    phenylacetamide
    VI-41 (S)-2-amino-N-(2,2-diethoxyethyl)-N-(3,3-diphenylpropyl)-3- 79 XV-41
    phenylpropanamide
  • TABLE VII-3
    Example yield
    No. chemical name (%) Int_1
    VI-42 (S)-2-amino-3-(benzyloxy)-N-(2,2-diethoxyethyl)-N-(3,3- 78 XV-42
    diphenylpropyl)propanamide
    VI-43 (S)-2-amino-N-(2,2-diethoxyethyl)-N-(3,3-diphenylpropyl)-3- 98 XV-43
    (naphthalen-1-yl)propanamide
    VI-44 (S)-2-amino-N-(2,2-diethoxyethyl)-N-(3,3-diphenylpropyl)-3- 92 XV-44
    (naphthalen-2-yl)propanamide
    VI-45 (S)-2-amino-N-(2,2-diethoxyethyl)-N-(naphthalen-2- 85 XV-45
    ylmethyl)propanamide
    VI-46 (S)-2-amino-3-(4-tert-butoxyphenyl)-N-(2,2-diethoxyethyl)-N- 72 XV-46
    (naphthalen-2-ylmethyl)propanamide
    VI-47 (S)-tert-butyl 5-amino-6-((2,2-diethoxyethyl)(naphthalen-2- 68 XV-47
    ylmethyl)amino)-6-oxohexylcarbamate
    VI-48 (S)-tert-butyl 3-amino-4-((2,2-diethoxyethyl)(naphthalen-2- 65 XV-48
    ylmethyl)amino)-4-oxobutanoate
    VI-49 (S)-2-amino-N1-(2,2-diethoxyethyl)-N1-(naphthalen-2-ylmethyl)- 58 XV-49
    N4-tritylsuccinamide
    VI-50 (S)-2-amino-3-tert-butoxy-N-(2,2-diethoxyethyl)-N-(naphthalen-2- 67 XV-50
    ylmethyl)propanamide
    VI-51 (S)-2-amino-N-(2,2-diethoxyethyl)-4-methyl-N-(naphthalen-2- 79 XV-51
    ylmethyl)pentanamide
    VI-52 (S)-2-amino-N-(2,2-diethoxyethyl)-N-(naphthalen-2-ylmethyl)-2- 81 XV-52
    phenylacetamide
    VI-53 (S)-2-amino-N-(2,2-diethoxyethyl)-N-(naphthalen-2-ylmethyl)-3- 74 XV-53
    phenylpropanamide
    VI-54 (S)-2-amino-N-(2,2-diethoxyethyl)-N-(naphthalen-2-ylmethyl)-4- 74 XV-54
    phenylbutanamide
    VI-55 (S)-tert-butyl 4-((2-amino-3-(4-tert-butoxyphenyl)-N-(2,2- 99 XV-55
    diethoxyethyl)propanamido)methyl)benzo[d]thiazol-2-ylcarbamate
    VI-56 (S)-2-amino-3-(4-tert-butoxyphenyl)-N-(2,2-diethoxyethyl)-N-((R)- 97 XV-56
    1-phenylethyl)propanamide
    VI-57 (S)-2-amino-3-(4-tert-butoxyphenyl)-N-(2,2-diethoxyethyl)-N- 97 XV-57
    (pyridin-4-ylmethyl)propanamide
    VI-58 (S)-2-amino-3-(4-tert-butoxyphenyl)-N-(2,2-diethoxyethyl)-N- 97 XV-58
    (pyridin-2-ylmethyl)propanamide
    VI-59 (S)-2-amino-3-(4-tert-butoxyphenyl)-N-(2,2-diethoxyethyl)-N-(2,4- 100 XV-59
    difluorobenzyl)propanamide
    VI-60 (S)-2-amino-N-benzyl-N-((R)-1,1-diethoxypropan-2- 84 XV-60
    yl)propanamide
  • TABLE VII-4
    Example yield
    No. chemical name (%) Int_1
    VI-61 (S)-2-amino-N-benzyl-3-(4-tert-butoxyphenyl)-N-((R)-1,1- 82 XV-61
    diethoxypropan-2-yl)propanamide
    VI-62 (S)-tert-butyl 3-amino-4-(benzyl((R)-1,1-diethoxypropan-2- 87 XV-62
    yl)amino)-4-oxobutanoate
    VI-63 (S)-2-amino-N-((R)-1,1-diethoxypropan-2-yl)-N-(naphthalen-1- 83 XV-63
    ylmethyl)propanamide
    VI-64 (S)-2-amino-3-(4-tert-butoxyphenyl)-N-((R)-1,1-diethoxypropan-2- 68 XV-64
    yl)-N-(naphthalen-1-ylmethyl)propanamide
    VI-65 tert-bulyl (S)-5-amino-6-(((R)-1,1-diethoxypropan-2- 100 XV-65
    yl)(naphthalen-1-ylmethyl)amino)-6-oxohexylcarbamate
    VI-66 (S)-tert-butyl 3-amino-4-(((R)-1,1-diethoxypropan-2- 100 XV-66
    yl)(naphthalen-1-ylmethyl)amino)-4-oxobutanoate
    VI-67 (S)-2-amino-N-((R)-1,1-diethoxypropan-2-yl)-N-(quinolin-8- 86 XV-67
    ylmethyl)propanamide
    VI-68 (S)-2-amino-3-(4-tert-butoxyphenyl)-N-((S)-1,1-diethoxypropan-2- 100 XV-68
    yl)-N-(quinolin-8-ylmethyl)propanamide
    VI-69 tert-butyl (S)-5-amino-6-(((R)-1,1-diethoxypropan-2-yl)(quinolin-8- 87 XV-69
    ylmethyl)amino)-6-oxohexylcarbamate
    VI-70 (S)-2-amino-N1-((R)-1,1-diethoxypropan-2-yl)-N1-(quinolin-8- 68 XV-70
    ylmethyl)-N4-tritylsuccinamide
    VI-71 (S)-2-amino-N-(benzo[b]thiophen-3-ylmethyl)-3-(4-tert- 72 XV-71
    butoxyphenyl)-N-((R)-1,1-diethoxypropan-2-yl)propanamide
    VI-72 tert-butyl (S)-5-amino-6-((benzo[b]thiophen-3-ylmethyl)((R)-1,1- 74 XV-72
    diethoxypropan-2-yl)amino)-6-oxohexylcarbamate
    VI-73 (S)-tert-butyl 3-amino-4-((benzo[b]thiophen-3-ylmethyl)((R)-1,1- 69 XV-73
    diethoxypropan-2-yl)amino)-4-oxobutanoate
    VI-74 (S)-2-amino-N1-(benzo[b]thiophen-3-ylmethyl)-N1-((S)-1,1- 57 XV-74
    diethoxypropan-2-yl)-N4-tritylsuccinamide
    • Example VI-32 Synthesis of (S)-2-amino-N-(2,2-diethoxyethyl)-3-(naphthalen-1-yl)-N-(3-phenylpropyl) propanamide (Compound VI-32)
  • To a solution of (S)-benzyl 1-((2,2-diethoxyethyl)(3-phenylpropyl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-ylcarbamate (Compound XV-32) 21.4 g (36.8 mmol) in methanol 200 ml, 10% of palladium on carbon (8 g) was added, then the mixture was stirred at H2 atmosphere overnight. The mixture was filtered and the filtrate was evaporated to obtain the title compound 14.5 g (yield 88%).
  • The following compound shown in Table VIII was obtained by a similar method to that described above. In the Table, “Int_1” means an intermediate compound number.
  • TABLE VIII
    Example yield
    No. chemical name (%) Int_1
    VI-33 (S)-2-amino-N-(2,2-diethoxyethyl)- 85 XV-33
    3-(naphthalen-2-yl)-N-(3-
    phenylpropyl)propanamide
    • Example V-1 Synthesis of 3-(3-benzylureido)thiophene-2-carboxylic acid (Compound V-1)
  • To a solution of methyl 3-amino-thiophene-2-carboxylate 9.43 g (60 mmol) in acetonitrile 12 ml, 2N-sodium hydroxide 36 ml (72 mmol) was added and the mixture was stirred for 5 hrs. at 85° C. The reaction mixture was neutralized with 2N-hydrochloric acid 36 ml (72 mmol), then saturated sodium bicarbonate solution 50 ml and a solution of benzyl isocyanate 7.41 ml (60 mmol) in acetonitrile 36 ml were added and the mixture was stirred overnight. The reaction mixture was basified with 2N-sodium hydroxide 60 ml and washed with ether 100 ml. The aqueous phase was acidified with 2N-hydrochloric acid 85 ml. The aqueous phase was filtered and washed with H2O. The solid was dried in vacuo to obtain the title compound 6.46 g (yield 39%)
  • The following compounds shown in Table IX were obtained by a similar method to that described above.
  • TABLE IX
    yield
    Example No. structure chemical name (%)
    V-2
    Figure US20180305373A1-20181025-C00036
         		3-(3-ethylureido)thiophene-2-carboxylic acid 15
    V-17
    Figure US20180305373A1-20181025-C00037
         		(R)-1-(3-benzylureido)pyrrolidine-2-carboxylic acid 23
    V-18
    Figure US20180305373A1-20181025-C00038
         		(S)-1-(3-benzylureido)pyrrolidine-2-carboxylic acid 27
    V-19
    Figure US20180305373A1-20181025-C00039
         		2-(3-benzylureido)thiophene-3-carboxylic acid 64
    V-20
    Figure US20180305373A1-20181025-C00040
         		2-(3-benzylureido)cyclopentanecarboxylic acid 32
    V-21
    Figure US20180305373A1-20181025-C00041
         		1-(3-benzylureido)-1H-pyrrole-2-carboxylic acid 92
    V-22
    Figure US20180305373A1-20181025-C00042
         		3-(3-benzylureido)-1H-pyrazole-4-carboxylic acid 29
    V-23
    Figure US20180305373A1-20181025-C00043
         		3-(3-benzylureido)isonicotinic acid 25
    • Example V-3 Synthesis of 3-(3-(pyridin-4-ylmethyl)ureido)thiophene-2-carboxylic acid (Compound V-3)
  • To a solution of methyl 3-aminothiophene-2-carboxylate 20.0 g (0.127 mol) in water 150 ml was added the aqueous solution of potassium hydroxide 10.7 g (0.191 mol). The resulting solution wad heated to 90° C. for 2 hrs. After being checked by TLC till the starting material was consumed, the reaction solution was cooled to 0° C. Then a solution of triphosgene 18.9 g (0.064 mol) in toluene 150 ml was added dropwise. The resulting solution was stirred at room temperature for 2 hrs. The residue was filtered, and the solid was recrystallized from tetrahydrofuran to obtain 1H-thieno[3,2-d][1,3]oxazine-2,4-dione 8.5 g (yield 40%).
  • A solution of the above compound 1.01 g (6.0 mmol) and 4-picolylamine 731 μl (7.2 mmol) in tetrahydrofuran 20 ml was stirred at room temperature for 18 hrs. After being checked by TLC, the precipitate was filtered, and washed with tetrahydrofuran 20 ml to obtain the title compound 1.47 g (yield 88%).
  • The following compounds shown in Table X were obtained by a similar method to that described above. In the Table, “Int_1” means an intermediate compound number.
  • TABLE X
    yield
    Example No. structure chemical name (%) Int_1
    V-4
    Figure US20180305373A1-20181025-C00044
         		3-(3-(4-chlorobenzyl)ureido)thiophene-2- carboxylic acid 66 XLVIII-1
    V-5
    Figure US20180305373A1-20181025-C00045
         		3-(3-(naphthalen-1- ylmethyl)ureido)thiophene-2-carobxylic acid 60 XLVIII-1
    V-6
    Figure US20180305373A1-20181025-C00046
         		3-(3-phenethylureido)thiophene-2- carboxylic acid 62 XLVIII-1
    V-7
    Figure US20180305373A1-20181025-C00047
         		3-(3-(3,3-diphenylpropyl)ureido)thiophene- 2-carboxylic acid 65 XLVIII-1
    V-8
    Figure US20180305373A1-20181025-C00048
         		3-(3-(cyclohexylmethyl)ureido)thiophene-2- carboxylic acid 66 XLVIII-1
    V-9
    Figure US20180305373A1-20181025-C00049
         		3-(3-isopropylureido)thiophene-2-carboxylic acid 70 XLVIIII-1
    V-10
    Figure US20180305373A1-20181025-C00050
         		3-(3-(2-(tert- butyldimethylsilyloxy)ethyl)ureido)thiophene- 2-carboxylic acid 58 XLVIII-1
    V-11
    Figure US20180305373A1-20181025-C00051
         		3-(3-(3-tert-butoxy-3- oxopropyl)ureido)thiophene-2-carboxylic acid 55 XLVIII-1
    V-12
    Figure US20180305373A1-20181025-C00052
         		3-(3-(3-methoxy-3- oxopropyl)ureido)thiophene-2-carboxylic acid 52 XLVIII-1
    V-13
    Figure US20180305373A1-20181025-C00053
         		3-(3-(4-fluorobenzyl)ureido)thiophene-2- carboxylic acid 68 XLVIII-1
    V-14
    Figure US20180305373A1-20181025-C00054
         		3-(3-(benzo[d][1,3]dioxol-5- ylmethyl)ureido)thiophene-2-carboxylic acid 63 XLVIII-1
    V-15
    Figure US20180305373A1-20181025-C00055
         		3-(3-(thiophen-2- ylmethyl)ureido)thiophene-2-carboxylic acid 71 XLVIII-1
    V-16
    Figure US20180305373A1-20181025-C00056
         		3-(3-(4-methylbenzyl)ureido)thiophene-2- carboxylic acid 75 XLVIII-1
    • Example XL-1 Synthesis of ethyl 2-(1-methylhydrazinyl)acetate (Compound XL-1)
  • To a solution of methylhydrazine 7.13 ml (150 mmol) and triethylamine 16.7 ml (120 mmol), ethyl 2-bromoacetate 16.7 g (100 mmol) in dichloromethane 50 ml was added and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate 300 ml and washed with brine 200 ml. The organic phase was dried over magnesium sulfate and filtered and the mother solution was concentrated in vacuo to obtain the title compound 10.2 g (77%).
    • Example XXXII-1 Synthesis of ethyl 2-(1-methyl-2-(benzylcarbamoyl)hydrazinyl)acetate (Compound XXXII-1)
  • To a solution of ethyl 2-(1-methylhydrazinyl)acetate (Compound XL-1) 10 ml (76 mmol) in tetrahydrofuran 40 ml, benzyl isocyanate 11.1 g (83.3 mmol) was added at 0° C. and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate 150 ml and washed with water 75 ml and brine 75 ml. The organic phase was dried over magnesium sulfate and filtered. The filtrate was concentrated in vacuo to obtain the title compound 15.2 g (76%).
    • Example VIII-1 Synthesis of 3-(3-benzylureido)propanoic acid (Compound VIII-1)
  • To a solution of β-alanine 5.0 g (56 mmol) in dichloromethane 56 ml and tetrahydrofuran 56 ml was added benzyl isocyanate 6.6 ml (53 mmol) at 0° C. After stirring at room temperature overnight, the reaction mixture was diluted with ethyl acetate 200 ml and washed with water 200 ml and brine 200 ml. The residual solution was concentrated to about 100 ml in vacuo. To the mixture was added 1N sodium hydroxide solution 60 ml at 0° C. The aqueous phase was acidified with 3N HCl aq. 20 ml and then extracted with ethyl acetate 100 ml twice. The extract was washed with brine 50 ml and dried over magnesium sulfate and filtered. The filtrate was concentrated in vacuo. To the residue was added ether:n-hexane=1:1 30 ml and the precipitate was corrected by filtration to obtain the title compound 7.05 g (59%).
    • Example VIII-2 Synthesis of 2-(2-(benzylcarbamoyl)-1-methylhydrazinyl)acetic acid (Compound VIII-2)
  • To a solution of ethyl 2-(1-methyl-2-(benzylcarbamoyl)hydrazinyl)acetate (Compound XXXII-1) 1.33 g (5.0 mmol) in tetrahydrofuran/methanol/water(2:3:1) 24 ml, lithium hydroxide monohydrate 420 mg (10.0 mmol) was added and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with water 25 ml and washed with ether 25 ml. The aqueous phase was acidified with 10%-citric acid 25 ml and extracted with chloroform 30 ml. The organic phase was washed with brine 25 ml and dried with magnesium sulfate and then filtered. The filtrate was concentrated in vacuo to obtain the title compound 1.05 g (88%).
    • Example XXXIV-1 Synthesis of N-methyl-N′-tert-butoxycarbonylhydrazine (Compound XXXIV-1)
  • To a solution of N-methylhydrazine 5.27 ml (100 mmol) and triethylamine 8.36 ml (60.0 mmol) in dichloromethane 200 ml, 30% benzoxyloxycarbonyl chloride in toluene 11.37 ml (20.0 mmol) was added and the mixture was stirred at 0° C. for 1 hr. The reaction mixture was diluted with chloroform 200 ml and washed with brine 200 ml. The organic phase was dried over magnesium sulfate and filtered. The mother solution was concentrated in vacuo to give N-benzoxyloxycarbonyl-N-methylhydrazine. The product was used without further purification.
  • To a solution of the above compound 3.60 g (20.0 mmol) and potassium carbonate 11.1 g (80.0 mmol) in water 42 ml, a solution of di-tert-butyl dicarbonate 9.19 ml (40.0 mmol) in acetonitrile 18 ml was added and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate 200 ml and washed with water 200 ml and brine 200 ml. The organic phase was dried over magnesium sulfate and filtered. The mother solution was concentrated in vacuo. The residue was purified on silica gel column chromatography (Merck 60N spherical, neutral elution by chloroform) to give N-benzoxyloxycarbonyl-N-methyl-N′-(tert-butyoxycarbonyl)hydrazine 4.08 g (72.8%).
  • To a solution of the above compound 5.61 g (20.0 mmol) in methanol 80 ml, 5% palladium on carbon 400 mg was added and the mixture was stirred at room temperature under hydrogen atmosphere overnight. The reaction mixture was filtered on celite and washed with methanol 400 ml. The mother solution was concentrated in vacuo to obtain the title compound 3.05 g (80.1%).
    • Example XLIII-1 Synthesis of (R)-benzyl 3-(4-(benzyloxy)phenyl)-2-hydroxypropanoate (Compound XLIII-1)
  • To a solution of 4-hydroxyphenylpyruvic acid 9.01 g (50.0 mmol) in tetrahydrofuran 120 ml, triethylamine 7.0 ml (50.0 mmol) was added and the mixture was stirred at −20° C. for 0.5 hr. A solution of (−)-B-chlorodiisopinocamphenylborane in 60% hexane 41.2 ml (70.0 mmol) was added to the reaction mixture dropwisely and the mixture was warmed to room temperature and stirred for 6 hrs. 1N sodium hydroxide solution 200 ml was added to the reaction mixture and the mixture was washed with ethyl ether 200 ml. 3N hydrochloride aq. 80 ml was added to the aqueous phase and the mixture was extracted with ethyl acetate 200 ml. The organic phase was washed with brine 200 ml and dried over magnesium sulfate and filtered. The filtrate was concentrated in vacuo and n-hexane:ethyl acetate=60:40 50 ml was added to the residue and the precipitate was corrected by filtration to obtain (R)-2-hydroxy-3-(4-hydroxyphenyl)propanoic acid 5.53 g (yield 61%).
  • To a solution of the above compound 2.73 g (15.0 mol) in N,N-dimethyl formamide 100 ml, potassium carbonate 5.18 g (37.5 mmol) was added and the mixture was stirred at 0° C. for 10 min. Benzyl bromide 3.92 ml (33.0 mmol) was added dropwisely and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate 300 ml and washed with water 300 ml and brine 300 ml. The organic phase was dried over magnesium sulfate and filtered. The filtrate was concentrated in vacuo and n-hexane:ethyl acetate=90:10 40 ml was added to the residue and the precipitate was corrected by filtration to obtain the title compound 3.78 g (yield 69%).
    • Example XXVII-1 Synthesis of (S)-benzyl 3-(4-(benzyloxy)phenyl)-2-hydroxypropanoate (Compound XXVIII-1)
  • To a solution of (R)-benzyl 3-(4-(benzyloxy)phenyl)-2-hydroxypropanoate (Compound XLIII-1) 1.81 g (5.00 mmol) and 2,6-lutidine 874 μl (7.50 mmol) in dichloromethane 15 ml, trifluoromethanesulfonic anhydride 1.26 ml (7.50 mmol) was added and the mixture was stirred at 0° C. for 0.5 hr. N-tert-butoxycarbonyl-N′-methylhydrazine (Compound XXXIV-1) 1.46 g (10.0 mol) was added to the solution mixture and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate 100 ml and washed with water 100 ml. The organic phase was washed with brine 100 ml and dried over magnesium sulfate and filtered. The mother solution was concentrated in vacuo and the residue was purified on silica gel column chromatography (Merck 60N spherical, neutral elution by chloroform) to obtain the title compound 0.97 g (17.3%).
    • Example XXVIII-1 Synthesis of (S)-benzyl 3-(4-(benzyloxy)phenyl)-2-(1,3-dioxoisoindolin-2-yloxy)propanoate (Compound XXVIII-2)
  • To a solution of (R)-benzyl 3-(4-(benzyloxy)phenyl)-2-hydroxypropanoate (Compound XLIII-1) 18.1 g (50.0 mmol) in dichloromethane 80 ml, trifluoromethanesulfonic anhydride 10.1 ml (60.0 mmol) and 2,6-lutidine 8.74 ml (75.0 mmol) were added and the mixture was stirred at room temperature for 0.5 hr. N-hydroxyphthalimide 8.16 g (50.0 mmol) and triethylamine 10.5 ml (75.0 mmol) were added to the reaction mixture and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo and diluted with ethyl acetate 500 ml and washed with saturated sodium bicarbonate solution 500 ml, water 500 ml and brine 500 ml. The organic phase was dried over magnesium sulfate and filtered. The filtrate was concentrated in vacuo and the residue was purified on silica gel column chromatography (Merck 60N spherical, neutral elution by n-hexane:ethyl acetate=90:10 to 70:30) to obtain the title compound 15.0 g (yield 59%).
    • Example XVIII-1 Synthesis of (S)-benzyl 3-(4-(benzyloxy)phenyl)-2-(1-methylhydrazinyl)propanoate (Compound XVIII-1)
  • To a solution of (S)-benzyl 3-(4-(benzyloxy)phenyl)-2-(N-(tert-butoxycarbonyl)-N′-methylhydrazinyl)propanoate (Compound XXVII-1) 491 mg (1.00 mmol) in dichloromethane 1 ml, trifluoroacetic acid 743 μl (10.0 mmol) was added and the mixture was stirred at room temperature for 0.5 hr. The reaction mixture was concentrated in vacuo and the residue was diluted with ethyl acetate 50 ml and washed with saturated sodium bicarbonate solution 50 ml. The organic phase was washed with water 50 ml and brine 50 ml. The organic phase was dried over magnesium sulfate and filtered. The mother solution was concentrated in vacuo to give the title compound, which was used without further purification.
    • Example XVIII-2 Synthesis of (S)-benzyl 2-(aminooxy)-3-(4-(benzyloxy)phenyl)propanoate (Compound XVIII-2)
  • To a mixed solution of (S)-benzyl 3-(4-(benzyloxy)phenyl)-2-(1,3-dioxoisoindolin-2-yloxy)propanoate (Compound XXVIII-1) 15.02 g (29.6 mmol) in tetrahydrofuran 60 ml and methanol 60 ml, hydrazine monohydrate 4.31 ml (88.8 mmol) was added and the mixture was stirred at room temperature for 1 hr. The reaction mixture was diluted with ethyl acetate 500 ml and washed with saturated sodium bicarbonate solution 200 ml, water 200 ml and brine 200 ml. The organic phase was dried over magnesium sulfate and filtered. The filtrate was concentrated in vacuo to give the title compound, which was used without further purification.
    • Example XVII-1 Synthesis of (S)-benzyl 3-(4-(benzyloxy)phenyl)-2-(2-(3-(3-benzylureido)propanoyl)-1-methylhydrazinyl)propanoate (Compound XVII-1)
  • To a solution of 3-(3-benzylureido)propanoic acid (Compound VIII-1) 267 mg (1.20 mmol) in dichloromethane 5 ml, N-hydroxybenztriazole 203 mg (1.50 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 288 mg (1.50 mmol) were added and the mixture was stirred at room temperature for 0.5 hr. (S)-benzyl 3-(4-(benzyloxy)phenyl)-2-(1-methylhydrazinyl)propanoate (Compound XVIII-1) 390 mg (1.00 mmol) and a solution of dimethylaminopyridine 61 mg (0.50 mmol) in dichloromethane 1 ml were added to the reaction mixture and the mixture was stirred at room temperature for 3 hrs. The reaction mixture was diluted with ethyl acetate 50 ml and washed with saturated sodium bicarbonate solution 50 ml twice, water 50 ml twice and brine 50 ml and the organic phase was dried over magnesium sulfate and filtered. The mother solution was concentrated in vacuo and the residue was purified on silica gel column chromatography (Merck 60N spherical, neutral elution by chloroform:methanol=100:0 to 95:5) to obtain the title compound 0.31 g (52.0%).
  • The following compounds shown in Table XI were obtained by a similar method to that described above. In the Table, “Int_1” and “Int_2” mean an intermediate compound number.
  • TABLE XI
    Example yield
    No. structure chemical name (%) Int_1 Int_2
    XVII-2
    Figure US20180305373A1-20181025-C00057
         		(S)-benzyl-3-(4-(benzyloxy)phenyl)- 2-(2-(3-(3-benzylureido)propanoyl)- 1-methylhydrazinyl)propanoate 55 VIII-2 XVIII-1
    XVII-3
    Figure US20180305373A1-20181025-C00058
         		(S)-benzyl 10-(4-(benzyloxy)benzyl)-5- methyl-3,7-dioxo-1-phenyl-9-oxa- 2,4,5,8-tetraazaundecan-11-oate 73 VIII-2 XVIII-2
    • Example XVII-4 Synthesis of (S)-benzyl 3-(4-(benzyloxy)phenyl)-2-(1-((3-benzylureido)methyl)cyclohexanecarboxamidooxy)propanoate (Compound XVII-4)
  • To a solution of Fmoc-1-aminomethyl-cyclohexane carboxylic acid 2.41 g (6.36 mmol), N-hydroxybenzotriazol 1.07 g (7.95 mmol) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 1.52 g (7.95 mmol) in dichloromethane 20 ml, a solution of (S)-benzyl 2-(aminooxy)-3-(4-(benzyloxy)phenyl)propanoate (Compound XVIII-2) 2.0 g (5.3 mmol) and 4-dimethylaminopyridine 65 mg (0.53 mmol) in dichloromethane 15 ml was added and the mixture was stirred at room temperature overnight. The reaction mixture was washed with saturated sodium bicarbonate solution 40 ml, water 40 ml and brine 40 ml. The organic phase was dried over magnesium sulfate and filtered. The filtrate was concentrated in vacuo and the residue was purified on silica gel column chromatography (Merck 60N spherical, neutral elution by n-hexanae:ethylacetate=100:0 to 70:30) to obtain (S)-benzyl 2-(1-((((9H-fluoren-9-yl)methoxy)carbonylamino)methyl)cyclohexanecarboxamidooxy)-3-(4-(benzyloxy)phenyl)propanoate 1.25 g (32%).
  • To the above compound 1.25 g (1.69 mol), 25%-piperidine/dichloromethane 20 ml was added and the mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated in vacuo and the residue was purified on silica gel column chromatography (Merck 60N spherical, neutral elution by n-hexane:ethyl acetate=100:0 to 70:30 and chloroform:methanol=100:0 to 80:20) to obtain (S)-benzyl 2-(1-(aminomethyl)cyclohexanecarboxamidooxy)-3-(4-(benzyloxy)phenyl)propanoate 528 mg (60%).
  • To a solution of (S)-benzyl 2-(1-(aminomethyl)cyclohexanecarboxamidooxy)-3-(4-(benzyloxy)phenyl)propanoate in dichloromethane 9 ml, benzyl isocyanate 143 μl (1.16 mmol) and triethylamine 271 μl (1.94 mmol) were added and the mixture was stirred at room temperature overnight. The reaction mixture was washed with water 10 ml and brine 10 ml. Then the organic phase was dried over magnesium sulfate, filtered and concentrated. The crude residue was purified on silica gel column chromatography (Merck 60N spherical, neutral elution by n-hexane:ethylacetate=100:0 to 70:30) to obtain the title compound 257 mg (41%).
    • Example VII-1 Synthesis of (S)-3-(4-(benzyloxy)phenyl)-2-(2-(3-(3-benzylureido)propanoyl)-1-methylhydrazinyl)propanoic acid (Compound VII-1)
  • To a solution of (S)-benzyl 3-(4-(benzyloxy)phenyl)-2-(2-(3-(3-benzylureido)propanoyl)-1-methylhydrazinyl)propanoate (Compound XVII-1) 149 mg (0.25 mmol) in tetrahydrofuran:methanol=1:1.5 1.5 ml, a solution of lithium hydroxide monohydrate 16 mg in water 0.3 ml was added and the mixture was stirred at room temperature for 1.5 hr. The reaction mixture was cooled to 0° C. and 1N HCl aq. 10 ml was added and the mixture was extracted with ethyl acetate 20 ml. The organic phase was washed with water 20 ml and brine 20 ml and dried over magnesium sulfate and filtered. The mother solution was concentrated in vacuo to obtain the title compound. The residue was used without further purification.
  • The following compounds shown in Table XII were obtained by a similar method to that described above. In the Table, “Int_1” means an intermediate compound number.
  • TABLE XII
    Example
    No. structure chemical name Int_1
    VII-2
    Figure US20180305373A1-20181025-C00059
         		(S)-2-(2-(2-(2-(benzylcarbamoyl)-1- methylhydrazinyl)acetyl)-1-methylhydrazinyl)-3-(4- (benzyloxy)phenyl)propanoic acid XVII-2
    VII-3
    Figure US20180305373A1-20181025-C00060
         		(S)-10-(4-(benzyloxy)benzyl)-5-methyl-3,7-dioxo-7- phenyl-9-oxa-2,4,5,8-tetraazaundecan-11-oic acid XVII-3
    VII-4
    Figure US20180305373A1-20181025-C00061
         		(S)-3-(4-(benzyloxy)phenyl)-2-(1-((3- benzylureido)methyl)cyclohexanecarboxamido- oxy)propanoic acid XVII-4
    • [Example II-1] (Syn. II-1) Synthesis of (S)—N-(1-(benzyl(2,2-diethoxyethyl)amino)-1-oxopropan-2-yl)-3-(3-benzylureido)thiophene-2-carboxamide (Compound II-1)
  • To a solution of 3-(3-benzylureido)thiophene-2-carboxylic acid (Compound V-1) 49.7 mg (0.18 mmol) and N-hydroxybenzotriazol 6.1 mg (0.045 mmol) in dichloromethane 1 ml, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 43.1 mg (0.225 mmol) was added and the mixture was stirred at room temperature for 0.5 hr. A solution of (S)-2-amino-N-benzyl-N-(2,2-diethoxyethyl)propanamide (Compound VI-1) 44.2 mg (0.15 mmol) in dichloromethane iml was added to the reaction mixture and the mixture was stirred at room temperature for 18 hrs. The reaction mixture was washed with sat. NaHCO3 aq. 1 ml, water 1 ml and brine 1 ml. The organic phase was filtered on celite 1 g and magnesium sulfate 150 mg. The mother solution was concentrated in vacuo and the residue was purified with PTLC (development solvent: chloroform:methanol=98:2) to obtain the titled compound 44.7 mg (54%).
    • [Example II-262] (Syn. II-2) Synthesis of (S)-3-(4-(benzyloxy)phenyl)-2-(2-(3-(3-benzylureido)propanoyl)-1-methylhydrazinyl)-N-(2,2-diethoxyethyl)-N-(naphthalen-1-ylmethyl)propanamide (Compound II-262)
  • To a solution of (S)-3-(4-(benzyloxy)phenyl)-2-(2-(3-(3-benzylureido)propanoyl)-1-methylhydrazinyl)propanoic acid (Compound VII-1) 126 mg (0.25 mmol) in dichloromethane 1.5 ml, 2,2-diethoxy-N-(naphthalen-1-ylmethyl)ethanamine (Compound IV-2) 85 mg (0.31 mmol) and DMT-MM 173 mg (0.63 mmol) were added and the mixture was stirred at room temperature for 3 hr. The reaction mixture was diluted with chloroform 50 ml and washed with water 50 ml twice and brine 50 ml twice and dried over magnesium sulfate and filtered. The mother solution was concentrated in vacuo and the residue was purified on silica gel column chromatography (Merck 60N spherical, neutral 10 ml elution by chloroform:methanol=100:0 to 90:10, each elution 50 ml) to give the desired product as pale yellow oil 85.0 mg (35.8%).
  • Typical examples of the compound having general formula II of the present invention that can be obtained by reacting and treating corresponding intermediates using any of the methods described in the present specification including the examples described above are shown in Tables XIII-1 to XIII-25. The compounds were prepared according to the preparation methods of the compound numbers (e.g., “II-1”) shown in the columns of “Syn” in the Tables, “Int_1” and “Int_2” indicate intermediate compound numbers. “n.d.” in the columns of “yield” means not determined in this step and was used to further reaction. In the column of “R”, “R1”, “R2” and “R3” were indicated as chemical groups in the general formula II.
  • Figure US20180305373A1-20181025-C00062
  • TABLE XIII-1
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C00063
    Figure US20180305373A1-20181025-C00064
         		R Int_1 Int_2 syn. yield (%)
    II-2
    Figure US20180305373A1-20181025-C00065
    Figure US20180305373A1-20181025-C00066
         		H
    Figure US20180305373A1-20181025-C00067
    Figure US20180305373A1-20181025-C00068
         		Ethyl VI-2 V-1 II-1 74
    II-3
    Figure US20180305373A1-20181025-C00069
    Figure US20180305373A1-20181025-C00070
         		H
    Figure US20180305373A1-20181025-C00071
    Figure US20180305373A1-20181025-C00072
         		Ethyl Vi-3 V-1 II-1 82
    II-4
    Figure US20180305373A1-20181025-C00073
    Figure US20180305373A1-20181025-C00074
         		H
    Figure US20180305373A1-20181025-C00075
    Figure US20180305373A1-20181025-C00076
         		Ethyl VI-4 V-1 II-1 63
    II-5
    Figure US20180305373A1-20181025-C00077
    Figure US20180305373A1-20181025-C00078
         		H
    Figure US20180305373A1-20181025-C00079
    Figure US20180305373A1-20181025-C00080
         		Ethyl VI-5 V-1 II-1 82
    II-6
    Figure US20180305373A1-20181025-C00081
    Figure US20180305373A1-20181025-C00082
         		H
    Figure US20180305373A1-20181025-C00083
    Figure US20180305373A1-20181025-C00084
         		Ethyl VI-6 V-1 II-1 38
    II-7
    Figure US20180305373A1-20181025-C00085
    Figure US20180305373A1-20181025-C00086
         		H
    Figure US20180305373A1-20181025-C00087
    Figure US20180305373A1-20181025-C00088
         		Ethyl VI-7 V-1 II-1 9
    II-8
    Figure US20180305373A1-20181025-C00089
    Figure US20180305373A1-20181025-C00090
         		H
    Figure US20180305373A1-20181025-C00091
    Figure US20180305373A1-20181025-C00092
         		Ethyl VI-8 V-1 II-1 100
    II-9
    Figure US20180305373A1-20181025-C00093
    Figure US20180305373A1-20181025-C00094
         		H
    Figure US20180305373A1-20181025-C00095
    Figure US20180305373A1-20181025-C00096
         		Ethyl VI-9 V-1 II-1 100
    II-10
    Figure US20180305373A1-20181025-C00097
    Figure US20180305373A1-20181025-C00098
         		H
    Figure US20180305373A1-20181025-C00099
    Figure US20180305373A1-20181025-C00100
         		Ethyl VI-2 V-3 II-1 64
    II-11
    Figure US20180305373A1-20181025-C00101
    Figure US20180305373A1-20181025-C00102
         		H
    Figure US20180305373A1-20181025-C00103
    Figure US20180305373A1-20181025-C00104
         		Ethyl VI-2 V-4 II-1 67
    II-12
    Figure US20180305373A1-20181025-C00105
    Figure US20180305373A1-20181025-C00106
         		H
    Figure US20180305373A1-20181025-C00107
    Figure US20180305373A1-20181025-C00108
         		Ethyl VI-2 V-5 II-1 39
  • TABLE XIII-2
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C00109
    Figure US20180305373A1-20181025-C00110
         		R Int_1 Int_2 syn. yield (%)
    II-13
    Figure US20180305373A1-20181025-C00111
    Figure US20180305373A1-20181025-C00112
         		H
    Figure US20180305373A1-20181025-C00113
    Figure US20180305373A1-20181025-C00114
         		Ethyl VI-2 V-2 II-1 61
    II-14
    Figure US20180305373A1-20181025-C00115
    Figure US20180305373A1-20181025-C00116
         		H
    Figure US20180305373A1-20181025-C00117
    Figure US20180305373A1-20181025-C00118
         		Ethyl VI-4 V-3 II-1 58
    II-15
    Figure US20180305373A1-20181025-C00119
    Figure US20180305373A1-20181025-C00120
         		H
    Figure US20180305373A1-20181025-C00121
    Figure US20180305373A1-20181025-C00122
         		Ethyl VI-4 V-4 II-1 67
    II-16
    Figure US20180305373A1-20181025-C00123
    Figure US20180305373A1-20181025-C00124
         		H
    Figure US20180305373A1-20181025-C00125
    Figure US20180305373A1-20181025-C00126
         		Ethyl VI-4 V-5 II-1 51
    II-17
    Figure US20180305373A1-20181025-C00127
    Figure US20180305373A1-20181025-C00128
         		H
    Figure US20180305373A1-20181025-C00129
    Figure US20180305373A1-20181025-C00130
         		Ethyl VI-4 V-2 II-1 72
    II-18
    Figure US20180305373A1-20181025-C00131
    Figure US20180305373A1-20181025-C00132
         		H
    Figure US20180305373A1-20181025-C00133
    Figure US20180305373A1-20181025-C00134
         		Ethyl VI-6 V-3 II-1 43
    II-19
    Figure US20180305373A1-20181025-C00135
    Figure US20180305373A1-20181025-C00136
         		H
    Figure US20180305373A1-20181025-C00137
    Figure US20180305373A1-20181025-C00138
         		Ethyl VI-6 V-4 II-1 15
    II-20
    Figure US20180305373A1-20181025-C00139
    Figure US20180305373A1-20181025-C00140
         		H
    Figure US20180305373A1-20181025-C00141
    Figure US20180305373A1-20181025-C00142
         		Ethyl VI-6 V-5 II-1 41
    II-21
    Figure US20180305373A1-20181025-C00143
    Figure US20180305373A1-20181025-C00144
         		H
    Figure US20180305373A1-20181025-C00145
    Figure US20180305373A1-20181025-C00146
         		Ethyl VI-6 V-2 II-1 16
    II-22
    Figure US20180305373A1-20181025-C00147
    Figure US20180305373A1-20181025-C00148
         		H
    Figure US20180305373A1-20181025-C00149
    Figure US20180305373A1-20181025-C00150
         		Ethyl VI-9 V-3 II-1 56
    II-23
    Figure US20180305373A1-20181025-C00151
    Figure US20180305373A1-20181025-C00152
         		H
    Figure US20180305373A1-20181025-C00153
    Figure US20180305373A1-20181025-C00154
         		Ethyl VI-9 V-4 II-1 59
  • TABLE XIII-3
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C00155
    Figure US20180305373A1-20181025-C00156
         		R Int_1 Int_2 syn. yield (%)
    II-24
    Figure US20180305373A1-20181025-C00157
    Figure US20180305373A1-20181025-C00158
         		H
    Figure US20180305373A1-20181025-C00159
    Figure US20180305373A1-20181025-C00160
         		Ethyl VI-9 V-5 II-1 37
    II-25
    Figure US20180305373A1-20181025-C00161
    Figure US20180305373A1-20181025-C00162
         		H
    Figure US20180305373A1-20181025-C00163
    Figure US20180305373A1-20181025-C00164
         		Ethyl VI-9 V-2 II-1 57
    II-26
    Figure US20180305373A1-20181025-C00165
    Figure US20180305373A1-20181025-C00166
         		H
    Figure US20180305373A1-20181025-C00167
    Figure US20180305373A1-20181025-C00168
         		Ethyl VI-10 V-5 II-1 n.d.
    II-27
    Figure US20180305373A1-20181025-C00169
    Figure US20180305373A1-20181025-C00170
         		H
    Figure US20180305373A1-20181025-C00171
    Figure US20180305373A1-20181025-C00172
         		Ethyl VI-11 V-1 II-1 n.d.
    II-28
    Figure US20180305373A1-20181025-C00173
    Figure US20180305373A1-20181025-C00174
         		H
    Figure US20180305373A1-20181025-C00175
    Figure US20180305373A1-20181025-C00176
         		Ethyl VI-11 V-3 II-1 n.d.
    II-29
    Figure US20180305373A1-20181025-C00177
    Figure US20180305373A1-20181025-C00178
         		H
    Figure US20180305373A1-20181025-C00179
    Figure US20180305373A1-20181025-C00180
         		Ethyl VI-11 V-6 II-1 n.d.
    II-30
    Figure US20180305373A1-20181025-C00181
    Figure US20180305373A1-20181025-C00182
         		H
    Figure US20180305373A1-20181025-C00183
    Figure US20180305373A1-20181025-C00184
         		Ethyl VI-11 V-5 II-1 n.d.
    II-31
    Figure US20180305373A1-20181025-C00185
    Figure US20180305373A1-20181025-C00186
         		H
    Figure US20180305373A1-20181025-C00187
    Figure US20180305373A1-20181025-C00188
         		Ethyl VI-11 V-7 II-1 n.d.
    II-32
    Figure US20180305373A1-20181025-C00189
    Figure US20180305373A1-20181025-C00190
         		H
    Figure US20180305373A1-20181025-C00191
    Figure US20180305373A1-20181025-C00192
         		Ethyl VI-11 V-8 II-1 n.d.
    II-33
    Figure US20180305373A1-20181025-C00193
    Figure US20180305373A1-20181025-C00194
         		H
    Figure US20180305373A1-20181025-C00195
    Figure US20180305373A1-20181025-C00196
         		Ethyl VI-11 V-9 II-1 n.d.
    II-34
    Figure US20180305373A1-20181025-C00197
    Figure US20180305373A1-20181025-C00198
         		H
    Figure US20180305373A1-20181025-C00199
    Figure US20180305373A1-20181025-C00200
         		Ethyl VI-12 V-5 II-1 n.d.
  • TABLE XIII-4
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C00201
    Figure US20180305373A1-20181025-C00202
         		R Int_1 Int_2 syn. yield (%)
    II-35
    Figure US20180305373A1-20181025-C00203
    Figure US20180305373A1-20181025-C00204
         		H
    Figure US20180305373A1-20181025-C00205
    Figure US20180305373A1-20181025-C00206
         		Ethyl VI-13 V-5 II-1 n.d.
    II-36
    Figure US20180305373A1-20181025-C00207
    Figure US20180305373A1-20181025-C00208
         		H
    Figure US20180305373A1-20181025-C00209
    Figure US20180305373A1-20181025-C00210
         		Ethyl VI-14 V-5 II-1 n.d.
    II-37
    Figure US20180305373A1-20181025-C00211
    Figure US20180305373A1-20181025-C00212
         		H
    Figure US20180305373A1-20181025-C00213
    Figure US20180305373A1-20181025-C00214
         		Ethyl VI-15 V-5 II-1 n.d.
    II-38
    Figure US20180305373A1-20181025-C00215
    Figure US20180305373A1-20181025-C00216
         		H
    Figure US20180305373A1-20181025-C00217
    Figure US20180305373A1-20181025-C00218
         		Ethyl VI-16 V-5 II-1 n.d.
    II-39
    Figure US20180305373A1-20181025-C00219
    Figure US20180305373A1-20181025-C00220
         		H
    Figure US20180305373A1-20181025-C00221
    Figure US20180305373A1-20181025-C00222
         		Ethyl VI-17 V-5 II-1 n.d.
    II-40
    Figure US20180305373A1-20181025-C00223
    Figure US20180305373A1-20181025-C00224
         		H
    Figure US20180305373A1-20181025-C00225
    Figure US20180305373A1-20181025-C00226
         		Ethyl VI-18 V-5 II-1 n.d.
    II-41
    Figure US20180305373A1-20181025-C00227
    Figure US20180305373A1-20181025-C00228
         		H
    Figure US20180305373A1-20181025-C00229
    Figure US20180305373A1-20181025-C00230
         		Ethyl VI-19 V-5 II-1 n.d.
    II-42
    Figure US20180305373A1-20181025-C00231
    Figure US20180305373A1-20181025-C00232
         		H
    Figure US20180305373A1-20181025-C00233
    Figure US20180305373A1-20181025-C00234
         		Ethyl VI-20 V-5 II-1 n.d.
    II-43
    Figure US20180305373A1-20181025-C00235
    Figure US20180305373A1-20181025-C00236
         		H
    Figure US20180305373A1-20181025-C00237
    Figure US20180305373A1-20181025-C00238
         		Ethyl VI-20 V-7 II-1 n.d.
    II-44
    Figure US20180305373A1-20181025-C00239
    Figure US20180305373A1-20181025-C00240
         		H
    Figure US20180305373A1-20181025-C00241
    Figure US20180305373A1-20181025-C00242
         		Ethyl VI-20 V-8 II-1 n.d.
    II-45
    Figure US20180305373A1-20181025-C00243
    Figure US20180305373A1-20181025-C00244
         		H
    Figure US20180305373A1-20181025-C00245
    Figure US20180305373A1-20181025-C00246
         		Ethyl VI-20 V-9 II-1 n.d.
  • TABLE XIII-5
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C00247
    Figure US20180305373A1-20181025-C00248
         		R Int_1 Int_2 syn. yield (%)
    II-46
    Figure US20180305373A1-20181025-C00249
    Figure US20180305373A1-20181025-C00250
         		H
    Figure US20180305373A1-20181025-C00251
    Figure US20180305373A1-20181025-C00252
         		Ethyl VI-21 V-5 II-1 n.d.
    II-47
    Figure US20180305373A1-20181025-C00253
    Figure US20180305373A1-20181025-C00254
         		H
    Figure US20180305373A1-20181025-C00255
    Figure US20180305373A1-20181025-C00256
         		Ethyl VI-22 V-1 II-1 n.d.
    II-48
    Figure US20180305373A1-20181025-C00257
    Figure US20180305373A1-20181025-C00258
         		H
    Figure US20180305373A1-20181025-C00259
    Figure US20180305373A1-20181025-C00260
         		Ethyl VI-22 V-3 II-1 n.d.
    II-49
    Figure US20180305373A1-20181025-C00261
    Figure US20180305373A1-20181025-C00262
         		H
    Figure US20180305373A1-20181025-C00263
    Figure US20180305373A1-20181025-C00264
         		Ethyl VI-22 V-6 II-1 n.d.
    II-50
    Figure US20180305373A1-20181025-C00265
    Figure US20180305373A1-20181025-C00266
         		H
    Figure US20180305373A1-20181025-C00267
    Figure US20180305373A1-20181025-C00268
         		Ethyl VI-22 V-5 II-1 n.d.
    II-51
    Figure US20180305373A1-20181025-C00269
    Figure US20180305373A1-20181025-C00270
         		H
    Figure US20180305373A1-20181025-C00271
    Figure US20180305373A1-20181025-C00272
         		Ethyl VI-10 V-10 II-1 n.d.
    II-52
    Figure US20180305373A1-20181025-C00273
    Figure US20180305373A1-20181025-C00274
         		H
    Figure US20180305373A1-20181025-C00275
    Figure US20180305373A1-20181025-C00276
         		Ethyl VI-10 V-11 II-1 n.d.
    II-53
    Figure US20180305373A1-20181025-C00277
    Figure US20180305373A1-20181025-C00278
         		H
    Figure US20180305373A1-20181025-C00279
    Figure US20180305373A1-20181025-C00280
         		Ethyl VI-10 V-12 II-1 n.d.
    II-54
    Figure US20180305373A1-20181025-C00281
    Figure US20180305373A1-20181025-C00282
         		H
    Figure US20180305373A1-20181025-C00283
    Figure US20180305373A1-20181025-C00284
         		Ethyl VI-10 V-14 II-1 n.d.
    II-55
    Figure US20180305373A1-20181025-C00285
    Figure US20180305373A1-20181025-C00286
         		H
    Figure US20180305373A1-20181025-C00287
    Figure US20180305373A1-20181025-C00288
         		Ethyl VI-10 V-15 II-1 n.d.
    II-56
    Figure US20180305373A1-20181025-C00289
    Figure US20180305373A1-20181025-C00290
         		H
    Figure US20180305373A1-20181025-C00291
    Figure US20180305373A1-20181025-C00292
         		Ethyl VI-11 V-15 II-1 n.d.
  • TABLE XIII-6
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C00293
    Figure US20180305373A1-20181025-C00294
         		R Int_1 Int_2 syn. yield (%)
    II-57
    Figure US20180305373A1-20181025-C00295
    Figure US20180305373A1-20181025-C00296
         		H
    Figure US20180305373A1-20181025-C00297
    Figure US20180305373A1-20181025-C00298
         		Ethyl VI-11 V-16 II-1 n.d.
    II-58
    Figure US20180305373A1-20181025-C00299
    Figure US20180305373A1-20181025-C00300
         		H
    Figure US20180305373A1-20181025-C00301
    Figure US20180305373A1-20181025-C00302
         		Ethyl VI-12 V-15 II-1 n.d.
    II-59
    Figure US20180305373A1-20181025-C00303
    Figure US20180305373A1-20181025-C00304
         		H
    Figure US20180305373A1-20181025-C00305
    Figure US20180305373A1-20181025-C00306
         		Ethyl VI-13 V-15 II-1 n.d.
    II-60
    Figure US20180305373A1-20181025-C00307
    Figure US20180305373A1-20181025-C00308
         		H
    Figure US20180305373A1-20181025-C00309
    Figure US20180305373A1-20181025-C00310
         		Ethyl VI-14 V-15 II-1 n.d.
    II-61
    Figure US20180305373A1-20181025-C00311
    Figure US20180305373A1-20181025-C00312
         		H
    Figure US20180305373A1-20181025-C00313
    Figure US20180305373A1-20181025-C00314
         		Ethyl VI-15 V-15 II-1 n.d.
    II-62
    Figure US20180305373A1-20181025-C00315
    Figure US20180305373A1-20181025-C00316
         		H
    Figure US20180305373A1-20181025-C00317
    Figure US20180305373A1-20181025-C00318
         		Ethyl VI-16 V-15 II-1 n.d.
    II-63
    Figure US20180305373A1-20181025-C00319
    Figure US20180305373A1-20181025-C00320
         		H
    Figure US20180305373A1-20181025-C00321
    Figure US20180305373A1-20181025-C00322
         		Ethyl VI-17 V-15 II-1 n.d.
    II-64
    Figure US20180305373A1-20181025-C00323
    Figure US20180305373A1-20181025-C00324
         		H
    Figure US20180305373A1-20181025-C00325
    Figure US20180305373A1-20181025-C00326
         		Ethyl VI-18 V-10 II-1 n.d.
    II-65
    Figure US20180305373A1-20181025-C00327
    Figure US20180305373A1-20181025-C00328
         		H
    Figure US20180305373A1-20181025-C00329
    Figure US20180305373A1-20181025-C00330
         		Ethyl VI-18 V-11 II-1 n.d.
    II-66
    Figure US20180305373A1-20181025-C00331
    Figure US20180305373A1-20181025-C00332
         		H
    Figure US20180305373A1-20181025-C00333
    Figure US20180305373A1-20181025-C00334
         		Ethyl VI-18 V-12 II-1 n.d.
    II-67
    Figure US20180305373A1-20181025-C00335
    Figure US20180305373A1-20181025-C00336
         		H
    Figure US20180305373A1-20181025-C00337
    Figure US20180305373A1-20181025-C00338
         		Ethyl VI-18 V-13 II-1 n.d.
  • TABLE XIII-7
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C00339
    Figure US20180305373A1-20181025-C00340
         		R Int_1 Int_2 syn. yield (%)
    II-68
    Figure US20180305373A1-20181025-C00341
    Figure US20180305373A1-20181025-C00342
         		H
    Figure US20180305373A1-20181025-C00343
    Figure US20180305373A1-20181025-C00344
         		Ethyl VI-18 V-15 II-1 n.d.
    II-69
    Figure US20180305373A1-20181025-C00345
    Figure US20180305373A1-20181025-C00346
         		H
    Figure US20180305373A1-20181025-C00347
    Figure US20180305373A1-20181025-C00348
         		Ethyl VI-21 V-13 II-1 n.d.
    II-70
    Figure US20180305373A1-20181025-C00349
    Figure US20180305373A1-20181025-C00350
         		H
    Figure US20180305373A1-20181025-C00351
    Figure US20180305373A1-20181025-C00352
         		Ethyl VI-21 V-14 II-1 n.d.
    II-71
    Figure US20180305373A1-20181025-C00353
    Figure US20180305373A1-20181025-C00354
         		H
    Figure US20180305373A1-20181025-C00355
    Figure US20180305373A1-20181025-C00356
         		Ethyl VI-21 V-15 II-1 n.d.
    II-72
    Figure US20180305373A1-20181025-C00357
    Figure US20180305373A1-20181025-C00358
         		H
    Figure US20180305373A1-20181025-C00359
    Figure US20180305373A1-20181025-C00360
         		Ethyl VI-21 VI-16 II-1 n.d.
    II-73
    Figure US20180305373A1-20181025-C00361
    Figure US20180305373A1-20181025-C00362
         		H
    Figure US20180305373A1-20181025-C00363
    Figure US20180305373A1-20181025-C00364
         		Ethyl VI-23 V-6 II-1 n.d.
    II-74
    Figure US20180305373A1-20181025-C00365
    Figure US20180305373A1-20181025-C00366
         		H
    Figure US20180305373A1-20181025-C00367
    Figure US20180305373A1-20181025-C00368
         		Ethyl VI-23 V-5 II-1 n.d.
    II-75
    Figure US20180305373A1-20181025-C00369
    Figure US20180305373A1-20181025-C00370
         		H
    Figure US20180305373A1-20181025-C00371
    Figure US20180305373A1-20181025-C00372
         		Ethyl VI-23 V-7 II-1 n.d.
    II-76
    Figure US20180305373A1-20181025-C00373
    Figure US20180305373A1-20181025-C00374
         		H
    Figure US20180305373A1-20181025-C00375
    Figure US20180305373A1-20181025-C00376
         		Ethyl VI-23 V-8 II-1 n.d.
    II-77
    Figure US20180305373A1-20181025-C00377
    Figure US20180305373A1-20181025-C00378
         		H
    Figure US20180305373A1-20181025-C00379
    Figure US20180305373A1-20181025-C00380
         		Ethyl VI-23 V-9 II-1 n.d.
    II-78
    Figure US20180305373A1-20181025-C00381
    Figure US20180305373A1-20181025-C00382
         		H
    Figure US20180305373A1-20181025-C00383
    Figure US20180305373A1-20181025-C00384
         		Ethyl VI-24 V-1 II-1 n.d.
  • TABLE XIII-8
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C00385
    Figure US20180305373A1-20181025-C00386
         		R Int_1 Int_2 syn. yield (%)
    II-79
    Figure US20180305373A1-20181025-C00387
    Figure US20180305373A1-20181025-C00388
         		H
    Figure US20180305373A1-20181025-C00389
    Figure US20180305373A1-20181025-C00390
         		Ethyl VI-24 V-6 II-1 n.d.
    II-80
    Figure US20180305373A1-20181025-C00391
    Figure US20180305373A1-20181025-C00392
         		H
    Figure US20180305373A1-20181025-C00393
    Figure US20180305373A1-20181025-C00394
         		Ethyl VI-24 V-5 II-1 n.d.
    II-81
    Figure US20180305373A1-20181025-C00395
    Figure US20180305373A1-20181025-C00396
         		H
    Figure US20180305373A1-20181025-C00397
    Figure US20180305373A1-20181025-C00398
         		Ethyl VI-24 V-7 II-1 n.d.
    II-82
    Figure US20180305373A1-20181025-C00399
    Figure US20180305373A1-20181025-C00400
         		H
    Figure US20180305373A1-20181025-C00401
    Figure US20180305373A1-20181025-C00402
         		Ethyl VI-24 V-8 II-1 n.d.
    II-83
    Figure US20180305373A1-20181025-C00403
    Figure US20180305373A1-20181025-C00404
         		H
    Figure US20180305373A1-20181025-C00405
    Figure US20180305373A1-20181025-C00406
         		Ethyl VI-24 V-9 II-1 n.d.
    II-84
    Figure US20180305373A1-20181025-C00407
    Figure US20180305373A1-20181025-C00408
         		H
    Figure US20180305373A1-20181025-C00409
    Figure US20180305373A1-20181025-C00410
         		Ethyl VI-25 V-6 II-1 n.d.
    II-85
    Figure US20180305373A1-20181025-C00411
    Figure US20180305373A1-20181025-C00412
         		H
    Figure US20180305373A1-20181025-C00413
    Figure US20180305373A1-20181025-C00414
         		Ethyl VI-26 V-6 II-1 n.d.
    II-86
    Figure US20180305373A1-20181025-C00415
    Figure US20180305373A1-20181025-C00416
         		H
    Figure US20180305373A1-20181025-C00417
    Figure US20180305373A1-20181025-C00418
         		Ethyl VI-27 V-6 II-1 n.d.
    II-87
    Figure US20180305373A1-20181025-C00419
    Figure US20180305373A1-20181025-C00420
         		H
    Figure US20180305373A1-20181025-C00421
    Figure US20180305373A1-20181025-C00422
         		Ethyl VI-28 V-6 II-1 n.d.
    II-88
    Figure US20180305373A1-20181025-C00423
    Figure US20180305373A1-20181025-C00424
         		H
    Figure US20180305373A1-20181025-C00425
    Figure US20180305373A1-20181025-C00426
         		Ethyl VI-29 V-6 II-1 n.d.
    II-89
    Figure US20180305373A1-20181025-C00427
    Figure US20180305373A1-20181025-C00428
         		H
    Figure US20180305373A1-20181025-C00429
    Figure US20180305373A1-20181025-C00430
         		Ethyl VI-30 V-1 II-1 n.d.
  • TABLE XIII-9
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C00431
    Figure US20180305373A1-20181025-C00432
         		R Int_1 Int_2 syn. yield (%)
    II-90
    Figure US20180305373A1-20181025-C00433
    Figure US20180305373A1-20181025-C00434
         		H
    Figure US20180305373A1-20181025-C00435
    Figure US20180305373A1-20181025-C00436
         		Ethyl VI-30 V-6 II-1 n.d.
    II-91
    Figure US20180305373A1-20181025-C00437
    Figure US20180305373A1-20181025-C00438
         		H
    Figure US20180305373A1-20181025-C00439
    Figure US20180305373A1-20181025-C00440
         		Ethyl VI-23 V-10 II-1 n.d.
    II-92
    Figure US20180305373A1-20181025-C00441
    Figure US20180305373A1-20181025-C00442
         		H
    Figure US20180305373A1-20181025-C00443
    Figure US20180305373A1-20181025-C00444
         		Ethyl VI-23 V-11 II-1 n.d.
    II-93
    Figure US20180305373A1-20181025-C00445
    Figure US20180305373A1-20181025-C00446
         		H
    Figure US20180305373A1-20181025-C00447
    Figure US20180305373A1-20181025-C00448
         		Ethyl VI-23 VI-12 II-1 n.d.
    II-94
    Figure US20180305373A1-20181025-C00449
    Figure US20180305373A1-20181025-C00450
         		H
    Figure US20180305373A1-20181025-C00451
    Figure US20180305373A1-20181025-C00452
         		Ethyl VI-24 V-10 II-1 n.d.
    II-95
    Figure US20180305373A1-20181025-C00453
    Figure US20180305373A1-20181025-C00454
         		H
    Figure US20180305373A1-20181025-C00455
    Figure US20180305373A1-20181025-C00456
         		Ethyl VI-24 V-11 II-1 n.d.
    II-96
    Figure US20180305373A1-20181025-C00457
    Figure US20180305373A1-20181025-C00458
         		H
    Figure US20180305373A1-20181025-C00459
    Figure US20180305373A1-20181025-C00460
         		Ethyl VI-24 V-12 II-1 n.d.
    II-97
    Figure US20180305373A1-20181025-C00461
    Figure US20180305373A1-20181025-C00462
         		H
    Figure US20180305373A1-20181025-C00463
    Figure US20180305373A1-20181025-C00464
         		Ethyl VI-24 V-13 II-1 n.d.
    II-98
    Figure US20180305373A1-20181025-C00465
    Figure US20180305373A1-20181025-C00466
         		H
    Figure US20180305373A1-20181025-C00467
    Figure US20180305373A1-20181025-C00468
         		Ethyl VI-24 V-14 II-1 n.d.
    II-99
    Figure US20180305373A1-20181025-C00469
    Figure US20180305373A1-20181025-C00470
         		H
    Figure US20180305373A1-20181025-C00471
    Figure US20180305373A1-20181025-C00472
         		Ethyl VI-24 V-15 II-1 n.d.
    II-100
    Figure US20180305373A1-20181025-C00473
    Figure US20180305373A1-20181025-C00474
         		H
    Figure US20180305373A1-20181025-C00475
    Figure US20180305373A1-20181025-C00476
         		Ethyl VI-24 V-16 II-1 n.d.
  • TABLE XIII-10
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C00477
    Figure US20180305373A1-20181025-C00478
         		R Int_1 Int_2 syn. yield (%)
    II-101
    Figure US20180305373A1-20181025-C00479
    Figure US20180305373A1-20181025-C00480
         		H
    Figure US20180305373A1-20181025-C00481
    Figure US20180305373A1-20181025-C00482
         		Ethyl VI-25 V-13 II-1 n.d.
    II-102
    Figure US20180305373A1-20181025-C00483
    Figure US20180305373A1-20181025-C00484
         		H
    Figure US20180305373A1-20181025-C00485
    Figure US20180305373A1-20181025-C00486
         		Ethyl VI-25 V-15 II-1 n.d.
    II-103
    Figure US20180305373A1-20181025-C00487
    Figure US20180305373A1-20181025-C00488
         		H
    Figure US20180305373A1-20181025-C00489
    Figure US20180305373A1-20181025-C00490
         		Ethyl VI-26 V-13 II-1 n.d.
    II-104
    Figure US20180305373A1-20181025-C00491
    Figure US20180305373A1-20181025-C00492
         		H
    Figure US20180305373A1-20181025-C00493
    Figure US20180305373A1-20181025-C00494
         		Ethyl VI-26 V-15 II-1 n.d.
    II-105
    Figure US20180305373A1-20181025-C00495
    Figure US20180305373A1-20181025-C00496
         		H
    Figure US20180305373A1-20181025-C00497
    Figure US20180305373A1-20181025-C00498
         		Ethyl VI-27 V-13 II-1 n.d.
    II-106
    Figure US20180305373A1-20181025-C00499
    Figure US20180305373A1-20181025-C00500
         		H
    Figure US20180305373A1-20181025-C00501
    Figure US20180305373A1-20181025-C00502
         		Ethyl VI-27 V-15 II-1 n.d.
    II-107
    Figure US20180305373A1-20181025-C00503
    Figure US20180305373A1-20181025-C00504
         		H
    Figure US20180305373A1-20181025-C00505
    Figure US20180305373A1-20181025-C00506
         		Ethyl VI-28 V-13 II-1 n.d.
    II-108
    Figure US20180305373A1-20181025-C00507
    Figure US20180305373A1-20181025-C00508
         		H
    Figure US20180305373A1-20181025-C00509
    Figure US20180305373A1-20181025-C00510
         		Ethyl VI-28 V-15 II-1 n.d.
    II-109
    Figure US20180305373A1-20181025-C00511
    Figure US20180305373A1-20181025-C00512
         		H
    Figure US20180305373A1-20181025-C00513
    Figure US20180305373A1-20181025-C00514
         		Ethyl VI-29 V-13 II-1 n.d.
    II-110
    Figure US20180305373A1-20181025-C00515
    Figure US20180305373A1-20181025-C00516
         		H
    Figure US20180305373A1-20181025-C00517
    Figure US20180305373A1-20181025-C00518
         		Ethyl VI-29 V-15 II-1 n.d.
    II-111
    Figure US20180305373A1-20181025-C00519
    Figure US20180305373A1-20181025-C00520
         		H
    Figure US20180305373A1-20181025-C00521
    Figure US20180305373A1-20181025-C00522
         		Ethyl VI-30 V-13 II-1 n.d.
  • TABLE XIII-11
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C00523
    Figure US20180305373A1-20181025-C00524
         		R Int_1 Int_2 syn. yield (%)
    II-112
    Figure US20180305373A1-20181025-C00525
    Figure US20180305373A1-20181025-C00526
         		H
    Figure US20180305373A1-20181025-C00527
    Figure US20180305373A1-20181025-C00528
         		Ethyl VI-30 V-14 II-1 n.d.
    II-113
    Figure US20180305373A1-20181025-C00529
    Figure US20180305373A1-20181025-C00530
         		H
    Figure US20180305373A1-20181025-C00531
    Figure US20180305373A1-20181025-C00532
         		Ethyl VI-30 V-15 II-1 n.d.
    II-114
    Figure US20180305373A1-20181025-C00533
    Figure US20180305373A1-20181025-C00534
         		H
    Figure US20180305373A1-20181025-C00535
    Figure US20180305373A1-20181025-C00536
         		Ethyl VI-30 V-16 II-1 n.d.
    II-115
    Figure US20180305373A1-20181025-C00537
    Figure US20180305373A1-20181025-C00538
         		H
    Figure US20180305373A1-20181025-C00539
    Figure US20180305373A1-20181025-C00540
         		Ethyl VI-31 V-8 II-1 n.d.
    II-116
    Figure US20180305373A1-20181025-C00541
    Figure US20180305373A1-20181025-C00542
         		H
    Figure US20180305373A1-20181025-C00543
    Figure US20180305373A1-20181025-C00544
         		Ethyl VI-31 V-9 II-1 n.d.
    II-117
    Figure US20180305373A1-20181025-C00545
    Figure US20180305373A1-20181025-C00546
         		H
    Figure US20180305373A1-20181025-C00547
    Figure US20180305373A1-20181025-C00548
         		Ethyl VI-32 V-8 II-1 n.d.
    II-118
    Figure US20180305373A1-20181025-C00549
    Figure US20180305373A1-20181025-C00550
         		H
    Figure US20180305373A1-20181025-C00551
    Figure US20180305373A1-20181025-C00552
         		Ethyl VI-33 V-8 II-1 n.d.
    II-119
    Figure US20180305373A1-20181025-C00553
    Figure US20180305373A1-20181025-C00554
         		H
    Figure US20180305373A1-20181025-C00555
    Figure US20180305373A1-20181025-C00556
         		Ethyl VI-35 V-1 II-1 n.d.
    II-120
    Figure US20180305373A1-20181025-C00557
    Figure US20180305373A1-20181025-C00558
         		H
    Figure US20180305373A1-20181025-C00559
    Figure US20180305373A1-20181025-C00560
         		Ethyl VI-35 V-3 II-1 n.d.
    II-121
    Figure US20180305373A1-20181025-C00561
    Figure US20180305373A1-20181025-C00562
         		H
    Figure US20180305373A1-20181025-C00563
    Figure US20180305373A1-20181025-C00564
         		Ethyl VI-35 V-6 II-1 n.d.
    II-122
    Figure US20180305373A1-20181025-C00565
    Figure US20180305373A1-20181025-C00566
         		H
    Figure US20180305373A1-20181025-C00567
    Figure US20180305373A1-20181025-C00568
         		Ethyl VI-35 V-5 II-1 n.d.
  • TABLE XIII-12
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C00569
    Figure US20180305373A1-20181025-C00570
         		R Int_1 Int_2 syn. yield (%)
    II-123
    Figure US20180305373A1-20181025-C00571
    Figure US20180305373A1-20181025-C00572
         		H
    Figure US20180305373A1-20181025-C00573
    Figure US20180305373A1-20181025-C00574
         		Ethyl VI-35 V-7 II-1 n.d.
    II-124
    Figure US20180305373A1-20181025-C00575
    Figure US20180305373A1-20181025-C00576
         		H
    Figure US20180305373A1-20181025-C00577
    Figure US20180305373A1-20181025-C00578
         		Ethyl VI-35 V-8 II-1 n.d.
    II-125
    Figure US20180305373A1-20181025-C00579
    Figure US20180305373A1-20181025-C00580
         		H
    Figure US20180305373A1-20181025-C00581
    Figure US20180305373A1-20181025-C00582
         		Ethyl VI-35 V-9 II-1 n.d.
    II-126
    Figure US20180305373A1-20181025-C00583
    Figure US20180305373A1-20181025-C00584
         		H
    Figure US20180305373A1-20181025-C00585
    Figure US20180305373A1-20181025-C00586
         		Ethyl VI-36 V-1 II-1 n.d.
    II-127
    Figure US20180305373A1-20181025-C00587
    Figure US20180305373A1-20181025-C00588
         		H
    Figure US20180305373A1-20181025-C00589
    Figure US20180305373A1-20181025-C00590
         		Ethyl VI-36 V-3 II-1 n.d.
    II-128
    Figure US20180305373A1-20181025-C00591
    Figure US20180305373A1-20181025-C00592
         		H
    Figure US20180305373A1-20181025-C00593
    Figure US20180305373A1-20181025-C00594
         		Ethyl VI-36 V-6 II-1 n.d.
    II-129
    Figure US20180305373A1-20181025-C00595
    Figure US20180305373A1-20181025-C00596
         		H
    Figure US20180305373A1-20181025-C00597
    Figure US20180305373A1-20181025-C00598
         		Ethyl VI-36 V-5 II-1 n.d.
    II-130
    Figure US20180305373A1-20181025-C00599
    Figure US20180305373A1-20181025-C00600
         		H
    Figure US20180305373A1-20181025-C00601
    Figure US20180305373A1-20181025-C00602
         		Ethyl VI-36 V-7 II-1 n.d.
    II-131
    Figure US20180305373A1-20181025-C00603
    Figure US20180305373A1-20181025-C00604
         		H
    Figure US20180305373A1-20181025-C00605
    Figure US20180305373A1-20181025-C00606
         		Ethyl VI-36 V-8 II-1 n.d.
    II-132
    Figure US20180305373A1-20181025-C00607
    Figure US20180305373A1-20181025-C00608
         		H
    Figure US20180305373A1-20181025-C00609
    Figure US20180305373A1-20181025-C00610
         		Ethyl VI-36 V-9 II-1 n.d.
    II-133
    Figure US20180305373A1-20181025-C00611
    Figure US20180305373A1-20181025-C00612
         		H
    Figure US20180305373A1-20181025-C00613
    Figure US20180305373A1-20181025-C00614
         		Ethyl V I-41 V-1 II-1 n.d.
  • TABLE XIII-13
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C00615
    Figure US20180305373A1-20181025-C00616
         		R Int_1 Int_2 syn. yield (%)
    II-134
    Figure US20180305373A1-20181025-C00617
    Figure US20180305373A1-20181025-C00618
         		H
    Figure US20180305373A1-20181025-C00619
    Figure US20180305373A1-20181025-C00620
         		Ethyl VI-41 V-3 II-1 n.d.
    II-135
    Figure US20180305373A1-20181025-C00621
    Figure US20180305373A1-20181025-C00622
         		H
    Figure US20180305373A1-20181025-C00623
    Figure US20180305373A1-20181025-C00624
         		Ethyl VI-41 V-6 II-1 n.d.
    II-136
    Figure US20180305373A1-20181025-C00625
    Figure US20180305373A1-20181025-C00626
         		H
    Figure US20180305373A1-20181025-C00627
    Figure US20180305373A1-20181025-C00628
         		Ethyl VI-41 V-5 II-1 n.d.
    II-137
    Figure US20180305373A1-20181025-C00629
    Figure US20180305373A1-20181025-C00630
         		H
    Figure US20180305373A1-20181025-C00631
    Figure US20180305373A1-20181025-C00632
         		Ethyl VI-41 V-7 II-1 n.d.
    II-138
    Figure US20180305373A1-20181025-C00633
    Figure US20180305373A1-20181025-C00634
         		H
    Figure US20180305373A1-20181025-C00635
    Figure US20180305373A1-20181025-C00636
         		Ethyl VI-41 V-8 II-1 n.d.
    II-139
    Figure US20180305373A1-20181025-C00637
    Figure US20180305373A1-20181025-C00638
         		H
    Figure US20180305373A1-20181025-C00639
    Figure US20180305373A1-20181025-C00640
         		Ethyl VI-41 V-9 II-1 n.d.
    II-140
    Figure US20180305373A1-20181025-C00641
    Figure US20180305373A1-20181025-C00642
         		H
    Figure US20180305373A1-20181025-C00643
    Figure US20180305373A1-20181025-C00644
         		Ethyl VI-42 V-3 II-1 n.d.
    II-141
    Figure US20180305373A1-20181025-C00645
    Figure US20180305373A1-20181025-C00646
         		H
    Figure US20180305373A1-20181025-C00647
    Figure US20180305373A1-20181025-C00648
         		Ethyl VI-42 V-6 II-1 n.d.
    II-142
    Figure US20180305373A1-20181025-C00649
    Figure US20180305373A1-20181025-C00650
         		H
    Figure US20180305373A1-20181025-C00651
    Figure US20180305373A1-20181025-C00652
         		Ethyl VI-42 V-8 II-1 n.d.
    II-143
    Figure US20180305373A1-20181025-C00653
    Figure US20180305373A1-20181025-C00654
         		H
    Figure US20180305373A1-20181025-C00655
    Figure US20180305373A1-20181025-C00656
         		Ethyl VI-42 V-9 II-1 n.d.
    II-144
    Figure US20180305373A1-20181025-C00657
    Figure US20180305373A1-20181025-C00658
         		H
    Figure US20180305373A1-20181025-C00659
    Figure US20180305373A1-20181025-C00660
         		Ethyl VI-44 V-3 II-1 n.d.
  • TABLE XIII-14
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C00661
    Figure US20180305373A1-20181025-C00662
         		R Int_1 Int_2 syn. yield (%)
    II-145
    Figure US20180305373A1-20181025-C00663
    Figure US20180305373A1-20181025-C00664
         		H
    Figure US20180305373A1-20181025-C00665
    Figure US20180305373A1-20181025-C00666
         		Ethyl VI-4 V-6 II-1 n.d.
    II-146
    Figure US20180305373A1-20181025-C00667
    Figure US20180305373A1-20181025-C00668
         		H
    Figure US20180305373A1-20181025-C00669
    Figure US20180305373A1-20181025-C00670
         		Ethyl VI-44 V-8 II-1 n.d.
    II-147
    Figure US20180305373A1-20181025-C00671
    Figure US20180305373A1-20181025-C00672
         		H
    Figure US20180305373A1-20181025-C00673
    Figure US20180305373A1-20181025-C00674
         		Ethyl VI-44 V-9 II-1 n.d.
    II-148
    Figure US20180305373A1-20181025-C00675
    Figure US20180305373A1-20181025-C00676
         		H
    Figure US20180305373A1-20181025-C00677
    Figure US20180305373A1-20181025-C00678
         		Ethyl VI-34 V-12 II-1 n.d.
    II-149
    Figure US20180305373A1-20181025-C00679
    Figure US20180305373A1-20181025-C00680
         		H
    Figure US20180305373A1-20181025-C00681
    Figure US20180305373A1-20181025-C00682
         		Ethyl VI-34 V-14 II-1 n.d.
    II-150
    Figure US20180305373A1-20181025-C00683
    Figure US20180305373A1-20181025-C00684
         		H
    Figure US20180305373A1-20181025-C00685
    Figure US20180305373A1-20181025-C00686
         		Ethyl VI-34 V-15 II-1 n.d.
    II-151
    Figure US20180305373A1-20181025-C00687
    Figure US20180305373A1-20181025-C00688
         		H
    Figure US20180305373A1-20181025-C00689
    Figure US20180305373A1-20181025-C00690
         		Ethyl VI-35 V-12 II-1 n.d.
    II-152
    Figure US20180305373A1-20181025-C00691
    Figure US20180305373A1-20181025-C00692
         		H
    Figure US20180305373A1-20181025-C00693
    Figure US20180305373A1-20181025-C00694
         		Ethyl VI-35 V-14 II-1 n.d.
    II-153
    Figure US20180305373A1-20181025-C00695
    Figure US20180305373A1-20181025-C00696
         		H
    Figure US20180305373A1-20181025-C00697
    Figure US20180305373A1-20181025-C00698
         		Ethyl VI-35 V-15 II-1 n.d.
    II-154
    Figure US20180305373A1-20181025-C00699
    Figure US20180305373A1-20181025-C00700
         		H
    Figure US20180305373A1-20181025-C00701
    Figure US20180305373A1-20181025-C00702
         		Ethyl VI-36 V-12 II-1 n.d.
    II-155
    Figure US20180305373A1-20181025-C00703
    Figure US20180305373A1-20181025-C00704
         		H
    Figure US20180305373A1-20181025-C00705
    Figure US20180305373A1-20181025-C00706
         		Ethyl VI-36 V-14 II-1 n.d.
  • TABLE XIII-15
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C00707
    Figure US20180305373A1-20181025-C00708
         		R Int_1 Int_2 syn. yield (%)
    II-156
    Figure US20180305373A1-20181025-C00709
    Figure US20180305373A1-20181025-C00710
         		H
    Figure US20180305373A1-20181025-C00711
    Figure US20180305373A1-20181025-C00712
         		Ethyl VI-36 V-15 II-1 n.d.
    II-157
    Figure US20180305373A1-20181025-C00713
    Figure US20180305373A1-20181025-C00714
         		H
    Figure US20180305373A1-20181025-C00715
    Figure US20180305373A1-20181025-C00716
         		Ethyl VI-37 V-12 II-1 n.d.
    II-158
    Figure US20180305373A1-20181025-C00717
    Figure US20180305373A1-20181025-C00718
         		H
    Figure US20180305373A1-20181025-C00719
    Figure US20180305373A1-20181025-C00720
         		Ethyl VI-37 V-14 II-1 n.d.
    II-159
    Figure US20180305373A1-20181025-C00721
    Figure US20180305373A1-20181025-C00722
         		H
    Figure US20180305373A1-20181025-C00723
    Figure US20180305373A1-20181025-C00724
         		Ethyl VI-37 V-15 II-1 n.d.
    II-160
    Figure US20180305373A1-20181025-C00725
    Figure US20180305373A1-20181025-C00726
         		H
    Figure US20180305373A1-20181025-C00727
    Figure US20180305373A1-20181025-C00728
         		Ethyl VI-38 V-12 II-1 n.d.
    II-161
    Figure US20180305373A1-20181025-C00729
    Figure US20180305373A1-20181025-C00730
         		H
    Figure US20180305373A1-20181025-C00731
    Figure US20180305373A1-20181025-C00732
         		Ethyl VI-39 V-12 II-1 n.d.
    II-162
    Figure US20180305373A1-20181025-C00733
    Figure US20180305373A1-20181025-C00734
         		H
    Figure US20180305373A1-20181025-C00735
    Figure US20180305373A1-20181025-C00736
         		Ethyl VI-39 V-10 II-1 n.d.
    II-163
    Figure US20180305373A1-20181025-C00737
    Figure US20180305373A1-20181025-C00738
         		H
    Figure US20180305373A1-20181025-C00739
    Figure US20180305373A1-20181025-C00740
         		Ethyl VI-39 V-11 II-1 n.d.
    II-164
    Figure US20180305373A1-20181025-C00741
    Figure US20180305373A1-20181025-C00742
         		H
    Figure US20180305373A1-20181025-C00743
    Figure US20180305373A1-20181025-C00744
         		Ethyl VI-39 V-12 II-1 n.d.
    II-165
    Figure US20180305373A1-20181025-C00745
    Figure US20180305373A1-20181025-C00746
         		H
    Figure US20180305373A1-20181025-C00747
    Figure US20180305373A1-20181025-C00748
         		Ethyl VI-39 V-14 II-1 n.d.
    II-166
    Figure US20180305373A1-20181025-C00749
    Figure US20180305373A1-20181025-C00750
         		H
    Figure US20180305373A1-20181025-C00751
    Figure US20180305373A1-20181025-C00752
         		Ethyl VI-39 V-15 II-1 n.d.
  • TABLE XIII-16
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C00753
    Figure US20180305373A1-20181025-C00754
         		R Int_1 Int_2 syn. yield (%)
    II-167
    Figure US20180305373A1-20181025-C00755
    Figure US20180305373A1-20181025-C00756
         		H
    Figure US20180305373A1-20181025-C00757
    Figure US20180305373A1-20181025-C00758
         		Ethyl VI-40 V-10 II-1 n.d.
    II-168
    Figure US20180305373A1-20181025-C00759
    Figure US20180305373A1-20181025-C00760
         		H
    Figure US20180305373A1-20181025-C00761
    Figure US20180305373A1-20181025-C00762
         		Ethyl VI-40 V-11 II-1 n.d.
    II-169
    Figure US20180305373A1-20181025-C00763
    Figure US20180305373A1-20181025-C00764
         		H
    Figure US20180305373A1-20181025-C00765
    Figure US20180305373A1-20181025-C00766
         		Ethyl VI-40 V-12 II-1 n.d.
    II-170
    Figure US20180305373A1-20181025-C00767
    Figure US20180305373A1-20181025-C00768
         		H
    Figure US20180305373A1-20181025-C00769
    Figure US20180305373A1-20181025-C00770
         		Ethyl VI-40 V-14 II-1 n.d.
    II-171
    Figure US20180305373A1-20181025-C00771
    Figure US20180305373A1-20181025-C00772
         		H
    Figure US20180305373A1-20181025-C00773
    Figure US20180305373A1-20181025-C00774
         		Ethyl VI-40 V-15 II-1 n.d.
    II-172
    Figure US20180305373A1-20181025-C00775
    Figure US20180305373A1-20181025-C00776
         		H
    Figure US20180305373A1-20181025-C00777
    Figure US20180305373A1-20181025-C00778
         		Ethyl VI-42 V-10 II-1 n.d.
    II-173
    Figure US20180305373A1-20181025-C00779
    Figure US20180305373A1-20181025-C00780
         		H
    Figure US20180305373A1-20181025-C00781
    Figure US20180305373A1-20181025-C00782
         		Ethyl VI-42 V-11 II-1 n.d.
    II-174
    Figure US20180305373A1-20181025-C00783
    Figure US20180305373A1-20181025-C00784
         		H
    Figure US20180305373A1-20181025-C00785
    Figure US20180305373A1-20181025-C00786
         		Ethyl VI-42 V-12 II-1 n.d.
    II-175
    Figure US20180305373A1-20181025-C00787
    Figure US20180305373A1-20181025-C00788
         		H
    Figure US20180305373A1-20181025-C00789
    Figure US20180305373A1-20181025-C00790
         		Ethyl VI-43 V-10 II-1 n.d.
    II-176
    Figure US20180305373A1-20181025-C00791
    Figure US20180305373A1-20181025-C00792
         		H
    Figure US20180305373A1-20181025-C00793
    Figure US20180305373A1-20181025-C00794
         		Ethyl VI-43 V-11 II-1 n.d.
    II-177
    Figure US20180305373A1-20181025-C00795
    Figure US20180305373A1-20181025-C00796
         		H
    Figure US20180305373A1-20181025-C00797
    Figure US20180305373A1-20181025-C00798
         		Ethyl VI-43 V-12 II-1 n.d.
  • TABLE XIII-17
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C00799
    Figure US20180305373A1-20181025-C00800
         		R Int_1 Int_2 syn. yield (%)
    II-178
    Figure US20180305373A1-20181025-C00801
    Figure US20180305373A1-20181025-C00802
         		H
    Figure US20180305373A1-20181025-C00803
    Figure US20180305373A1-20181025-C00804
         		Ethyl VI-45 V-1 II-1 n.d.
    II-179
    Figure US20180305373A1-20181025-C00805
    Figure US20180305373A1-20181025-C00806
         		H
    Figure US20180305373A1-20181025-C00807
    Figure US20180305373A1-20181025-C00808
         		Ethyl VI-45 V-8 II-1 n.d.
    II-180
    Figure US20180305373A1-20181025-C00809
    Figure US20180305373A1-20181025-C00810
         		H
    Figure US20180305373A1-20181025-C00811
    Figure US20180305373A1-20181025-C00812
         		Ethyl VI-46 V-1 II-1 n.d.
    II-181
    Figure US20180305373A1-20181025-C00813
    Figure US20180305373A1-20181025-C00814
         		H
    Figure US20180305373A1-20181025-C00815
    Figure US20180305373A1-20181025-C00816
         		Ethyl VI-46 V-8 II-1 n.d.
    II-182
    Figure US20180305373A1-20181025-C00817
    Figure US20180305373A1-20181025-C00818
         		H
    Figure US20180305373A1-20181025-C00819
    Figure US20180305373A1-20181025-C00820
         		Ethyl VI-46 V-9 II-1 n.d.
    II-183
    Figure US20180305373A1-20181025-C00821
    Figure US20180305373A1-20181025-C00822
         		H
    Figure US20180305373A1-20181025-C00823
    Figure US20180305373A1-20181025-C00824
         		Ethyl VI-47 V-1 II-1 n.d.
    II-184
    Figure US20180305373A1-20181025-C00825
    Figure US20180305373A1-20181025-C00826
         		H
    Figure US20180305373A1-20181025-C00827
    Figure US20180305373A1-20181025-C00828
         		Ethyl VI-47 V-9 II-1 n.d.
    II-185
    Figure US20180305373A1-20181025-C00829
    Figure US20180305373A1-20181025-C00830
         		H
    Figure US20180305373A1-20181025-C00831
    Figure US20180305373A1-20181025-C00832
         		Ethyl VI-48 V-1 II-1 n.d.
    II-186
    Figure US20180305373A1-20181025-C00833
    Figure US20180305373A1-20181025-C00834
         		H
    Figure US20180305373A1-20181025-C00835
    Figure US20180305373A1-20181025-C00836
         		Ethyl VI-48 V-9 II-1 n.d.
    II-187
    Figure US20180305373A1-20181025-C00837
    Figure US20180305373A1-20181025-C00838
         		H
    Figure US20180305373A1-20181025-C00839
    Figure US20180305373A1-20181025-C00840
         		Ethyl VI-49 V-1 II-1 n.d.
    II-188
    Figure US20180305373A1-20181025-C00841
    Figure US20180305373A1-20181025-C00842
         		H
    Figure US20180305373A1-20181025-C00843
    Figure US20180305373A1-20181025-C00844
         		Ethyl VI-49 V-9 II-1 n.d.
  • TABLE XIII-18
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C00845
    Figure US20180305373A1-20181025-C00846
         		R Int_1 Int_2 syn. yield (%)
    II-189
    Figure US20180305373A1-20181025-C00847
    Figure US20180305373A1-20181025-C00848
         		H
    Figure US20180305373A1-20181025-C00849
    Figure US20180305373A1-20181025-C00850
         		Ethyl VI-50 V-1 II-1 n.d.
    II-190
    Figure US20180305373A1-20181025-C00851
    Figure US20180305373A1-20181025-C00852
         		H
    Figure US20180305373A1-20181025-C00853
    Figure US20180305373A1-20181025-C00854
         		Ethyl VI-50 V-9 II-1 n.d.
    II-191
    Figure US20180305373A1-20181025-C00855
    Figure US20180305373A1-20181025-C00856
         		H
    Figure US20180305373A1-20181025-C00857
    Figure US20180305373A1-20181025-C00858
         		Ethyl VI-51 V-1 II-1 n.d.
    II-192
    Figure US20180305373A1-20181025-C00859
    Figure US20180305373A1-20181025-C00860
         		H
    Figure US20180305373A1-20181025-C00861
    Figure US20180305373A1-20181025-C00862
         		Ethyl VI-51 V-9 II-1 n.d.
    II-193
    Figure US20180305373A1-20181025-C00863
    Figure US20180305373A1-20181025-C00864
         		H
    Figure US20180305373A1-20181025-C00865
    Figure US20180305373A1-20181025-C00866
         		Ethyl VI-52 V-1 II-1 n.d.
    II-194
    Figure US20180305373A1-20181025-C00867
    Figure US20180305373A1-20181025-C00868
         		H
    Figure US20180305373A1-20181025-C00869
    Figure US20180305373A1-20181025-C00870
         		Ethyl VI-52 V-8 II-1 n.d.
    II-195
    Figure US20180305373A1-20181025-C00871
    Figure US20180305373A1-20181025-C00872
         		H
    Figure US20180305373A1-20181025-C00873
    Figure US20180305373A1-20181025-C00874
         		Ethyl VI-53 V-1 II-1 n.d.
    II-196
    Figure US20180305373A1-20181025-C00875
    Figure US20180305373A1-20181025-C00876
         		H
    Figure US20180305373A1-20181025-C00877
    Figure US20180305373A1-20181025-C00878
         		Ethyl VI-53 V-8 II-1 n.d.
    II-197
    Figure US20180305373A1-20181025-C00879
    Figure US20180305373A1-20181025-C00880
         		H
    Figure US20180305373A1-20181025-C00881
    Figure US20180305373A1-20181025-C00882
         		Ethyl VI-54 V-1 II-1 n.d.
    II-198
    Figure US20180305373A1-20181025-C00883
    Figure US20180305373A1-20181025-C00884
         		H
    Figure US20180305373A1-20181025-C00885
    Figure US20180305373A1-20181025-C00886
         		Ethyl VI-54 V-8 II-1 n.d.
    II-199
    Figure US20180305373A1-20181025-C00887
    Figure US20180305373A1-20181025-C00888
         		H
    Figure US20180305373A1-20181025-C00889
    Figure US20180305373A1-20181025-C00890
         		Ethyl VI-45 V-12 II-1 n.d.
  • TABLE XIII-19
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C00891
    Figure US20180305373A1-20181025-C00892
         		R Int_1 Int_2 syn. yield (%)
    II-200
    Figure US20180305373A1-20181025-C00893
    Figure US20180305373A1-20181025-C00894
         		H
    Figure US20180305373A1-20181025-C00895
    Figure US20180305373A1-20181025-C00896
         		Ethyl VI-45 V-14 II-1 n.d.
    II-201
    Figure US20180305373A1-20181025-C00897
    Figure US20180305373A1-20181025-C00898
         		H
    Figure US20180305373A1-20181025-C00899
    Figure US20180305373A1-20181025-C00900
         		Ethyl VI-45 V-16 II-1 n.d.
    II-202
    Figure US20180305373A1-20181025-C00901
    Figure US20180305373A1-20181025-C00902
         		H
    Figure US20180305373A1-20181025-C00903
    Figure US20180305373A1-20181025-C00904
         		Ethyl VI-46 V-12 II-1 n.d.
    II-203
    Figure US20180305373A1-20181025-C00905
    Figure US20180305373A1-20181025-C00906
         		H
    Figure US20180305373A1-20181025-C00907
    Figure US20180305373A1-20181025-C00908
         		Ethyl VI-46 V-14 II-1 n.d.
    II-204
    Figure US20180305373A1-20181025-C00909
    Figure US20180305373A1-20181025-C00910
         		H
    Figure US20180305373A1-20181025-C00911
    Figure US20180305373A1-20181025-C00912
         		Ethyl VI-52 V-10 II-1 n.d.
    II-205
    Figure US20180305373A1-20181025-C00913
    Figure US20180305373A1-20181025-C00914
         		H
    Figure US20180305373A1-20181025-C00915
    Figure US20180305373A1-20181025-C00916
         		Ethyl VI-52 V-11 II-1 n.d.
    II-206
    Figure US20180305373A1-20181025-C00917
    Figure US20180305373A1-20181025-C00918
         		H
    Figure US20180305373A1-20181025-C00919
    Figure US20180305373A1-20181025-C00920
         		Ethyl VI-52 V-12 II-1 n.d.
    II-207
    Figure US20180305373A1-20181025-C00921
    Figure US20180305373A1-20181025-C00922
         		H
    Figure US20180305373A1-20181025-C00923
    Figure US20180305373A1-20181025-C00924
         		Ethyl VI-52 V -13 II-1 n.d.
    II-208
    Figure US20180305373A1-20181025-C00925
    Figure US20180305373A1-20181025-C00926
         		H
    Figure US20180305373A1-20181025-C00927
    Figure US20180305373A1-20181025-C00928
         		Ethyl VI-52 V-14 II-1 n.d.
    II-209
    Figure US20180305373A1-20181025-C00929
    Figure US20180305373A1-20181025-C00930
         		H
    Figure US20180305373A1-20181025-C00931
    Figure US20180305373A1-20181025-C00932
         		Ethyl VI-54 V-10 II-1 n.d.
    II-210
    Figure US20180305373A1-20181025-C00933
    Figure US20180305373A1-20181025-C00934
         		H
    Figure US20180305373A1-20181025-C00935
    Figure US20180305373A1-20181025-C00936
         		Ethyl VI-54 V-11 II-1 n.d.
  • TABLE XIII-20
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C00937
    Figure US20180305373A1-20181025-C00938
         		R Int_1 Int_2 syn. yield (%)
    II-211
    Figure US20180305373A1-20181025-C00939
    Figure US20180305373A1-20181025-C00940
         		H
    Figure US20180305373A1-20181025-C00941
    Figure US20180305373A1-20181025-C00942
         		Ethyl VI-54 V-12 II-1 n.d.
    II-212
    Figure US20180305373A1-20181025-C00943
    Figure US20180305373A1-20181025-C00944
         		H
    Figure US20180305373A1-20181025-C00945
    Figure US20180305373A1-20181025-C00946
         		Ethyl VI-54 V-13 II-1 n.d.
    II-213
    Figure US20180305373A1-20181025-C00947
    Figure US20180305373A1-20181025-C00948
         		H
    Figure US20180305373A1-20181025-C00949
    Figure US20180305373A1-20181025-C00950
         		Ethyl VI-54 V-14 II-1 n.d.
    II-214
    Figure US20180305373A1-20181025-C00951
    Figure US20180305373A1-20181025-C00952
         		Me
    Figure US20180305373A1-20181025-C00953
    Figure US20180305373A1-20181025-C00954
         		Ethyl VI-60 V-3 II-1 n.d.
    II-215
    Figure US20180305373A1-20181025-C00955
    Figure US20180305373A1-20181025-C00956
         		Me
    Figure US20180305373A1-20181025-C00957
    Figure US20180305373A1-20181025-C00958
         		Ethyl VI-60 V-4 II-1 n.d.
    II-216
    Figure US20180305373A1-20181025-C00959
    Figure US20180305373A1-20181025-C00960
         		Me
    Figure US20180305373A1-20181025-C00961
    Figure US20180305373A1-20181025-C00962
         		Ethyl VI-60 V-5 II-1 n.d.
    II-217
    Figure US20180305373A1-20181025-C00963
    Figure US20180305373A1-20181025-C00964
         		Me
    Figure US20180305373A1-20181025-C00965
    Figure US20180305373A1-20181025-C00966
         		Ethyl VI-61 V-3 II-1 n.d.
    II-218
    Figure US20180305373A1-20181025-C00967
    Figure US20180305373A1-20181025-C00968
         		Me
    Figure US20180305373A1-20181025-C00969
    Figure US20180305373A1-20181025-C00970
         		Ethyl VI-61 V-4 II-1 n.d.
    II-219
    Figure US20180305373A1-20181025-C00971
    Figure US20180305373A1-20181025-C00972
         		Me
    Figure US20180305373A1-20181025-C00973
    Figure US20180305373A1-20181025-C00974
         		Ethyl VI-61 V-5 II-1 n.d.
    II-220
    Figure US20180305373A1-20181025-C00975
    Figure US20180305373A1-20181025-C00976
         		Me
    Figure US20180305373A1-20181025-C00977
    Figure US20180305373A1-20181025-C00978
         		Ethyl VI-62 V-3 II-1 n.d.
    II-221
    Figure US20180305373A1-20181025-C00979
    Figure US20180305373A1-20181025-C00980
         		Me
    Figure US20180305373A1-20181025-C00981
    Figure US20180305373A1-20181025-C00982
         		Ethyl VI-62 V-4 II-1 n.d.
  • TABLE XIII-21
    Exam- ple No. R1 R2 R3
    Figure US20180305373A1-20181025-C00983
    Figure US20180305373A1-20181025-C00984
         		R Int_1 Int_2 syn. yield (%)
    II-222
    Figure US20180305373A1-20181025-C00985
    Figure US20180305373A1-20181025-C00986
         		Me
    Figure US20180305373A1-20181025-C00987
    Figure US20180305373A1-20181025-C00988
         		Ethyl VI-62 V-5 II-1 n.d.
    II-223
    Figure US20180305373A1-20181025-C00989
    Figure US20180305373A1-20181025-C00990
         		Me
    Figure US20180305373A1-20181025-C00991
    Figure US20180305373A1-20181025-C00992
         		Ethyl VI-63 V-3 II-1 n.d.
    II-224
    Figure US20180305373A1-20181025-C00993
    Figure US20180305373A1-20181025-C00994
         		Me
    Figure US20180305373A1-20181025-C00995
    Figure US20180305373A1-20181025-C00996
         		Ethyl VI-63 V-4 II-1 n.d.
    II-225
    Figure US20180305373A1-20181025-C00997
    Figure US20180305373A1-20181025-C00998
         		Me
    Figure US20180305373A1-20181025-C00999
    Figure US20180305373A1-20181025-C01000
         		Ethyl VI-64 V-3 II-1 n.d.
    II-226
    Figure US20180305373A1-20181025-C01001
    Figure US20180305373A1-20181025-C01002
         		Me
    Figure US20180305373A1-20181025-C01003
    Figure US20180305373A1-20181025-C01004
         		Ethyl VI-64 V-4 II-1 n.d.
    II-227
    Figure US20180305373A1-20181025-C01005
    Figure US20180305373A1-20181025-C01006
         		Me
    Figure US20180305373A1-20181025-C01007
    Figure US20180305373A1-20181025-C01008
         		Ethyl VI-65 V-3 II-1 n.d.
    II-228
    Figure US20180305373A1-20181025-C01009
    Figure US20180305373A1-20181025-C01010
         		Me
    Figure US20180305373A1-20181025-C01011
    Figure US20180305373A1-20181025-C01012
         		Ethyl VI-65 V-4 II-1 n.d.
    II-229
    Figure US20180305373A1-20181025-C01013
    Figure US20180305373A1-20181025-C01014
         		Me
    Figure US20180305373A1-20181025-C01015
    Figure US20180305373A1-20181025-C01016
         		Ethyl VI-66 V-3 II-1 n.d.
    II-230
    Figure US20180305373A1-20181025-C01017
    Figure US20180305373A1-20181025-C01018
         		Me
    Figure US20180305373A1-20181025-C01019
    Figure US20180305373A1-20181025-C01020
         		Ethyl VI-66 V-4 II-1 n.d.
    II-231
    Figure US20180305373A1-20181025-C01021
    Figure US20180305373A1-20181025-C01022
         		Me
    Figure US20180305373A1-20181025-C01023
    Figure US20180305373A1-20181025-C01024
         		Ethyl VI-67 V-4 II-1 n.d.
    II-232
    Figure US20180305373A1-20181025-C01025
    Figure US20180305373A1-20181025-C01026
         		Me
    Figure US20180305373A1-20181025-C01027
    Figure US20180305373A1-20181025-C01028
         		Ethyl VI-67 V-5 II-1 n.d.
  • TABLE XIII-22
    Exam- ple No. R1 R2 R3
    Figure US20180305373A1-20181025-C01029
    Figure US20180305373A1-20181025-C01030
         		R Int_1 Int_2 syn. yield (%)
    II-233
    Figure US20180305373A1-20181025-C01031
    Figure US20180305373A1-20181025-C01032
         		Me
    Figure US20180305373A1-20181025-C01033
    Figure US20180305373A1-20181025-C01034
         		Ethyl VI-68 V-4 II-1 n.d.
    II-234
    Figure US20180305373A1-20181025-C01035
    Figure US20180305373A1-20181025-C01036
         		Me
    Figure US20180305373A1-20181025-C01037
    Figure US20180305373A1-20181025-C01038
         		Ethyl VI-69 V-4 II-1 n.d.
    II-235
    Figure US20180305373A1-20181025-C01039
    Figure US20180305373A1-20181025-C01040
         		Me
    Figure US20180305373A1-20181025-C01041
    Figure US20180305373A1-20181025-C01042
         		Ethyl VI-69 V-5 II-1 n.d.
    II-236
    Figure US20180305373A1-20181025-C01043
    Figure US20180305373A1-20181025-C01044
         		Me
    Figure US20180305373A1-20181025-C01045
    Figure US20180305373A1-20181025-C01046
         		Ethyl VI-70 V-4 II-1 n.d.
    II-237
    Figure US20180305373A1-20181025-C01047
    Figure US20180305373A1-20181025-C01048
         		Me
    Figure US20180305373A1-20181025-C01049
    Figure US20180305373A1-20181025-C01050
         		Ethyl VI-70 V-5 II-1 n.d.
    II-238
    Figure US20180305373A1-20181025-C01051
    Figure US20180305373A1-20181025-C01052
         		Me
    Figure US20180305373A1-20181025-C01053
    Figure US20180305373A1-20181025-C01054
         		Ethyl VI-71 V-3 II-1 n.d.
    II-239
    Figure US20180305373A1-20181025-C01055
    Figure US20180305373A1-20181025-C01056
         		Me
    Figure US20180305373A1-20181025-C01057
    Figure US20180305373A1-20181025-C01058
         		Ethyl VI-71 V-5 II-1 n.d.
    II-240
    Figure US20180305373A1-20181025-C01059
    Figure US20180305373A1-20181025-C01060
         		Me
    Figure US20180305373A1-20181025-C01061
    Figure US20180305373A1-20181025-C01062
         		Ethyl VI-72 V-3 II-1 n.d.
    II-241
    Figure US20180305373A1-20181025-C01063
    Figure US20180305373A1-20181025-C01064
         		Me
    Figure US20180305373A1-20181025-C01065
    Figure US20180305373A1-20181025-C01066
         		Ethyl VI-72 V-5 II-1 n.d.
    II-242
    Figure US20180305373A1-20181025-C01067
    Figure US20180305373A1-20181025-C01068
         		Me
    Figure US20180305373A1-20181025-C01069
    Figure US20180305373A1-20181025-C01070
         		Ethyl VI-73 V-3 II-1 n.d.
    II-243
    Figure US20180305373A1-20181025-C01071
    Figure US20180305373A1-20181025-C01072
         		Me
    Figure US20180305373A1-20181025-C01073
    Figure US20180305373A1-20181025-C01074
         		Ethyl VI-73 V-5 II-1 n.d.
  • TABLE XIII-23
    Ex- am- ple No. R1 R2 R3
    Figure US20180305373A1-20181025-C01075
    Figure US20180305373A1-20181025-C01076
         		R Int_1 Int_2 syn. yield (%)
    II- 244
    Figure US20180305373A1-20181025-C01077
    Figure US20180305373A1-20181025-C01078
         		Me
    Figure US20180305373A1-20181025-C01079
    Figure US20180305373A1-20181025-C01080
         		Ethyl VI-74 V-3 II-1 n.d.
    II- 245
    Figure US20180305373A1-20181025-C01081
    Figure US20180305373A1-20181025-C01082
         		Me
    Figure US20180305373A1-20181025-C01083
    Figure US20180305373A1-20181025-C01084
         		Ethyl VI-74 V-5 II-1 n.d.
    II- 246
    Figure US20180305373A1-20181025-C01085
    Figure US20180305373A1-20181025-C01086
         		H
    Figure US20180305373A1-20181025-C01087
    Figure US20180305373A1-20181025-C01088
         		Ethyl VI-4 V-17 II-1 79
    II- 247
    Figure US20180305373A1-20181025-C01089
    Figure US20180305373A1-20181025-C01090
         		H
    Figure US20180305373A1-20181025-C01091
    Figure US20180305373A1-20181025-C01092
         		Ethyl VI-55 V-17 II-1 77
    II- 248
    Figure US20180305373A1-20181025-C01093
    Figure US20180305373A1-20181025-C01094
         		H
    Figure US20180305373A1-20181025-C01095
    Figure US20180305373A1-20181025-C01096
         		Ethyl VI-4 V-18 II-1 88
    II- 249
    Figure US20180305373A1-20181025-C01097
    Figure US20180305373A1-20181025-C01098
         		H
    Figure US20180305373A1-20181025-C01099
    Figure US20180305373A1-20181025-C01100
         		Ethyl VI-55 V-18 II-1 72
    II- 250
    Figure US20180305373A1-20181025-C01101
    Figure US20180305373A1-20181025-C01102
         		H
    Figure US20180305373A1-20181025-C01103
    Figure US20180305373A1-20181025-C01104
         		Ethyl VI-4 V-19 II-1 90
    II- 251
    Figure US20180305373A1-20181025-C01105
    Figure US20180305373A1-20181025-C01106
         		H
    Figure US20180305373A1-20181025-C01107
    Figure US20180305373A1-20181025-C01108
         		Ethyl VI-55 V-1 II-1 62
    II- 252
    Figure US20180305373A1-20181025-C01109
    Figure US20180305373A1-20181025-C01110
         		H
    Figure US20180305373A1-20181025-C01111
    Figure US20180305373A1-20181025-C01112
         		Ethyl VI-55 V-19 II-1 37
  • TABLE XIII-24
    Ex- am- ple No. R1 R2 R3
    Figure US20180305373A1-20181025-C01113
    Figure US20180305373A1-20181025-C01114
         		R Int_1 Int_2 syn. yield (%)
    II-253
    Figure US20180305373A1-20181025-C01115
    Figure US20180305373A1-20181025-C01116
         		H
    Figure US20180305373A1-20181025-C01117
    Figure US20180305373A1-20181025-C01118
         		Ethyl VI-4 V-23 II-1 25
    II-254
    Figure US20180305373A1-20181025-C01119
    Figure US20180305373A1-20181025-C01120
         		H
    Figure US20180305373A1-20181025-C01121
    Figure US20180305373A1-20181025-C01122
         		Ethyl VI-4 V-21 II-1 11
    II-255
    Figure US20180305373A1-20181025-C01123
    Figure US20180305373A1-20181025-C01124
         		H
    Figure US20180305373A1-20181025-C01125
    Figure US20180305373A1-20181025-C01126
         		Ethyl VI-4 V-22 II-1 42
    II-256
    Figure US20180305373A1-20181025-C01127
    Figure US20180305373A1-20181025-C01128
         		H
    Figure US20180305373A1-20181025-C01129
    Figure US20180305373A1-20181025-C01130
         		Ethyl VI-56 V-1 II-1 18
    II-257
    Figure US20180305373A1-20181025-C01131
    Figure US20180305373A1-20181025-C01132
         		H
    Figure US20180305373A1-20181025-C01133
    Figure US20180305373A1-20181025-C01134
         		Ethyl VI-57 V-1 II-1 22
    II-258
    Figure US20180305373A1-20181025-C01135
    Figure US20180305373A1-20181025-C01136
         		H
    Figure US20180305373A1-20181025-C01137
    Figure US20180305373A1-20181025-C01138
         		Ethyl VI-58 V-1 II-1 20
    II-259
    Figure US20180305373A1-20181025-C01139
    Figure US20180305373A1-20181025-C01140
         		H
    Figure US20180305373A1-20181025-C01141
    Figure US20180305373A1-20181025-C01142
         		Ethyl VI-59 V-1 II-1 31
    II-260
    Figure US20180305373A1-20181025-C01143
    Figure US20180305373A1-20181025-C01144
         		H
    Figure US20180305373A1-20181025-C01145
    Figure US20180305373A1-20181025-C01146
         		Ethyl VI-4 V-20 II-1 76
    II-261
    Figure US20180305373A1-20181025-C01147
    Figure US20180305373A1-20181025-C01148
         		H
    Figure US20180305373A1-20181025-C01149
    Figure US20180305373A1-20181025-C01150
         		Ethyl VI-6 V-23 II-1 22
  • TABLE XIII-25
    Ex- am- ple No. R1 R2 R3
    Figure US20180305373A1-20181025-C01151
    Figure US20180305373A1-20181025-C01152
         		R Int_1 Int_2 syn. yield (%)
    II- 262
    Figure US20180305373A1-20181025-C01153
    Figure US20180305373A1-20181025-C01154
         		H
    Figure US20180305373A1-20181025-C01155
    Figure US20180305373A1-20181025-C01156
         		Ethyl VII-1 IV-2 II-2 36
    II- 263
    Figure US20180305373A1-20181025-C01157
    Figure US20180305373A1-20181025-C01158
         		H
    Figure US20180305373A1-20181025-C01159
    Figure US20180305373A1-20181025-C01160
         		Ethyl VII-1 IV- 12 II-2 26
    II- 264
    Figure US20180305373A1-20181025-C01161
    Figure US20180305373A1-20181025-C01162
         		H
    Figure US20180305373A1-20181025-C01163
    Figure US20180305373A1-20181025-C01164
         		Ethyl VII-2 IV-2 II-2 56
    II- 265
    Figure US20180305373A1-20181025-C01165
    Figure US20180305373A1-20181025-C01166
         		H
    Figure US20180305373A1-20181025-C01167
    Figure US20180305373A1-20181025-C01168
         		Ethyl VII-2 IV-3 II-2 77
    II- 266
    Figure US20180305373A1-20181025-C01169
    Figure US20180305373A1-20181025-C01170
         		H
    Figure US20180305373A1-20181025-C01171
    Figure US20180305373A1-20181025-C01172
         		Ethyl VII-2 IV- 12 II-2 62
    II- 267
    Figure US20180305373A1-20181025-C01173
    Figure US20180305373A1-20181025-C01174
         		H
    Figure US20180305373A1-20181025-C01175
    Figure US20180305373A1-20181025-C01176
         		Ethyl VII-3 IV-2 II-2 71
    II- 268
    Figure US20180305373A1-20181025-C01177
    Figure US20180305373A1-20181025-C01178
         		H
    Figure US20180305373A1-20181025-C01179
    Figure US20180305373A1-20181025-C01180
         		Ethyl VII-4 IV-2 II-2 46
    • [Example I-1] (Syn. I-1) Synthesis of (8S)—N, 6-dibenzyl-8-methyl-7,10-dioxo-4a,5,6,7,8,10-hexahydro-4H-pyradino[1,2-a]thieno[3,2-d]pyrimidine-4-carboxamide (Compound I-1)
  • To (S)—N-(1-(benzyl(2,2-diethoxyethyl)amino)-1-oxopropan-2-yl)-3-(3-benzylureido)thiophene-2-carboxamide (Compound II-1) 44.7 mg (0.08 mmol), formic acid 2 ml was added and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo and the residue was purified with PTLC (development solvent chloroform:methanol=95:5) to obtain the titled compound 28 mg (76%).
    • [Example 1-268] (Syn. I-2) Synthesis of (2S)—N-benzyl-2-(4-hydroxybenzyl)-1-methyl-4-(naphthalen-1-ylmethyl)-3,9-dioxooctahydropyrimido[1,2-b][1,2,5]triazepine-6(7H)-carboxamide (Compound I-268)
  • (2S)—N-benzyl-2-(4-(benzyloxy)benzyl)-1-methyl-4-(naphthalen-1-ylmethyl)-3,9-dioxooctahydropyrimido[1,2-b][1,2,5]triazepine-6(7H)-carboxamide (Compound 1-267) 33 mg (0.05 mmol) was dissolved in 25% HBr acetic acid solution 0.2 ml and the mixture was stirred at room temperature for 5 hr. Ether 1.2 ml and n-hexane 0.8 ml were added to the reaction mixture and the mixture was concentrated in vacuo. The precipitation was purified on silica gel column chromatography (chloroform:methanol=100:0 to 95:5) to obtain the title compound 7.3 mg (yield 25%).
  • Typical examples of the compound I of the present invention that can be given by reacting and treating corresponding starting compounds using any of the methods described in the present specification are shown in Tables XIV-1 to XIV-25. The compounds were prepared according to the preparation methods of the compound numbers (e.g., “I-1”) shown in the columns of “Syn” in the Tables. “Int” means an intermediate compound number. In the Tables mentioned below, data indicated by “RT” mean data of liquid chromatography retention time. In the columns of “Mass”, data of mass spectrometry were shown. In the columns of “method”, elution conditions of the liquid chromatography are described. For the indication of retention time in the liquid chromatography, the indication “A” for elution condition means that measurement was performed by elution with a linear gradient of 5 to 100% (v/v) Solution B from 0 minute to 5 minutes and then with 100% Solution B until 6 minutes.
  • Figure US20180305373A1-20181025-C01181
  • TABLE XIV-1
    Ex- am- ple No. R1 R2 R3
    Figure US20180305373A1-20181025-C01182
    Figure US20180305373A1-20181025-C01183
         		Syn. Int me- thod RT Mass
    I-2
    Figure US20180305373A1-20181025-C01184
    Figure US20180305373A1-20181025-C01185
         		H
    Figure US20180305373A1-20181025-C01186
    Figure US20180305373A1-20181025-C01187
         		I-1 II-2 A 4.61 553
    I-3
    Figure US20180305373A1-20181025-C01188
    Figure US20180305373A1-20181025-C01189
         		H
    Figure US20180305373A1-20181025-C01190
    Figure US20180305373A1-20181025-C01191
         		I-1 II-3 A 3.24 518
    I-4
    Figure US20180305373A1-20181025-C01192
    Figure US20180305373A1-20181025-C01193
         		H
    Figure US20180305373A1-20181025-C01194
    Figure US20180305373A1-20181025-C01195
         		I-1 II-4 A 5 603
    I-5
    Figure US20180305373A1-20181025-C01196
    Figure US20180305373A1-20181025-C01197
         		H
    Figure US20180305373A1-20181025-C01198
    Figure US20180305373A1-20181025-C01199
         		I-1 II-5 A 4.67 555
    I-6
    Figure US20180305373A1-20181025-C01200
    Figure US20180305373A1-20181025-C01201
         		H
    Figure US20180305373A1-20181025-C01202
    Figure US20180305373A1-20181025-C01203
         		I-1 II-6 A 4.31 604
    I-7
    Figure US20180305373A1-20181025-C01204
    Figure US20180305373A1-20181025-C01205
         		H
    Figure US20180305373A1-20181025-C01206
    Figure US20180305373A1-20181025-C01207
         		I-1 II-7 A 3.85 555
    I-8
    Figure US20180305373A1-20181025-C01208
    Figure US20180305373A1-20181025-C01209
         		H
    Figure US20180305373A1-20181025-C01210
    Figure US20180305373A1-20181025-C01211
         		I-1 II-8 A 4.95 517
    I-9
    Figure US20180305373A1-20181025-C01212
    Figure US20180305373A1-20181025-C01213
         		H
    Figure US20180305373A1-20181025-C01214
    Figure US20180305373A1-20181025-C01215
         		I-1 II-9 A 4.98 609
    I-10
    Figure US20180305373A1-20181025-C01216
    Figure US20180305373A1-20181025-C01217
         		H
    Figure US20180305373A1-20181025-C01218
    Figure US20180305373A1-20181025-C01219
         		I-1 II-10 A 2.94 554
    I-11
    Figure US20180305373A1-20181025-C01220
    Figure US20180305373A1-20181025-C01221
         		H
    Figure US20180305373A1-20181025-C01222
    Figure US20180305373A1-20181025-C01223
         		I-1 II-11 A 4.95 587
    I-12
    Figure US20180305373A1-20181025-C01224
    Figure US20180305373A1-20181025-C01225
         		H
    Figure US20180305373A1-20181025-C01226
    Figure US20180305373A1-20181025-C01227
         		I-1 II-12 A 5 603
  • TABLE XIV-2
    Ex- am- ple No. R1 R2 R3
    Figure US20180305373A1-20181025-C01228
    Figure US20180305373A1-20181025-C01229
         		Syn. Int me- thod RT Mass
    I-13
    Figure US20180305373A1-20181025-C01230
    Figure US20180305373A1-20181025-C01231
         		H
    Figure US20180305373A1-20181025-C01232
    Figure US20180305373A1-20181025-C01233
         		I-1 II-13 A 4.13 491
    I-14
    Figure US20180305373A1-20181025-C01234
    Figure US20180305373A1-20181025-C01235
         		H
    Figure US20180305373A1-20181025-C01236
    Figure US20180305373A1-20181025-C01237
         		I-1 II-14 A 3.32 604
    I-15
    Figure US20180305373A1-20181025-C01238
    Figure US20180305373A1-20181025-C01239
         		H
    Figure US20180305373A1-20181025-C01240
    Figure US20180305373A1-20181025-C01241
         		I-1 II-15 A 5.3 637
    I-16
    Figure US20180305373A1-20181025-C01242
    Figure US20180305373A1-20181025-C01243
         		H
    Figure US20180305373A1-20181025-C01244
    Figure US20180305373A1-20181025-C01245
         		I-1 II-16 A 5.42 653
    I-17
    Figure US20180305373A1-20181025-C01246
    Figure US20180305373A1-20181025-C01247
         		H
    Figure US20180305373A1-20181025-C01248
    Figure US20180305373A1-20181025-C01249
         		I-1 II-17 A 4.57 541
    I-18
    Figure US20180305373A1-20181025-C01250
    Figure US20180305373A1-20181025-C01251
         		H
    Figure US20180305373A1-20181025-C01252
    Figure US20180305373A1-20181025-C01253
         		I-1 II-18 A 2.75 605
    I-19
    Figure US20180305373A1-20181025-C01254
    Figure US20180305373A1-20181025-C01255
         		H
    Figure US20180305373A1-20181025-C01256
    Figure US20180305373A1-20181025-C01257
         		I-1 II-19 A 4.61 638
    I-20
    Figure US20180305373A1-20181025-C01258
    Figure US20180305373A1-20181025-C01259
         		H
    Figure US20180305373A1-20181025-C01260
    Figure US20180305373A1-20181025-C01261
         		I-1 II-20 A 4.77 654
    I-21
    Figure US20180305373A1-20181025-C01262
    Figure US20180305373A1-20181025-C01263
         		H
    Figure US20180305373A1-20181025-C01264
    Figure US20180305373A1-20181025-C01265
         		I-1 II-21 A 3.68 542
    I-22
    Figure US20180305373A1-20181025-C01266
    Figure US20180305373A1-20181025-C01267
         		H
    Figure US20180305373A1-20181025-C01268
    Figure US20180305373A1-20181025-C01269
         		I-1 II-22 A 3.28 610
    I-23
    Figure US20180305373A1-20181025-C01270
    Figure US20180305373A1-20181025-C01271
         		H
    Figure US20180305373A1-20181025-C01272
    Figure US20180305373A1-20181025-C01273
         		I-1 II-23 A 5.26 643
  • TABLE XIV-3
    Ex- am- ple No. R1 R2 R3
    Figure US20180305373A1-20181025-C01274
    Figure US20180305373A1-20181025-C01275
         		Syn. Int me- thod RT Mass
    I-24
    Figure US20180305373A1-20181025-C01276
    Figure US20180305373A1-20181025-C01277
         		H
    Figure US20180305373A1-20181025-C01278
    Figure US20180305373A1-20181025-C01279
         		I-1 II-24 A 5.36 659
    I-25
    Figure US20180305373A1-20181025-C01280
    Figure US20180305373A1-20181025-C01281
         		H
    Figure US20180305373A1-20181025-C01282
    Figure US20180305373A1-20181025-C01283
         		I-1 II-25 A 4.53 547
    I-26
    Figure US20180305373A1-20181025-C01284
    Figure US20180305373A1-20181025-C01285
         		H
    Figure US20180305373A1-20181025-C01286
    Figure US20180305373A1-20181025-C01287
         		I-1 II-26 A 5.18 491
    I-27
    Figure US20180305373A1-20181025-C01288
    Figure US20180305373A1-20181025-C01289
         		H
    Figure US20180305373A1-20181025-C01290
    Figure US20180305373A1-20181025-C01291
         		I-1 II-27 A 4.77 533
    I-28
    Figure US20180305373A1-20181025-C01292
    Figure US20180305373A1-20181025-C01293
         		H
    Figure US20180305373A1-20181025-C01294
    Figure US20180305373A1-20181025-C01295
         		I-1 II-28 A 3 534
    I-29
    Figure US20180305373A1-20181025-C01296
    Figure US20180305373A1-20181025-C01297
         		H
    Figure US20180305373A1-20181025-C01298
    Figure US20180305373A1-20181025-C01299
         		I-1 II-29 A 4.95 547
    I-30
    Figure US20180305373A1-20181025-C01300
    Figure US20180305373A1-20181025-C01301
         		H
    Figure US20180305373A1-20181025-C01302
    Figure US20180305373A1-20181025-C01303
         		I-1 II-30 A 5.17 583
    I-31
    Figure US20180305373A1-20181025-C01304
    Figure US20180305373A1-20181025-C01305
         		H
    Figure US20180305373A1-20181025-C01306
    Figure US20180305373A1-20181025-C01307
         		I-1 II-31 A 5.47 637
    I-32
    Figure US20180305373A1-20181025-C01308
    Figure US20180305373A1-20181025-C01309
         		H
    Figure US20180305373A1-20181025-C01310
    Figure US20180305373A1-20181025-C01311
         		I-1 II-32 A 5.27 539
    I-33
    Figure US20180305373A1-20181025-C01312
    Figure US20180305373A1-20181025-C01313
         		H
    Figure US20180305373A1-20181025-C01314
    Figure US20180305373A1-20181025-C01315
         		I-1 II-33 A 4.5 485
    I-34
    Figure US20180305373A1-20181025-C01316
    Figure US20180305373A1-20181025-C01317
         		H
    Figure US20180305373A1-20181025-C01318
    Figure US20180305373A1-20181025-C01319
         		I-1 II-34 A 3.6 548
  • TABLE XIV-4
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C01320
    Figure US20180305373A1-20181025-C01321
         		Syn. Int method RT Mass
    I-35
    Figure US20180305373A1-20181025-C01322
    Figure US20180305373A1-20181025-C01323
         		H
    Figure US20180305373A1-20181025-C01324
    Figure US20180305373A1-20181025-C01325
         		I-1 II-35 A 4.87 535
    I-36
    Figure US20180305373A1-20181025-C01326
    Figure US20180305373A1-20181025-C01327
         		H
    Figure US20180305373A1-20181025-C01328
    Figure US20180305373A1-20181025-C01329
         		I-1 II-36 A 4.67 534
    I-37
    Figure US20180305373A1-20181025-C01330
    Figure US20180305373A1-20181025-C01331
         		H
    Figure US20180305373A1-20181025-C01332
    Figure US20180305373A1-20181025-C01333
         		I-1 II-37 A 4.87 507
    I-38
    Figure US20180305373A1-20181025-C01334
    Figure US20180305373A1-20181025-C01335
         		H
    Figure US20180305373A1-20181025-C01336
    Figure US20180305373A1-20181025-C01337
         		I-1 II-38 A 5.67 533
    I-39
    Figure US20180305373A1-20181025-C01338
    Figure US20180305373A1-20181025-C01339
         		H
    Figure US20180305373A1-20181025-C01340
    Figure US20180305373A1-20181025-C01341
         		I-1 II-39 A 5.62 553
    I-40
    Figure US20180305373A1-20181025-C01342
    Figure US20180305373A1-20181025-C01343
         		H
    Figure US20180305373A1-20181025-C01344
    Figure US20180305373A1-20181025-C01345
         		I-1 II-40 A 5.65 567
    I-41
    Figure US20180305373A1-20181025-C01346
    Figure US20180305373A1-20181025-C01347
         		H
    Figure US20180305373A1-20181025-C01348
    Figure US20180305373A1-20181025-C01349
         		I-1 II-41 A 5.8 581
    I-42
    Figure US20180305373A1-20181025-C01350
    Figure US20180305373A1-20181025-C01351
         		H
    Figure US20180305373A1-20181025-C01352
    Figure US20180305373A1-20181025-C01353
         		I-1 II-42 A 5.78 597
    I-43
    Figure US20180305373A1-20181025-C01354
    Figure US20180305373A1-20181025-C01355
         		H
    Figure US20180305373A1-20181025-C01356
    Figure US20180305373A1-20181025-C01357
         		I-1 II-43 A 5.93 651
    I-44
    Figure US20180305373A1-20181025-C01358
    Figure US20180305373A1-20181025-C01359
         		H
    Figure US20180305373A1-20181025-C01360
    Figure US20180305373A1-20181025-C01361
         		I-1 II-44 A 5.88 553
    I-45
    Figure US20180305373A1-20181025-C01362
    Figure US20180305373A1-20181025-C01363
         		H
    Figure US20180305373A1-20181025-C01364
    Figure US20180305373A1-20181025-C01365
         		I-1 II-45 A 5.15 499
  • TABLE XIV-5
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C01366
    Figure US20180305373A1-20181025-C01367
         		Syn. Int method RT Mass
    I-46
    Figure US20180305373A1-20181025-C01368
    Figure US20180305373A1-20181025-C01369
         		H
    Figure US20180305373A1-20181025-C01370
    Figure US20180305373A1-20181025-C01371
         		I-1 II-46 A 6 617
    I-47
    Figure US20180305373A1-20181025-C01372
    Figure US20180305373A1-20181025-C01373
         		H
    Figure US20180305373A1-20181025-C01374
    Figure US20180305373A1-20181025-C01375
         		I-1 II-47 A 5.6 567
    I-48
    Figure US20180305373A1-20181025-C01376
    Figure US20180305373A1-20181025-C01377
         		H
    Figure US20180305373A1-20181025-C01378
    Figure US20180305373A1-20181025-C01379
         		I-1 II-48 A 3.82 568
    I-49
    Figure US20180305373A1-20181025-C01380
    Figure US20180305373A1-20181025-C01381
         		H
    Figure US20180305373A1-20181025-C01382
    Figure US20180305373A1-20181025-C01383
         		I-1 II-49 A 5.75 581
    I-50
    Figure US20180305373A1-20181025-C01384
    Figure US20180305373A1-20181025-C01385
         		H
    Figure US20180305373A1-20181025-C01386
    Figure US20180305373A1-20181025-C01387
         		I-1 II-50 A 5.98 617
    I-51
    Figure US20180305373A1-20181025-C01388
    Figure US20180305373A1-20181025-C01389
         		H
    Figure US20180305373A1-20181025-C01390
    Figure US20180305373A1-20181025-C01391
         		I-1 II-51 A 3.43 395
    I-52
    Figure US20180305373A1-20181025-C01392
    Figure US20180305373A1-20181025-C01393
         		H
    Figure US20180305373A1-20181025-C01394
    Figure US20180305373A1-20181025-C01395
         		I-1 II-52 A 3.58 423
    I-53
    Figure US20180305373A1-20181025-C01396
    Figure US20180305373A1-20181025-C01397
         		H
    Figure US20180305373A1-20181025-C01398
    Figure US20180305373A1-20181025-C01399
         		I-1 II-53 A 4.03 437
    I-54
    Figure US20180305373A1-20181025-C01400
    Figure US20180305373A1-20181025-C01401
         		H
    Figure US20180305373A1-20181025-C01402
    Figure US20180305373A1-20181025-C01403
         		I-1 II-54 A 4.62 485
    I-55
    Figure US20180305373A1-20181025-C01404
    Figure US20180305373A1-20181025-C01405
         		H
    Figure US20180305373A1-20181025-C01406
    Figure US20180305373A1-20181025-C01407
         		I-1 II-55 A 4.62 447
    I-56
    Figure US20180305373A1-20181025-C01408
    Figure US20180305373A1-20181025-C01409
         		H
    Figure US20180305373A1-20181025-C01410
    Figure US20180305373A1-20181025-C01411
         		I-1 II-56 A 4.75 539
  • TABLE XIV-6
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C01412
    Figure US20180305373A1-20181025-C01413
         		Syn. Int method RT Mass
    I-57
    Figure US20180305373A1-20181025-C01414
    Figure US20180305373A1-20181025-C01415
         		H
    Figure US20180305373A1-20181025-C01416
    Figure US20180305373A1-20181025-C01417
         		I-1 II-57 A 4.97 547
    I-58
    Figure US20180305373A1-20181025-C01418
    Figure US20180305373A1-20181025-C01419
         		H
    Figure US20180305373A1-20181025-C01420
    Figure US20180305373A1-20181025-C01421
         		I-1 II-58 A 3.27 504
    I-59
    Figure US20180305373A1-20181025-C01422
    Figure US20180305373A1-20181025-C01423
         		H
    Figure US20180305373A1-20181025-C01424
    Figure US20180305373A1-20181025-C01425
         		I-1 II-59 A 4.4 491
    I-60
    Figure US20180305373A1-20181025-C01426
    Figure US20180305373A1-20181025-C01427
         		H
    Figure US20180305373A1-20181025-C01428
    Figure US20180305373A1-20181025-C01429
         		I-1 II-60 A 4.12 490
    I-61
    Figure US20180305373A1-20181025-C01430
    Figure US20180305373A1-20181025-C01431
         		H
    Figure US20180305373A1-20181025-C01432
    Figure US20180305373A1-20181025-C01433
         		I-1 II-61 A 4.32 463
    I-62
    Figure US20180305373A1-20181025-C01434
    Figure US20180305373A1-20181025-C01435
         		H
    Figure US20180305373A1-20181025-C01436
    Figure US20180305373A1-20181025-C01437
         		I-1 II-62 A 5.15 489
    I-63
    Figure US20180305373A1-20181025-C01438
    Figure US20180305373A1-20181025-C01439
         		H
    Figure US20180305373A1-20181025-C01440
    Figure US20180305373A1-20181025-C01441
         		I-1 II-63 A 5.13 509
    I-64
    Figure US20180305373A1-20181025-C01442
    Figure US20180305373A1-20181025-C01443
         		H
    Figure US20180305373A1-20181025-C01444
    Figure US20180305373A1-20181025-C01445
         		I-1 II-64 A 4.03 471
    I-65
    Figure US20180305373A1-20181025-C01446
    Figure US20180305373A1-20181025-C01447
         		H
    Figure US20180305373A1-20181025-C01448
    Figure US20180305373A1-20181025-C01449
         		I-1 II-65 A 4.13 499
    I-66
    Figure US20180305373A1-20181025-C01450
    Figure US20180305373A1-20181025-C01451
         		H
    Figure US20180305373A1-20181025-C01452
    Figure US20180305373A1-20181025-C01453
         		I-1 II-66 A 4.63 513
    I-67
    Figure US20180305373A1-20181025-C01454
    Figure US20180305373A1-20181025-C01455
         		H
    Figure US20180305373A1-20181025-C01456
    Figure US20180305373A1-20181025-C01457
         		I-1 II-67 A 5.25 535
  • TABLE XIV-7
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C01458
    Figure US20180305373A1-20181025-C01459
         		Syn. Int method RT Mass
    I-68
    Figure US20180305373A1-20181025-C01460
    Figure US20180305373A1-20181025-C01461
         		H
    Figure US20180305373A1-20181025-C01462
    Figure US20180305373A1-20181025-C01463
         		I-1 II-68 A 5.13 523
    I-69
    Figure US20180305373A1-20181025-C01464
    Figure US20180305373A1-20181025-C01465
         		H
    Figure US20180305373A1-20181025-C01466
    Figure US20180305373A1-20181025-C01467
         		I-1 II-69 A 5.62 585
    I-70
    Figure US20180305373A1-20181025-C01468
    Figure US20180305373A1-20181025-C01469
         		H
    Figure US20180305373A1-20181025-C01470
    Figure US20180305373A1-20181025-C01471
         		I-1 II-70 A 5.52 611
    I-71
    Figure US20180305373A1-20181025-C01472
    Figure US20180305373A1-20181025-C01473
         		H
    Figure US20180305373A1-20181025-C01474
    Figure US20180305373A1-20181025-C01475
         		I-1 II-71 A 5.53 573
    I-72
    Figure US20180305373A1-20181025-C01476
    Figure US20180305373A1-20181025-C01477
         		H
    Figure US20180305373A1-20181025-C01478
    Figure US20180305373A1-20181025-C01479
         		I-1 II-72 A 5.83 581
    I-73
    Figure US20180305373A1-20181025-C01480
    Figure US20180305373A1-20181025-C01481
         		H
    Figure US20180305373A1-20181025-C01482
    Figure US20180305373A1-20181025-C01483
         		I-1 II-73 A 4.78 489
    I-74
    Figure US20180305373A1-20181025-C01484
    Figure US20180305373A1-20181025-C01485
         		H
    Figure US20180305373A1-20181025-C01486
    Figure US20180305373A1-20181025-C01487
         		I-1 II-74 A 5.1 525
    I-75
    Figure US20180305373A1-20181025-C01488
    Figure US20180305373A1-20181025-C01489
         		H
    Figure US20180305373A1-20181025-C01490
    Figure US20180305373A1-20181025-C01491
         		I-1 II-75 A 5.37 579
    I-76
    Figure US20180305373A1-20181025-C01492
    Figure US20180305373A1-20181025-C01493
         		H
    Figure US20180305373A1-20181025-C01494
    Figure US20180305373A1-20181025-C01495
         		I-1 II-76 A 5.15 481
    I-77
    Figure US20180305373A1-20181025-C01496
    Figure US20180305373A1-20181025-C01497
         		H
    Figure US20180305373A1-20181025-C01498
    Figure US20180305373A1-20181025-C01499
         		I-1 II-77 A 4.28 427
    I-78
    Figure US20180305373A1-20181025-C01500
    Figure US20180305373A1-20181025-C01501
         		H
    Figure US20180305373A1-20181025-C01502
    Figure US20180305373A1-20181025-C01503
         		I-1 II-78 A 4.67 567
  • TABLE XIV-8
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C01504
    Figure US20180305373A1-20181025-C01505
         		Syn. Int method RT Mass
    I-79
    Figure US20180305373A1-20181025-C01506
    Figure US20180305373A1-20181025-C01507
         		H
    Figure US20180305373A1-20181025-C01508
    Figure US20180305373A1-20181025-C01509
         		I-1 II-79 A 4.83 581
    I-80
    Figure US20180305373A1-20181025-C01510
    Figure US20180305373A1-20181025-C01511
         		H
    Figure US20180305373A1-20181025-C01512
    Figure US20180305373A1-20181025-C01513
         		I-1 II-80 A 5.08 617
    I-81
    Figure US20180305373A1-20181025-C01514
    Figure US20180305373A1-20181025-C01515
         		H
    Figure US20180305373A1-20181025-C01516
    Figure US20180305373A1-20181025-C01517
         		I-1 II-81 A 5.37 671
    I-82
    Figure US20180305373A1-20181025-C01518
    Figure US20180305373A1-20181025-C01519
         		H
    Figure US20180305373A1-20181025-C01520
    Figure US20180305373A1-20181025-C01521
         		I-1 II-82 A 5.13 573
    I-83
    Figure US20180305373A1-20181025-C01522
    Figure US20180305373A1-20181025-C01523
         		H
    Figure US20180305373A1-20181025-C01524
    Figure US20180305373A1-20181025-C01525
         		I-1 II-83 A 4.4 519
    I-84
    Figure US20180305373A1-20181025-C01526
    Figure US20180305373A1-20181025-C01527
         		H
    Figure US20180305373A1-20181025-C01528
    Figure US20180305373A1-20181025-C01529
         		I-1 II-84 A 3.9 546
    I-85
    Figure US20180305373A1-20181025-C01530
    Figure US20180305373A1-20181025-C01531
         		H
    Figure US20180305373A1-20181025-C01532
    Figure US20180305373A1-20181025-C01533
         		I-1 II-85 A 4.33 519
    I-86
    Figure US20180305373A1-20181025-C01534
    Figure US20180305373A1-20181025-C01535
         		H
    Figure US20180305373A1-20181025-C01536
    Figure US20180305373A1-20181025-C01537
         		I-1 II-86 A 4.48 533
    I-87
    Figure US20180305373A1-20181025-C01538
    Figure US20180305373A1-20181025-C01539
         		H
    Figure US20180305373A1-20181025-C01540
    Figure US20180305373A1-20181025-C01541
         		I-1 II-87 A 4.47 505
    I-88
    Figure US20180305373A1-20181025-C01542
    Figure US20180305373A1-20181025-C01543
         		H
    Figure US20180305373A1-20181025-C01544
    Figure US20180305373A1-20181025-C01545
         		I-1 II-88 A 5.32 531
    I-89
    Figure US20180305373A1-20181025-C01546
    Figure US20180305373A1-20181025-C01547
         		H
    Figure US20180305373A1-20181025-C01548
    Figure US20180305373A1-20181025-C01549
         		I-1 II-89 A 5.28 565
  • TABLE XIV-9
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C01550
    Figure US20180305373A1-20181025-C01551
         		Syn. Int method RT Mass
    I-90
    Figure US20180305373A1-20181025-C01552
    Figure US20180305373A1-20181025-C01553
         		H
    Figure US20180305373A1-20181025-C01554
    Figure US20180305373A1-20181025-C01555
         		I-1 II-90 A 5.43 579
    I-91
    Figure US20180305373A1-20181025-C01556
    Figure US20180305373A1-20181025-C01557
         		H
    Figure US20180305373A1-20181025-C01558
    Figure US20180305373A1-20181025-C01559
         		I-1 II-91 A 3.4 429
    I-92
    Figure US20180305373A1-20181025-C01560
    Figure US20180305373A1-20181025-C01561
         		H
    Figure US20180305373A1-20181025-C01562
    Figure US20180305373A1-20181025-C01563
         		I-1 II-92 A 3.53 457
    I-93
    Figure US20180305373A1-20181025-C01564
    Figure US20180305373A1-20181025-C01565
         		H
    Figure US20180305373A1-20181025-C01566
    Figure US20180305373A1-20181025-C01567
         		I-1 II-93 A 3.95 471
    I-94
    Figure US20180305373A1-20181025-C01568
    Figure US20180305373A1-20181025-C01569
         		H
    Figure US20180305373A1-20181025-C01570
    Figure US20180305373A1-20181025-C01571
         		I-1 II-94 A 3.65 521
    I-95
    Figure US20180305373A1-20181025-C01572
    Figure US20180305373A1-20181025-C01573
         		H
    Figure US20180305373A1-20181025-C01574
    Figure US20180305373A1-20181025-C01575
         		I-1 II-95 A 3.75 549
    I-96
    Figure US20180305373A1-20181025-C01576
    Figure US20180305373A1-20181025-C01577
         		H
    Figure US20180305373A1-20181025-C01578
    Figure US20180305373A1-20181025-C01579
         		I-1 II-96 A 4.13 563
    I-97
    Figure US20180305373A1-20181025-C01580
    Figure US20180305373A1-20181025-C01581
         		H
    Figure US20180305373A1-20181025-C01582
    Figure US20180305373A1-20181025-C01583
         		I-1 II-97 A 4.75 585
    I-98
    Figure US20180305373A1-20181025-C01584
    Figure US20180305373A1-20181025-C01585
         		H
    Figure US20180305373A1-20181025-C01586
    Figure US20180305373A1-20181025-C01587
         		I-1 II-98 A 4.62 611
    I-99
    Figure US20180305373A1-20181025-C01588
    Figure US20180305373A1-20181025-C01589
         		H
    Figure US20180305373A1-20181025-C01590
    Figure US20180305373A1-20181025-C01591
         		I-1 II-99 A 4.6 573
    I-100
    Figure US20180305373A1-20181025-C01592
    Figure US20180305373A1-20181025-C01593
         		H
    Figure US20180305373A1-20181025-C01594
    Figure US20180305373A1-20181025-C01595
         		I-1 II-100 A 4.88 581
  • TABLE XIV-10
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C01596
    Figure US20180305373A1-20181025-C01597
         		Syn. Int method RT Mass
    I-101
    Figure US20180305373A1-20181025-C01598
    Figure US20180305373A1-20181025-C01599
         		H
    Figure US20180305373A1-20181025-C01600
    Figure US20180305373A1-20181025-C01601
         		I-1 II-101 A 3.82 550
    I-102
    Figure US20180305373A1-20181025-C01602
    Figure US20180305373A1-20181025-C01603
         		H
    Figure US20180305373A1-20181025-C01604
    Figure US20180305373A1-20181025-C01605
         		I-1 II-102 A 3.7 538
    I-103
    Figure US20180305373A1-20181025-C01606
    Figure US20180305373A1-20181025-C01607
         		H
    Figure US20180305373A1-20181025-C01608
    Figure US20180305373A1-20181025-C01609
         		I-1 II-103 A 4.43 537
    I-104
    Figure US20180305373A1-20181025-C01610
    Figure US20180305373A1-20181025-C01611
         		H
    Figure US20180305373A1-20181025-C01612
    Figure US20180305373A1-20181025-C01613
         		I-1 II-104 A 4.25 525
    I-105
    Figure US20180305373A1-20181025-C01614
    Figure US20180305373A1-20181025-C01615
         		H
    Figure US20180305373A1-20181025-C01616
    Figure US20180305373A1-20181025-C01617
         		I-1 II-105 A 4.18 536
    I-106
    Figure US20180305373A1-20181025-C01618
    Figure US20180305373A1-20181025-C01619
         		H
    Figure US20180305373A1-20181025-C01620
    Figure US20180305373A1-20181025-C01621
         		I-1 II-106 A 4.05 524
    I-107
    Figure US20180305373A1-20181025-C01622
    Figure US20180305373A1-20181025-C01623
         		H
    Figure US20180305373A1-20181025-C01624
    Figure US20180305373A1-20181025-C01625
         		I-1 II-107 A 4.37 509
    I-108
    Figure US20180305373A1-20181025-C01626
    Figure US20180305373A1-20181025-C01627
         		H
    Figure US20180305373A1-20181025-C01628
    Figure US20180305373A1-20181025-C01629
         		I-1 II-108 A 4.23 497
    I-109
    Figure US20180305373A1-20181025-C01630
    Figure US20180305373A1-20181025-C01631
         		H
    Figure US20180305373A1-20181025-C01632
    Figure US20180305373A1-20181025-C01633
         		I-1 II-109 A 5.15 535
    I-110
    Figure US20180305373A1-20181025-C01634
    Figure US20180305373A1-20181025-C01635
         		H
    Figure US20180305373A1-20181025-C01636
    Figure US20180305373A1-20181025-C01637
         		I-1 II-110 A 5.05 523
    I-111
    Figure US20180305373A1-20181025-C01638
    Figure US20180305373A1-20181025-C01639
         		H
    Figure US20180305373A1-20181025-C01640
    Figure US20180305373A1-20181025-C01641
         		I-1 II-111 A 5.3 583
  • TABLE XIV-11
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C01642
    Figure US20180305373A1-20181025-C01643
         		Syn. Int me- thod RT Mass
    I-112
    Figure US20180305373A1-20181025-C01644
    Figure US20180305373A1-20181025-C01645
         		H
    Figure US20180305373A1-20181025-C01646
    Figure US20180305373A1-20181025-C01647
         		I-1 II-112 A 5.18 609
    I-113
    Figure US20180305373A1-20181025-C01648
    Figure US20180305373A1-20181025-C01649
         		H
    Figure US20180305373A1-20181025-C01650
    Figure US20180305373A1-20181025-C01651
         		I-1 II-113 A 5.27 571
    I-114
    Figure US20180305373A1-20181025-C01652
    Figure US20180305373A1-20181025-C01653
         		H
    Figure US20180305373A1-20181025-C01654
    Figure US20180305373A1-20181025-C01655
         		I-1 II-114 A 5.52 579
    I-115
    Figure US20180305373A1-20181025-C01656
    Figure US20180305373A1-20181025-C01657
         		H
    Figure US20180305373A1-20181025-C01658
    Figure US20180305373A1-20181025-C01659
         		I-1 II-115 A 5.98 601
    I-116
    Figure US20180305373A1-20181025-C01660
    Figure US20180305373A1-20181025-C01661
         		H
    Figure US20180305373A1-20181025-C01662
    Figure US20180305373A1-20181025-C01663
         		I-1 II-116 A 5.25 547
    I-117
    Figure US20180305373A1-20181025-C01664
    Figure US20180305373A1-20181025-C01665
         		H
    Figure US20180305373A1-20181025-C01666
    Figure US20180305373A1-20181025-C01667
         		I-1 II-117 A 6.2  621
    I-118
    Figure US20180305373A1-20181025-C01668
    Figure US20180305373A1-20181025-C01669
         		H
    Figure US20180305373A1-20181025-C01670
    Figure US20180305373A1-20181025-C01671
         		I-1 II-118 A 6.17 621
    I-119
    Figure US20180305373A1-20181025-C01672
    Figure US20180305373A1-20181025-C01673
         		H
    Figure US20180305373A1-20181025-C01674
    Figure US20180305373A1-20181025-C01675
         		I-1 II-119 A 5.25 657
    I-120
    Figure US20180305373A1-20181025-C01676
    Figure US20180305373A1-20181025-C01677
         		H
    Figure US20180305373A1-20181025-C01678
    Figure US20180305373A1-20181025-C01679
         		I-1 II-120 A 3.87 658
    I-121
    Figure US20180305373A1-20181025-C01680
    Figure US20180305373A1-20181025-C01681
         		H
    Figure US20180305373A1-20181025-C01682
    Figure US20180305373A1-20181025-C01683
         		I-1 II-121 A 5.4  671
    I-122
    Figure US20180305373A1-20181025-C01684
    Figure US20180305373A1-20181025-C01685
         		H
    Figure US20180305373A1-20181025-C01686
    Figure US20180305373A1-20181025-C01687
         		I-1 II-122 A 5.6  707
  • TABLE XIV-12
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C01688
    Figure US20180305373A1-20181025-C01689
         		Syn. Int me- thod RT Mass
    I-123
    Figure US20180305373A1-20181025-C01690
    Figure US20180305373A1-20181025-C01691
         		H
    Figure US20180305373A1-20181025-C01692
    Figure US20180305373A1-20181025-C01693
         		I-1 II-123 A 5.8  761
    I-124
    Figure US20180305373A1-20181025-C01694
    Figure US20180305373A1-20181025-C01695
         		H
    Figure US20180305373A1-20181025-C01696
    Figure US20180305373A1-20181025-C01697
         		I-1 II-124 A 5.68 663
    I-125
    Figure US20180305373A1-20181025-C01698
    Figure US20180305373A1-20181025-C01699
         		H
    Figure US20180305373A1-20181025-C01700
    Figure US20180305373A1-20181025-C01701
         		I-1 II-125 A 5.07 609
    I-126
    Figure US20180305373A1-20181025-C01702
    Figure US20180305373A1-20181025-C01703
         		H
    Figure US20180305373A1-20181025-C01704
    Figure US20180305373A1-20181025-C01705
         		I-1 II-126 A 4.27 622
    I-127
    Figure US20180305373A1-20181025-C01706
    Figure US20180305373A1-20181025-C01707
         		H
    Figure US20180305373A1-20181025-C01708
    Figure US20180305373A1-20181025-C01709
         		I-1 II-127 A 4.23 623
    I-128
    Figure US20180305373A1-20181025-C01710
    Figure US20180305373A1-20181025-C01711
         		H
    Figure US20180305373A1-20181025-C01712
    Figure US20180305373A1-20181025-C01713
         		I-1 II-128 A 4.4  636
    I-129
    Figure US20180305373A1-20181025-C01714
    Figure US20180305373A1-20181025-C01715
         		H
    Figure US20180305373A1-20181025-C01716
    Figure US20180305373A1-20181025-C01717
         		I-1 II-129 A 4.53 672
    I-130
    Figure US20180305373A1-20181025-C01718
    Figure US20180305373A1-20181025-C01719
         		H
    Figure US20180305373A1-20181025-C01720
    Figure US20180305373A1-20181025-C01721
         		I-1 II-130 A 4.77 726
    I-131
    Figure US20180305373A1-20181025-C01722
    Figure US20180305373A1-20181025-C01723
         		H
    Figure US20180305373A1-20181025-C01724
    Figure US20180305373A1-20181025-C01725
         		I-1 II-131 A 4.57 628
    I-132
    Figure US20180305373A1-20181025-C01726
    Figure US20180305373A1-20181025-C01727
         		H
    Figure US20180305373A1-20181025-C01728
    Figure US20180305373A1-20181025-C01729
         		I-1 II-132 A 4.07 574
    I-133
    Figure US20180305373A1-20181025-C01730
    Figure US20180305373A1-20181025-C01731
         		H
    Figure US20180305373A1-20181025-C01732
    Figure US20180305373A1-20181025-C01733
         		I-1 II-133 A 5.67 641
  • TABLE XIV-13
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C01734
    Figure US20180305373A1-20181025-C01735
         		Syn. Int me- thod RT Mass
    I-134
    Figure US20180305373A1-20181025-C01736
    Figure US20180305373A1-20181025-C01737
         		H
    Figure US20180305373A1-20181025-C01738
    Figure US20180305373A1-20181025-C01739
         		I-1 II-134 A 4.07 642
    I-135
    Figure US20180305373A1-20181025-C01740
    Figure US20180305373A1-20181025-C01741
         		H
    Figure US20180305373A1-20181025-C01742
    Figure US20180305373A1-20181025-C01743
         		I-1 II-135 A 5.82 655
    I-136
    Figure US20180305373A1-20181025-C01744
    Figure US20180305373A1-20181025-C01745
         		H
    Figure US20180305373A1-20181025-C01746
    Figure US20180305373A1-20181025-C01747
         		I-1 II-136 A 6   691
    I-137
    Figure US20180305373A1-20181025-C01748
    Figure US20180305373A1-20181025-C01749
         		H
    Figure US20180305373A1-20181025-C01750
    Figure US20180305373A1-20181025-C01751
         		I-1 II-137 A 6.15 745
    I-138
    Figure US20180305373A1-20181025-C01752
    Figure US20180305373A1-20181025-C01753
         		H
    Figure US20180305373A1-20181025-C01754
    Figure US20180305373A1-20181025-C01755
         		I-1 II-138 A 6.13 647
    I-139
    Figure US20180305373A1-20181025-C01756
    Figure US20180305373A1-20181025-C01757
         		H
    Figure US20180305373A1-20181025-C01758
    Figure US20180305373A1-20181025-C01759
         		I-1 II-139 A 5.53 593
    I-140
    Figure US20180305373A1-20181025-C01760
    Figure US20180305373A1-20181025-C01761
         		H
    Figure US20180305373A1-20181025-C01762
    Figure US20180305373A1-20181025-C01763
         		I-1 II-140 A 4.15 672
    I-141
    Figure US20180305373A1-20181025-C01764
    Figure US20180305373A1-20181025-C01765
         		H
    Figure US20180305373A1-20181025-C01766
    Figure US20180305373A1-20181025-C01767
         		I-1 II-141 A 5.92 667
    I-142
    Figure US20180305373A1-20181025-C01768
    Figure US20180305373A1-20181025-C01769
         		H
    Figure US20180305373A1-20181025-C01770
    Figure US20180305373A1-20181025-C01771
         		I-1 II-142 A 6.2  677
    I-143
    Figure US20180305373A1-20181025-C01772
    Figure US20180305373A1-20181025-C01773
         		H
    Figure US20180305373A1-20181025-C01774
    Figure US20180305373A1-20181025-C01775
         		I-1 II-143 A 5.6  623
    I-144
    Figure US20180305373A1-20181025-C01776
    Figure US20180305373A1-20181025-C01777
         		H
    Figure US20180305373A1-20181025-C01778
    Figure US20180305373A1-20181025-C01779
         		I-1 II-144 A 4.32 692
  • TABLE XIV-14
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C01780
    Figure US20180305373A1-20181025-C01781
         		Syn. Int me- thod RT Mass
    I-145
    Figure US20180305373A1-20181025-C01782
    Figure US20180305373A1-20181025-C01783
         		H
    Figure US20180305373A1-20181025-C01784
    Figure US20180305373A1-20181025-C01785
         		I-1 II-145 A 6.07 705
    I-146
    Figure US20180305373A1-20181025-C01786
    Figure US20180305373A1-20181025-C01787
         		H
    Figure US20180305373A1-20181025-C01788
    Figure US20180305373A1-20181025-C01789
         		I-1 II-146 A 6.42 697
    I-147
    Figure US20180305373A1-20181025-C01790
    Figure US20180305373A1-20181025-C01791
         		H
    Figure US20180305373A1-20181025-C01792
    Figure US20180305373A1-20181025-C01793
         		I-1 II-147 A 5.85 643
    I-148
    Figure US20180305373A1-20181025-C01794
    Figure US20180305373A1-20181025-C01795
         		H
    Figure US20180305373A1-20181025-C01796
    Figure US20180305373A1-20181025-C01797
         		I-1 II-148 A 4.72 561
    I-149
    Figure US20180305373A1-20181025-C01798
    Figure US20180305373A1-20181025-C01799
         		H
    Figure US20180305373A1-20181025-C01800
    Figure US20180305373A1-20181025-C01801
         		I-1 II-149 A 5.15 609
    I-150
    Figure US20180305373A1-20181025-C01802
    Figure US20180305373A1-20181025-C01803
         		H
    Figure US20180305373A1-20181025-C01804
    Figure US20180305373A1-20181025-C01805
         		I-1 II-150 A 5.22 571
    I-151
    Figure US20180305373A1-20181025-C01806
    Figure US20180305373A1-20181025-C01807
         		H
    Figure US20180305373A1-20181025-C01808
    Figure US20180305373A1-20181025-C01809
         		I-1 II-151 A 4.32 653
    I-152
    Figure US20180305373A1-20181025-C01810
    Figure US20180305373A1-20181025-C01811
         		H
    Figure US20180305373A1-20181025-C01812
    Figure US20180305373A1-20181025-C01813
         		I-1 II-152 A 5.2  701
    I-153
    Figure US20180305373A1-20181025-C01814
    Figure US20180305373A1-20181025-C01815
         		H
    Figure US20180305373A1-20181025-C01816
    Figure US20180305373A1-20181025-C01817
         		I-1 II-153 A 5.2  663
    I-154
    Figure US20180305373A1-20181025-C01818
    Figure US20180305373A1-20181025-C01819
         		H
    Figure US20180305373A1-20181025-C01820
    Figure US20180305373A1-20181025-C01821
         		I-1 II-154 A 3.93 618
    I-155
    Figure US20180305373A1-20181025-C01822
    Figure US20180305373A1-20181025-C01823
         		H
    Figure US20180305373A1-20181025-C01824
    Figure US20180305373A1-20181025-C01825
         		I-1 II-155 A 4.23 666
  • TABLE XIV-15
    Example No R1 R2 R3
    Figure US20180305373A1-20181025-C01826
    Figure US20180305373A1-20181025-C01827
         		Syn. Int me- thod RT Mass
    I-156
    Figure US20180305373A1-20181025-C01828
    Figure US20180305373A1-20181025-C01829
         		H
    Figure US20180305373A1-20181025-C01830
    Figure US20180305373A1-20181025-C01831
         		I-1 II-156 A 4.25 628
    I-157
    Figure US20180305373A1-20181025-C01832
    Figure US20180305373A1-20181025-C01833
         		H
    Figure US20180305373A1-20181025-C01834
    Figure US20180305373A1-20181025-C01835
         		I-1 II-157 A 4.48 605
    I-158
    Figure US20180305373A1-20181025-C01836
    Figure US20180305373A1-20181025-C01837
         		H
    Figure US20180305373A1-20181025-C01838
    Figure US20180305373A1-20181025-C01839
         		I-1 II-158 A 4.9 653
    I-159
    Figure US20180305373A1-20181025-C01840
    Figure US20180305373A1-20181025-C01841
         		H
    Figure US20180305373A1-20181025-C01842
    Figure US20180305373A1-20181025-C01843
         		I-1 II-159 A 4.92 615
    I-160
    Figure US20180305373A1-20181025-C01844
    Figure US20180305373A1-20181025-C01845
         		H
    Figure US20180305373A1-20181025-C01846
    Figure US20180305373A1-20181025-C01847
         		I-1 II-160 A 4.32 604
    I-161
    Figure US20180305373A1-20181025-C01848
    Figure US20180305373A1-20181025-C01849
         		H
    Figure US20180305373A1-20181025-C01850
    Figure US20180305373A1-20181025-C01851
         		I-1 II-161 A 4.47 577
    I-162
    Figure US20180305373A1-20181025-C01852
    Figure US20180305373A1-20181025-C01853
         		H
    Figure US20180305373A1-20181025-C01854
    Figure US20180305373A1-20181025-C01855
         		I-1 II-162 A 4.7  561
    I-163
    Figure US20180305373A1-20181025-C01856
    Figure US20180305373A1-20181025-C01857
         		H
    Figure US20180305373A1-20181025-C01858
    Figure US20180305373A1-20181025-C01859
         		I-1 II-163 A 4.75 589
    I-164
    Figure US20180305373A1-20181025-C01860
    Figure US20180305373A1-20181025-C01861
         		H
    Figure US20180305373A1-20181025-C01862
    Figure US20180305373A1-20181025-C01863
         		I-1 II-164 A 5.22 603
    I-165
    Figure US20180305373A1-20181025-C01864
    Figure US20180305373A1-20181025-C01865
         		H
    Figure US20180305373A1-20181025-C01866
    Figure US20180305373A1-20181025-C01867
         		I-1 II-165 A 5.58 651
    I-166
    Figure US20180305373A1-20181025-C01868
    Figure US20180305373A1-20181025-C01869
         		H
    Figure US20180305373A1-20181025-C01870
    Figure US20180305373A1-20181025-C01871
         		I-1 II-166 A 5.62 613
  • TABLE XIV-16
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C01872
    Figure US20180305373A1-20181025-C01873
         		Syn. Int me- thod RT Mass
    I-167
    Figure US20180305373A1-20181025-C01874
    Figure US20180305373A1-20181025-C01875
         		H
    Figure US20180305373A1-20181025-C01876
    Figure US20180305373A1-20181025-C01877
         		I-1 II-167 A 4.68 531
    I-168
    Figure US20180305373A1-20181025-C01878
    Figure US20180305373A1-20181025-C01879
         		H
    Figure US20180305373A1-20181025-C01880
    Figure US20180305373A1-20181025-C01881
         		I-1 II-168 A 4.75 609
    I-169
    Figure US20180305373A1-20181025-C01882
    Figure US20180305373A1-20181025-C01883
         		H
    Figure US20180305373A1-20181025-C01884
    Figure US20180305373A1-20181025-C01885
         		I-1 II-169 A 5.17 623
    I-170
    Figure US20180305373A1-20181025-C01886
    Figure US20180305373A1-20181025-C01887
         		H
    Figure US20180305373A1-20181025-C01888
    Figure US20180305373A1-20181025-C01889
         		I-1 II-170 A 5.53 671
    I-171
    Figure US20180305373A1-20181025-C01890
    Figure US20180305373A1-20181025-C01891
         		H
    Figure US20180305373A1-20181025-C01892
    Figure US20180305373A1-20181025-C01893
         		I-1 II-171 A 5.57 633
    I-172
    Figure US20180305373A1-20181025-C01894
    Figure US20180305373A1-20181025-C01895
         		H
    Figure US20180305373A1-20181025-C01896
    Figure US20180305373A1-20181025-C01897
         		I-1 II-172 A 4.82 625
    I-173
    Figure US20180305373A1-20181025-C01898
    Figure US20180305373A1-20181025-C01899
         		H
    Figure US20180305373A1-20181025-C01900
    Figure US20180305373A1-20181025-C01901
         		I-1 II-173 A 4.83 653
    I-174
    Figure US20180305373A1-20181025-C01902
    Figure US20180305373A1-20181025-C01903
         		H
    Figure US20180305373A1-20181025-C01904
    Figure US20180305373A1-20181025-C01905
         		I-1 II-174 A 5.28 667
    I-175
    Figure US20180305373A1-20181025-C01906
    Figure US20180305373A1-20181025-C01907
         		H
    Figure US20180305373A1-20181025-C01908
    Figure US20180305373A1-20181025-C01909
         		I-1 II-175 A 5.05 645
    I-176
    Figure US20180305373A1-20181025-C01910
    Figure US20180305373A1-20181025-C01911
         		H
    Figure US20180305373A1-20181025-C01912
    Figure US20180305373A1-20181025-C01913
         		I-1 II-176 A 5.07 673
    I-177
    Figure US20180305373A1-20181025-C01914
    Figure US20180305373A1-20181025-C01915
         		H
    Figure US20180305373A1-20181025-C01916
    Figure US20180305373A1-20181025-C01917
         		I-1 II-177 A 5.55 687
  • TABLE XIV-17
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C01918
    Figure US20180305373A1-20181025-C01919
         		Syn. Int me- thod RT Mass
    I-178
    Figure US20180305373A1-20181025-C01920
    Figure US20180305373A1-20181025-C01921
         		H
    Figure US20180305373A1-20181025-C01922
    Figure US20180305373A1-20181025-C01923
         		I-1 II-178 A 4.98 511
    I-179
    Figure US20180305373A1-20181025-C01924
    Figure US20180305373A1-20181025-C01925
         		H
    Figure US20180305373A1-20181025-C01926
    Figure US20180305373A1-20181025-C01927
         		I-1 II-179 A 5.55 517
    I-180
    Figure US20180305373A1-20181025-C01928
    Figure US20180305373A1-20181025-C01929
         		H
    Figure US20180305373A1-20181025-C01930
    Figure US20180305373A1-20181025-C01931
         		I-1 II-180 A 5.03 603
    I-181
    Figure US20180305373A1-20181025-C01932
    Figure US20180305373A1-20181025-C01933
         		H
    Figure US20180305373A1-20181025-C01934
    Figure US20180305373A1-20181025-C01935
         		I-1 II-181 A 5.48 609
    I-182
    Figure US20180305373A1-20181025-C01936
    Figure US20180305373A1-20181025-C01937
         		H
    Figure US20180305373A1-20181025-C01938
    Figure US20180305373A1-20181025-C01939
         		I-1 II-182 A 4.82 555
    I-183
    Figure US20180305373A1-20181025-C01940
    Figure US20180305373A1-20181025-C01941
         		H
    Figure US20180305373A1-20181025-C01942
    Figure US20180305373A1-20181025-C01943
         		I-1 II-133 A 4.05 563
    I-184
    Figure US20180305373A1-20181025-C01944
    Figure US20180305373A1-20181025-C01945
         		H
    Figure US20180305373A1-20181025-C01946
    Figure US20180305373A1-20181025-C01947
         		I-1 II-134 A 3.35 520
    I-185
    Figure US20180305373A1-20181025-C01948
    Figure US20180305373A1-20181025-C01949
         		H
    Figure US20180305373A1-20181025-C01950
    Figure US20180305373A1-20181025-C01951
         		I-1 II-185 A 4.7  555
    I-186
    Figure US20180305373A1-20181025-C01952
    Figure US20180305373A1-20181025-C01953
         		H
    Figure US20180305373A1-20181025-C01954
    Figure US20180305373A1-20181025-C01955
         		I-1 II-186 A 4.45 507
    I-187
    Figure US20180305373A1-20181025-C01956
    Figure US20180305373A1-20181025-C01957
         		H
    Figure US20180305373A1-20181025-C01958
    Figure US20180305373A1-20181025-C01959
         		I-1 II-187 A 4.52 554
    I-188
    Figure US20180305373A1-20181025-C01960
    Figure US20180305373A1-20181025-C01961
         		H
    Figure US20180305373A1-20181025-C01962
    Figure US20180305373A1-20181025-C01963
         		I-1 II-188 A 4.25 506
  • TABLE XIV-18
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C01964
    Figure US20180305373A1-20181025-C01965
         		Syn. Int me- thod RT Mass
    I-189
    Figure US20180305373A1-20181025-C01966
    Figure US20180305373A1-20181025-C01967
         		H
    Figure US20180305373A1-20181025-C01968
    Figure US20180305373A1-20181025-C01969
         		I-1 II-189 A 4.72 527
    I-190
    Figure US20180305373A1-20181025-C01970
    Figure US20180305373A1-20181025-C01971
         		H
    Figure US20180305373A1-20181025-C01972
    Figure US20180305373A1-20181025-C01973
         		I-1 II-190 A 4.42 479
    I-191
    Figure US20180305373A1-20181025-C01974
    Figure US20180305373A1-20181025-C01975
         		H
    Figure US20180305373A1-20181025-C01976
    Figure US20180305373A1-20181025-C01977
         		I-1 II-191 A 5.5  553
    I-192
    Figure US20180305373A1-20181025-C01978
    Figure US20180305373A1-20181025-C01979
         		H
    Figure US20180305373A1-20181025-C01980
    Figure US20180305373A1-20181025-C01981
         		I-1 II-192 A 5.28 505
    I-193
    Figure US20180305373A1-20181025-C01982
    Figure US20180305373A1-20181025-C01983
         		H
    Figure US20180305373A1-20181025-C01984
    Figure US20180305373A1-20181025-C01985
         		I-1 II-193 A 5.43 573
    I-194
    Figure US20180305373A1-20181025-C01986
    Figure US20180305373A1-20181025-C01987
         		H
    Figure US20180305373A1-20181025-C01988
    Figure US20180305373A1-20181025-C01989
         		I-1 II-194 A 5.93 579
    I-195
    Figure US20180305373A1-20181025-C01990
    Figure US20180305373A1-20181025-C01991
         		H
    Figure US20180305373A1-20181025-C01992
    Figure US20180305373A1-20181025-C01993
         		I-1 II-195 A 5.5  587
    I-196
    Figure US20180305373A1-20181025-C01994
    Figure US20180305373A1-20181025-C01995
         		H
    Figure US20180305373A1-20181025-C01996
    Figure US20180305373A1-20181025-C01997
         		I-1 II-196 A 6   593
    I-197
    Figure US20180305373A1-20181025-C01998
    Figure US20180305373A1-20181025-C01999
         		H
    Figure US20180305373A1-20181025-C02000
    Figure US20180305373A1-20181025-C02001
         		I-1 II-197 A 5.62 601
    I-198
    Figure US20180305373A1-20181025-C02002
    Figure US20180305373A1-20181025-C02003
         		H
    Figure US20180305373A1-20181025-C02004
    Figure US20180305373A1-20181025-C02005
         		I-1 II-198 A 6.12 607
    I-199
    Figure US20180305373A1-20181025-C02006
    Figure US20180305373A1-20181025-C02007
         		H
    Figure US20180305373A1-20181025-C02008
    Figure US20180305373A1-20181025-C02009
         		I-1 II-199 A 4.42 507
  • TABLE XIV-19
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C02010
    Figure US20180305373A1-20181025-C02011
         		Syn. Int me- thod RT Mass
    I-200
    Figure US20180305373A1-20181025-C02012
    Figure US20180305373A1-20181025-C02013
         		H
    Figure US20180305373A1-20181025-C02014
    Figure US20180305373A1-20181025-C02015
         		I-1 II-200 A 4.92 555
    I-201
    Figure US20180305373A1-20181025-C02016
    Figure US20180305373A1-20181025-C02017
         		H
    Figure US20180305373A1-20181025-C02018
    Figure US20180305373A1-20181025-C02019
         		I-1 II-201 A 5.27 525
    I-202
    Figure US20180305373A1-20181025-C02020
    Figure US20180305373A1-20181025-C02021
         		H
    Figure US20180305373A1-20181025-C02022
    Figure US20180305373A1-20181025-C02023
         		I-1 II-202 A 4.55 599
    I-203
    Figure US20180305373A1-20181025-C02024
    Figure US20180305373A1-20181025-C02025
         		H
    Figure US20180305373A1-20181025-C02026
    Figure US20180305373A1-20181025-C02027
         		I-1 II-203 A 4.98 647
    I-204
    Figure US20180305373A1-20181025-C02028
    Figure US20180305373A1-20181025-C02029
         		H
    Figure US20180305373A1-20181025-C02030
    Figure US20180305373A1-20181025-C02031
         		I-1 II-204 A 4.4  527
    I-205
    Figure US20180305373A1-20181025-C02032
    Figure US20180305373A1-20181025-C02033
         		H
    Figure US20180305373A1-20181025-C02034
    Figure US20180305373A1-20181025-C02035
         		I-1 II-205 A 4.48 555
    I-206
    Figure US20180305373A1-20181025-C02036
    Figure US20180305373A1-20181025-C02037
         		H
    Figure US20180305373A1-20181025-C02038
    Figure US20180305373A1-20181025-C02039
         		I-1 II-206 A 4.93 569
    I-207
    Figure US20180305373A1-20181025-C02040
    Figure US20180305373A1-20181025-C02041
         		H
    Figure US20180305373A1-20181025-C02042
    Figure US20180305373A1-20181025-C02043
         		I-1 II-207 A 5.45 591
    I-208
    Figure US20180305373A1-20181025-C02044
    Figure US20180305373A1-20181025-C02045
         		H
    Figure US20180305373A1-20181025-C02046
    Figure US20180305373A1-20181025-C02047
         		I-1 II-208 A 5.35 617
    I-209
    Figure US20180305373A1-20181025-C02048
    Figure US20180305373A1-20181025-C02049
         		H
    Figure US20180305373A1-20181025-C02050
    Figure US20180305373A1-20181025-C02051
         		I-1 II-209 A 4.58 555
    I-210
    Figure US20180305373A1-20181025-C02052
    Figure US20180305373A1-20181025-C02053
         		H
    Figure US20180305373A1-20181025-C02054
    Figure US20180305373A1-20181025-C02055
         		I-1 II-210 A 4.67 583
  • TABLE XIV-20
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C02056
    Figure US20180305373A1-20181025-C02057
         		Syn. Int me- thod RT Mass
    I-211
    Figure US20180305373A1-20181025-C02058
    Figure US20180305373A1-20181025-C02059
         		H
    Figure US20180305373A1-20181025-C02060
    Figure US20180305373A1-20181025-C02061
         		I-1 II-211 A 5.1  597
    I-212
    Figure US20180305373A1-20181025-C02062
    Figure US20180305373A1-20181025-C02063
         		H
    Figure US20180305373A1-20181025-C02064
    Figure US20180305373A1-20181025-C02065
         		I-1 II-212 A 5.62 619
    I-213
    Figure US20180305373A1-20181025-C02066
    Figure US20180305373A1-20181025-C02067
         		H
    Figure US20180305373A1-20181025-C02068
    Figure US20180305373A1-20181025-C02069
         		I-1 II-213 A 5.5  645
    I-214
    Figure US20180305373A1-20181025-C02070
    Figure US20180305373A1-20181025-C02071
         		Me
    Figure US20180305373A1-20181025-C02072
    Figure US20180305373A1-20181025-C02073
         		I-1 II-214 A 3.17 476
    I-215
    Figure US20180305373A1-20181025-C02074
    Figure US20180305373A1-20181025-C02075
         		Me
    Figure US20180305373A1-20181025-C02076
    Figure US20180305373A1-20181025-C02077
         		I-1 II-215 A 4.95 510
    I-216
    Figure US20180305373A1-20181025-C02078
    Figure US20180305373A1-20181025-C02079
         		Me
    Figure US20180305373A1-20181025-C02080
    Figure US20180305373A1-20181025-C02081
         		I-1 II-216 A 5.13 525
    I-217
    Figure US20180305373A1-20181025-C02082
    Figure US20180305373A1-20181025-C02083
         		Me
    Figure US20180305373A1-20181025-C02084
    Figure US20180305373A1-20181025-C02085
         		I-1 II-217 A 3.35 563
    I-218
    Figure US20180305373A1-20181025-C02086
    Figure US20180305373A1-20181025-C02087
         		Me
    Figure US20180305373A1-20181025-C02088
    Figure US20180305373A1-20181025-C02089
         		I-1 II-218 A 5   602
    I-219
    Figure US20180305373A1-20181025-C02090
    Figure US20180305373A1-20181025-C02091
         		Me
    Figure US20180305373A1-20181025-C02092
    Figure US20180305373A1-20181025-C02093
         		I-1 II-219 A 5.15 617
    I-220
    Figure US20180305373A1-20181025-C02094
    Figure US20180305373A1-20181025-C02095
         		Me
    Figure US20180305373A1-20181025-C02096
    Figure US20180305373A1-20181025-C02097
         		I-1 II-220 A 3.12 520
    I-221
    Figure US20180305373A1-20181025-C02098
    Figure US20180305373A1-20181025-C02099
         		Me
    Figure US20180305373A1-20181025-C02100
    Figure US20180305373A1-20181025-C02101
         		I-1 II-221 A 4.62 554
  • TABLE XIV-21
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C02102
    Figure US20180305373A1-20181025-C02103
         		Syn. Int me- thod RT Mass
    I-222
    Figure US20180305373A1-20181025-C02104
    Figure US20180305373A1-20181025-C02105
         		Me
    Figure US20180305373A1-20181025-C02106
    Figure US20180305373A1-20181025-C02107
         		I-1 II-222 A 4.77 569
    I-223
    Figure US20180305373A1-20181025-C02108
    Figure US20180305373A1-20181025-C02109
         		Me
    Figure US20180305373A1-20181025-C02110
    Figure US20180305373A1-20181025-C02111
         		I-1 II-223 A 3.48 526
    I-224
    Figure US20180305373A1-20181025-C02112
    Figure US20180305373A1-20181025-C02113
         		Me
    Figure US20180305373A1-20181025-C02114
    Figure US20180305373A1-20181025-C02115
         		I-1 II-224 A 5.37 560
    I-225
    Figure US20180305373A1-20181025-C02116
    Figure US20180305373A1-20181025-C02117
         		Me
    Figure US20180305373A1-20181025-C02118
    Figure US20180305373A1-20181025-C02119
         		I-1 II-225 A 3.68 618
    I-226
    Figure US20180305373A1-20181025-C02120
    Figure US20180305373A1-20181025-C02121
         		Me
    Figure US20180305373A1-20181025-C02122
    Figure US20180305373A1-20181025-C02123
         		I-1 II-226 A 5.35 652
    I-227
    Figure US20180305373A1-20181025-C02124
    Figure US20180305373A1-20181025-C02125
         		Me
    Figure US20180305373A1-20181025-C02126
    Figure US20180305373A1-20181025-C02127
         		I-1 II-227 A 3.13 583
    I-228
    Figure US20180305373A1-20181025-C02128
    Figure US20180305373A1-20181025-C02129
         		Me
    Figure US20180305373A1-20181025-C02130
    Figure US20180305373A1-20181025-C02131
         		I-1 II-228 A 4.23 617
    I-229
    Figure US20180305373A1-20181025-C02132
    Figure US20180305373A1-20181025-C02133
         		Me
    Figure US20180305373A1-20181025-C02134
    Figure US20180305373A1-20181025-C02135
         		I-1 II-229 A 3.45 570
    I-230
    Figure US20180305373A1-20181025-C02136
    Figure US20180305373A1-20181025-C02137
         		Me
    Figure US20180305373A1-20181025-C02138
    Figure US20180305373A1-20181025-C02139
         		I-1 II-230 A 4.95 604
    I-231
    Figure US20180305373A1-20181025-C02140
    Figure US20180305373A1-20181025-C02141
         		Me
    Figure US20180305373A1-20181025-C02142
    Figure US20180305373A1-20181025-C02143
         		I-1 II-231 A 4.35 561
    I-232
    Figure US20180305373A1-20181025-C02144
    Figure US20180305373A1-20181025-C02145
         		Me
    Figure US20180305373A1-20181025-C02146
    Figure US20180305373A1-20181025-C02147
         		I-1 II-232 A 4.53 576
  • TABLE XIV-22
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C02148
    Figure US20180305373A1-20181025-C02149
         		Syn. Int me- thod RT Mass
    I-233
    Figure US20180305373A1-20181025-C02150
    Figure US20180305373A1-20181025-C02151
         		Me
    Figure US20180305373A1-20181025-C02152
    Figure US20180305373A1-20181025-C02153
         		I-1 II-233 A 4.47 653
    I-234
    Figure US20180305373A1-20181025-C02154
    Figure US20180305373A1-20181025-C02155
         		Me
    Figure US20180305373A1-20181025-C02156
    Figure US20180305373A1-20181025-C02157
         		I-1 II-234 A 3.67 618
    I-235
    Figure US20180305373A1-20181025-C02158
    Figure US20180305373A1-20181025-C02159
         		Me
    Figure US20180305373A1-20181025-C02160
    Figure US20180305373A1-20181025-C02161
         		I-1 II-235 A 3.78 633
    I-236
    Figure US20180305373A1-20181025-C02162
    Figure US20180305373A1-20181025-C02163
         		Me
    Figure US20180305373A1-20181025-C02164
    Figure US20180305373A1-20181025-C02165
         		I-1 II-236 A 3.95 604
    I-237
    Figure US20180305373A1-20181025-C02166
    Figure US20180305373A1-20181025-C02167
         		Me
    Figure US20180305373A1-20181025-C02168
    Figure US20180305373A1-20181025-C02169
         		I-1 II-237 A 4.02 619
    I-238
    Figure US20180305373A1-20181025-C02170
    Figure US20180305373A1-20181025-C02171
         		Me
    Figure US20180305373A1-20181025-C02172
    Figure US20180305373A1-20181025-C02173
         		I-1 II-238 A 3.65 624
    I-239
    Figure US20180305373A1-20181025-C02174
    Figure US20180305373A1-20181025-C02175
         		Me
    Figure US20180305373A1-20181025-C02176
    Figure US20180305373A1-20181025-C02177
         		I-1 II-239 A 5.43 673
    I-240
    Figure US20180305373A1-20181025-C02178
    Figure US20180305373A1-20181025-C02179
         		Me
    Figure US20180305373A1-20181025-C02180
    Figure US20180305373A1-20181025-C02181
         		I-1 II-240 A 3.1  589
    I-241
    Figure US20180305373A1-20181025-C02182
    Figure US20180305373A1-20181025-C02183
         		Me
    Figure US20180305373A1-20181025-C02184
    Figure US20180305373A1-20181025-C02185
         		I-1 II-241 A 4.27 638
    I-242
    Figure US20180305373A1-20181025-C02186
    Figure US20180305373A1-20181025-C02187
         		Me
    Figure US20180305373A1-20181025-C02188
    Figure US20180305373A1-20181025-C02189
         		I-1 II-242 A 3.42 576
    I-243
    Figure US20180305373A1-20181025-C02190
    Figure US20180305373A1-20181025-C02191
         		Me
    Figure US20180305373A1-20181025-C02192
    Figure US20180305373A1-20181025-C02193
         		I-1 II-243 A 5.05 625
  • TABLE XIV-23
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C02194
    Figure US20180305373A1-20181025-C02195
         		Syn. Int me- thod RT Mass
    I-244
    Figure US20180305373A1-20181025-C02196
    Figure US20180305373A1-20181025-C02197
         		Me
    Figure US20180305373A1-20181025-C02198
    Figure US20180305373A1-20181025-C02199
         		I-1 II-244 A 3.28 575
    I-245
    Figure US20180305373A1-20181025-C02200
    Figure US20180305373A1-20181025-C02201
         		Me
    Figure US20180305373A1-20181025-C02202
    Figure US20180305373A1-20181025-C02203
         		I-1 II-245 A 4.87 624
    I-246
    Figure US20180305373A1-20181025-C02204
    Figure US20180305373A1-20181025-C02205
         		H
    Figure US20180305373A1-20181025-C02206
    Figure US20180305373A1-20181025-C02207
         		I-1 II-246 A 4.93 590
    I-247
    Figure US20180305373A1-20181025-C02208
    Figure US20180305373A1-20181025-C02209
         		H
    Figure US20180305373A1-20181025-C02210
    Figure US20180305373A1-20181025-C02211
         		I-1 II-247 A 4   612
    I-248
    Figure US20180305373A1-20181025-C02212
    Figure US20180305373A1-20181025-C02213
         		H
    Figure US20180305373A1-20181025-C02214
    Figure US20180305373A1-20181025-C02215
         		I-1 II-248 A 4.85 590
    I-249
    Figure US20180305373A1-20181025-C02216
    Figure US20180305373A1-20181025-C02217
         		H
    Figure US20180305373A1-20181025-C02218
    Figure US20180305373A1-20181025-C02219
         		I-1 II-249 A 3.32 612
    I-250
    Figure US20180305373A1-20181025-C02220
    Figure US20180305373A1-20181025-C02221
         		H
    Figure US20180305373A1-20181025-C02222
    Figure US20180305373A1-20181025-C02223
         		I-1 II-250 A 5.1  603
    I-251
    Figure US20180305373A1-20181025-C02224
    Figure US20180305373A1-20181025-C02225
         		H
    Figure US20180305373A1-20181025-C02226
    Figure US20180305373A1-20181025-C02227
         		I-1 II-251 A 4.38 625
    I-252
    Figure US20180305373A1-20181025-C02228
    Figure US20180305373A1-20181025-C02229
         		H
    Figure US20180305373A1-20181025-C02230
    Figure US20180305373A1-20181025-C02231
         		I-1 II-252 A 4.47 625
    I-253
    Figure US20180305373A1-20181025-C02232
    Figure US20180305373A1-20181025-C02233
         		H
    Figure US20180305373A1-20181025-C02234
    Figure US20180305373A1-20181025-C02235
         		I-1 II-253 A 4.73 598
  • TABLE XIV-24
    Example No. R1 R2 R3
    Figure US20180305373A1-20181025-C02236
    Figure US20180305373A1-20181025-C02237
         		Syn. Int me- thod RT Mass
    I-254
    Figure US20180305373A1-20181025-C02238
    Figure US20180305373A1-20181025-C02239
         		H
    Figure US20180305373A1-20181025-C02240
    Figure US20180305373A1-20181025-C02241
         		I-1 II-254 A 5.02 536
    I-255
    Figure US20180305373A1-20181025-C02242
    Figure US20180305373A1-20181025-C02243
         		H
    Figure US20180305373A1-20181025-C02244
    Figure US20180305373A1-20181025-C02245
         		I-1 II-255 A 4.68 587
    I-256
    Figure US20180305373A1-20181025-C02246
    Figure US20180305373A1-20181025-C02247
         		H
    Figure US20180305373A1-20181025-C02248
    Figure US20180305373A1-20181025-C02249
         		I-1 II-255 A 4.63 587
    I-257
    Figure US20180305373A1-20181025-C02250
    Figure US20180305373A1-20181025-C02251
         		H
    Figure US20180305373A1-20181025-C02252
    Figure US20180305373A1-20181025-C02253
         		I-1 II-256 A 4.8  567
    I-258
    Figure US20180305373A1-20181025-C02254
    Figure US20180305373A1-20181025-C02255
         		H
    Figure US20180305373A1-20181025-C02256
    Figure US20180305373A1-20181025-C02257
         		I-1 II-257 A 2.98 554
    I-259
    Figure US20180305373A1-20181025-C02258
    Figure US20180305373A1-20181025-C02259
         		H
    Figure US20180305373A1-20181025-C02260
    Figure US20180305373A1-20181025-C02261
         		I-1 II-258 A 3.67 554
    I-260
    Figure US20180305373A1-20181025-C02262
    Figure US20180305373A1-20181025-C02263
         		H
    Figure US20180305373A1-20181025-C02264
    Figure US20180305373A1-20181025-C02265
         		I-1 II-259 A 4.75 589
    I-261
    Figure US20180305373A1-20181025-C02266
    Figure US20180305373A1-20181025-C02267
         		H
    Figure US20180305373A1-20181025-C02268
    Figure US20180305373A1-20181025-C02269
         		I-1 II-260 A 4.78 589
    I-262
    Figure US20180305373A1-20181025-C02270
    Figure US20180305373A1-20181025-C02271
         		H
    Figure US20180305373A1-20181025-C02272
    Figure US20180305373A1-20181025-C02273
         		I-1 II-261 A 3.93 599
  • Ex- ample No. R1 R2 R3
    Figure US20180305373A1-20181025-C02274
    Figure US20180305373A1-20181025-C02275
         		Syn. Int me- thod RT Mass
    I-263
    Figure US20180305373A1-20181025-C02276
    Figure US20180305373A1-20181025-C02277
         		H
    Figure US20180305373A1-20181025-C02278
    Figure US20180305373A1-20181025-C02279
         		I-1 II-262 A 5.93 668
    I-264
    Figure US20180305373A1-20181025-C02280
    Figure US20180305373A1-20181025-C02281
         		H
    Figure US20180305373A1-20181025-C02282
    Figure US20180305373A1-20181025-C02283
         		I-1 II-263 A 6.15 683
    I-265
    Figure US20180305373A1-20181025-C02284
    Figure US20180305373A1-20181025-C02285
         		H
    Figure US20180305373A1-20181025-C02286
    Figure US20180305373A1-20181025-C02287
         		I-1 II-264 A 5.85 684
    I-266
    Figure US20180305373A1-20181025-C02288
    Figure US20180305373A1-20181025-C02289
         		H
    Figure US20180305373A1-20181025-C02290
    Figure US20180305373A1-20181025-C02291
         		I-1 II-265 A 5.05 705
    I-267
    Figure US20180305373A1-20181025-C02292
    Figure US20180305373A1-20181025-C02293
         		H
    Figure US20180305373A1-20181025-C02294
    Figure US20180305373A1-20181025-C02295
         		I-1 II-266 A 6.59 723
    I-268
    Figure US20180305373A1-20181025-C02296
    Figure US20180305373A1-20181025-C02297
         		H
    Figure US20180305373A1-20181025-C02298
    Figure US20180305373A1-20181025-C02299
         		I-2 II-267 A 4.92 578
    I-269
    Figure US20180305373A1-20181025-C02300
    Figure US20180305373A1-20181025-C02301
         		H
    Figure US20180305373A1-20181025-C02302
    Figure US20180305373A1-20181025-C02303
         		I-2 II-268 A 5.17 593
    I-270
    Figure US20180305373A1-20181025-C02304
    Figure US20180305373A1-20181025-C02305
         		H
    Figure US20180305373A1-20181025-C02306
    Figure US20180305373A1-20181025-C02307
         		I-2 II-269 A 3.64 594
    I-271
    Figure US20180305373A1-20181025-C02308
    Figure US20180305373A1-20181025-C02309
         		H
    Figure US20180305373A1-20181025-C02310
    Figure US20180305373A1-20181025-C02311
         		I-2 II-270 A 3.87 615
    I-272
    Figure US20180305373A1-20181025-C02312
    Figure US20180305373A1-20181025-C02313
         		H
    Figure US20180305373A1-20181025-C02314
    Figure US20180305373A1-20181025-C02315
         		I-2 II-271 A 7.05 633
    • INDUSTRIAL APPLICABILITY
  • The compound of the formula (I) in the present invention blocks TCF4/β-catenin transcriptional pathway by inhibiting CBP, and therefore can be used for treatment of cancer, especially colorectal cancer, and fibrotic diseases.
  • This application is based on provisional application Nos. 61/176,348 and 61/176,363 filed in U.S.A., the contents of which are hereby incorporated by reference.
  • Although only some exemplary embodiments of this invention have been described in detail above, those skilled in the art will readily appreciate that many modifications are possible in the exemplary embodiments without materially departing from the novel teachings and advantages of this invention. Accordingly, all such modifications are intended to be included within the scope of this invention.

Claims (17)

1. A compound having the following general formula (I):
Figure US20180305373A1-20181025-C02316
wherein
Figure US20180305373A1-20181025-P00001
is single bond or double bond;
A is —CHR7—,
wherein
R7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
E is bond, —CHR5—, —O— or —NR8—,
wherein
R5 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl, and
R8 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
B is void or optionally substituted monocyclic ring formed together with G and Y;
D is void or optionally substituted spiro ring formed together with Y;
with the proviso that
B and D are not both present,
when B is present, then G and Y are independently carbon atom or nitrogen atom,
when D is present, then Y is carbon atom and G is —NR6—, —O—, —CHR6— or —C(R6)2—,
when both B and D are void, then G and Y are the same or different and each is —NR6—, —O—, —CHR6— or —C(R6)2—,
wherein
each R6 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl, and
when E is bond, then D is void, B is optionally substituted monocyclic ring, and G and Y are independently carbon atom or nitrogen atom;
R1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
R2 is —W21—W22—Rb—R20,
wherein
W21 is —(CO)— or —(SO2)—,
W22 is bond, —O—, —NH— or optionally substituted lower alkylene,
Rb is bond or optionally substituted alkylene, and
R20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl; and
R3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
with the proviso that
when D is void, E is bond, B is benzene, and R2 is —W21—W22—Rb—R20, wherein W21 is —(CO)—, W22 is —NH—, and Rb is bond, then R20 should not be optionally substituted phenyl;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1,
wherein
Figure US20180305373A1-20181025-P00001
is single bond or double bond;
A is —CHR7—,
wherein
R7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
E is —CHR5—, —O— or —NR8—,
wherein
R5 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl, and
R8 is hydrogen or optionally substituted alkyl;
B is void or optionally substituted monocyclic ring formed together with G and Y;
D is void or optionally substituted spiro ring formed together with Y;
with the proviso that
B and D are not both present,
when B is present, then G and Y are independently carbon atom or nitrogen atom,
when D is present, then Y is carbon atom and G is —NR6—, —O—, —CHR6— or —C(R6)2—, and
when both B and D are void, then G and Y are the same or different and each is —NR6—, —O—, —CHR6— or —C(R6)2—,
wherein
each R6 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl;
R1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
R2 is —W21—W22—Rb—R20,
wherein
W21 is —(CO)— or —(SO2)—,
W22 is bond, —O—, —NH— or optionally substituted lower alkylene,
Rb is bond or optionally substituted alkylene, and
R20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl; and
R3 is hydrogen or optionally substituted alkyl.
3. The compound of claim 1, which has the following general formula (I-d):
Figure US20180305373A1-20181025-C02317
wherein
Figure US20180305373A1-20181025-P00001
is single bond or double bond;
A is —(CHR7)—;
wherein
R7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
B is optionally substituted monocyclic ring;
G is carbon atom or nitrogen atom;
R1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
R2 is —W21—W22—Rb—R20,
wherein
W21 is —(CO)— or —(SO2)—,
W22 is bond, —O—, —NH— or optionally substituted lower alkylene,
Rb is bond or optionally substituted lower alkylene, and
R20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl; and
R3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
with the proviso that
when B is benzene, and R2 is —W21—W22—Rb—R20, wherein W21 is —(CO)—, W22 is —NH—, and Rb is bond, then R20 should not be optionally substituted phenyl.
4. The compound of claim 1,
wherein
D is void; and
B is optionally substituted 3-, 4-, 5-, 6- or 7-membered saturated or unsaturated mono cyclic ring formed together with G and Y.
5. The compound of claim 1,
wherein
D is void; and
B is optionally substituted 4-, 5-, 6- or 7 membered saturated or unsaturated heterocyclic ring formed together with G and Y and the hetero atom is selected from S, N and O and the number of hetero atoms is an integer of 1-3.
6. The compound of claim 1,
wherein
both B and D are void; and
at least one of G and Y is —NR6′—, —CHR6′— or —C(R6′)2—,
wherein
each R6′ is independently hydrogen, optionally substituted cyclic or noncyclic lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl.
7-21. (canceled)
22. The compound of claim 1,
wherein
E is bond, —CHR5—, —O— or —NR8—,
wherein
R5 is lower alkyl, lower alkenyl, lower alkynyl or lower arylalkyl; and
R8 is hydrogen or alkyl.
23. The compound of claim 22,
D is void; and
B is optionally substituted 3-, 4-, 5-, 6- or 7 membered saturated or unsaturated heterocyclic ring formed together with G and Y.
24. The compound of claim 22,
wherein
both B and D are void, and
at least one of G and Y is —NR6′—, —CHR6′— or —C(R6′)2—,
wherein
each R6′ is independently hydrogen, optionally substituted, cyclic or non-cyclic lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl.
25-32. (canceled)
33. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier or diluent.
34-36. (canceled)
37. A method of treating or preventing a disease or condition selected from the group consisting of cancer, fibrosis, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, tuberous sclerosis complex (TSC), KSHV-associated tumor, hair loss, and Alzheimer's disease, comprising administering to a subject in need thereof a compound according to claim 1 or a pharmaceutically acceptable salt thereof in an amount effective to treat or prevent said disease or condition.
38-46. (canceled)
47. A compound having the following general formula (II):
Figure US20180305373A1-20181025-C02318
wherein
Figure US20180305373A1-20181025-P00001
is single bond or double bond;
A is —CHR7—,
wherein
R7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
E is bond, —CHR5—, —O— or —NR8—,
wherein
R5 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl, and
R8 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
B is void or optionally substituted monocyclic ring formed together with G and Y;
D is void or optionally substituted spiro ring formed together with Y;
with the proviso that
B and D are not both present,
when B is present, then G and Y are independently carbon atom or nitrogen atom,
when D is present, then Y is carbon atom and G is —NR6—, —O—, —CHR6— or —C(R6)2—,
when both B and D are void, then G and Y are the same or different and each is —NR6—, —O—, —CHR6— or —C(R6)2—,
wherein
each R6 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl, and
when E is bond, then D is void, B is optionally substituted monocyclic ring, and G and Y are independently carbon atom or nitrogen atom;
R1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
R2 is —W21—W22—Rb—R20,
wherein
W21 is —(CO)— or —(SO2)—,
W22 is bond, —O—, —NH— or optionally substituted lower alkylene,
Rb is bond or optionally substituted alkylene, and
R20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl;
R3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
R91 is selected from optionally substituted alkyl, linker and solid support; and
R92 is selected from optionally substituted alkyl, linker and solid support;
with the proviso that
when D is void, E is bond, B is benzene, and R2 is —W21—W22—Rb—R20, wherein W21 is —(CO)—, W22 is —NH—, and Rb is bond, then R20 should not be optionally substituted phenyl;
or a salt thereof.
48. A process for preparing a compound having the following general formula (I):
Figure US20180305373A1-20181025-C02319
wherein
Figure US20180305373A1-20181025-P00001
is single bond or double bond;
A is —CHR7—,
wherein
R7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
E is bond, —CHR5—, —O— or —NR8—,
wherein
R5 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl, and
R8 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
B is void or optionally substituted monocyclic ring formed together with G and Y;
D is void or optionally substituted spiro ring formed together with Y;
with the proviso that
B and D are not both present,
when B is present, then G and Y are independently carbon atom or nitrogen atom,
when D is present, then Y is carbon atom and G is —NR6—, —O—, —CHR6— or —C(R6)2—,
when both B and D are void, then G and Y are the same or different and each is —NR6—, —O—, —CHR6— or —C(R6)2—,
wherein
each R6 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl, and
when E is bond, then D is void, B is optionally substituted monocyclic ring, and G and Y are independently carbon atom or nitrogen atom;
R1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
R2 is —W21—W22—Rb—R20,
wherein
W21 is —(CO)— or —(SO2)—,
W22 is bond, —O—, —NH— or optionally substituted lower alkylene,
Rb is bond or optionally substituted alkylene, and
R20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl; and
R3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
with the proviso that
when D is void, E is bond, B is benzene, and R2 is —W21—W22—Rb—R20, wherein W21 is —(CO)—, W22 is —NH—, and Rb is bond, then R20 should not be optionally substituted phenyl;
or a salt thereof, which comprises reacting a compound having the following general formula (II):
Figure US20180305373A1-20181025-C02320
wherein
R91 is selected from optionally substituted alkyl, linker and solid support;
R92 is selected from optionally substituted alkyl, linker and solid support; and
the other symbols are as defined above, or a salt thereof, with an acid.
US16/024,262 2009-05-07 2018-06-29 Alpha helix mimetics and methods relating thereto Abandoned US20180305373A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/024,262 US20180305373A1 (en) 2009-05-07 2018-06-29 Alpha helix mimetics and methods relating thereto

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US17636309P 2009-05-07 2009-05-07
US17634809P 2009-05-07 2009-05-07
PCT/JP2010/058141 WO2010128685A1 (en) 2009-05-07 2010-05-07 Alpha helix mimetics and methods relating thereto
US201113319071A 2011-12-28 2011-12-28
US14/720,690 US10017522B2 (en) 2009-05-07 2015-05-22 Alpha helix mimetics and methods relating thereto
US16/024,262 US20180305373A1 (en) 2009-05-07 2018-06-29 Alpha helix mimetics and methods relating thereto

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/720,690 Continuation US10017522B2 (en) 2009-05-07 2015-05-22 Alpha helix mimetics and methods relating thereto

Publications (1)

Publication Number Publication Date
US20180305373A1 true US20180305373A1 (en) 2018-10-25

Family

ID=42299169

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/319,071 Active 2031-03-02 US9040531B2 (en) 2009-05-07 2010-05-07 Alpha helix mimetics and methods relating thereto
US14/720,690 Active US10017522B2 (en) 2009-05-07 2015-05-22 Alpha helix mimetics and methods relating thereto
US16/024,262 Abandoned US20180305373A1 (en) 2009-05-07 2018-06-29 Alpha helix mimetics and methods relating thereto

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US13/319,071 Active 2031-03-02 US9040531B2 (en) 2009-05-07 2010-05-07 Alpha helix mimetics and methods relating thereto
US14/720,690 Active US10017522B2 (en) 2009-05-07 2015-05-22 Alpha helix mimetics and methods relating thereto

Country Status (6)

Country Link
US (3) US9040531B2 (en)
EP (1) EP2427451B1 (en)
JP (2) JP5768239B2 (en)
CN (1) CN102482258B (en)
HK (1) HK1171440A1 (en)
WO (1) WO2010128685A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102168006B1 (en) 2010-10-07 2020-10-20 유니버시티 오브 써던 캘리포니아 Cbp/catenin antagonists for enhancing asymmetric division of somatic stem cells
AU2011329854B2 (en) 2010-11-16 2017-03-30 University Of Southern California CBP/catenin antagonists for enhancing asymmetric division of somatic stem cells
US9371330B2 (en) 2010-11-16 2016-06-21 University Of Southern California Substituted pyrazino[1,2-a]pyrimidines useful as CBP/catenin antagonists for enhancing asymmetric division of somatic stem cells
AR084070A1 (en) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc BROMODOMINIUM INHIBITORS AND USES OF THE SAME
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
WO2012083181A1 (en) * 2010-12-16 2012-06-21 Indiana University Research And Technology Corporation Alpha helix mimetics and methods for using
JP2014509298A (en) 2011-02-25 2014-04-17 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ Alpha helix mimetics and related methods
JP6037392B2 (en) 2011-02-28 2016-12-07 国立研究開発法人理化学研究所 Auxin biosynthesis inhibitor
WO2012151512A2 (en) 2011-05-04 2012-11-08 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2721031B1 (en) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2768536A4 (en) * 2011-10-19 2015-07-15 Hiroyuki Kouji Method for treating type i and type ii diabetes
EP2864336B1 (en) 2012-06-06 2016-11-23 Constellation Pharmaceuticals, Inc. Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof
TWI602820B (en) 2012-06-06 2017-10-21 星宿藥物公司 Bromodomain inhibitors and uses thereof
JP6303112B2 (en) 2012-12-12 2018-04-04 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ Preventive or therapeutic agent for liver fibrosis
CN103304494B (en) * 2013-06-20 2015-05-27 河北大学 Indene (1,2-b) quinoxaline-11-ketoxime derivatives and preparation method as well as application thereof
WO2015013579A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
US20160263131A1 (en) 2013-10-18 2016-09-15 Hiroyuki Kouji Treatment of hepatic fibrosis using an inhibitor of cbp/catenin
CN105017034B (en) * 2014-04-17 2019-02-15 中国科学院上海药物研究所 Alkamine compound, preparation method, the medical composition and its use comprising such compound
CA2952830C (en) 2014-06-20 2022-11-01 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
MX2022005056A (en) 2019-10-29 2022-05-18 Eisai R&D Man Co Ltd Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer.
EP4238567A1 (en) 2020-10-30 2023-09-06 Keio University Novel treatment and prevention of sarcopenia-related diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013878A2 (en) 1991-02-07 1992-08-20 Board Of Trustees Of The University Of Illinois Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
AU679460B2 (en) 1992-08-06 1997-07-03 Molecumetics, Ltd. Conformationally restricted mimetics of reverse turns and peptides containing the same
US6013458A (en) 1995-10-27 2000-01-11 Molecumetics, Ltd. Reverse-turn mimetics and methods relating thereto
US5929237A (en) 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US6184223B1 (en) 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US6294525B1 (en) 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
WO2002100399A1 (en) * 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
US7576084B2 (en) 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7232822B2 (en) * 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
AU2002348649B9 (en) 2001-10-12 2008-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7671054B1 (en) 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US20040072831A1 (en) * 2001-10-12 2004-04-15 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US6762185B1 (en) * 2002-03-01 2004-07-13 Choongwae Pharma Corporation Compounds useful for treatment of cancer, compositions containing the same, and methods of their use
AU2003284120A1 (en) 2002-10-17 2004-05-04 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
MXPA05008288A (en) 2003-02-13 2006-03-21 Sanofi Aventis Deutschland Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, method for the production and use thereof as medicaments.
US7390814B2 (en) 2003-02-13 2008-06-24 Sanofi-Aventis Deutschland Gmbh Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments
US7531320B2 (en) 2003-08-28 2009-05-12 Choongwae Pharma Corporation Modulation of β-catenin/TCF-activated transcription
US20050222158A1 (en) 2004-03-19 2005-10-06 Andres Charles J Jr Method of treating migraine headaches using calcitonin gene related peptide mimetics
US20050209256A1 (en) 2004-03-19 2005-09-22 Andres Charles J Jr Novel beta-turn mimetics as calcitonin gene related peptide receptor antagonists
AU2006227776A1 (en) * 2005-03-18 2006-09-28 Institute For Chemical Genomics Alpha-helix mimetics and methods relating to the treatment of fibrosis
JP5536336B2 (en) * 2005-11-08 2014-07-02 チョンウェ ファーマ コーポレイション Methods for the treatment of α-helix analogs and cancer stem cells
US20080009500A1 (en) 2005-11-08 2008-01-10 Michael Kahn Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders
KR101671535B1 (en) 2008-06-06 2016-11-01 가부시키가이샤 프리즘 파마 Alpha helix mimetics and methods relating thereto
US8691819B2 (en) 2008-10-14 2014-04-08 Prism Biolab Corporation Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions

Also Published As

Publication number Publication date
CN102482258A (en) 2012-05-30
EP2427451B1 (en) 2019-03-20
EP2427451A1 (en) 2012-03-14
WO2010128685A1 (en) 2010-11-11
US10017522B2 (en) 2018-07-10
US20120088770A1 (en) 2012-04-12
JP2012526042A (en) 2012-10-25
CN102482258B (en) 2014-06-25
JP2015187127A (en) 2015-10-29
JP6040344B2 (en) 2016-12-07
JP5768239B2 (en) 2015-08-26
US20150368262A1 (en) 2015-12-24
HK1171440A1 (en) 2013-03-28
US9040531B2 (en) 2015-05-26

Similar Documents

Publication Publication Date Title
US20180305373A1 (en) Alpha helix mimetics and methods relating thereto
US9193734B2 (en) Alpha helix mimetics and methods relating thereto
US9682996B2 (en) Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions
US20140051706A1 (en) Alpha helix mimetics and methods relating thereto

Legal Events

Date Code Title Description
AS Assignment

Owner name: PRISM BIOLAB CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PRISM PHARMA CO., LTD.;REEL/FRAME:046244/0886

Effective date: 20140724

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION